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Abstract 
 
Preference information is routinely used in healthcare decision-making, such as in health 
technology assessment, where preferences for health states are used to estimate quality-
adjusted life years. However, there is debate over whose preferences should be considered. 
This debate extends to other areas in health economics where preferences are elicited to 
inform decision-making. Common stated preference methodologies include discrete choice 
experiments (DCEs) and contingent valuation (CV), which produce information that can be 
used in economic evaluations and benefit-risk assessments. This thesis expands the 
‘preference debate’ beyond health utilities by considering the use of DCE and CV studies in 
decision-making. It also extends the debate by considering more than ‘patients’ and the 
general population; introducing four user groups that differ in their relative experience. The 
thesis’ aim is to explore whether, and how, differences in individuals’ experience of a 
healthcare intervention/health issue might influence preferences. It uses a weight loss 
maintenance intervention from the NULevel trial (ISRCTN14657176) as a case study. 
Chapter One introduces the thesis premise and Chapter Two outlines the economic theory 
underpinning the methodologies used. Chapter Three discusses the use of economic 
evaluation, providing a review of the ‘preference debate’ and recent developments. CV and 
DCE methodologies are next outlined and the use of information from DCEs in healthcare 
decision-making reviewed. Chapter Four systematically reviews the DCE literature in health 
economics to determine whether respondents can be classified as either a patient or general 
population sample. Building upon previous chapters, Chapter Five introduces an alternative 
framework for classifying respondent samples in DCE studies in terms of their relative 
experience; this defines the user groups for the empirical work (conducted via NULevel and 
an online panel). The research questions are next outlined. Chapter Six summarises the 
NULevel trial, the recruitment plan and the online survey design (containing both a DCE and 
CV task) used to address the research questions. Chapters Seven to Nine present results and 
Chapter Ten provides a discussion of implications, strengths and limitations of the work.  
The empirical work suggests that preferences differ according to the relative experience of 
respondents; raising concerns surrounding the generalisability of DCE studies. This is 
important given the increasing application of preference studies in decision-making. If this 
trend continues the implications will be even greater in future. 
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Chapter 1. Introduction 
 
The overall aim of this thesis is to explore whether, and how, differences in individuals’ 
experience of a healthcare intervention and/or a health issue might influence their preferences 
for a related healthcare intervention. The importance of this relates to the use of quantitative 
preference information in healthcare decision-making. If preferences differ across stakeholder 
groups, and preferences influence decision-making, the decisions that are made may differ 
depending on whose preferences are considered. On the other hand, if preferences do not 
differ significantly across stakeholder groups then it does not matter whose preferences are 
considered. It is therefore important to explore whether, and how, preferences might differ 
between different groups of individuals. 
In this chapter, section one sets out the broad topic area by outlining how preferences are 
elicited by health economists for use in healthcare decision-making, and the issue of whose 
preferences to elicit for this purpose. Section two explains the overall motivation and the 
importance of the project. Section three sets out the four research questions that are addressed 
in the empirical work. Section four briefly describes the case study that is used in this thesis. 
Finally, section five outlines the overall structure of the thesis and describes the purpose of 
each of the following chapters. 
1.1 Background 
Individuals’ preferences are often quantified by health economists using a set of tools known 
as stated preference methodologies (Drummond et al., 2015). These methodologies are highly 
beneficial where preferences are not known (or revealed), which could be a result of non-
existent markets, or market failures. Quantitative data from stated preferences studies can be, 
and routinely are, used in healthcare decision-making where revealed preference data is not 
available (Brazier et al., 2016).  
Perhaps the most common example of stated preference data being used in healthcare 
decision-making is in health technology assessment (HTA). It is common, particularly in the 
United Kingdom (UK), for cost-utility analysis (CUA) to be conducted in order to evaluate 
the cost-effectiveness of a healthcare intervention (Drummond et al., 2015; see section 3.1.1). 
The most common measure of benefit used in a CUA is the quality-adjusted life year 
(QALY), which combines estimates of both length of life and quality of life (Tsuchiya & 
Dolan, 2005). Quality of life is typically measured on a zero to one scale, where zero 
represents being dead and one represents some notion of ‘perfect health’. In order to obtain 
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these values, referred to as health state utilities, stated preference tasks are conducted (Brazier 
et al., 1999; see section 3.1.2). This is necessary because one cannot observe individuals’ 
preferences for health states; they must be elicited.  
When it comes to conducting CUA for HTA, the issue of whose preferences to elicit is a 
contentious one (Brazier et al., 2005). Specifically, the question relates to whether preferences 
of patients or the general population are more appropriate to incorporate into analyses that 
aim to inform healthcare decision-making. The debate, which can be linked directly to the 
theory of welfare economics (Gandjour, 2010), is yet to be fully resolved by the academic 
community (see section 3.1.4) due to its normative nature (Versteegh & Brouwer, 2016). 
Health state utilities are not the only example where individuals’ preferences are elicited. 
Contingent valuation (CV) studies have been used in healthcare since the 1980s (Smith & 
Sach, 2010; see section 3.2) to approximate the economic concepts of compensating variation 
and equivalent variation (see section 2.2). The estimates derived from these studies, known as 
willingness to pay (WTP) or willingness to accept (WTA), can be used in cost-benefit 
analysis (CBA) where the market values of benefits are not known (McIntosh et al., 2010). 
Estimates of WTP and WTA can also be produced using discrete choice experiment (DCE) 
methodology and the number of published studies that use a DCE approach has increased 
significantly since their first reported use in health economics in the 1990s (de Bekker-Grob 
et al., 2012; see section 3.3). As DCEs offer more than the opportunity to estimate WTP and 
WTA, there has been an increasing interest in using this methodology to assist healthcare 
decision-making. However, the use of DCEs in decision-making is in its infancy, with only a 
small number of examples to date (see section 3.4). 
1.2 Study Motivation 
If current trends continue (see sections 3.3 and 3.4), one might expect DCEs to play a larger 
role in healthcare decision-making over time. The inevitable question to ask once this happens 
is: whose preferences should be elicited? Many of the arguments made in the ‘preference 
debate’ from the health state valuation literature also apply when considering the use of DCEs 
in healthcare decision-making (Mott & Najafzadeh, 2016; see section 3.4). Therefore, there is 
clear justification for exploring how preferences might differ between patients and the general 
population in this context. 
However, it is important not to ignore the fact that there has been an increasing interest in 
‘patient-centred’ decision-making in recent years (Barry & Edgman-Levitan, 2012). This 
interest has led to calls for a more ‘patient-centric’ HTA process (Mühlbacher, 2015; Facey et 
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al., 2017), where patient preferences can potentially play a larger role. DCEs could be used to 
achieve this aim. Indeed, DCE methodology was originally put forward as a way to capture 
patient experiences (Ryan et al., 2001).  
It should also be noted that the comparison between patients and the general population has 
been referred to as a ‘false dichotomy’ in the context of health state valuation on the grounds 
that experience can differ significantly between individuals within each group (Dolan, 1999). 
With all of this in mind, there is clear justification for exploring how preferences might differ 
between groups of patients with differing levels of experience, rather than focusing solely on 
comparisons of patients and the general population. 
Ultimately, if quantitative preference data from DCEs are to be used in analyses that inform 
healthcare decision-making, it is important to understand how preferences might differ 
amongst the different stakeholder groups that could be recruited for these studies. If 
significant differences in preferences are found between the different groups, it will be 
important to consider why these differences exist and how they might influence decision-
making. It might be the case that experienced individuals have ‘better defined’ preferences 
than those with less experience and have significantly different preferences to those with less 
experience. Individuals with no experience might focus solely on clinical effectiveness and 
efficiency-related aspects of healthcare (Bryan & Dolan, 2004). 
Understanding the differences that could occur in a DCE because of the type of respondents 
could make it easier to provide guidance on the use of DCEs, which would help to improve 
the credibility of the methodology, as well as improving decision-making processes. 
However, it is also important to consider that the choice of methodology may have an impact 
on the results of preference studies too. Given that WTP can be elicited using both CV and 
DCE methodologies, utilising both methods could provide a useful insight into this area.  
1.3 Research Questions 
Chapter Five sets out a framework that describes how respondent samples could differ in 
relation to their relative experience of a health condition and its associated treatment. The 
empirical work in this thesis subsequently tests whether preferences differ between these four 
user groups. In order to recruit samples of each user group, an online survey was designed 
(see Chapter Six) and delivered to individuals that had participated in a randomised controlled 
trial (RCT), as well as to individuals in an online panel (see section 6.2 for a detailed 
overview of the sampling process). 
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The specific research questions to be addressed in the empirical work (see section 5.4 for a 
more detailed overview) are: 
1. To what extent do preferences for a health service, elicited via a DCE, differ between 
different user groups, and why might these differences occur? 
2. In relation to WTP estimates: 
a. To what extent do the estimates differ between different user groups, and why 
might these differences occur? 
b. To what extent do the estimates differ if they are elicited indirectly (via DCE) 
or directly (via CV)? 
3. To what extent do certain user groups have better defined preferences than other user 
groups, and why might these differences occur? 
4. To what extent might differences in preferences between the user groups be attributed 
to the recruitment vehicle (RCT vs. online panel)? 
1.4 The Case Study: Weight Loss Maintenance 
A recent report suggests that over a quarter of adults in the UK are obese (OECD, 2017). In 
addition, it is estimated that 40% of adults worldwide attempted to lose weight between 2010 
and 2015 (Santos et al., 2017). The risks of being obese are increasingly well understood in 
the general population and, as a result, achieving a healthy weight is increasingly desirable. 
The case study used in this thesis is that of a weight loss maintenance (WLM) intervention. 
WLM is becoming increasingly important to public health researchers. This is because, whilst 
a vast amount of research has been undertaken to improve the lifestyles of those that are 
obese, little focus has been given to the maintenance of lifestyle improvements following 
successful and significant weight loss (Dombrowski et al., 2014). Studies have shown that 
people often fail to maintain weight loss over time, creating a ‘yo-yo effect’ where 
individuals’ weight fluctuates regularly (Avenell et al., 2004). Specifically, the interventions 
used in the stated preference tasks in the empirical work of this thesis are specifically based 
upon a WLM intervention from the NULevel RCT. The NULevel trial was undertaken by a 
team of researchers at Newcastle University (Evans et al., 2015) and is outlined in detail in 
section 6.1. 
The work contained in this thesis is independent of the NULevel trial itself. NULevel trial 
participants that had consented to be contacted for future studies were invited to participate in 
this study, which went through its own ethical approval process (see section 6.8), upon 
completion of the trial. However, members of the NULevel trial team were involved at the 
‘defining attributes and levels’ stage of the DCE design (see section 6.4). 
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1.5 Thesis Structure 
This chapter has provided an overview of the setting and the motivation behind the thesis. In 
addition, the research questions and the case study have been outlined. All of this is developed 
further and in greater detail in the subsequent chapters of this thesis. 
Chapter Two outlines the economic theory that underpins the various methodologies used in 
this thesis. This includes an overview of consumer choice theory and welfare changes, as well 
an explanation of different types of value. It finishes by outlining key concepts in welfare 
economics and the theoretical foundation of CBA. 
Chapter Three follows on from Chapter Two by discussing the use of economic evaluation 
methods such as CBA and CUA in health economics. It also provides a narrative review of 
the ‘preference debate’ and outlines recent developments in relation to both areas. Following 
this, CV and DCE methodologies are introduced and outlined. Finally, the use of quantitative 
preference information from DCEs in healthcare decision-making is reviewed and the 
‘preference debate’ is discussed in this context. 
Chapter Four builds upon Chapter Three by systematically reviewing the published DCE 
literature in health economics. The aim of the review is to determine whose preferences are 
typically elicited in DCE studies that elicit preferences for healthcare services. Respondent 
samples are classified as either a patient sample or a general population sample in order to 
determine whether DCEs are typically used to elicit patient preferences. 
Chapter Five reflects the findings of Chapters Three and Four and introduces an alternative 
framework for classifying respondent samples in DCE studies in terms of their relative 
experience. This sets out the user groups to be recruited for the empirical work. In addition, 
this chapter outlines the four research questions from section 1.3 in greater detail. 
Chapter Six is a methodological chapter that outlines the case study from section 1.4 in 
greater detail. The chapter then details the recruitment plan and the overall design of an online 
survey that is used to address the research questions. The latter involves a set of screening 
questions to classify the respondents, the design of the DCE and CV tasks, and additional data 
collection. The chapter also outlines the process undertaken to obtain ethical approval. 
Chapters Seven and Eight are results chapters that provide the results for research questions 
one to three, as well as some discussion points. Chapter Seven provides results from the 
NULevel trial sample and Chapter Eight provides results from the online panel sample. 
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Chapter Nine combines the two samples and provides overall results and discussion points 
relating to all four research questions. 
Chapter Ten provides a summary of the results of the empirical work and discusses the 
implications to different stakeholders such as researchers and policymakers. The chapter also 
outlines the strengths and limitations of the empirical work, provides suggestions for further 
research and, finally, concludes the thesis. 
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Chapter 2. Economic Theory 
 
The aim of this chapter is to outline the economic theory of which the various concepts 
addressed in this thesis are based upon (e.g. economic evaluation methodologies and CV) or 
influenced by (e.g. DCEs). 
This chapter begins with a section overviewing the basic concepts and assumptions in 
consumer choice theory. Section two uses these concepts to illustrate how welfare changes 
can be measured according to economic theory. Section three discusses the value of a good, 
the existence of ‘use’ and ‘non-use’ values, and explains how an alternate theory of consumer 
demand addresses value. Section four moves beyond the individual consumer by discussing 
concepts from welfare economics, which is concerned with social welfare. The theory 
discussed in this final section provides the theoretical basis for an important economic 
evaluation method (CBA) and hence provides a starting point for the discussion of economic 
evaluation in health (see Chapter Three). 
2.1 The Basics of Consumer Choice Theory 
The theory of consumer choice is concerned with the consumer’s approach to decision-
making in relation to consumption. This section will firstly present an overview of the choice 
problem and secondly provide further detail on the assumptions that are made with respect to 
consumer preferences in consumer choice theory. 
2.1.1 The Choice Problem 
The typical setup of the choice problem is to consider a ‘rational consumer’ i that wishes to 
consume goods1 such that his or her utility is maximised. Utility here is used to denote the 
subjective sensations that are derived from consumption, such as satisfaction or pleasure 
(Gravelle & Rees, 2004). The problem faced by the consumer is that they are constrained by a 
finite budget. Hence, the challenge is for the consumer to consume goods in line with his or 
her preferences and within their budget such that their utility is maximised.  
The choice problem is often set out algebraically in a hypothetical world where only two 
goods exist, typically denoted X and Y. Equation 2.1 sets out the choice problem described 
above in this world, where Ui is the utility function of consumer i, Px and Py represent the 
prices of good X and Y respectively and M represents the consumer’s income. 
                                                 
1 As is convention, the term ‘goods’ throughout this chapter is meant as an umbrella term for any kind of product 
or service. 
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Max 𝑈𝑖 = 𝑓(𝑋, 𝑌) 𝑠𝑢𝑏𝑗𝑒𝑐𝑡 𝑡𝑜 𝑀 = 𝑃𝑋𝑋 + 𝑃𝑌𝑌 (2.1) 
The choice problem is also often expressed diagrammatically using indifference curves and 
budget constraints. The former are curved lines that illustrate the different combinations of 
goods (i.e. bundles of X and Y) that generate a particular level of utility, whereas the latter is 
a straight line that represents the budget constraint from equation 2.1. 
Figure 2.1 Indifference Curve & Budget Constraint Diagram 
 
 
 
 
 
 
 
 
 
 
 
 
The budget line (BL in figure 2.1) illustrates the possible combinations of X and Y that can be 
consumed if the consumer spends all of their income. Hence any combination of X and Y 
below the budget line is feasible (costing less than the consumer’s total income) and any 
combination of X and Y above the budget line are not feasible (costing more than the 
consumer’s total income).  
The two indifference curves in figure 2.1 represent different levels of utility for consumer i. A 
higher indifference curve (away from the origin) represents a higher level of utility, thus the 
consumer has a higher utility on IC2 than on IC1. This is clear when comparing the two 
bundles A and B. If the consumer consumes bundle A (on IC1) the consumer receives a 
combination of X1 and Y1, whereas if the consumer consumes bundle B (on IC2) the 
consumer receives more of both (X2 and Y2). In fact, bundle B is where IC2 is tangential to 
the budget line and hence represents a utility maximising point because the consumer cannot 
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consume a bundle of goods that contains more of one good, but no less of the other, given the 
funds that they have available. 
It should follow that a higher income provides the consumer with the opportunity to reach a 
utility-maximising point that is on a higher indifference curve as the budget line will shift to 
the right (they can afford more of X and/or Y). Additionally, as the slope of the budget line is 
the ratio of prices for X and Y, a favourable change in the ratio (price decreases) will also 
provide the consumer with the opportunity to reach a higher indifference curve by shifting or 
tilting the budget line away from the origin. The opposite is also the case; an unfavourable 
change in the ratio (price increases) will shift or tilt the budget line toward the origin, 
resulting in the consumer only being able to reach a lower indifference curve. 
2.1.2 Preference Axioms 
In consumer choice theory a number of assumptions, referred to as axioms by convention, are 
made about consumer preferences; these are implied in the consumer problem outlined in the 
previous subsection.  
1. Complete Preferences 
The consumer has defined preferences for all bundles of goods. That is to say that one of the 
following will always be true: 
i. The consumer prefers bundle A to bundle B (𝐴 ≻ 𝐵) 
ii. The consumer prefers bundle B to bundle A (𝐵 ≻ 𝐴) 
iii. The consumer is indifferent between bundles A and B (𝐴 ~ 𝐵) 
This implication of this assumption is that any bundle of goods will lie on an indifference 
curve. 
2. Continuous Preferences 
There are no ‘jumps’ in the consumer’s preferences. That is to say that if bundle A is 
preferred to bundle B, other bundles of goods that are very close to bundle A will also be 
preferred to bundle B.  
3. Transitive Preferences 
Given three bundles of goods (A, B and C), the consumer’s preferences are such that: 
𝐼𝑓 𝐴 ≻ 𝐵 𝑎𝑛𝑑 𝐵 ≻ 𝐶 𝑡ℎ𝑒𝑛 𝐴 ≻ 𝐶 
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The implication of this assumption, in conjunction with axiom 2, is that indifference curves 
cannot intersect. 
4. Non-satiation 
The consumer is not totally satisfied with the amounts of each good that is already obtained 
and, as such, would always prefer to have more of each good. There is never a situation for 
the consumer where increased consumption results in a decrease in overall utility (i.e. no good 
is ‘bad’). The implication of this assumption is that any increase in the amount of a good 
obtained (providing there is no decrease elsewhere) will allow the consumer to reach a higher 
indifference curve. 
5. Diminishing Marginal Rates of Substitution 
As more of X is consumed, progressively less of good Y will be sacrificed for each extra unit 
of X if utility is to be unchanged. This is a consequence of diminishing marginal utility for 
each good. The implication of this assumption is that indifference curves are convex to the 
origin (the slope diminishes as we move from left to right along its length).  
These assumptions enable consumer choice theory to be explained and illustrated in the 
manner shown in the previous subsection. Additionally, these assumptions can be tested 
empirically to determine whether the behaviour of an individual corresponds with that of a 
rational consumer as defined by economic theory. 
2.2 Welfare Changes 
It is often desirable to measure (or estimate) the change in welfare that occurs after an 
economic change in order to inform future policy decisions. As shown in section 2.1, price 
changes (just one example of an economic change) directly impact the utility of the consumer 
because they alter the range of indifference curves that the consumer can reach. The problem 
that economists face when trying to measure or estimate welfare changes is that changes in 
utility are unobservable i.e. it is not possible to measure the difference in utility obtained 
between IC1 and IC2 in figure 2.1. As a result, it is necessary for analyses to estimate welfare 
changes using a measure that is observable. As lump-sum transfers of money can offset 
economic changes, the common interpretation is that the size of such transfers are 
proportional to the magnitude of the associated welfare change. Hence, economists use 
measures based on this principle in order to examine welfare changes. This section will 
outline the two most common measures used to estimate welfare changes in economics; 
compensating variation and equivalent variation.  
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2.2.1 Compensating Variation 
The compensating variation is the adjustment in income that returns the consumer to their 
original utility following an economic change. This can be made clearer using an example, 
such as a price change as previously discussed in this chapter. Consider figure 2.2, set up in a 
similar fashion to figure 2.1, where the original budget line BL1 leads to a utility-maximising 
point A where the indifference curve IC1 is tangential to BL1. If the price of good X increases 
and the price of good Y remains constant the consumer is faced with a new budget line BL2. 
On BL2 the utility-maximising point B is on a lower indifference curve IC2.  
This process can be broken down into two different components: the price rise making the 
consumer worse-off; and the change in the relative prices of the two goods (Y is now 
relatively cheaper than it was before). The former is the ‘income effect’ which shifts the 
budget line and the latter is the ‘substitution effect’ which rotates it. An intermediate budget 
line, BL*, that is tangential to the original indifference curve IC1 at point C can be drawn to 
illustrate this. In this case, BL* and point C illustrate how the consumer would maximise their 
utility if the price ratio had changed but their income had not been affected as a result. 
Figure 2.2 Compensating Variation 
 
The compensating variation is the magnitude of the shift from the final position of the budget 
line, BL2, to the intermediate budget line BL*. It is the minimum amount of extra income that 
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the consumer would need to be compensated in order to return to the original indifference 
curve and hence become indifferent to the price change. 
2.2.2 Equivalent Variation 
The equivalent variation is the adjustment in income that changes the consumer’s utility to the 
level that would occur if the event had happened. Consider again a price increase scenario 
exactly the same as the one used previously to explain compensating variation. The key 
difference between the two measures can be seen when comparing figures 2.2 and 2.3. The 
intermediate budget line BL* in figure 2.3 is instead based on the old price ratio and moved 
such that it is tangential at point E on the lower (new) indifference curve IC2. BL* and point E 
illustrate how the consumer would maximise their utility had their income changed but the 
price ratio remained the same. 
Figure 2.3 Equivalent Variation 
 
The equivalent variation is therefore the magnitude of the shift from the intermediate budget 
line BL* to the original budget line BL1. It is the amount of income that would need to be 
taken away to lower the consumer’s utility to the level that would have been experienced had 
the change happened. Had the example been a price decrease in good X (with the price of Y 
remaining constant), the equivalent variation would instead be interpreted as the increase in 
income that would give the consumer the same additional utility that they would have 
received had the change happened. 
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It is often the case that economists wish to identify the value of a good i.e. the amount 
consumers are willing to pay for the good. This is not the same as the market price for a good, 
as at a market equilibrium there will always be consumers that were willing to pay more for 
the good than the market price2. Nonetheless, goods that are available in the market are easier 
to assess and incorporate into analyses simply because they have a market price and 
consumers actively reveal their preferences when making purchasing decisions for the good.  
There are often situations where goods are not available in the market either due to the fact 
that they are public goods3 or because they are simply not provided through the free market 
e.g. services provided by the National Health Service (NHS) in the UK. In such scenarios, 
stated preference methods such as CV and DCEs can be used to estimate WTP (i.e. 
compensating variation) and WTA (i.e. equivalent variation). These methods will be 
discussed further in the next chapter. 
2.3 The Value of a Good 
The most common practical application of compensating variation and equivalent variation is 
when WTP and WTA are estimated. In other words, it is often the case that researchers wish 
to value goods in a hypothetical setting due to reasons such as those outlined in the previous 
section. However, it is not necessarily the case that all hypothetical settings give rise to the 
same types of value. This section will first differentiate between use and non-use values, and 
describe how Lancaster’s theory of consumer demand reflects on value, which is slightly 
different to consumer choice theory. 
2.3.1 Use and Non-Use Values 
Eliciting an individual’s willingness to pay for a good through stated preference methods 
provides an estimate of the value of that good to the individual. However, it need not be the 
case that a good is valued based on the individual’s current, or even their likely future, use of 
the good. That is, individuals may value a good for reasons that relate to more than simply 
their own expected consumption of the good. In this sense, a distinction can be made between 
the types of value that can be derived in tasks that aim to elicit willingness to pay i.e. use and 
non-use values.  
One of the most commonly cited examples of a non-use value is the ‘option’ value (Smith, 
2007). This is often seen in environmental economics where individuals express a willingness 
to pay for the preservation of a natural resource such as a national park. The value expressed 
                                                 
2 This leads to the consumer surplus, an alternate welfare measure that will not be covered in this chapter. 
3 A public good is defined as a good that is both non-excludable and non-rivalrous, such as street lighting. 
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is not a use value in the typical sense. The individual is not necessarily stating how much they 
would pay for access to the national park. Rather, the value provided is considered an option 
value because they are instead stating that they value having the option to use and benefit 
from the national park. 
Another commonly cited example of a non-use value is the ‘caring externality’ (Smith, 2007). 
For example, an individual may express a willingness to pay for the provision of a healthcare 
service that is not at all relevant to them as an individual (e.g. a gender-specific cancer 
service). Despite the fact that they will not ever use the service, the individual could certainly 
value its availability to others and hence the stated WTP value is altruistic and not considered 
to be a use value. 
In practice, the type of value elicited in a hypothetical stated preference task can be 
determined by the researcher through the wording of the questions. For example, a male 
participant could, although unlikely in practice, be asked to imagine that they need a health 
service that is in reality only consumed by females and to provide a WTP value (in this case a 
use value). It is useful therefore to be aware of the different types of WTP value as they can 
all potentially play a role in the economic analysis of a good or service. 
2.3.2 Lancaster’s Theory of Consumer Demand 
In contrast to traditional consumer theory outlined earlier in this chapter, in 1966 Lancaster 
published an alternative theory of consumer demand (Lancaster, 1966). One of the major 
differences was the notion that individuals derive utility from the characteristics of a good 
rather than from the good in itself. Hence, while a good could be valued in a stated preference 
task as a whole (a typical CV task; see section 3.2), it may be more beneficial to value the 
attributes of a good individually to derive value (possible in a typical DCE task; see section 
3.3). 
2.4 Beyond the Individual Consumer: Social Welfare 
In order to provide economic analyses to support macro-level decision-making, it is necessary 
to look beyond the utility of the individual consumer and instead focus on the welfare of 
society as a whole. The field of welfare economics is concerned with the maximisation of 
social welfare and provides a theoretical basis for such analyses.  
This section will briefly outline the key theoretical concepts such as Paretian value 
judgements, Pareto improvements and Pareto efficiency. Following this, the Kaldor and Hicks 
criteria will be outlined to provide a theoretical background for future discussion of CBA and 
related economic evaluation methodologies (Chapter Three). 
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2.4.1 Key Concepts in Welfare Economics 
When moving beyond the individual consumer the problem becomes that of how best to 
maximise the welfare of society, subject to the constraint of scarce resources. Therefore, in 
comparison to the previous section on consumer theory, instead of focusing on an individual 
consumption bundle, the focus becomes that of the complete allocation of resources across 
society. Hence, the latter not only incorporates the former (i.e. consumption) but also 
incorporates production.  
Maximising social welfare can be split into two components: the identification of a (set of) 
Pareto efficient allocation(s) of resources and; the identification of a Pareto efficient 
allocation of resources that optimises societal welfare.  
Before defining Pareto improvements and Pareto efficiency, it is important to note that these 
concepts are all based on a set of value judgements. These Paretian value judgements 
(sometimes referred to as Pareto postulates) are somewhat controversial and are as follows 
(Gravelle & Rees, 2004): 
1. Process Independence 
It is assumed that the way in which an allocation of resources is reached is irrelevant to the 
maximisation of societal welfare. In other words, it is only the final allocation of resources 
that matters, not the process. 
2. Individualism 
It is assumed that societal welfare is simply the sum of every individual’s utility. In other 
words, society is simply considered to consist of a group of individuals. 
3. Non-Paternalism 
It is assumed that individuals are their own best judge of their welfare. In other words, so long 
as the individual is maximising their utility, there is no concern as to whether their 
consumption could be detrimental.  
4. Benevolence 
It is assumed that an increase in the utility of an individual, with all else remaining equal, will 
have a positive effect on social welfare. In other words, any potential inequalities between the 
beneficiary and other individuals are irrelevant to the determination of societal welfare. 
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Given a specific allocation of resources across all individuals within a society, a Pareto 
improvement can be defined as the movement to a new allocation of resources where at least 
one individual is better-off and no individuals are made worse-off. Therefore, it follows that a 
Pareto efficient allocation of resources is an allocation where it is not possible to improve the 
utility of an individual without decreasing the utility of another (Varian, 2014).  
Figure 2.4 Edgeworth Box Diagram 
 
The Edgeworth box in figure 2.4 illustrates the concept of Pareto efficiency. The box depicts a 
pure trade economy with two individuals (A and B) and two goods (X and Y). The width of 
the box represents the total amount of good X in the economy and the height of the box 
represents the total amount of good Y in the economy. At the origins 0A and 0B, neither 
individual has any units of either good. However, this is not the allocation of resources in this 
economy, as indicated by the indifference curves. ICA is an indifference curve of individual 
A, which is convex to A’s origin at 0A. Likewise, ICB is an indifference curve of individual B, 
which is convex to B’s origin at 0B. At point E where the two indifference curves are 
tangential, individual A receives ?̅?𝐴 units of good X and ?̅?𝐴 units of good Y. Similarly, 
individual B receives ?̅?𝐵 units of good X and ?̅?𝐵 units of good Y. At this point, the total 
endowment of the two goods is allocated between the two individuals. Now imagine a 
movement from point E to the north-east; at this point, individual A can reach a higher 
indifference curve (i.e. this is further from A’s origin) but individual B can only reach a lower 
indifference curve (i.e. this is closer to B’s origin). This would not be a Pareto improvement 
because individual B would be made worse off. In fact, no movement from point E would 
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result in a Pareto improvement. Hence, point E is a Pareto efficient allocation of resources; 
one of many possible such allocations within the Edgeworth box4. 
Figure 2.5 Utility Possibility Frontier & Welfare Optimum 
 
It is not the case that a Pareto efficient allocation of resources (a Pareto optimum) is 
necessarily a welfare optimum (although the reverse is true). That is, there are numerous 
possible allocations of resources that could be Pareto efficient but only one point that 
maximises welfare. This is illustrated in figure 2.5; W* indicates a single welfare optimum on 
the utility possibility frontier (Estrin et al., 2012). The welfare optimum is dependent on the 
welfare system adopted by the society in question. For example, a society may take an 
egalitarian view where social welfare is improved only if individual utilities are made more 
equal. In this case, the welfare optimum would be found at the Pareto optimal point that 
produces the most equal distribution of utility across individuals. 
2.4.2 The Theoretical Foundation of Cost-Benefit Analysis 
It should be clear from the previous section that a movement from an existing allocation of 
resources to a new allocation of resources where one or more individuals are made worse-off 
                                                 
4 Although Pareto improvements might not be possible from points such as point E in figure 2.4, there are many 
possible locations in an Edgeworth box where an indifference curve for individual A could be tangential to an 
indifference curve for individual B. Hence, there are many possible Pareto efficient points. The locus of these 
tangential points, known as the contract curve, is sometimes drawn to illustrate this point. 
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is not a Pareto improvement. In practice, achieving a Pareto improvement is likely to be 
highly difficult. However, the Kaldor and Hicks criteria (sometimes jointly referred to as the 
compensation test or principle) can provide a justification for the reallocation of resources in 
circumstances where some individuals are made worse-off. 
The Kaldor criterion states that if it is possible at the new allocation for the ‘winners’ (i.e. 
those that are made better-off) to jointly compensate the ‘losers’ (i.e. those that are made 
worse-off) and that the winners are still better off than they previously were, then the 
movement to the new allocation should be made. In a similar vein, the Hicks criterion states 
that if, before the change, the ‘losers-to-be’ could jointly bribe the ‘winners-to-be’ so that 
without the change at least one person is better off and nobody is made worse off, the 
movement to the new allocation should not be made (Brazier et al., 2016). One of the major 
issues with the Kaldor and Hicks criteria is that they do not require the compensation to 
actually be paid, inevitably leading to some individuals being made worse-off and no Pareto 
improvement being achieved.  
Nonetheless, the operationalisation of the Kaldor criterion where the gains to the winners are 
referred to as ‘benefits’ and the losses to the losers are referred to as ‘costs’ is CBA, which is 
a commonly utilised approach to economic evaluation. In a CBA, all of the relevant societal 
costs and benefits of an intervention are measured in commensurate units (often money). 
2.5 Conclusion 
This chapter has outlined the key economic theory that forms the basis of the concepts and 
techniques that will be referred to, and put into practice, within this thesis. While the 
discussion of economic evaluation techniques is central to the work within this thesis, the 
application of such techniques to health-related issues has involved development that goes 
beyond the remit of traditional welfare economics. Such developments (i.e. the move to an 
‘extra-welfarist’ approach) sit more comfortably within the sub discipline of health economics 
rather than economics itself and hence will be addressed separately in the next chapter. 
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Chapter 3. The Preference Debate and the Use of Quantitative Preference 
Information in Health Economics 
 
The aim of this chapter is to illustrate how the preference debate in health state valuation can 
be readily applied when considering the use, and potential uses, of quantitative preference 
information in healthcare decision-making.  
In order to achieve this aim the first section in this chapter begins by providing a brief 
overview of economic evaluation in the context of health and explains the ‘preference 
question’ that arises through the use of QALYs. It then explains how economic evaluation 
guidelines, subsequent published literature and recent economic evaluation developments 
have shaped the preference debate. The second section provides an overview of the CV 
method and describes how CV studies have been utilised in health over time. The third 
section provides an overview of DCEs and outlines how DCE studies have increasingly been 
published in the health economics literature, in particular those that elicit preferences for 
healthcare services. The fourth section then describes the numerous potential ways in which 
the results of a DCE study have, and could be, used to influence healthcare decision-making 
at both the macro and micro-level. Alongside this, it is argued that these potential applications 
of DCEs give rise to a debate that is comparable in many ways to the preference debate in 
health state valuation: whose preferences should be elicited in each application? 
3.1 Economic Evaluation & the Preference Debate 
3.1.1 Economic Evaluation in Health 
In order to maximise output, economic analyses are conducted to examine how best to 
allocate scarce resources. The Kaldor criterion outlined in section 2.4.2 provides an 
underlying rationale for CBA; a form of economic evaluation which measures all of the 
relevant societal costs and benefits of an intervention in commensurate units. Typically 
conducting a CBA involves pricing the costs and valuing the benefits using existing market 
prices as a guide. Where markets do not exist, which is often the case with the benefits in a 
health setting, stated preference methods may be used to provide values5. Stated preference 
methods typically involve surveys where respondents state, directly or indirectly, their WTP 
for the benefit in question or their WTA compensation for a negative situation. If the benefits 
of an intervention outweigh its costs (i.e. using the Kaldor criterion ‘winners’ could 
                                                 
5 In the past, the human capital approach has also been used for this purpose – see Johannesson (1996). 
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potentially compensate the ‘losers’; net benefit>0) then resources should be allocated such 
that the intervention is provided.  
The strong theoretical basis for CBA and its ability to directly address the question of whether 
resources should be allocated to a given purpose provides a solid justification for its use. In 
the United Kingdom (UK), Her Majesty’s Treasury recommend its use for appraisals of 
policies, programmes and projects in The Green Book (2011). CBA is grounded in welfare 
economic theory and relies on the assumption that individuals are their own best judge of 
their welfare, it is therefore often referred to as a ‘welfarist’ approach to economic evaluation. 
In health, the welfarist approach is rarely applied (Buchanan & Wandsworth, 2015). One 
likely explanation for this is the resistance of the medical community and general public 
towards attaching a monetary value to life. Additionally, CBA requires individual-level 
assessment of the benefits of a healthcare intervention; this means that the monetary value 
associated with the benefits of a healthcare intervention must be considered for each 
individual separately, which is likely to be affected by the individual’s income level. While 
the potential inequalities caused by the latter could be dealt with by using some form of 
‘distributional weights’, the concern around attaching a monetary value to life is unavoidable 
when using a welfarist CBA to evaluate a healthcare intervention (Brazier et al., 2016).  
Cost-effectiveness analysis (CEA) is a form of economic evaluation that is more commonly 
applied in health and, to an extent, avoids some of the issues relating to the use of CBA. CEA 
compares different approaches to achieving a particular objective, with the aim of identifying 
the most cost-effective approach. While CEAs can use a wide range of different measures of 
benefit, a specific variant of CEA dominates the area of health: CUA. CUAs compare the 
costs of healthcare interventions with their benefits, where the costs are represented in 
monetary terms and the benefits are represented using a measure such as the QALY. The 
QALY is a composite measure of health that combines both quantity and quality of life, 
where one QALY corresponds to a year in perfect health. QALY gains are calculated by 
multiplying the change in length of life by the change in quality of life associated with a 
healthcare intervention. Thus, CUA uses ‘incremental cost per QALY’ as its comparator and 
hence aims to maximise health rather than individual utility. This approach to economic 
evaluation in health is often referred to as extra-welfarist for this reason. 
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3.1.2 Health State Valuation & the Preference Question 
For the calculation of QALYs an individual’s quality of life is described on a 0 to 1 scale, 
where 0 represents being dead and 1 represents perfect health6. These values are referred to as 
quality of life weights, or health state utility values (HSUVs), and are generated by eliciting 
the preferences of individuals such as the general population, patients, health professionals or 
policymakers. 
Various different methods have been used to elicit the preferences of individuals in order to 
value health states. Early studies typically used rating scales; the most popular, the visual 
analogue scale (VAS), requires respondents to rate the health state between 0 and 100 (where 
0 represents being dead and 100 represents perfect health). It was later argued that choice-
based methods could be a better alternative to rating scales because they introduce the notion 
of opportunity cost (Green et al., 2000). Time trade-off (TTO) and standard gamble (SG) are 
the two most commonly used choice-based preference elicitation methods for health state 
valuation. 
TTO requires respondents to choose between a given amount of time in the health state that is 
being valued (followed by death) and a shorter amount of time in full health (also followed by 
death). The length of time in full health is varied until the respondent expresses indifference 
between the two choices, and the HSUV is calculated from this indifference point (Torrance, 
1986). SG requires respondents to choose between a certain option (a given amount of time in 
the health state being valued) and a risky option (a gamble between living in full health for the 
given amount of time, or instant death). The probability of living in full health that renders the 
respondent indifferent between the gamble and the certain option provides the HSUV 
(Torrance, 1986). 
As the methods for health state valuation developed, various studies in the literature began to 
explore how preferences for health states might differ according to respondents’ 
characteristics and experiences (Rosser & Kind, 1978; Llewellyn-Thomas et al., 1984; 
Froberg & Kane, 1989). By the early 1990s studies began to raise an important question 
regarding the generation and use of HSUVs (Boyd et al., 1990; Hadorn, 1991): whose 
preferences should be elicited? Should it be individuals that are experiencing the health state 
(patients) or members of the public that are not, necessarily, experiencing the health state 
                                                 
6 It is possible, however, that some health states are considered worse than dead and result in negative values 
(Tilling et al., 2010). 
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(general population)? This is a particularly important question because, due to the use of 
HSUVs in CUA, the preferences elicited can directly influence resource allocation decisions.  
3.1.3 The Washington Panel & Economic Evaluation Guidelines 
As the use of economic evaluation methods in health grew, guidance on how best to conduct 
CUAs became increasingly desirable. In 1996, a group of academics convened for an in-depth 
discussion regarding the use of CUA for the economic evaluation of healthcare interventions. 
The group, now widely referred to as the ‘Washington Panel’, provided a range of guidance 
for the conduct of CUAs (Gold et al., 1996). As CUAs use QALYs as the measure of benefit, 
the Washington Panel discussed a number of issues regarding their calculation, including the 
question of whose preferences to elicit when generating HSUVs. 
The Washington Panel recommended that preferences from the general population should be 
elicited in order to generate HSUVs. The main argument put forward for this viewpoint was 
that, due to the influence of CUAs on resource allocation, such evaluations should adopt a 
societal perspective and incorporate societal preferences. It was also suggested that general 
population preferences may theoretically be suitable based on the ‘veil of ignorance’ thought 
experiment discussed by the likes of Rawls and Harsanyi (Gandjour, 2010). It is theorised 
that, when acting under a veil of ignorance, a rational public would decide the best (morally 
acceptable) course of action, as individuals would be blind to their own self-interest. The veil 
of ignorance is relevant here because with health conditions it is often the case that 
individuals in the general population have the potential to be affected by them but do not 
know if this will be the case in the future. In contrast, patients by definition are affected by 
the health condition and hence have a vested interest in decision-making relating to it; they 
are not likely to be neutral judges. 
Arguments for using patient preferences were also considered by the Washington Panel. A 
key argument is that patients have actually experienced the health state in question, unlike the 
average member of the general population. In addition, the general population may have 
biased preferences due to stereotypes or a fear associated with certain conditions, such as 
cancer (Kahneman, 2006). However, the fact that patients are experiencing the health state 
has been used as a criticism due to the issue of ‘adaptation’. Patients may adapt to their health 
state and revise their expectations regarding quality of life once they are faced with a chronic 
condition, resulting in health state valuations that are higher than what might be expected. 
This has the potential knock-on effect of healthcare interventions appearing less cost-effective 
(as the benefits could appear less substantial), potentially reducing the likelihood of resources 
being allocated for the intervention. As a result, it has been suggested that using patient 
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preferences may actually work against patients’ interests, although this is another normative 
debate in itself (i.e. should adaptation be taken into account or not?). 
The advice of the Washington Panel is thought to have been highly influential in the 
generation of guidelines by regulatory authorities, such as those produced by the National 
Institute of Health and Care Excellence (NICE) in England and Wales and the Canadian 
Agency for Drugs and Technologies in Health (CADTH) in Canada (Brazier et al., 2005). 
Both NICE and CADTH recommend the use of HSUVs generated from general population 
preferences in their guidelines to this day (NICE, 2013; CADTH, 2017). However, it should 
be noted that this is not the case in every country, such as in Sweden where utilities from 
those experiencing the health state are preferred (Pharmaceutical Benefits Board, 2003). 
3.1.4 Further Preference Debate Developments 
The Washington Panel’s recommendations, as well as other guidelines, for the economic 
evaluation of healthcare interventions provided a practical answer to the question of whose 
preferences to use when generating HSUVs for use in a CUA. In fact, the second edition of 
the influential text produced by the Washington Panel has since reiterated their previous 
recommendation (Neumann et al., 2016). However, this debate has nonetheless remained a 
regular feature in the health economics literature due to its normative nature (Brazier et al., 
2005; Stamuli, 2011; Versteegh & Brouwer, 2016). 
A number of studies continued to explore the extent to which patient and general population 
HSUVs differ (de Wit et al., 2000; Ubel et al., 2003; Oldridge et al., 2008; Little et al., 2014; 
Papageorgiou et al., 2015) and a relatively recent meta-analysis has verified that disparities 
typically do exist between the preferences of the two populations (Peeters & Stiggelbout, 
2010). More specifically, it is generally found that patients provide larger HSUVs than 
members of the general population for a given health state. That is, the loss of utility as a 
result of a deviation from full health is smaller for those that have actually experienced the 
(suboptimal) health state. These findings confirm the importance of the debate, given that it 
would make no difference whose preferences are incorporated if they were identical.  
Other studies have put forward frameworks to describe how and why these disparities may 
occur (Dolan, 1999; Stiggelbout & de Vogel-Voogt, 2008). Stiggelbout & de Vogel-Voogt 
(2008) created a framework that aims to describe the decision-making process in health state 
valuation based on theories of information processing from social cognition theory. Their 
framework provides a range of ideas as to why disparities exist such as the lack of scope in 
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health state descriptions and a range of potential biases that might affect interpretation, 
judgement and the final response to a health state valuation task.  
Dolan (1999), on the other hand, focuses largely on how personal experience, both direct and 
indirect, may affect an individual’s preferences. The typical presentation of the preference 
debate (patient vs. general population) is criticised, with Dolan arguing that this is a false 
dichotomy as “the distinction between those with and without experience of illness is very 
blurred” (p.483). This argument is developed slightly further and applied to another area of 
preference elicitation in Chapter Five. 
Gandjour (2010) examined the theoretical basis for using general population values, by 
considering the ethical theories cited by the Washington Panel in their justification for the use 
of general population values (e.g. theories that use the veil of ignorance). In addition to this, 
Gandjour (2010) considered Sen’s capability approach (Sen, 1985) and traditional welfare 
economics as theoretical justification for the use of general population values. His conclusion 
was that there is no compelling theoretical basis for their use in this context. 
An alternative approach to this debate was taken by Dolan & Kahneman (2008). They suggest 
that the standard debate considers only types of ‘decision utility’ (the preference or desire for 
an outcome), whereas it may be more appropriate to consider ‘experienced utility’ (the 
hedonic experience of an outcome). On the one hand, this may sound like support for patient 
preferences (only patients experience the health state), however this ultimately implies that 
HSUVs may not be appropriate at all because they are only a measure of decision utility 
regardless of the source (Dolan, 2008). If, as suggested by Dolan (2008), QALYs are too 
narrow whereas broader measures such as subjective well-being (SWB) may be more 
appropriate. A further implication is that a typical CUA may simply be too narrow for 
assessing the cost-effectiveness of healthcare interventions. 
The commonly cited points that are raised in the preference debate have recently been 
developed even further. Versteegh & Brouwer (2016) revisited the debate and, by examining 
the most commonly cited arguments for using general population preferences, showed that the 
common justification for the use of general population preferences is incomplete at best. For 
example, the authors argue that a general population sample does not exclude individuals that 
are unhealthy and hence may expect to experience a particular health state, which means that 
the veil of ignorance argument is imperfect. Additionally, the authors argue that under a veil 
of ignorance individuals, given that they may struggle to imagine health states, may actually 
prefer that individuals with experience value them. The authors also question whether 
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adaptation is a good argument for using general population preferences, pointing out that 
patients might not always benefit from the lower HSUVs typically reported by the general 
population. Furthermore, the fact that adaptation is also likely to occur when patients describe 
their health state is highlighted to show that adaptation cannot be entirely avoided by focusing 
on general population preferences alone. As a result, the authors conclude that it may be best 
for economic evaluations to use two sets of HSUVs, utilising values from both the general 
population and patients, in order to provide decision makers with all of the necessary 
evidence.  
3.1.5 Further Economic Evaluation Developments 
While CUA is still the recommended method for economic evaluation method in health in 
many countries (Rowen et al., 2017) there are several concerns about its narrowness, largely 
due to the use of QALYs as the measure of benefit. QALYs only consider the health of an 
individual in terms of quality and quantity of life, whereas it may be the case that other 
outcomes should be considered too (Coast et al., 2008; Mitchell et al., 2017). 
A growing literature is emerging that attempts to operationalise Sen’s capability approach 
(Sen, 1985) for the purpose of economic evaluation in health due to it being considered a 
broader outcome measure. For example, the “ICEpop CAPability measure for Adults” 
(ICECAP-A) measure has been developed with an accompanying tariff such that it could be 
used as an alternative to QALYs (Al-Janabi et al., 2012; Flynn et al., 2015). While using the 
ICECAP-A might go some way in addressing the narrowness of CUA, it is not free from the 
issues raised in the preference debate (whose preferences should be elicited in the valuation 
task?) and does not measure experienced utility as advocated by Dolan (2008). 
Another issue with CUA arises when evaluating the cost-effectiveness of public health 
interventions. Public health interventions aim to promote health within a community or 
population and hence are broader by nature than clinical interventions that are concerned with 
individual health. As a result, the benefits of a public health intervention are likely to be far 
broader than those of a clinical intervention. The use of QALYs in a CUA is perhaps better 
suited to assessing the benefits of the latter than the former. This has been taken into 
consideration by NICE in England and Wales; they acknowledge that CBA may sometimes 
be the most appropriate method to evaluate the cost-effectiveness of public health 
interventions (NICE, 2014). Specifically, NICE state that in some circumstances: 
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“The tools used for economic evaluation must reflect a wider remit than health and 
allow greater local variation. The nature of the evidence and that of the outcomes 
being measured may place more emphasis on cost–consequences analysis and cost–
benefit analysis for interventions in these areas.” (NICE, 2014, p.135) 
Given that, as discussed earlier, CBA is a welfarist approach and CUA is an extra-welfarist 
approach to economic evaluation, the advice from NICE to an extent creates an ideological 
debate when conducting economic evaluations in England and Wales. A public health 
intervention evaluated using a CBA considers the preferences of the individuals affected by 
the intervention, whereas a clinical intervention evaluated using a CUA considers the 
preferences of the general population. Which is the more appropriate approach when trying to 
influence decision-making surrounding the allocation of resources? Further to this, does this 
advice suggest that a welfarist CUA (using health state utilities elicited from patients) or an 
extra-welfarist CBA (eliciting WTP from the general population), both of which are possible 
(Brazier et al. 2016), would be equally acceptable where the methodology is appropriate?  
Economic evaluation methodologies and guidance are constantly evolving to ensure that 
healthcare interventions are assessed appropriately. This is important in ensuring an efficient 
allocation of resources, regardless of the desideratum (be it maximising population health or 
social welfare). A major focus in the health economics literature appears to be the narrowness 
of CUA which, in addition to the points discussed above, may also be influenced by the 
increasing pressure to achieve patient-centred healthcare (given that extra-welfarist CUA does 
not incorporate patient preferences) (Barry & Edgman-Levitan, 2012).  
3.1.6 Conclusion 
Over time, the preference debate and different approaches to economic evaluation have 
developed considerably. It would seem that quantitative preference information including, but 
not limited to, HSUVs have a role to play in informing healthcare decision-making. At this 
stage, there is nothing to suggest that the importance of such information will decline over 
time. In fact, there is evidence to suggest that the number of publications utilising stated 
preference methods such as CV and DCE is increasing (Smith & Sach, 2010; de Bekker-Grob 
et al., 2012; Clark et al., 2014; Vass, Rigby et al., 2017). This suggests that it may be 
increasingly important for individuals’ preferences to be elicited and, potentially, incorporated 
into healthcare decision-making. What is less clear is how the preference debate outlined in 
this section may apply to the use of CV and DCE methodologies. The following two sections 
examine the application of these methodologies in further detail. 
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3.2 Contingent Valuation: An Overview 
CV is a hypothetical and direct survey-based method used to estimate the monetary value of a 
good or service (Diener, 1998; Klose, 1999). Monetary values elicited using CV can be used 
in CBAs when a market for the good or service of interest does not exist. In a CV survey, 
individuals are asked the maximum that they are willing to pay or the minimum amount of 
compensation that they are willing to accept for a particular good or service or, sometimes, a 
broader scenario. WTP is an approximation of the compensating variation and WTA is an 
approximation of the equivalent variation (recall sections 2.2 and 3.1.1). In the context of 
health, CV is typically used to elicit the monetary value of a healthcare intervention (Olsen & 
Smith, 2001; Smith & Sach, 2010). CV is a particularly useful tool in this context given that, 
in many countries, the healthcare system is publicly funded and thus there is no true market 
price for healthcare interventions. Furthermore, even in countries where there is a market, 
market failure may mean that the market price is not a reflection of the true value. 
The simplest format of a CV survey is open-ended, where an individual is asked to provide a 
figure relating to their maximum WTP, or minimum WTA, themselves (Johannesson et al., 
1991). Another format is the bidding-game where respondents are asked if they are willing to 
pay at a given price and, based on their response, are subsequently asked if they would pay at 
a different price; the prices provided are based on a pre-determined algorithm designed by the 
researcher (McNamee et al., 2010). Other formats include the payment card where 
respondents are given a list of potential values and asked to select the maximum that they 
would be willing to pay (Stewart et al., 2002), and dichotomous choice approaches where 
respondents are typically asked up to two ‘yes or no’ questions (Ryan et al., 2004). The 
various formats have been contrasted and critiqued in the literature over time (Frew et al., 
2004; Ryan et al., 2004; Whynes et al., 2004). However, despite an attempt dating as far back 
as 1993 to agree upon a set of guidelines (Arrow et al., 1993), no clear consensus exists on the 
best format to use e.g. the least biased and the most precise. 
Systematic reviews of the use of the CV method in health have explored how the method has 
been used over time (Olsen & Smith, 2001; Smith & Sach, 2010). Figure 3.1 illustrates how 
the number of CV studies has increased over time. The use of the method in health dates back 
to at least 1985, with notable increases from the early 1990s, although the peak in 2005 
corresponds to fewer than 40 published studies. Smith & Sach (2010) note that the method 
has been used to value drugs, surgery, screening and various other healthcare interventions.  
Smith & Sach (2010) also found that the majority of CV studies elicited use values (recall 
section 2.3.1) from users that, in this context, are typically patients. In fact, only 24% of the 
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published studies included in their review elicited preferences from the general population. 
This is perhaps unsurprising given that WTP and WTA values are likely to be used in CBA, a 
traditionally welfarist method of economic evaluation. It also follows that the output from CV 
studies arguably has limited use in healthcare decision-making given that CBA is rarely 
utilised in practice. Indeed, Smith & Sach (2010) note that CV has had a limited influence in 
decision-making in healthcare. Whilst their review only goes as far as 2005, a recent study has 
provided evidence to suggest that DCEs are becoming more popular than CV in health as well 
as in other areas of applied microeconomics (Mahieu et al., 2014). It may be the case that the 
criticisms of the methodology and its limited potential for use in decision-making in contrast 
with DCEs are key factors in this finding. 
Figure 3.1 Published CV Studies in Health Economics Between 1985 and 2005 
Figure produced using data from Smith & Sach (2010) 
3.3 Discrete Choice Experiments: An Overview 
DCEs have emerged as an increasingly popular stated preference methodology that is 
regularly applied in health. A DCE survey requires respondents to choose between two or 
more alternatives, such as different types of healthcare interventions that are described using a 
static set of attributes, with alternating levels for each. After a sample of respondents have 
completed all of the scenarios, the data can be analysed to determine the relative importance 
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of the different attributes and levels, as well as to estimate marginal rates of substitution 
(Louviere & Lancsar, 2009). 
Although DCEs had been used earlier, they became better known in the health economics 
literature in the early 2000s after being put forward as a methodology that could potentially be 
used to incorporate patient preferences into the decision-making process (Ryan, 2004b; Ryan 
& Gerard, 2003). There are currently three published systematic reviews of DCE studies in 
health economics covering the period 1990 to 2012 (Ryan & Gerard, 2003; de Bekker-Grob et 
al., 2012; Clark et al., 2014). In addition, a recent systematic review regarding the use of 
qualitative research to inform DCE studies has been published that provides overall data on 
the number of DCE studies beyond this point, up to 2015 (Vass, Rigby et al., 2017). Over this 
26 year period, the use of DCE methodology has substantially increased as indicated by the 
number of publications; figure 3.2 illustrates this trend and the findings in Chapter Four 
suggest that there is no sign of this trend abating (see section 4.2.1). 
Figure 3.2 Published DCE Studies in Health Economics Between 1990 and 2015 
 
Figure produced using data from Ryan & Gerard (2003), de Bekker-Grob et al. (2012) and Vass, Rigby et al. (2017)7 
                                                 
7 2009-2012 data was grouped in Clark et al. (2014), hence Vass, Rigby et al. (2017) was used for this period, as 
well as 2013-2015. 
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The average number of published DCE studies has continuously increased over time, with 
119 studies published in 2015 (Vass, Rigby et al., 2017). The volume of studies may, in part, 
be due to the flexibility of the methodology. DCEs can be used to elicit preferences in any 
number of health-related contexts, such as: job choices made by healthcare professionals 
(Mangham & Hanson, 2008); priority setting in health (Shah et al., 2015); health insurance 
decisions (Obse et al., 2016); health state valuation (Devlin et al., 2017) and; comparisons of 
patient and physician preferences (Okumura et al., 2015).  
The literature reviews by de Bekker-Grob et al. (2012) and Clark et al. (2014) consider this 
flexibility by organising the published DCE studies by their main objective using eight 
categories: 
1. Valuing experience factors; 
2. Valuing health outcomes; 
3. Trade-offs between experience factors and health outcomes; 
4. Utility weights within a QALY framework; 
5. Job choices; 
6. Developing priority-setting frameworks; 
7. Health professional’s preferences; and 
8. Other 
The vast majority of published studies fit within the first three categories; 234 of the 327 
studies (72%) across the time period covered by de Bekker-Grob et al. (2012) and Clark et al. 
(2014). Whilst the distinction between these categories is important, in reality the DCEs will 
have been framed in a similar manner in order to be able to achieve these objectives. That is, 
respondents will typically have been asked to make a choice between hypothetical alternatives 
where the alternatives are healthcare services8. As such, a logical conclusion based on this 
information is that the majority of DCEs elicit preferences for healthcare services. 
Preference data generated from DCE studies in category four has a clear application in 
economic evaluation (i.e. to estimate utility tariffs in order to generate QALYs). There is little 
to say about whose preferences should be elicited that hasn’t already been said in the literature 
outlined in section 3.1. In addition, results from DCE studies in categories five to eight have 
little clear application to individual economic evaluations. 
                                                 
8 Here, ‘healthcare services’ is used as an umbrella term for any treatment, drug, programme or other 
intervention aimed at improving or maintaining the health of the service user. 
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In contrast, DCEs that elicit preferences for healthcare services provide preference 
information that could potentially play a role within or alongside an economic evaluation of a 
healthcare service (or even a benefit-risk assessment). However, it is not entirely clear how 
the results might be applied in practice and the question of whose preferences should be 
elicited has rarely been discussed. In an early editorial regarding the use of DCEs in health 
economics, Bryan and Dolan (2004) state that:  
“Whilst patients ex post might place a relatively high value on ‘non-health’ attributes 
(as seems to be the case from many, although not all, of the studies), tax-payers ex 
ante might value a more limited (and possibly more health-focused) set of attributes.” 
(p.200) 
However, there is little evidence to suggest that this has been taken into consideration. In the 
existing literature, DCE studies that elicit preferences for healthcare services have used both 
patient and general population samples (Ghijben et al., 2014; Quaife et al., 2017) but the 
relative merits of each population have not been clearly compared. 
This thesis therefore argues that this particular area within the DCE literature is where the 
preference debate might be most applicable and unique. Hence, the focus will be on DCE 
studies that elicit preferences for healthcare studies (which, from hereon, will simply be 
referred to as DCE studies). 
3.4 A Further Application of the Preference Debate: Discrete Choice Experiments 
In order to discuss whose preferences might be more appropriate to elicit in DCE studies it is 
important to first identify how the results of DCEs might actually be used in analyses that aim 
to support healthcare decision-making. This section will discuss how DCEs might be used in 
macro-level decision-making (section 3.4.1) and whose preferences might be more 
appropriate to elicit in each case. Following this, for completion, a short note will discuss the 
proposed use of DCEs in micro-level decision-making (section 3.4.2). 
3.4.1 DCEs & Macro-Level Decision-Making 
Economic Evaluation 
DCEs have rarely been formally incorporated into economic evaluations, however those that 
have been incorporated have done so in several different ways (see table 3.1), each of which 
will be outlined with examples in this section. There are also other potential ways in which 
DCEs might be incorporated into economic evaluations that are yet to be put into practice (or, 
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rather, published); some of these will also be outlined however it is not possible to be 
exhaustive given the hypothetical nature. 
In addition to the generation of utility tariffs, DCEs can also be formally incorporated into a 
CUA by generating HSUVs that directly relate to the outcomes in a specific economic 
evaluation. One such example exists where HSUVs were generated for a condition-specific 
measure of health with the aim of incorporating these values directly into a model-based CUA 
(Burr, Kilonzo et al., 2007; Burr, Mowatt et al., 2007). The DCE required respondents, a 
sample of glaucoma patients, to choose the worst description of health relating to living with 
glaucoma out of two alternatives. The results were then used to generate utility weights for 
any combination of the attribute levels, such that they could be incorporated into the 
economic evaluation. As this was one of the first studies that used a DCE for this purpose, the 
study suffered from the difficulties associated with anchoring health states on a full health-
dead scale (i.e. 0 did not represent being dead) and the choice of respondents did not match 
the NICE reference case guidance of using general population preferences (albeit the measure 
was condition-specific rather than generic). Nonetheless, this is the only known example of a 
DCE being formally incorporated into a CUA, where using utilities from a generic tariff 
generated from a DCE is not considered ‘formal incorporation’ (e.g. the use of EQ-5D 
utilities from a health state valuation study that used a DCE). 
Another study that formally incorporated a DCE into an economic evaluation used a CEA 
rather than the more common CUA (Benning et al., 2012). Instead of using QALYs as the 
measure of benefit, the study used utility more generally by using individual-level preferences 
elicited from a DCE about different breast cancer follow-up strategies. The DCE required 
respondents, a sample of patients that had completed breast cancer treatment, to choose 
between alternative follow-up strategies. The information on individual-level preferences 
were then combined with cost data in order to examine the cost-effectiveness of various 
follow-up strategies. This is a unique economic evaluation, not only because it formally 
incorporated a DCE into a CEA, but because it only considers ‘experience factors’ on the 
benefits side (there are no health outcomes included in the DCE) and the preferences 
incorporated into the analysis were individual-level rather than aggregated. 
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Table 3.1 Studies that Formally Incorporate a DCE into an Economic Evaluation 
Reference(s) 
Economic 
Evaluation 
Patient or General 
Population Preferences?  
Purpose of the DCE 
Vale (2004)  
McCormack et al. (2005)  
CBA Patients To obtain WTP estimates for different types of hernia 
surgery 
Burr, Kilonzo et al. (2007)  
Burr, Mowatt et al. (2007) 
CUA Patients To obtain utility weights for a condition-specific 
preference-based measure for glaucoma 
Regier (2008)  
Regier et al. (2009) 
CBA Patients (by proxy) To obtain WTP estimates for various genetic tests 
Burr et al. (2012) CBA General Population To obtain WTP estimates for interventions relating to 
ocular hypertension 
Benning et al. (2012) CEA Patients To predict individual-level utility for each program 
(benefit expressed in terms of utility, not QALYs) 
Buchanan (2015)  
Buchanan et al. (2016) 
CBA Patients To obtain WTP estimates for various genomic tests 
Tinelli et al. (2016) CBA Patients To obtain WTP estimates for a collaborative medicine 
review service between community pharmacists and 
general practitioners 
Boyers et al. (2016) 
Ramsay et al. (Forthcoming) 
Boyers (Forthcoming) 
CBA General Population To obtain WTP estimates for different interventions to 
prevent periodontal disease 
Quaife (2017) 
Quaife et al. (2017) 
CUA General Population To predict uptake for HIV prevention products (uptake 
parameters incorporated into decision model) 
Watson et al. (2017) CBA Patients and  
General Population 
To obtain WTP estimates for various haemorrhoidal 
treatments 
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Other studies that have formally incorporated DCEs into economic evaluations did so by 
using WTP estimates from DCEs in CBAs, a process that has been outlined in some detail in 
the literature (McIntosh, 2006; McIntosh, 2010). The first known published example of this 
involved estimating WTP from the preferences of past hernia patients elicited from a DCE 
about different types of hernia surgery (McCormack et al., 2005) and was used as part of the 
evidence presented to NICE. A later example involved using the preferences of the general 
population for different ocular hypertension monitoring services in order to generate WTP 
estimates for a CBA (Burr et al., 2012). Three examples of DCEs used to generate WTP 
estimates for use in CBA exist have been identified that formed components of PhD projects 
but are currently unpublished. The context of one of these studies was genetic testing for 
idiopathic developmental disability (Regier, 2008). Another study focused on genomic testing 
for patients with chronic lymphocytic leukaemia (Buchanan, 2015). The context of the third 
study is preventative interventions for periodontal disease (Boyers, forthcoming; Ramsay et 
al., forthcoming). Although the CBAs from these projects have, as yet, not been published in 
peer-reviewed journals, the DCEs from two of them have (Regier et al., 2009; Buchanan et 
al., 2016) and the DCE from the other study has been presented at a European conference 
(Boyers et al., 2016).  
A recent publication presented another example of using WTP estimates generated using a 
DCE in a CBA, but also explored how the estimates differed between different individuals 
(Tinelli et al., 2016). The context was a collaborative medicine review service between 
community pharmacists and general practitioners, and the data came from a RCT. The authors 
found that, for all trial participants, WTP for the intervention was -£26.48. However, once the 
sample was split into the two trial arms, they found that the treatment arm were willing to pay 
£3.52 relative to -£56.47 for the control arm. The difference was statistically significant and 
impacted the results of the CBA. The authors also explored how participants that chose to 
receive the service beyond the standard follow-up time compared with those that ceased to 
use the service, however this comparison is affected by selection bias. Finally, a recent Health 
Technology Assessment publication used a DCE to generate WTP estimates for various 
aspects of haemorrhoidal treatments (Watson et al., 2017). Interestingly, the authors elicit 
preferences from a patient sample and a general population sample. The authors explain that it 
is unclear whose preferences should be elicited for use in healthcare decision-making and cite 
an article that is based on work from this thesis (Mott & Najafzadeh, 2016). 
Given the existing guidance (e.g. NICE guidelines) and theory (i.e. welfarism vs. extra-
welfarism) relating to the three common economic evaluation methods there is little new to 
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say regarding the choice of preferences in the aforementioned studies. One would expect DCE 
studies that are used in CUAs and CEAs to typically elicit general population preferences, 
whereas patient preferences might be elicited for use in CBAs. Such trends are not observed 
among the studies that formally incorporate a DCE into an economic evaluation. However, 
given the normative nature of the preference debate and the fact that many of these studies 
may have exploratory in nature it would be unreasonable to critique their choice of sample for 
their DCE studies. It is also perhaps unlikely that the preference debate was considered when 
these studies were devised and conducted. Nonetheless, this thesis argues that the choice of 
sample should be an important consideration in any DCE study that aims to provide 
information for use in an economic evaluation. 
In addition, as DCEs can be used to predict uptake for hypothetical health care interventions 
(van der Pol et al., 2010; Ghijben et al., 2014), it has been suggested that DCE results could 
be used to provide uptake parameters for use in decision models for economic evaluations. A 
recent Health Economics letter outlines an approach to do this using uptake for human 
immunodeficiency virus (HIV) prevention technologies as an example (Terris-Prestholt et al., 
2016). The study found that uptake is likely to vary significantly according to user 
characteristics and the efficacy of the technology; as a result, the authors conclude that this 
approach is likely to be superior to current practice (where assumptions of uniform uptake 
that are based on expert opinion are common). A PhD project used this approach to 
incorporate uptake estimates derived from a DCE into a decision model for a CUA of HIV 
prevention products in South Africa (Quaife, 2017). Thus far, the protocol and the results of 
the DCE have been published (Quaife et al., 2016; Quaife et al., 2017) but the CUA has not. 
With regard to the preference question, it would only seem logical to elicit preferences from 
those that are likely to undertake, or are currently undertaking, a related intervention to those 
included in the DCE. As a result, it should be patient preferences that are elicited in this case. 
It has also been suggested that DCEs could also be used to estimate minimally important 
differences (MIDs) in trial outcomes. This could be done by designing a DCE that covers the 
key attributes of interest, estimating the MRS between those attributes and calculating the 
MID using this information (Hughes, Charles et al., 2016). The example given by Hughes et 
al. (2016) is the trade-off between remission and survival, generating the MID in the primary 
outcome measure (probability of survival) between choosing the trial intervention or not. 
MIDs are often estimated from the perspective of patients or clinicians and hence it would be 
expected that the DCE would be administered to a sample of either population; hence there is 
little scope here to argue for the use of a general population. 
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Finally, DCEs may also be used to provide preference information prior to an economic 
evaluation. For example, a DCE could be used in conjunction with a RCT of a healthcare 
intervention before the economic evaluation stage. During the development of the trial 
intervention, a DCE could be used to inform the design; the trial team could aim to provide 
the (feasible) intervention that is expected to maximise uptake and/or utility. Alternatively, a 
DCE could be delivered to trial participants at the end of the trial in order to obtain preference 
information based on their experience and to use this to refine the intervention further (as well 
as to generate uptake estimates for an economic evaluation as described in the previous 
paragraph). Refinement may be particularly useful when the results of the RCT were 
equivocal. In either case it would seem logical to elicit the preferences of the trial population, 
which may be a fairly representative sample of the patient population. However, it is 
impossible to escape the notion of opportunity cost. If healthcare interventions are designed 
based on patient preferences, it is possible that a costlier intervention is created than is 
necessary to achieve the desired health outcome. However, it should be acknowledged that an 
intervention designed based on patient preferences could lead to better adherence. Regardless, 
given that the cost is borne by the general population in a public funded healthcare system, an 
argument remains that the general population’s preferences should be favoured.  
Although relatively few DCEs have been formally incorporated into published economic 
evaluations and several of the applications listed above are currently hypothetical, there is 
clear interest from HTA agencies in utilising DCE data. In Germany, the Institute for Quality 
and Efficiency in Health Care (IQWiG) conducted a pilot study where a DCE was 
administered to patients to elicit their preferences for antiviral therapy for chronic hepatitis C 
(Mühlbacher et al., 2017). The purpose of the study was to examine the relative importance of 
multiple ‘patient-relevant outcomes’ according to patient preferences. It is argued that 
focusing largely on a single primary endpoint, as is standard in a RCT, is too narrow and not 
reflective of the wide range of factors that affect patients. The authors concluded that DCEs 
could potentially provide useful information to support decision-making, although no final 
conclusions were drawn.  
Similarly, there is an ongoing project at NICE exploring how preference elicitation methods 
could be used in a HTA setting. This exploratory project will involve providing a survey to, 
and conducting a focus group with, myeloma patients in order to determine their needs and 
subsequently the most appropriate method(s) to use, which may include DCE (L Cowie, 
Personal Communication, 11 May 2017). This work, in collaboration with Myeloma UK, will 
continue through to 2018. The focus on patient preferences is interesting when contrasted 
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with the NICE reference case that recommends general population preferences for HSUVs. 
One might argue that this guidance is slightly outdated if the intention is to achieve a more 
patient-centric HTA process (Mühlbacher, 2015). Indeed, a focus on patient (or experienced) 
HSUVs is supported by various recent preference debate publications outlined in section 3.1. 
Nonetheless, a normative argument can be made that patients should not be the only ones to 
have their preferences considered in the healthcare decision-making process. 
Regulatory Decisions 
It should also be noted that health-related DCEs may also be used to provide preference 
information for other types of macro-level decision-making. Regulatory bodies such as the 
US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) 
evaluate medicinal products with regards to their quality, safety and efficacy. Using England 
& Wales as an example, the EMA would determine whether a medicine can be provided (e.g. 
whether it is safe enough to justify its use) whereas NICE determine whether it should be 
made available on the NHS (e.g. whether it is cost-effective).  
In a move that is likely to have been motivated by the push towards patient-centred healthcare 
the Center for Devices and Radiological Health (CDRH), part of the FDA, has recently 
incorporated preference information from a DCE in a benefit-risk assessment (BRA) for a 
weight loss device9. The DCE contained several attributes describing risks and benefits 
relating to the device and hence benefit-risk trade-offs could be examined, which is key for 
BRA (Ho et al., 2015). Subsequent guidance has been published by the CDRH, along with 
another FDA centre (Center for Biologics Evaluation and Research; CBER), which reaffirms 
the importance of patient preferences and states that DCEs are a suitable method for eliciting 
patient preferences for this purpose (FDA, 2016). The passing of legislation such as the FDA 
Reauthorisation Act and the 21st Century Cures Act has reinforced the focus on patients, and 
has led to the FDA producing a “plan for issuance of patient-focused drug development 
guidance” (FDA 2017), which will lead to a series of new guidance documentation being 
finalised between 2019 and 2021. It would seem likely that this guidance will lead to a rise in 
the collection and incorporation of patient preference data in regulatory decision-making in 
the US. 
In addition to the use of DCEs in the US, a recent project by the EMA under the Innovative 
Medicines Initiative (IMI), called the Pharmacoepidemiological Research on Outcomes of 
Therapeutics by a European Consortium (PROTECT) project, concluded the DCEs were the 
                                                 
9 For a comprehensive overview of the developments that led to this CDRH study, see Irony et al. (2016) 
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preferred “utility survey technique” of those that it explored (Hughes et al., 2013; Hughes, 
Waddingham et al., 2016). Another, ongoing, IMI project called PREFER is looking into this 
area by taking a broader perspective. The project aims to “develop a systematic approach for 
considering the use of patient preferences across the medical treatment life cycle”, with final 
recommendations due in autumn 2021 (de Bekker-Grob et al., 2017). 
With regard to the question of whose preferences to elicit in the above examples, it would 
seem logical to elicit preferences from existing or likely future patients. The guidance from 
the CDRH only refers to the elicitation of patient preferences, whereas the PROTECT report 
is less direct but does state that patient preferences are considered important by many 
stakeholders (Hughes et al., 2013). In addition, the PREFER project is clearly focused on 
patient preferences. While the preference debate may not have traditionally been considered 
in the context of BRA directly, it was certainly relevant given that many BRAs use QALYs as 
the measure of benefit. Assuming that utility tariffs are commonly applied in such cases, it 
would appear that BRAs have often been incorporating general population preferences given 
that most tariffs are based on general population preferences (Brazier et al., 2016). It is hard to 
argue against the suggestion that patient preferences regarding benefit-risk trade-offs are 
perhaps more relevant, but many issues raised in the preference debate in the context of health 
state valuation cannot be avoided even when DCEs are used to elicit preferences. For 
example, patients have a vested self-interest in decisions relating to them and any implication 
that a study may affect a regulatory decision could lead to biased results. A DCE study found 
that patients expressed a preference for new anticoagulant therapies over existing therapies 
regardless of their related benefits and risks (Najafzadeh et al., 2014). As a result, this thesis 
argues that it is just as important to consider the choice of sample (and, perhaps more 
importantly, the wording/design of the survey due to the previous example) for a DCE that is 
intended to contribute to regulatory decision-making. 
3.4.2 DCEs & Micro-Level Decision-Making 
As DCE studies typically provide aggregate-level information about the preferences of a 
particular sample, it is somewhat questionable that DCEs can be used to aid micro-level 
decision-making. Attempting to reach conclusions regarding an individual’s preferences from 
aggregated information is fundamentally flawed; this is the ecological fallacy (King, 2013). A 
recent debate arose in the European Journal for Person Centered Care on this very issue. 
Kaltoft et al. (2015) argue that DCE studies should not claim to offer any clinically relevant 
information (e.g. to assist person-centered care/shared decision-making) for this very reason 
and use several examples from the DCE literature to illustrate the ‘false’ claims that might be 
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used (Kaltoft et al., 2015). However, a response by Pedersen et al. (2015) offers a more 
optimistic view on the matter. They state that while DCE results could not be used in isolation 
to assist clinical decision-making (between a doctor and patient) they can be used as a starting 
point and provide a better insight into what the patient’s preference might be based on their 
characteristics (as subgroup analysis is common in DCE studies and indeed in many clinical 
studies) (Pedersen et al., 2015). In this sense, DCEs contribute to breaking down information 
barriers between the doctor and the patient. Regardless of the extent to which DCEs may 
influence micro-level decision-making, it would be hard to argue against the use of patient 
preferences when the aim is to reduce the asymmetric information between doctors and 
patients. 
3.5 Conclusion 
This chapter provided an overview of economic evaluation in health and the preference debate 
that arose from the use of QALYs in CUA. Following this, CV and DCE methodologies were 
outlined. Given the abundant potential of the method, the use of DCEs in healthcare decision-
making was considered and suggestions were made surrounding the choice of whose 
preferences to elicit in each context. It should be clear that the vast majority of arguments 
made in the preference debate could also be made in the context of DCEs when the intention 
is for the results to be incorporated into analyses that will influence decision-making. Unlike 
the systematic review of CV studies by Smith & Sach (2010), none of the major systematic 
reviews of DCE studies in healthcare (Ryan & Gerard, 2003; de Bekker-Grob et al., 2012; 
Clark et al., 2014) have explored whose preferences are being elicited. To fill this gap, the 
next chapter will review the published DCE literature in order to examine whose preferences 
are typically elicited. 
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Chapter 4. Whose Preferences Are Elicited in DCEs? A Systematic Review 
 
The aim of this chapter is to examine the type of respondent sample that has been used in 
published DCE studies that elicit preferences for health services, and to examine any existing 
studies that have compared patient and general public preferences for a health service. 
In order to achieve this aim the first section in this chapter will outline the review process that 
was used to identify DCE studies that elicit preferences for health services and the definitions 
used to classify respondent samples. Section two outlines the main results from the review 
and section three discusses the implications of the findings and discusses the potential 
differences in preferences between different types of respondent sample. Finally, section four 
concludes the chapter. 
4.1 Outline of the Review 
4.1.1 Review Objectives 
The previous chapter outlined how DCE studies that elicit preferences for healthcare services 
could be used to inform decision-making in various settings. Given that DCEs provide 
preference data, this gives rise to a normative debate surrounding whose preferences should 
be elicited. As the direct use of DCEs in healthcare decision-making is relatively novel, there 
is little insight to be gained by examining the choice of respondent sample in the existing 
examples. Hence, the next best option in lieu of substantial applications of DCE data in 
healthcare decision-making would be to search the published DCE literature and examine the 
choice of respondent samples. It may be the case that relatively few of the published DCE 
studies were planned with the intention of the results being used to support a specific 
decision. Regardless, all research intends to provide useful information that addresses a gap in 
the collective knowledgebase. Therefore, all published DCE studies have the potential to 
influence decision-making, if only indirectly.  
Consistent with the preference debate in health state valuation, this review will only compare 
the number of DCE studies that elicit the preferences of patient or general public samples. It is 
assumed that DCE studies eliciting the preferences of physicians or policymakers are far less 
likely to be used in the various decision-making processes outlined in Chapter Three and 
hence these are not of interest. This is also consistent with the preference debate in health 
state valuation; physicians and policymakers could also value health states but are relatively 
rarely ever considered in this area of literature. For simplicity, it is also assumed that DCE 
studies that make comparisons between different respondent samples primarily aim to provide 
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information on the potential discordance between groups and thus are less likely to be 
relevant. For example, it is quite common for DCEs to be used to examine the principal-agent 
relationship between patients and physicians (Mühlbacher & Juhnke, 2013). While the 
preference data from the patient samples could also be used elsewhere in isolation, including 
such studies under the patient category may unfairly inflate the results and therefore such 
studies will not be considered in this review. However, any studies comparing the preferences 
of patient and general public samples are clearly highly relevant and will also be reviewed, 
separately, within this chapter.  
Hence, the objectives of this systematic review are: 
1. To examine, and attempt to classify, the samples of respondents that have been used in 
published DCE studies in the health economics literature. 
2. To identify any studies that compare the preferences of both a patient and general 
public sample using the same DCE. 
4.1.2 Respondent Sample Definitions 
Classifying a respondent sample as ‘patients’ or ‘general public’ in the context of DCEs is 
somewhat more complex than in the case of health state valuation10 because the task involves 
both a health issue and some form of health service. The key difference between the two user 
groups in the preference debate outlined in Chapter Three is the experience of a health state. 
To remain aligned with this debate, the definitions outlined in table 4.1 use experience as the 
main differentiator in this context and are the definitions that will be applied in this review.  
Table 4.1 Respondent Sample Definitions 
User Group Definition 
Patient Individuals that have been recruited due to their experience of the 
health issue that the DCE addresses (current or past) and/or 
experience of existing services similar to those described in the 
DCE scenarios. 
General Public Individuals that have not been recruited due to any specific 
experience of the health issue that the DCE addresses or of existing 
services similar to those described in the DCE scenarios. 
                                                 
10 It has been argued recently this terminology is also complex in health state valuation. Patient samples typically 
value more than their own health state, hence a patient sample does not exclusively provide ‘experienced’ utility 
values. See Brazier et al (2017) for a detailed discussion. 
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The definitions are intentionally worded carefully as it can be difficult to classify a respondent 
sample as patients or the general public in certain scenarios. It should be clear from the 
definition in table 4.1 that there is no requirement for a general public sample to be 
representative of a country’s general population. This allows for a sample of respondents of, 
for example, a particular gender and age to still be classified as a general public sample if they 
do not have experience of a particular health issue or service.  
Defining the two types of sample based on the recruitment strategy of the study is an attempt 
at reducing the subjectivity of the classifications. For example, it is common for DCEs to 
elicit preferences for generic health services such as general practitioner (GP) appointments 
(Hole, 2008; Gerard et al., 2008) or vaccinations (Brown et al., 2014; Marshall et al., 2016). 
One might assume that most individuals have experience of both GP appointments and 
vaccinations and should be classified as patients accordingly; however, the definitions in table 
4.1 avoid this assumption. For example, one might recruit a sample for the former from a 
GP’s waiting room (a patient sample according to table 4.1) and a sample for the latter from 
an online panel with no vaccination-related screening questions (a general public sample 
according to table 4.1). In contrast, one might recruit a sample for the former from an online 
panel with no GP-related screening questions (general public) and a sample for the latter from 
a vaccination clinic (patients). While this classification process may be somewhat convoluted, 
it means that the classification is not solely reliant on the terminology used within the study to 
refer to the sample (which can be inconsistent across studies) nor is it solely reliant on the 
opinion of the reviewer (which is subjective and may not be replicable). 
Finally, it should be noted that studies eliciting preferences by proxy are classified in the same 
manner. That is, if a study recruits caregivers of individuals with a specific health issue and 
elicits their preferences for a health service on behalf of the individuals that they care for, this 
is classified as a patient sample. 
4.1.3 Search Strategy (2011 to 2013) 
A literature search was undertaken using PubMed in January 2014 looking for papers 
published between 2011 and 2013 which contained a DCE in a health economics context. 
Titles and abstracts were searched using the same keywords that were used by Ryan and 
Gerard (2003) and de Bekker-Grob et al. (2012); these are listed in box 4.1. The algorithm 
used to search PubMed was checked by applying it to the range of years (2001 to 2008) used 
by de Bekker-Grob et al. (2012) and all of the papers included in their review were 
successfully identified.  
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Box 4.1 Keywords used in the first literature search 
discrete choice experiment 
discrete choice experiments 
stated preference 
part-worth utilities 
functional measurement 
paired comparisons 
pairwise choices 
conjoint analysis 
conjoint measurement 
 
conjoint studies 
conjoint choice experiment 
conjoint choice experiments 
discrete choice modelling 
discrete choice modeling  
 
 
4.1.4 Search Strategy (2014 to March 2017) 
Two additional searches were conducted to keep up to date with the literature and to prepare a 
database for a subsequent update to the review. The search was conducted in two parts: the 
first was in May 2016 which covered 2014 to 25th May 2016; the second was in March 2017 
and covered May 2016 to 27th March 2017. The results from both searches were merged into 
one EndNote library with duplicates removed. These searches varied slightly from the one 
outlined in the previous section as a subsequent review of DCE studies in health economics 
had been published to follow on from de Bekker-Grob et al. (2012) that included some 
additional search terms (Clark et al., 2014). The full selection of search terms used in these 
additional searches can be found in box 4.2 with the new terms in bold. 
Box 4.2 Keywords used in subsequent literature searches 
discrete choice experiment 
discrete choice experiments 
stated preference 
part-worth utilities 
functional measurement 
paired comparisons 
pairwise choices 
conjoint analysis 
conjoint measurement 
 
conjoint studies 
conjoint choice experiment 
conjoint choice experiments 
discrete choice modelling 
discrete choice modeling  
DCE 
conjoint 
discrete choice conjoint experiment 
discrete choice conjoint experiments 
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4.1.5 Inclusion & Exclusion Criteria 
For clarity, the inclusion and exclusion criteria are outlined below. 
Studies were eligible for the review if they: 
• Contained a DCE that elicited preferences from a general public or patient sample 
(proxies allowed) for a health service or; 
• Contained a comparison of preferences between a general public and a patient sample. 
Studies were considered ineligible for the review if they: 
• Had been published previously (e.g. methodological studies, further publications of 
the same study). 
• Did not elicit preferences for a health service (other common applications include 
health states, health insurance, health-related jobs, priority setting). 
• Did not report any results (e.g. conference abstracts, protocols). 
• Contained a comparison of preferences between any other types of respondent sample 
(e.g. patient and physician samples). 
4.1.6 Data Extraction 
Although the objectives of this review result in a relatively simple data extraction process (i.e. 
classification of the respondent sample), additional data was extracted in the initial review 
(2011 to 2013) to get a feel for the published literature and explore possible trends. This 
included the study location and sample size, the type of attributes used in the study, the 
payment vehicle (if a cost attribute was used) and the type of results presented. However, this 
supplementary information was not deemed particularly relevant for consideration in this 
review following feedback from a session at a European Health Economics Association 
(EuHEA) conference. Hence, this information is not presented within this chapter but the 
conference paper can be found in Appendix A-1. The full data extraction table for the 2011 to 
2013 review can be found in Appendix A-2. The 2014 to March 2017 data extraction process 
was subsequently simplified to focus only on the classification of the respondent sample, 
which included the extraction of a direct quote (about the sample) from the study but little 
else. This decision was made because the scope of the review had been determined at this 
stage, and it was known that information on results and other aspects of the studies would not 
be fully utilised. The full data extraction table for the 2014 to March 2017 review can be 
found in Appendix A-3. Full reference information for all of the included studies can be found 
in Appendix A-4. 
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4.2 Results 
4.2.1 Literature Search 
The 2011 to 2013 search identified a total of 787 records and the 2014 to March 2017 search 
identified a total of 2,639 records. While an increase in published DCE studies in health 
economics would be expected over this period given the trends in previous reviews, the large 
number of records in the more recent search was largely due to the additional keywords. For 
instance, a large number of irrelevant records were identified as a result of the inclusion of 
‘DCE’ and ‘conjoint’ as keywords. The former resulted in numerous records about dynamic-
contrast enhanced magnetic resonance imaging (DCE MRI) and the latter is a common term 
across medical studies. The title and abstract screening process resulted in the exclusion of 
2,554 records across the 2011 to March 2017 time period. The primary objective at this stage 
was to remove ineligible records, hence any preference studies were included for more 
detailed examination in the next stage. In general, it was easy to determine whether the record 
was irrelevant based on the information provided within these fields.  
The final screening stage involved a closer examination of abstracts and, where necessary, the 
examination of full-texts, of 872 records in order to determine whether the DCE elicited 
preferences from a general public or patient sample for a health service. Full-text examination 
was required when clarity was needed regarding the preference elicitation method used in the 
study as DCEs are often incorrectly labelled as conjoint analyses and, occasionally, the 
opposite is true11. In total, 518 studies were removed at this stage: 214 due to an irrelevant 
topic (i.e. not a health service); 152 due to an irrelevant study sample such as physicians (or 
irrelevant comparisons); and 152 due to data concerns (e.g. not a DCE or no primary data). 
This resulted in a total of 123 studies from 2011 to 2013 being included in the review and 231 
studies from 2014 to March 2017 being eligible for review. Figure 4.1 presents a Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) flow diagram that 
describes the aforementioned search process (Moher et al., 2009). 
 
  
                                                 
11 Conjoint analyses are often ranking tasks and are not based on random utility theory (outlined in 6.4.7). The 
importance of the latter is explained in detail in Louviere et al. (2010). 
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Figure 4.1 PRISMA Flow Diagram 
 
4.2.2 Respondent Sample Classification  
All of the 123 eligible studies between 2011 and 2013 that were identified were included in 
the review. Table 4.2 contains the key extracted information: 68% of the included studies 
elicited preferences from a respondent sample that, based on the definitions in table 4.1, was 
classified as a patient sample. 
Table 4.2 Classification of Respondent Samples (2011 to 2013) 
Classification of Respondent Sample Number of Studies 
Patient Sample 82 (68%) 
General Public Sample 39 (32%) 
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For the subsequent review period (2014 to March 2017), the decision was made to review 
only 10% of the included studies due to the high number of eligible records (n=231). It was 
believed that 10% would be a sufficient sample to establish a trend, given that it was not 
expected that there would be a major change between review periods. The main reason that no 
change was expected in the 2014 to March 2017 review period was the continued, and 
seemingly increasing, focus on patient preferences in health economics as identified from 
informal evidence. This included unsystematic literature reviewing (i.e. keeping up with DCE 
developments in health economics), attending conferences and engaging with researchers 
conducting health preference research (where there was an increasing focus on patient 
preferences) as well as keeping up to date with guidance released by, and case studies 
conducted by, various HTA bodies and regulatory agencies. In the latter case, it became clear 
that patient preferences were a key focus, especially in the case of the FDA’s CDRH (see 
Chapter Three). In fact, a number of the studies described in Chapter Three were recent 
developments (i.e. published following the initial search period in this review – January 
2014).   
Hence, data was extracted from only 23 studies to examine whether the trend identified 
between 2011 and 2013 had continued. The studies were selected at random using a random 
number generation function in Microsoft Excel. Table 4.3 contains the key extracted 
information: 74% of the included studies elicited preferences from a respondent sample that, 
based on the definitions in table 4.1, was classified as a patient sample (relative to 68% in the 
previous period). 
Table 4.3 Classification of Respondent Samples (2014 to March 2017) 
Classification of Respondent Sample Number of Studies 
Patient Sample 17 (74%) 
General Public Sample 6 (26%) 
 
This is only 10% of the identified studies, hence it cannot be concluded with certainty that the 
trend identified in the previous period had indeed strengthened. A 95% confidence interval 
was calculated around this estimated proportion using equation 4.1. 
74% ± 1.96 × √
74% (1 − 74%)
𝑁 = 23
 
(4.1) 
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This produces a 95% confidence interval with a lower bound of 56% and an upper bound at 
92% (74% ± 18%). Hence, with considerable confidence it can be concluded that the majority 
of studies in the latter review period are likely to have elicited preferences from a patient 
sample (as defined by table 4.1). 
4.2.3 Patient & General Public Comparisons 
The search for published studies that compared the preferences of a patient and a general 
public sample for a health service using a DCE was conducted as part of the 
inclusion/exclusion criteria screening stage. Hence, all 872 records across the full 2011 to 
March 2017 time period were checked. However, only three published studies were identified 
(Najafzadeh et al., 2013; Finkelstein et al., 2015; Landfeldt et al., 2016).  
The first study, based in Canada, elicited preferences for hypothetical genomic testing for 
guiding cancer treatment for a cancer described as aggressive but curable (Najafzadeh et al., 
2013). The patient sample was made up of current and former cancer patients (n=38) and a 
selection of the general public sample were matched to the patient sample using propensity 
scoring (n=533 to n=83). The authors found that the two samples expressed different 
preferences regarding the value of the various aspects of genomic testing, with patients caring 
more about the sensitivity of the tests and being more willing to opt-out of a test if it was not 
sensitive enough relative to the matched public sample. The differences in coefficients lead to 
large differences in WTP estimates, both for individual attribute levels as well as genomic 
tests overall: 
“…the public was willing to pay as high as $6050 for having a genetic test while 
patients’ WTP for genetic testing was only $919.” (p.8) 
The second study, based in Singapore, elicited preferences for end of life (EOL) treatment 
(Finkelstein et al., 2015). The patient sample was made up of individuals with advanced 
(stage four) cancer (n=320) whereas the general public sample was made up of individuals 
aged over 50 described in the study as “community dwelling older adults” (n=522). The 
authors found that the two samples expressed different preferences, such as with regard to the 
source of payment for treatment and the prolongation of life. The differences in coefficients 
lead to large differences in WTP estimates, with patients expressing a higher WTP for nearly 
all attributes compared to the general public sample. For example, the patient sample were 
willing to pay S$11,043 (95% CI: S$3,061, S$16,426) for an additional life year compared 
with the general public sample that were willing to pay S$1,587 (95% CI: -S$1,299, 
S$4,379). Despite the wide and slightly overlapping confidence intervals, the difference is 
statistically significant at the 5% level. 
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The final study, based in Germany and Sweden, elicited preferences for hypothetical 
treatments for relapsed/refractory (r/r) chronic lymphocytic leukaemia (CLL) (Landfeldt et 
al., 2016). The patient sample was made up of individuals with CLL (n=43), and the general 
public sample contained respondents that were over 18 and did not know anybody with a 
malignant hematologic disease (n=196). Physicians that had treated patients with CLL (n=72) 
were also included as a separate sample. The only statistically significant differences (at the 
5% level) between the patient and the general public sample were in relation to the relative 
importance of progression free survival (9% and 11.1%, respectively) and treatment 
administration (18% and 13.2%, respectively). No welfare estimates were provided within 
this study. 
4.3 Discussion 
4.3.1 The Emphasis on Patient Preferences  
It is somewhat unsurprising that more studies elicit the preferences of patients. Early 
introductory articles about the use of DCEs discussed their potential use for incorporating the 
patient voice (Ryan, 2004b) and others identified a similar trend to the one identified in this 
review when the literature base was in its infancy (Bryan & Dolan, 2004). To this day it very 
much appears to be the case that DCEs are seen as a tool to elicit patient preferences and little 
has been written about the justification and implications of this patient focus since the 
commentary by Bryan & Dolan (2004). 
That is not to say that there are not a substantial number of DCE studies eliciting the 
preferences of an inexperienced, general public sample. However, many of these studies elicit 
preferences for fairly generic services e.g. those that are relevant for a wide range of potential 
users (Boonen et al., 2011; McAteer et al., 2015). In addition, many of these studies elicit 
preferences from a subset of the general public whom may be more appropriate than a 
completely random or representative sample. For example, studies often elicit preferences 
from a sample of respondents that fit within a certain age range that is appropriate for a 
particular health issue (Ghijben et al., 2014; Kistler et al., 2015). 
One might attribute this lack of random or representative general public samples to the 
guidance provided by experienced choice modellers. It is often recommended that a DCE is 
only provided to individuals that will, or may, have to make a similar decision in real life (S 
Hess, Personal Communication, 3 April 2014). This advice is provided with data quality in 
mind, but combined with the way in which DCEs were introduced into the health economics 
literature, it provides a strong basis for rejecting inexperienced respondent samples in DCE 
studies. Additionally, many of the examples provided in the previous chapter surrounding the 
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incorporation of DCE data into analyses that will be used to inform decision-making have 
considered patient preferences in the first instance. 
However, at least one study that elicited preferences from a general public sample justified 
their choice on a normative basis as outlined in this thesis. The study elicited preferences for 
treatments for Fabry disease (Lloyd et al., 2017). The authors stated that: 
“The general public (rather than people with Fabry disease) were recruited because 
this study was done from a societal perspective. Decision makers such as the National 
Institute of Health and Care Excellence (NICE) in the UK state that decisions should 
reflect the preferences of the general public because of the central role of taxation in 
funding health care. Outcome measures like the widely used EQ-5D are based on 
societal preferences (rather than weights derived from patients).” (p.25)  
It may be the case that more studies in the future will consider this approach if the use of 
preferences elicited from DCE data begins to influence decision-making to a greater extent. 
However, a sceptic may question the true rationale of the sample used in Lloyd et al. (2017), 
given that Fabry disease may only have an incidence rate of 1 in 117,000 (Germain, 2010). 
4.3.2 Patient & General Public Comparisons 
There is a clear lack of evidence regarding the potential differences in preferences between a 
patient and a general public sample that might occur in a DCE study that elicits preferences 
for a health service. The existing published studies provide some evidence to suggest that 
preferences vary to a significant extent, which in turn creates large differences in welfare 
estimates (Najafzadeh et al., 2013; Finkelstein et al., 2015). However, it could be the case that 
differences are not always as extreme, as appears to be the case in Landfeldt et al. (2016). It is 
interesting to note, however, that Najafzadeh et al. (2013) did try to match respondents using 
propensity scoring and Finkelstein et al. (2015) restricted their general public sample to over 
50s. Hence, the existing evidence, while mixed, indicates a significant probability that 
preferences for health services may differ between general public and patient samples. 
Landfeldt et al. (2016) did not provide any rationale for their examination of both patient and 
general public preferences (and physicians). However, the other two studies did provide a 
rationale for examining preferences of both samples, and these varied slightly. Najafzadeh et 
al. (2013) expressed the need for public preferences in order to assist reimbursement 
decisions, as discussed by Lloyd et al. (2017) and in the previous chapter: 
“In general, approval and use of genomic tests varies widely across different 
jurisdictions and for different populations. Publicly (or privately) funded health care 
benefit providers are often interested in learning about tax payers’ (or privately 
insured populations’) opinion about the value of these genomic tests. Knowledge 
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about these preferences will enable health benefit providers to select genomic tests 
with the highest perceived value when making funding decisions.” (p.2) 
Finkelstein et al. (2015) justified their decision based on the fact that the most relevant group 
of individuals affected by coverage decisions may vary depending on the decision-maker’s 
definition and preferences may differ between groups: 
“In making coverage decisions, many governments consider preferences of its 
relevant constituents [7,8]. In Singapore, for EOL care, the largest constituents 
consist of older adults and those with life limiting illnesses as they are the ones most 
immediately affected by any health care reform concerning coverage for EOL 
treatments [9]. Yet, it is likely that preferences and willingness to pay for life 
extending treatments among these two groups differ.” (p.1483) 
It should also be noted that other DCE comparison studies exist but were excluded based on 
the exclusion criteria. For example, Marshall et al. (2016) elicited preferences from both 
adults and adolescents for meningococcal B vaccines. While the vaccine may be more 
relevant for adolescents, the sampling strategy meant that both samples were considered to be 
from the general public based on the definitions in table 4.1. Additionally, Sossong et al. 
(2016) elicited preferences of patients and non-patients for health states related to rheumatoid 
arthritis. While one of the attributes related to treatment duration, the alternatives were 
described/framed as health states and hence this study was excluded. Finally, the Tinelli et al. 
(2016) paper described in section 3.4.1 was identified during this review was of high 
relevance to this thesis but does not compare patient and general public preferences and hence 
was excluded.  
4.3.3 The Definition of a Patient Sample 
Throughout the review process it became clear that the definition of a patient sample often 
varied across studies. Hence, two or more DCE studies that aim to elicit the preferences of a 
sample of the same general patient population may not be particularly comparable. Logically, 
this also means that the results of a single DCE study may not be particularly generalisable 
either without further clarification of the sample used.  
Some differences in patient sample characteristics were fairly minor. Two studies with almost 
identical titles aimed to elicit patient preferences for disease-modifying therapies for treatment 
of multiple sclerosis (Utz et al., 2014; Garcia-Dominguez et al., 2016). However, one study 
required that respondents had a diagnosis of relapsing-remitting multiple sclerosis (Utz et al., 
2014) whereas the other only required a diagnosis of multiple sclerosis (Garcia-Dominguez et 
al., 2016). As a result, only 72% of respondents in the latter had relapsing-remitting multiple 
sclerosis; it may be the case that preferences differ for those individuals relative to others. 
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Differences were more substantial between other studies. Two studies aimed to elicit patient 
preferences for anticoagulation therapy in atrial fibrillation (Ghijben et al., 2014; Bӧttger et 
al., 2015). However, only one of these studies actually had a diagnosis of atrial fibrillation as 
an inclusion criterion (Bӧttger et al., 2015). The other study instead elicited preferences from 
members of the general public aged over 40 (a general public sample by the definitions in 
table 4.1); only 6 respondents had a history of atrial fibrillation. Hence in this example, the 
type of patients differed not only between the two studies but also within the Ghijben et al. 
(2014) study.  
Differences in patient characteristics across similar studies could occur as a result of the 
source of the patient sample. For example, some studies may use online panels (Giles et al., 
2016) whereas others may use clinical trials (Tinelli et al., 2016) to recruit their sample. 
Clinical trials have their own inclusion/exclusion criteria which researchers will be restricted 
by. Additionally, online panels may prevent certain inclusion/exclusion criteria being used 
because researchers might be unable to identify and/or verify certain patient characteristics. 
4.3.4 Limitations of this Review 
This review is not without its limitations. First, the definitions used within this review to 
classify a sample as patients or the general public would not necessarily be consistent with 
those used if others conducted a similar review. However, the definitions are explicit and 
hence can be questioned and replicated if necessary. Furthermore, attempts were made to keep 
the definitions in line with the preference debate in health state valuation and to try and base 
the classification on the inclusion/exclusion criteria used within each study. Second, the 
search strategies may have been suboptimal due to the use of different keywords in the second 
and third searches as well as the use of only one database (PubMed). However, published 
systematic reviews of DCE studies from the literature were closely followed when 
determining the search strategy in this review. As a result, improvements by Clark et al. 
(2014) to the search strategy used by de Bekker-Grob et al. (2012) were therefore 
implemented into the updates in this review. In addition, it is quite unlikely other databases 
would have contained a significant number of relevant articles that could feasibly affect the 
conclusion of this review; for example, there is no reason to believe that articles contained 
within Embase and not PubMed are any less likely to elicit patient preferences. Finally, the 
results from this review cannot be used to conclude that most decision-making using DCE 
data has used patient preferences. However, the clear emphasis on patient preferences does 
appear to suggest that DCEs are generally considered to be a tool for eliciting patient 
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preferences and hence future guidance from HTA or regulatory bodies that suggest the use of 
data from DCEs may well be a recommendation for using patient preference information.  
4.4 Conclusion 
This review has identified that the vast majority of published DCE studies from 2011 to 2013 
that elicit preferences for health services do so from a sample of patients. It also appears 
(based on a 10% random sample) that this trend continued between 2014 and March 2017. 
Only one example (Lloyd et al., 2017) was identified where a general public sample was used 
on the normative grounds that were outlined in the previous chapter (e.g. that resource 
allocation decisions should be based on societal preferences in tax-funded systems). However, 
in reality this sample may be better characterised as a convenience sample given the rarity of 
the disease that the study is based on.  
This review also identified a very small number of studies that compared the preferences of a 
patient and a general public sample. In two of the three examples, there were large and 
statistically significant differences that translated to very large differences in WTP estimates. 
However, little can be concluded from three studies and further research would be highly 
beneficial in this area. In particular, it may be useful to see if such differences exist when the 
subject of the DCE is easier for the general public to understand e.g. a public health 
intervention rather than, for example, genomic testing. Finally, this review also identified that 
there is a range of heterogeneity in the characteristics of patient samples that are used in DCE 
studies, which may translate to considerable preference heterogeneity within and across 
studies. It may also mean that DCE studies are not, in general, particularly generalisable i.e. it 
may be inaccurate to conclude that patients prefer a particular treatment attribute based on 
only one study with a specific patient sample. 
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Chapter 5. A Framework for Classifying Respondent Samples in DCE 
Studies & Related Research Questions 
 
The aim of this chapter is to put forward an alternative framework for classifying respondent 
samples in DCE studies that elicit preferences for health services.  
The first section of this chapter follows on from the previous chapter by discussing the 
usefulness of comparing patients with the general public in the context of DCEs where there 
may be considerable differences within each type of respondent sample when they are 
classified in this manner. The subsequent section puts forward a framework that could be used 
to classify respondent samples in relation to their level of experience, which could be used to 
compare preferences across different types of user group. Section three summarises the 
overall research aims of the thesis and the final section outlines the four specific research 
questions that will be examined within the empirical work in this thesis. 
5.1 Patients vs. General Public: A False Dichotomy? 
In the context of health state valuation, it is fairly simple to categorise a survey sample as 
patients or the general public. The key distinction is simply whether or not the sample of 
respondents are experiencing the health state(s) in question. As DCE studies that elicit 
preferences for healthcare services are so broad, this distinction is not as clear.  
One possible approach, used in the previous chapter, is to define a sample of patients as 
individuals that have experienced the health issue, and/or have used an equivalent service in 
the past. In contrast, a general public sample would be defined as individuals that have not 
necessarily experienced the health issue or equivalent services. This broad approach keeps 
experience as the primary differential between the two populations which, whilst enabling 
most of the issues raised in the preference debate to be easily applied to DCE studies, may be 
over simplistic when discussing the choice of whose preferences to elicit for different 
purposes. For example, a sample of individuals over the age of 65 that has been generated at 
random for a DCE about bowel cancer treatments would be classified as a general public 
sample under this definition, despite this being a highly relevant sample given the topic of 
research. It is also quite plausible that, in an example like this, that respondents in a certain 
age range will be aware of the relevance of the health issue to them. This could mean that the 
respondents have vastly different preferences compared to younger individuals. Hence, the 
sample in this case may be better off classified in a different way. 
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Similarly, there may be some merit in distinguishing between respondent samples that have 
been generated from a RCT, which indicates that the respondents have experience with some 
form of intervention for the health issue, and those with the health issue identified from an 
online panel or patient registry. This is because preferences for health services may be highly 
influenced by the respondents’ prior experience of related treatments. 
It is not the aim of this chapter, nor this thesis, to provide a comprehensive framework of all 
of the different types of sample that could be used to elicit preferences in a DCE study, while 
this may be possible and comparable to the frameworks of perspectives that have been 
introduced and extended (Dolan et al., 2003; Tsuchiya & Watson, 2017). However, this thesis 
argues that whilst the preference debate is appropriate and should be considered in the context 
of DCE studies, limiting the debate to patients vs. general public preferences is a false 
dichotomy because it is hypothesised that preferences will differ across narrower user groups. 
This argument is in line with the seminal paper by Dolan (1999) that raises similar concerns 
in the context of health state valuation. Hence, an alternative framework to classify 
respondent samples beyond simply patients or the general public will be put forward in the 
next section. 
5.2 An Alternative Preference Framework for DCE Studies 
A simple alternative approach to classifying samples of respondents in DCE studies involves 
more careful consideration of the recruitment process and the extent of the respondents’ 
experience of the healthcare issue and/or service in question (i.e. related to the topic of the 
DCE). Note that this refers to the recruitment of samples, hence while individuals within the 
sample may fit into several classifications, the sample itself should have one overall 
classification based on the recruitment process. Table 5.1 outlines a simplistic framework that 
could be used to classify different samples in DCE studies into four different categories. 
Using this framework would enable samples of respondents to be categorised more closely in 
line with their true characteristics, which may help to reduce preference heterogeneity in DCE 
studies and improve the generalisability of their results. This framework allows for at-risk 
samples to be classified separately from more general samples, as well as opening up the 
definition of a patient by considering respondent’s experience of related healthcare services, 
which is a likely source of preference heterogeneity. It should be clear that placing a group of 
individuals into one of these categories will be a somewhat subjective process, however these 
categories should be distinct considering that they are determined by the recruitment process 
itself. 
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Table 5.1 User Groups and Their Definitions 
Group Definition 
Service User (SU) A group of individuals that have (or have had) an observable need for 
the healthcare service in question and have used a related healthcare 
service in the past. 
Potential Service User 
(PSU) 
A group of individuals that have an observable need for the healthcare 
service in question but have not necessarily used a related healthcare 
service in the past. 
Potential Beneficiary 
(PB) 
A group of individuals that can reasonably be considered as being at-
risk of developing a future need for the healthcare service. 
Non-User (NU) A group of individuals that have no specific need for the healthcare 
service, or prior experience of related healthcare services. 
 
Considering the different ways in which preference information from DCEs could be used in 
macro-level decision-making, this framework could be used to help justify the choice of 
sample in such studies and potentially improve the relevance of the results that are used in 
decision-making. For example, if the aim of the DCE is to provide information that will help 
to design or refine a healthcare service that is in development (e.g. a trial intervention) it 
would make sense to elicit the preferences of ‘service users’ because these individuals will 
have experienced how related healthcare services work (or the trial intervention itself if the 
RCT participants are used as the sample). If the aim of the DCE is to provide information 
regarding expected user uptake it may be more useful to elicit the preferences of ‘potential 
service users’ where possible, or alternatively ‘potential beneficiaries’ could be used as a 
proxy where it is not possible to recruit a sample of the former. DCEs designed for 
incorporation into economic evaluations should, as always, follow the relevant guidance but 
typically may elicit the preferences of ‘non-users’ (e.g. in extra-welfarist evaluations) or 
(potential) service users (e.g. in welfarist evaluations). In any case, this thesis argues that this 
framework would be an improvement over the typical use of classifying a sample of 
respondents as patients or the general public.  
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It could be the case that service users express preferences that are largely in line with those of 
potential service users as both groups suffer from some kind of health issue and the only 
difference is that the former have experienced some treatment. On a similar note, potential 
service users may not express vastly different preferences to potential beneficiaries if the 
former do not personally consider themselves to be in significant need of treatment.  
5.3 Research Aims 
The empirical work in this thesis aims to examine the differences in preferences between all 
four groups in this framework in order to provide some evidence regarding the 
appropriateness of these classifications. In a typical health setting it may be difficult to 
identify potential service users because it may be unrealistic that individuals suffering from a 
health issue could be identified and recruited to a DCE study prior to receiving any treatment. 
However, in the case of public health interventions this may be more plausible, given that 
such interventions tend to focus on dealing with broad health issues that are not likely to 
cause morbidity in the short-term. Furthermore, public health interventions are a good 
example where a sample of respondents that has not been recruited based on any specific 
characteristics is likely to contain individuals that fit into several of the different 
classifications. Additionally, public health interventions are typically easy to understand in 
that they will rarely involve clinical jargon and be associated with risks, such as harmful side 
effects. This has the added benefit that differences in preferences in this context are perhaps 
more meaningful in that they cannot be readily discarded as differences in respondent 
understanding of the context. 
For these reasons, the empirical work in this thesis will conduct a DCE that elicits preferences 
for different compositions of a public health intervention that aims to promote weight loss 
maintenance. Respondent samples that fit within the described framework will be recruited. 
This allows for a comparison of patients vs. the general public (where the former could be any 
of the first three user groups and the latter the non-user group) but also allows for the 
framework to be tested by making comparisons across all four groups. The next section 
formally outlines the specific research questions. 
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5.4 Research Questions 
5.4.1 Research Question One 
RQ1: To what extent do preferences for a health service, elicited via a discrete choice 
experiment, differ between different user groups, and why might these differences occur? 
This research question comes directly out of the discussion of the preference debate (Chapter 
Three), the lack of evidence in the literature (Chapter Four) and the limitations of the patient 
and general public dichotomy, hence the potential need for an alternative classification 
framework. The different user groups to be examined will be those within the framework in 
table 5.1: service users; potential service users; potential beneficiaries and; non-users. As 
discussed in previous chapters, if preferences between these groups differ significantly then 
the choice of whose preferences to elicit in DCE studies that aim to influence decision-
making becomes a more difficult question. If statistically significant differences in 
preferences are found, it is hoped that additional information could shed some light on the 
reasons behind the differences. 
5.4.2 Research Question Two 
RQ2a: To what extent do WTP estimates differ between different user groups, and why might 
these differences occur? 
RQ2b: How might WTP estimates differ if they are elicited indirectly or directly? 
Part (a) of this research question links directly with RQ1: if preferences differ between the 
four user groups then how does this translate into differences in WTP estimates? As WTP 
estimates could be used in the likes of CBA the use of one set of WTP estimates could lead to 
different resource allocation decisions being made when compared to those based on another 
set of WTP estimates. Hence it would be of interest to examine how WTP estimates differ 
between the four user groups. 
In addition to this, part (b) of this research question aims to explore a methodological 
question: the difference between WTP estimates when they are elicited directly (via CV) or 
indirectly (via DCE). Existing studies are limited and use various different types of CV tasks, 
however the general finding in a health context is that WTP estimates from DCEs are 
typically larger than those from CV questions (van der Pol et al., 2008; Ryan and Watson, 
2009; Danyliv et al., 2012), although in some cases they may not differ at all (Ryan, 2004a). 
Part (b) of this research question aims to provide additional insight into this sparsely explored 
area of the literature. The design and implementation of a CV task also provides the 
61 
 
opportunity for additional exploration of how WTP estimates differ across user groups i.e. 
part (a) of this research question.  
5.4.3 Research Question Three 
RQ3: To what extent do certain user groups have better defined preferences than other user 
groups, and why might these differences occur?  
It may be the case that individuals in certain user groups have better defined preferences and 
are able to express these clearly when responding to a DCE, whereas individuals from other 
user groups may not have such clearly defined preferences. This could be seen in the quality 
of the preference data, but also in the success rates for embedded rationality tests within the 
DCE that test the preference axioms outlined in Chapter Two, such as non-satiation and 
transitivity tests (Miguel et al., 2005). Lower fail rates in certain groups might indicate that 
individuals within these groups have better defined preferences, which could provide support 
for their use over another group’s preferences. Another interpretation might be that people 
that pass the rationality tests are better able to cope with the cognitive demands from a DCE.  
There may be other factors, beyond the classification of the individual (into one of the four 
user groups), that affect the probability of a respondent failing a rationality test or providing 
poor quality preference data, which can also be examined by collecting additional data such as 
demographic characteristics and attitudinal information. This could provide some insight into 
some of the questions raised by Ryan et al. (2009) surrounding the decision over whether it is 
right to exclude responses when rationality tests are failed. 
5.4.4 Research Question Four 
RQ4: To what extent might differences in preferences between the user groups be attributed 
to the recruitment vehicle? 
A potential criticism when it comes to examining differences between the four user groups is 
that the groups might not be recruited from the same place. In the empirical work in this thesis 
this is the case; a clinical trial is used to recruit potential service users and an online panel is 
used to recruit the other three groups (see section 6.2). Although this may be unavoidable, it is 
important to consider that the recruitment vehicle may explain some of the differences in 
preferences that might occur between user groups. Therefore, research question four aims to 
explore this. In relation to research questions one and two, this can involve pooling the data 
for the groups recruited via the online panel and comparing this with the trial sample. For 
research question three, rationality test results can also be pooled across the online panel 
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groups, and a variable relating to the recruitment vehicle can be used in regression analyses 
(see section 6.4.3). 
5.5 Conclusion 
This chapter has critically assessed the idea that respondents can be described as either 
patients or the general public and put forward a generic framework for classifying respondent 
samples in DCE studies that elicit preferences for health services. Following this, the overall 
aims of the empirical work were outlined (i.e. to make comparisons between the user groups) 
and the specific research questions that will be addressed were summarised in turn. 
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Part II. Methodology 
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Chapter 6. Designing a Survey to Test the Research Questions 
 
The aim of this chapter is to outline the design process of the online survey used to collect 
data in order to examine the research questions outlined in the previous chapter.  
Section one describes the case study that was used in this project. Section two provides an 
overview of the sampling process that was followed in order to obtain samples of the four 
user groups of interest. Section three explains how screening questions were devised in order 
to classify the respondent samples that were recruited from the online panel. Section four 
outlines the design of the DCE in detail, covering: the selection of attributes and levels; the 
generation of an experimental design; the design of rationality tests; the piloting process; the 
determination of sample sizes; the online programming and; the proposed analyses. Section 
five outlines the design of the CV tasks in detail, covering; the perspective of the tasks; the 
object being valued and; the use of different health outcomes. Section six describes the 
sociodemographic and health-related questions that were included in the survey. Section 
seven describes the attitudinal questions that were included in the survey. Section eight details 
the process undertaken in order to obtain ethical approval for the empirical work. Finally, 
section nine concludes the chapter. For reference, the full survey can be found in Appendix B-
1, but to provide a clear overview the overall structure of the survey is illustrated in figure 6.1. 
Figure 6.1 Structure of the Online Survey 
 
Information Pages
Ranking Task
DCE Task
CV Task
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66 
 
6.1 The Case Study: Weight Loss Maintenance & The NULevel Trial 
While a vast amount of research has been undertaken within public health to improve the 
lifestyles of those that are obese, little focus has been given to the maintenance of lifestyle 
improvements following successful and significant weight loss (Dombrowski et al., 2014). 
Studies have shown that people typically fail to maintain weight loss over time, leading to 
what is sometimes referred to as the yo-yo effect where weight fluctuates regularly (Avenell 
et al., 2004). As a result, there is an increasing interest in researching how weight loss can be 
maintained over time.  
The NULevel RCT that was undertaken by a team of researchers at Newcastle University 
examined the effectiveness of an intervention aimed at weight loss maintenance (Evans et al., 
2015). The trial involved the application of a novel technology-based intervention that was 
provided to a treatment group of 144 participants. The key component of the trial intervention 
required participants to weigh themselves daily on a set of scales provided to them as part of 
the trial. The scales sent weight information to the trial team via a cellular network, enabling 
the trial team to access the information and for the information to be displayed graphically 
online for the participants. In the first two weeks, participants were reminded to weigh 
themselves (via text message) if they failed to do so within a 24-hour period; this was 
extended to a 72-hour period thereafter. In a single face-to-face consultation at baseline, the 
participants agreed weight-related targets with a facilitator of the trial intervention such that 
three different ‘zones’ can be identified: green, yellow and red. The different zones indicated 
how close a participant was to achieving their agreed target, with green indicating that they 
were on target, yellow indicating that their weight is increasing and red indicating that weight 
re-gain is substantial. Whilst the intervention was being delivered, participants also received a 
variety of automated and tailored remote feedback via text message (or phone call if requested 
by the participant). The amount of feedback received by the participant related to the zone 
that they were in, with a ‘lighter touch’ provided to those in the green zone. The control group 
consisted of 144 participants that received a set of scales but were not advised on how to use 
them. In addition, rather than receiving any feedback they were provided with quarterly text 
messages that contained links to evidence-based, weight management guidance. 
The area of WLM, and the NULevel trial intervention in particular, is used as a case study for 
the purpose of examining the research questions in this empirical work. The research 
questions could be readily applied to a preference elicitation study about almost any 
healthcare service, but this is an ideal case study for two reasons in particular: 
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(1) The question of whose preferences should be elicited for use in healthcare decision-
making is particularly relevant in the context of public health interventions, as it is 
more likely that CBA may be used to evaluate them, relative to the economic 
evaluation of a drug. As DCEs that elicit preferences for a health service can provide 
WTP estimates for use in a CBA, using a public health intervention in this project may 
be particularly relevant. 
(2) It is hypothesised that the vast majority of individuals can relate to weight loss, weight 
gain and hence WLM, with minimal difficulty. As a result, preference information 
from individuals that would not necessarily need a WLM intervention should be of a 
higher quality than that expected from, for example, a survey about a niche, clinical 
intervention. Should it be the case that substantial differences in preferences are found 
for this type of intervention, one might hypothesise that preferences will differ even 
more in a niche, clinical setting. 
In the context of WLM research, information about individual’s preferences for WLM 
programmes is currently not readily available; it is expected that this project will be the first 
to apply DCE and CV methodology in this area of public health. Furthermore, the results 
from the project could be particularly useful for future development of the NULevel trial 
intervention, given that the research will be framed around this particular WLM intervention. 
6.2 Sampling Overview 
In order to examine the research questions in this thesis, samples of the four different user 
groups from the framework in Chapter Five need to be recruited. The NULevel trial provided 
individuals with experience of both the health issue and related treatment (i.e. service users). 
However, recruiting individuals for the other three user groups is somewhat more challenging. 
In this case, given that this is an easily relatable health issue, the most effective option (in 
terms of both recruitment speed and cost) is likely to be delivering the survey to online panel 
with detailed screening questions used to categorise respondents into the other three user 
groups. Figure 6.2 illustrates this recruitment process. 
  
68 
 
Figure 6.2 Recruitment Vehicles for the Four User Groups 
As the framework in Chapter Five is so broad, such that it can be readily applied to a range of 
different research areas, it is necessary to define the four user groups specifically for this 
context. Table 6.1 defines the four user groups in the context of WLM. 
Table 6.1 User Groups in a WLM Context 
User Group Definition (in a WLM context) 
Service Users (SU) Obese individuals that have lost weight, attempted to maintain the 
weight loss and have experienced a WLM intervention (NULevel) to 
help them achieve this. 
Potential Service Users 
(PSU) 
Obese individuals that have lost a clinically significant amount of 
weight recently and could benefit from WLM intervention today, 
but have not necessarily experienced a WLM intervention. 
Potential Beneficiaries 
(PB) 
Individuals that are currently overweight or obese that have not lost 
a clinically significant amount of weight recently, but could 
potentially benefit from a WLM intervention in the near future if 
they do so. 
Non-Users (NU) Individuals that are currently a normal weight with no clear need to 
lose weight at present or in the foreseeable future. They cannot 
feasibly be considered potential beneficiaries of a WLM 
intervention at present. 
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6.3 Screening Questions (for the Online Panel Sample) 
The NULevel participants, the SU group in this project, were subject to a wide range of 
inclusion and exclusion criteria before their acceptance into the trial. In order to reduce the 
subjectivity of the PSU group definition, and because the DCE is based on the NULevel 
intervention specifically, the classification of individuals to this group is also based on these 
criteria. The full inclusion and exclusion criteria for the NULevel trial are listed below (Evans 
et al., 2015). 
Individuals are eligible to participate if they meet the following eligibility criteria: 
1. A body mass index (BMI) of ≥30 kg/m2 any time in the 24 calendar months preceding 
trial entry (i.e. the date of consent); the BMI threshold is ≥28 kg/m2 for individuals of 
South Asian descent (WHO Expert Consultation, 2004); 
2. A weight loss of ≥5 % in the 12 calendar months preceding trial entry. Written 
verification of this weight loss should be provided by a physician, weight loss 
counsellor or friend; if no such evidence from a third party is available, participants 
may self-certify their weight loss; 
3. Ordinarily living or working in the North East of England; 
4. Access to and willingness to use an internet-enabled mobile telephone in order to 
receive messages from the research team, containing embedded links to relevant 
online content; 
5. Ability to use a standing scale for weight measurements.  
Individuals are excluded from participation on the following grounds: 
1. Participation in prior development studies of the intervention; 
2. Weight loss due to illness or surgical procedures, including bariatric surgery; 
3. Pregnancy or plans to become pregnant in the next year; 
4. Breastfeeding an infant under 6 months of age; 
5. Current involvement in other weight intervention research studies; 
6. Inability to understand written material or telephone conversations in English; 
7. A diagnosis of anorexia nervosa, bulimia nervosa or purging disorder, or of any 
condition which may preclude increasing mild to moderate physical activities such as 
walking; 
8. Baseline weight of >175 kg (due to the measurement range of the provided scales); 
9. Plans to leave the area or to undertake long-term travel in the forthcoming 12 months. 
The inclusion and exclusion criteria are comprehensive and pose a challenge for recruiting a 
significant number of similar individuals for the PSU group, however not all are relevant for 
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this project and hence some can be reasonably ignored. It should also be noted that, for 
pragmatic reasons, minimising the number of screening questions was seen as desirable. With 
regards to the inclusion criteria it is argued here that there is no need for this project to 
replicate the third criterion; the specific inclusion of individuals living in the North East of 
England is practical for the trial but not necessary for this project. Otherwise, the other 
inclusion criteria are highly relevant for the PSU group. With regards to the exclusion criteria 
it is argued that several of the criteria are unnecessary for use in generating the PSU group. 
Specifically, exclusion criteria one, two, five and nine are not considered as part of the 
screening questions for the recruitment of the PSU group due to concerns over their relevance 
and practicality. All other exclusion criteria are considered, to a varying extent, within the 
screening questions. 
After careful consideration, the following 12 screening questions were considered to be the 
minimum number necessary in order to classify respondents into one of the three user groups: 
1. What is your age? 
2. What is your gender? 
3. Are you currently pregnant or breastfeeding?  
4. What are your preferred units of measurement for height & weight? 
5. What is your height? 
6. What is your current weight? 
7. What is your ethnic group? 
8. Have you attempted to lose weight in past 12 months? 
9. Have you ever attempted to lose weight? 
10. What was your highest weight in the past 12 months? 
11. Are you able to use a set of scales to weigh yourself? (It doesn’t matter if you 
don’t own a set of scales) 
12. Do you have access to a mobile phone that can connect to the Internet?  
Questions one to three are used to remove respondents that are under 18 or currently pregnant 
or breastfeeding (covering exclusion criteria three and four for the most part). Questions four 
to seven enable the calculation of body mass index (BMI) and hence classification into a BMI 
category (covering inclusion criterion one, exclusion criterion eight and partially exclusion 
criterion seven by excluding underweight respondents). BMI was calculated using the 
equation 6.1 and the classification system from the NULevel trial, illustrated in table 6.2, was 
used. 
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𝐵𝑀𝐼 =
𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝐾𝐺
(ℎ𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑚𝑒𝑡𝑟𝑒𝑠)2
 𝑜𝑟 703 × 
𝑤𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑙𝑏𝑠
(ℎ𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑖𝑛𝑐ℎ𝑒𝑠)2
 (6.1) 
Questions eight to 10 provide an insight into the respondent’s weight management history 
(covering inclusion criterion two and, to an extent, exclusion criterion two by use of the word 
‘attempted’). Questions 11 and 12 are used to determine whether an obese person that has lost 
≥5% of their weight in the past 12 months, according to their responses in questions four to 
10, meet the other relevant criteria from the NULevel trial (covering inclusion criteria four 
and five). Figure 6.3 illustrates the way these screening questions were used to classify 
respondents into one of the three user groups. 
Table 6.2 BMI Classifications 
Classification BMI (South Asian)12 BMI (All Other Ethnicities) 
Underweight <1<18.5 1.    <18.5 
Normal 18.5-22.9 18.5-24.9 
Overweight 23-27.4 25-29.9 
Obese 27.5+ 30+ 
 
Defined in full, the PSU group is a group of individuals that: have been obese in the past 12 
months and are still obese; have lost ≥5% of their weight in the past 12 months; are able to 
use a mobile phone to access the Internet; are able to use a set of standing scales; are not 
currently pregnant or breastfeeding; and do not weigh over 175kg. This group is therefore 
subtly different to the SU group, because at the baseline of the NULevel trial it was not 
necessary that the participants were still obese (e.g. an individual that was obese and lost ≥5% 
of their weight, moving them into the overweight classification, are excluded here whereas 
they wouldn’t have been in the trial). This is a consequence of arranging the screening 
questions to make them as efficient as possible, as well as to reduce the programming 
requirements of the survey. For completion, the PB group are defined as group of individuals 
that are overweight, or are obese but do not meet the NULevel trial criteria and the NU group 
are defined as a group of individuals that are a normal weight. 
  
                                                 
12 BMI classifications are different for individuals of South Asian descent, see WHO Expert Consultation (2004). 
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Figure 6.3 Screening Questions for the Online Panel Sample 
 
The online panel sample was recruited using Research Now (http://www.researchnow.com), a 
global market research company that owns large nationally representative panels of individuals 
that can be invited to respond to online surveys. Participants are provided with rewards upon 
completion of surveys with a value in the region of £1-2. It was requested that each user group 
contained respondents with a split of sociodemographic characteristics that is comparable to 
the UK general population and that the split was comparable across the three user groups. 
6.4 The Discrete Choice Experiment 
The key component of the survey is the DCE that will be used to elicit the preferences of the 
respondents for hypothetical WLM interventions, hence significant efforts were made to 
follow best practice guidelines throughout (Lancsar and Louviere, 2008; Bridges et al., 2011; 
Reed Johnson et al., 2013). This subsection will outline the design of the DCE in seven 
stages: defining attributes & levels; experimental design; embedded rationality tests; piloting; 
determining sample sizes; online programming and; analysis. 
 
From Q1-7 
> Not under 18 
> Not pregnant 
> Not breastfeeding
> Not underweight 
> Not over 175kg
BMI Classification
Normal
User Group
Non-User
BMI Classification
Overweight
User Group
Potential Beneficiary
BMI Classification
Obese
From Q8-12
> Lost 5% weight in past 12 
months
> Able to use a set of scales
> Has access to a mobile phone 
with Internet access
User Group
Potential Service User 
(if one or more of the above is 
not true: Potential Beneficiary)
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6.4.1 Defining Attributes & Levels 
In this empirical work, the primary aim of the DCE is to examine the differences in 
preferences between different user groups. As a result, once the context of the DCE was 
identified as WLM, and the NULevel trial intervention in particular, its specific application 
was determined during discussions with key members of the NULevel trial team and 
supplemented by reviewing relevant literature. The latter included a highly relevant 
systematic review conducted by members of the trial team and others (Dombrowski et al., 
2014). As the ideal application of the DCE from the perspective of the trial team was to 
provide additional useful information for refining the trial intervention once the trial was 
complete, no additional qualitative research was conducted at this stage as it was not deemed 
necessary. For example, it was felt that a focus group with members of the general public to 
discuss WLM interventions may well have provided interesting information but would not 
have provided superior guidance on how best to frame the NULevel trial intervention in a 
DCE compared to guidance from the trial team. Another concern was that involving NULevel 
trial participants in qualitative work (or piloting) could potentially interfere with the trial and 
possibly result in fewer eligible participants for the SU group (i.e. if participation in 
qualitative work ruled them out of completing the survey at a later date). 
During the discussions with the trial team, several research questions were identified that could 
be investigated using the DCE. Three important questions were: 
▪ Would reminders delivered by a different medium be preferred? 
Reminders for individuals (in the treatment arm) to weigh themselves were sent via text 
message. As the efficacy of these reminders is so important to the intervention, the trial team 
were interested in determining whether it would be better to deliver them via an alternative 
delivery mode. 
▪ How important is face-to-face feedback? 
As one aim of the NULevel trial is to produce a scalable intervention, the trial team believed 
that it may be beneficial if the intervention could be delivered without the need for any face-to-
face feedback. The trial team wished to know whether this would be acceptable to participants 
and hence it was considered important to examine the importance of face-to-face feedback 
relative to other delivery modes. 
▪ Would individuals be willing to pay for a WLM intervention? 
A recent DCE study regarding lifestyle interventions found that individuals would need to be 
incentivised/compensated to take part in the interventions (Ryan et al., 2015). As a result, the 
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initial expectation was that the DCE in this project would consider financial incentives rather 
than personal payments. However, following discussions with the NULevel trial team it was 
decided that it would be unrealistic for incentives to be offered in practice and that one avenue 
for a future roll-out of the trial intervention might be through a weight loss company (rather 
than the NHS). As a result, an examination of willingness to pay was considered extremely 
useful by the trial team. 
Considering the research questions raised during discussions with the NULevel trial team, as 
well as the design of the trial intervention itself, the following six attributes were generated: 
length of the programme; delivery of reminders to weigh yourself; delivery of feedback from 
programme staff; availability of online tool(s) to track your progress; weight re-gain; personal 
cost (per month). Table 6.3 contains full definitions of these attributes as well as the levels 
assigned to each. 
The levels for ‘delivery of reminders to weigh yourself’, ‘delivery of feedback from 
programme staff’ and ‘availability of online tools to track your progress’ were based on the 
existing design of the NULevel trial intervention and feasible alternatives as determined by 
the trial team. The use of four attribute levels was sufficient for these three attributes, hence it 
was decided from this point to aim for four attribute levels (or multiples of four) for the other 
attributes as this would be beneficial in the experimental design stage with respect to level 
balance (Reed Johnson et al., 2013). 
For ‘personal cost (per month)’ the prices of commercial weight loss services such as 
Slimming World and Weight Watchers were examined in order to provide a feasible price 
range. On 20th April 2015, Slimming World were charging approximately £26 a month for 
online membership and approximately £21 a month for group membership (approximations 
due to membership bundles). On the same date, Weight Watchers were charging £12.95 a 
month for their online service, and £21.45 a month for their “monthly pass”. While these are 
not strictly WLM interventions and hence not necessarily competing services, the price range 
of £0-30 per month was deemed suitable for use in the DCE based on this information as 
individuals regularly pay for these services.  
The levels for ‘length of the programme’ were based on the typical programme lengths for 
existing WLM interventions based on a recent systematic review (Dombrowski et al. 2014). 
The review found that the vast majority of trials lasted between 12 and 18 months, with trial 
interventions rarely being delivered beyond 24 months. 
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Table 6.3 Attributes and Levels for the DCE 
Attribute Definition Possible Options Continuous/Categorical Variable Name(s) 
Length of the 
Programme 
How long the programme will last in 
total (in months). 
6 months; 12 months; 18 
months; 24 months 
Continuous Length 
Delivery of 
Reminders to 
Weigh Yourself 
How you are reminded if you forget to 
weigh yourself for over 48 hours (if you 
are reminded at all). 
No reminders; via phone call; 
via text message; via the 
online tool(s) 
Categorical RENone*, REText, 
REPhone, REOnline 
Delivery of 
Feedback from 
Programme Staff 
How you will receive feedback on your 
progress from programme staff. 
Via phone call; via text 
message; via the online 
tool(s); face to face 
Categorical FBFace*, FBPhone, 
FBOnline, FBText 
Availability of 
Online Tools to 
Track Your 
Progress 
The type of online tool(s) provided, if 
any, so that you can track your progress 
independently. 
No online tool; website only; 
mobile phone application 
only; website & mobile phone 
application 
Categorical OTNone*, OTApp, 
OTWeb, OTBoth 
Weight Re-gain The amount of weight that you re-gain, 
as a percentage of the amount that you 
lost originally. 
0%; 10%; 20%; 40%; 60%; 
80%; 90%; 100% 
Continuous Outcome 
Personal Cost (per 
month) 
The cost, to you, of the programme each 
month. 
£0; £10; £20; £30 Continuous Cost 
*Chosen as base level; see section 6.4.7
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Finally, it was decided that the levels for “weight re-gain” should be more comprehensive 
than simply using four levels as the extreme ends of the scale (0% and 100%) are both 
perfectly plausible in this context. To choose only an additional two levels was therefore a 
challenge. Hence the decision was made to include eight attribute levels for the 0-100% 
weight re-gain range in order to provide a wider range of possible outcomes. The aim was to 
increase the sensitivity at the extreme ends, hence the 20 percentage point gaps in the middle 
of the range and 10 percentage point gaps at either end of the scale. 
One could argue that not conducting additional qualitative work with a group, or groups, of 
potential survey participants in order to identify attributes and levels is potentially 
problematic. Indeed, a recently published review has highlighted the importance of qualitative 
work to inform DCE studies (Vass, Rigby et al., 2017). However, Clark et al. (2014) state the 
following in relation to an observed reduction in the use of qualitative methods in DCE 
studies between 2009 and 2012: 
“It would be of little concern, however, if the recent reduction in the use of qualitative 
methods to inform attribute selection was triggered by the wider use of DCEs in 
contexts in which the decision framework is already known (for example, if DCEs are 
conducted alongside clinical trials).” (p.892) 
Hence in this case it is believed that the work undertaken to generate the attributes and levels 
as described in this section is sufficient because the ‘decision framework’ was already known. 
Additional attributes of apparent importance may have been identified had additional 
qualitative work been conducted, but these may not have been particularly relevant to the 
NULevel trial. In addition, the use of four different samples in this study means that 
qualitative work aimed at potential beneficiaries or non-users (for example) may have 
produced irrelevant additional attributes for service users or potential service users. It is also 
possible that the findings of qualitative studies are influenced by the prior experience of the 
participants, hence using potential service users to identify additional attributes might have 
produced attributes that were not important to actual service users (those that had experienced 
‘treatment’). In this case, it was not plausible to conduct qualitative work with NULevel trial 
participants (i.e. service users) as the trial was on-going, as well as the fact that this might 
have reduced the potential number of survey respondents from the trial (i.e. if they were 
excluded from participating as a result of being involved at an earlier stage). 
6.4.2 Experimental Design 
It was decided that the DCE should include two alternatives as well as an opt-out option 
(defined as ‘no programme’). The opt-out option adds an element of realism as individuals 
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would not be forced to partake in a WLM intervention in real life. It is generally accepted that 
this also allows for more realistic uptake rates to be predicted (Clark et al., 2014), which may 
be a useful route for analysis outside of the research questions addressed in this thesis. 
However, it is unclear whether the presence of an opt-out option might have an influence on 
responses. Veldwijk et al. (2014) explored this by providing individuals with both a forced-
choice task (no opt-out) and an unforced choice task (with opt-out). Their results suggest that 
including an opt-out option may influence choice behaviour and they conclude that its 
inclusion may lead to an unnecessary loss of effectiveness in relation to the efficiency of the 
DCE, as many individuals may choose this option. 
In order to minimise any effect of the opt-out option on choice behaviour and to minimise the 
risk associated with too many respondents choosing the opt-out in the first instance (i.e. 
providing unusable data), a second (forced) choice was required for each scenario. The second 
choice asked respondents “of the remaining two options, which would you choose?” This 
format is sometimes referred to as a ‘best-best’ DCE (Ghijben et al., 2014; Lancsar et al., 
2017). The plan at an early stage was to treat the second choice data as a backup. That is, the 
data would only be used in the ‘worst-case scenario’ where too many respondents chose the 
opt-out option in the first (unforced) choice. Therefore, the planned data analyses (see 
subsection 6.4.7) for this empirical work does not include the analysis of the data from the 
second (forced) choice. 
As with any DCE, combining all of the attributes and levels results in a large number of 
potential alternatives. If all of the attributes and levels in table 6.3 were to be used in the DCE, 
this would result in a total of 8,192 possible alternatives (45.81). Clearly this number of 
alternatives is too large to be considered by one individual, hence the DCE has to be designed 
with a far smaller subset of these. Several different software packages can be used to generate 
a range of different types of designs; for this DCE, Ngene (Rose & Bliemer, 2012) was used 
to generate an efficient design. Such designs use the D-optimality criterion in order to 
minimise the joint confidence sphere around the complete set of estimated model parameters 
by maximising the determinant of the inverse of the variance-covariance matrix in maximum-
likelihood estimation (Reed Johnson et al., 2013). Efficient designs are the most commonly 
applied in the health economics DCE literature (Clark et al., 2014). Efficient designs allow for 
attribute interactions to be considered at the design stage. Given the attributes and levels in 
table 6.3, it was thought that interactions between: ‘personal cost’ and ‘length of the 
programme’ (total cost); ‘length of the programme’ and ‘weight re-gain’ (rate of re-gain); as 
well as ‘personal cost’ and ‘weight re-gain’ (cost per % weight re-gain) might be relevant to 
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include in the analysis. Hence, these interactions were incorporated into the experimental 
design. Efficient designs also allow for constraints to be included; in the case of this DCE 
constraints were required because if no online tool is provided, it would not make sense for 
reminders or feedback to be provided via the online tool.  
It is generally considered beneficial to include as many choice scenarios as possible in order 
to generate more data for the choice models. As the intention was to include a transitivity test 
that would require three scenarios (see section 6.4.3), the final design contained forty choice 
scenarios split into four blocks such that respondents would see 10 choice scenarios from the 
DCE design and 13 in total (excluding a practice scenario). This was considered a feasible 
number of scenarios based on existing evidence within the literature (Clark et al., 2014). See 
Appendix B-2 for the full Ngene code used to generate the design, consisting of the number of 
rows and blocks, the constraints and the specifications of the utility functions. Appendix B-3 
contains the full experimental design (i.e. 40 rows) generated from the Ngene code. 
6.4.3 Embedded Rationality Tests 
Two rationality tests were included as part of the DCE component of the survey in order to 
examine research question three: a dominance (or non-satiation) test and a transitivity test. 
The dominance test was included as part of a practice scenario prior to the 13 choice scenarios 
where respondents were given a practice choice between two WLM programmes (and an opt-
out). In this particular scenario, the attribute levels assigned to each of the WLM programmes 
were based on rankings directly-elicited from the respondent earlier in the survey. Programme 
A contained the attribute levels that the respondent ranked as “most preferred” for the 
following attributes: length of the programme; delivery of reminders to weigh yourself; 
delivery of feedback from programme staff; and availability of online tool(s). Programme B 
contained the attribute levels that the respondent ranked as “least preferred” for the same four 
attributes. The attribute levels for ‘weight re-gain’ and ‘personal cost (per month)’ were fixed 
at 0% and £0 for programme A respectively while for programme B these were fixed at 100% 
and £30 respectively as respondents were not asked to rank the levels of these attributes. 
Respondents pass this test if they select programme A over programme B as the former is 
expected to be their most preferred WLM intervention. It should be noted however that as this 
test is part of a practice scenario, and because errors could be made during the ranking task, 
the margin for error is likely to be higher than in dominance tests used in other DCEs. 
The transitivity test, a test of the axiom of transitive preferences (see section 2.1.2), is slightly 
more complex. This test requires a series of choices to be made such that a full-ranking can be 
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determined between three hypothetical WLM programmes (labelled here as X, Y and Z). 
Hence in this two-alternative DCE (ignoring the opt-out) this test requires three choice 
scenarios. As the scenarios are not part of the experimental design of the DCE, the attribute 
levels for X, Y and Z had to be chosen manually. There is no clear guidance in the literature 
regarding the best approach for this decision, but to reduce potential confusion it was decided 
that the combination of attribute levels for X, Y and Z should be unique. In other words, the 
alternatives should not be identical to any alternatives in the experimental design and there 
should be no level overlap across the three scenarios. Table 6.4 defines programmes X, Y and 
Z by their respective attribute levels. 
Table 6.4 The Three Alternatives Used in the DCE Transitivity Test 
Attribute Alternative X Alternative Y Alternative Z 
Length of the Programme 6 months 18 months 12 months 
Delivery of Feedback from 
Programme Staff 
Via phone call Via the online tool Via text message 
Delivery of Reminders to 
Weigh Yourself 
No reminders Via the online tool Via phone call 
Availability of Online Tools 
to Track Your Progress 
Mobile application 
only 
Website only Mobile application 
and website 
Weight Re-Gain 60%  20%  40%  
Personal Cost £20 a month £10 a month £0 a month 
 
The key to passing the transitivity test is the following condition: 
If X ≻ Y and Y ≻ Z then it must be the case that X ≻ Z 
If the opt-out option is ignored, there are a total of 8 (23) rank-order combinations across the 
three choice scenarios where 6 would pass the test (75%). However, if the opt-out is included 
in the specification of the test it becomes more complicated. For example, where O denotes 
the opt-out option: 
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If X ≻ Y ≻ O and Y ≻ O ≻ Z then it must be the case that X ≻ O ≻ Z 
When the opt-out option is considered, there are a total of 216 (33) rank-order combinations 
across the three choice scenarios where 24 would pass the test (11%). 
It was decided that the scenarios relating to the transitivity test should be spread out as evenly 
as possible across the choice task, hence the test was structured in the following way: 
▪ Choice Scenario #4: Programme A = X, Programme B = Y 
▪ Choice Scenario #8: Programme A = Y, Programme B = Z 
▪ Choice Scenario #12: Programme A = X, Programme B = Z 
The positioning and configuration of these choice scenarios remained the same for all 
respondents, regardless of the block (of the experimental design) assigned to them. For clarity, 
figure 6.4 illustrates how the tests fit within the overall choice task seen by respondents. 
Figure 6.4 Structure of the Choice Tasks
 
To examine research question three, comparisons across user groups of the pass rates for each 
rationality test will be made. A simplistic percentage comparison can be made in the first 
instance, but a superior approach would be to estimate a series of regression models with a 
range of independent variables such that other factors can be controlled for whilst exploring 
Practice Scenario
Dominance Test
Scenarios 1-3
Experimental Design #1-3
Scenario 4
Transitivity Test #1
Scenarios 5-7
Experimental Design #4-6
Scenario 8
Transitivity Test #2
Scenarios 9-11
Experimental Design #7-9
Scenario 12
Transitivity Test #3
Scenario 13
Experimental Design #10
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whether there are differences across user groups. For example, equation 6.2 could be 
estimated: 
𝑦𝑖 = 𝜹𝑖 + 𝜸𝑖 + 𝜽𝑖 + 𝛽1𝑆𝑈𝑖 + 𝛽2𝑃𝑆𝑈𝑖 + 𝛽3𝑃𝑆𝑈𝑖 (6.2) 
Where yi is a dummy dependent variable that is equal to one if the rationality test was passed 
by individual i, δi is a vector of sociodemographic variables, γi is a vector of DCE-related 
variables (e.g. the block, difficulty rating) and θi is a vector of attitudinal variables (see 
section 6.7). The user group variables (SUi, PSUi and PBi) are dummy variables indicating 
membership of the user group and the coefficients (β’s) will indicate whether pass rates are 
likely to differ across user groups. Given the dummy dependent variable, the use of ordinary 
least squares (OLS) may be considered suboptimal as the linear probability model (LPM) 
suffers from well-known limitations (Gujarati & Porter, 2009). Therefore, it would be more 
appropriate to use logit models and estimate marginal effects in order to explore how pass 
rates may differ across user groups. 
6.4.4 Piloting 
Once the experimental design and rationality tests had been decided, a test version of the DCE 
task was created for pilot testing. This used only one block of the experimental design and 
respondents were asked to assume that they weigh 80kg and lost 10% of their weight. The 
plan in the final survey was to customise these figures according to respondents’ self-reported 
weight. However, as this requires highly complex programming it was not put into practice 
for the pilot tests. Figure 6.5 shows an example choice task in the pilot. 
Pilots were conducted as ‘think aloud’ pilots; these are conducted face-to-face and require the 
participant to explain their thought processes to the interviewer as they complete the task, and 
are thought to provide more useful information than online pilots (Ryan et al., 2009). Five 
think aloud pilots were conducted in total, with adjustments made to the wording and display 
of the DCE task in between pilots. The participants consisted of two PhD students from the 
Health Economics Group within the Institute of Health & Society at Newcastle University, as 
well as three individuals that had no link to the project nor any economics education.  
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Figure 6.5 An Example Choice Task Used in the Pilots 
 
It was clear from the pilots that the combination of the ‘weight re-gain’ and ‘personal cost 
(per month)’ attributes were often driving the choices being made, however only one 
respondent focused exclusively on one attribute (weight re-gain). The pilots also reinforced 
the expectations of interaction effects between the ‘length of programme’ attribute and others 
such as ‘personal cost (per month)’ (i.e. relating to the total cost of the programme) and 
‘weight re-gain’ (i.e. relating to the rate of weight re-gain).  
Changes made to the survey as a result of these pilots primarily related to clarifications about 
the way the programmes worked as well as general wording. An example of the former is 
that, prior to these pilots, the frequency of feedback was not stated during the DCE task 
however this was subsequently added to one of the information pages before the scenario 
questions. An example of the latter is that, prior to these pilots, the fact that most individuals 
re-gain 100% of their weight loss between 3-5 years (Avenell et al., 2004) was part of the 
wording above the table containing the different alternatives (see figure 6.5). It was felt that 
this was confusing when contrasted with the timeframes used in the “length of programme” 
attribute and hence this fact was moved to the information pages prior to the scenarios. 
83 
 
In addition to the think aloud pilots, Research Now conducted two pilots of the (near-
finalised) survey on 2nd February (n=177) and 10th February 2016 (n=113) in order to ensure 
that the data collection process was running as expected. No issues were identified with the 
DCE data in either pilot, although no choice modelling was undertaken with the pilot data. In 
health economics, where prior knowledge of DCE parameter estimates is rarely available, 
pilots are sometimes used to generate priors which can then be used to create a more efficient 
experimental design (Reed Johnson et al., 2013). In this case, it did not seem appropriate to 
take this approach. This is because the intention was to compare preferences across four 
different user groups; using one set of priors would have contradicted the hypothesis for RQ1, 
whereas using four sets of priors would have resulted in four experimental designs and reduce 
the comparability of the end results. Additionally, with such a small sample size (n=288) in 
the NULevel trial and the possibility of recruiting an insufficient number of respondents to 
run the choice models, it would have been too risky to use NULevel trial participants in a 
pilot (as this would render them ineligible for the final survey). 
6.4.5 Determining Sample Sizes 
The ideal method for determining sample sizes for a DCE is a point of contention in the 
literature. A recent paper states that 70% of the healthcare-related DCE studies published in 
2012 did not clearly report whether and what kind of sample size method was used (de Bekker-
Grob et al., 2015). Of those that did explain their method, there were three general approaches: 
rules of thumb; referring to existing literature; and parametric approaches. For this DCE, the 
former two approaches were utilised. 
Specifically, the rule of thumb by Johnson and Orme (2003) was used once the attributes and 
levels were determined. This involves the use of equation 6.3: 
𝑁 >
500𝑐
𝑡 × 𝑎
  (6.3) 
When considering main effects: c is equal to the highest number of levels used for an attribute, 
t is the number of choice tasks and a is the number of alternatives. For this DCE this translates 
to: 
𝑁 >
500 × 8
10 ×  3
= 𝑁 > 133.33 (6.4) 
This means that in order to estimate the main effects for the DCE the sample size should be 
greater than 133. As three different user groups will be generated from the online panel 
sample, this minimum sample size of 134 is applicable to each user group. This number also 
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satisfies the rules of thumb by Pearmain et al. (1991) and Lancsar and Louviere (2008) as 
these suggest significantly lower numbers would be sufficient. In addition, from the literature 
review in Chapter Four it was clear that this figure is in line with many existing published 
DCE studies. However, in an attempt to ensure that sample sizes would not cause any future 
issues due to analyses involving more than just main effects (for example) this number was 
inflated to a target of 200 respondents per user group (hence a target of n=600 for the online 
panel sample as a whole). The same sample size calculation is relevant for the trial sample, 
however due to the limited numbers of trial participants (n=288) the planned approach was 
simply to maximise the response rate. 
While it has been shown to be commonplace to use rules of thumb it should be noted that this 
is a suboptimal approach. Even the more advanced parametric approaches have been shown to 
be unsuitable (de Bekker-Grob et al., 2015). de Bekker-Grob et al. (2015) suggest a superior 
alternative, however this requires prior knowledge about the significance level, statistical 
power level, the statistical model that will be used in the analysis, initial beliefs about the 
parameter values (i.e. priors) and the DCE design itself. With this information, the variance-
covariance matrix is estimated and the minimum sample size is determined using the Equation 
6.5: 
𝑁 > ((𝑧1−𝛽 + 𝑧1−𝛼)√
∑  𝛾𝑘
𝛿
⁄ )
2
 (6.5) 
Where ∑  𝛾 is the variance-covariance matrix, δ are the effect sizes, 1-β is the power level, α is 
the confidence level and N is the required sample size. As no priors were estimated at the design 
stage for the DCE, it was not possible to use this method.  
6.4.6 Online Programming 
With the experimental design finalised and the rationality tests embedded, the next stage was 
to have the DCE exercise set up as part of the online survey. A market research company, 
Research Now (http://www.researchnow.com), was employed to undertake the online 
programming of the survey (in addition to their role of recruiting the online panel sample).  
A simplistic ranking exercise was included in the survey design prior to the DCE scenarios. 
This involved ranking the attributes in order of importance, as well as the attribute levels for 
each attribute. The attribute levels for the weight re-gain and cost attributes did not have to be 
ranked as these have an obvious rank-order and it was not felt that testing respondents in this 
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exercise would be necessary. Responses to the ranking questions were incorporated into the 
rationality tests as well as the CV task that followed the DCE (see section 6.5). 
In principle, the DCE task should be relatively straightforward for respondents however, due 
to concerns about respondent comprehension of the ‘weight re-gain’ attribute, it was decided 
that absolute values should be provided in addition to the relative attribute level (i.e. the 
percentages). This approach was taken in another DCE study and no issues were reported (see 
the supplementary material of Ho et al., 2015). It was implemented by taking the respondent’s 
self-reported current weight from the screening questions, calculating a 10% weight loss, and 
using this to provide values for the level of the “weight re-gain” attribute. For example, for a 
respondent weighing 80kg the DCE scenario would start with: 
“Imagine that you lost 10% of your current body weight. This would mean that you 
lost 8kg of weight.” 
Hence, in the table containing the DCE attributes and levels instead of stating “50%” (for 
example) in the “weight re-gain” cell it would say “50% (this means 4kg for you)”. It was 
hoped that using absolute weights would improve respondent understanding of the concept of 
WLM, aid respondents’ understanding of the task as percentages can be easily misunderstood 
and add an element of reality to the task for those that had not previously considered losing 
weight. The decision was made to choose an initial 10% weight loss (rather than the 5% used 
in the NULevel trial inclusion criteria and PSU group classification process) because for 
individuals with a normal BMI classification (i.e. the non-user group) a 5% weight loss may 
be too minute to relate to, and/or too minute to be able to feasibly distinguish between 
different attribute levels for ‘weight re-gain’. By way of example, consider a respondent that 
weighs 50kg being told to imagine that they lost 2.5kg (5% weight loss) and being asked to 
compare an intervention where they would re-gain 0.25kg (10%) with an intervention where 
they would re-gain 0.5kg (20%). Neither value is particularly large, nor is the difference 
between them, hence this may be difficult for the respondent to consider. Figure 6.6 shows the 
online presentation of a DCE scenario for a respondent that provided a self-reported weight of 
14 stone (preferred units of measurement: stones and pounds). 
6.4.7 Analysis 
As outlined in Chapter Two, DCEs draw upon Lancaster’s economic theory of value, which 
suggests that it is the characteristics of a good that determine the amount of utility it provides, 
rather than the good as a whole (Lancaster, 1966). DCEs are typically modelled upon a 
random utility framework where individuals have some construct of utility for choice 
alternatives and have perfect discrimination capability (McFadden, 1973). Researchers cannot 
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observe all of the factors affecting the preferences of an individual n, hence the latent utility 
of an alternative i is considered to be made up of two components. The first is an explainable 
component (V), known as an indirect utility function, that is specified as a function of the 
attributes and the second is a random component (Ɛin) representing unmeasured variation in 
preferences; this is expressed in equation 6.6: 
𝑈𝑖𝑛 = 𝑉(𝑋𝑖𝑛, 𝛽) +  𝜀𝑖𝑛 (6.6) 
When faced with the choice between a number of options in a DCE task it is believed that a 
rational individual would choose the option that they prefer, which is assumed to be the 
option that generates the highest utility. Hence alternative i is chosen if and only if that 
alternative maximises their utility amongst all J alternatives included in the choice set Cn. 
This is shown mathematically in equation 6.7: 
(𝑉𝑖𝑛 + 𝜀𝑖𝑛) > (𝑉𝑗𝑛 +  𝜀𝑗𝑛)  ∀𝑗 ≠ 𝑖 ∈ 𝐶𝑛 (6.7) 
Rearranging this gives equation 6.8: 
(𝑉𝑖𝑛 − 𝑉𝑗𝑛) > (𝜀𝑗𝑛 − 𝜀𝑖𝑛)  ∀𝑗 ≠ 𝑖 ∈ 𝐶𝑛 (6.8) 
As (Ɛjn – Ɛin) cannot be observed, we can only consider the probabilities of choice outcomes, 
as in Equation 6.9: 
𝑃𝑖𝑛 = 𝑃𝑟𝑜𝑏(𝑉𝑖𝑛 − 𝑉𝑗𝑛 > 𝜀𝑗𝑛 − 𝜀𝑖𝑛)  ∀𝑗 ≠ 𝑖 ∈ 𝐶𝑛 (6.9) 
The difficulty here is that the actual distribution of (Ɛjn – Ɛin) across the population is not 
known and hence assumptions must be made about which distribution or density function it 
follows in order to estimate choice probabilities. The various different ways in which the 
distribution of (Ɛjn – Ɛin) can be defined gives rise to a variety of probabilistic discrete choice 
models. The specification of the (indirect) utility function to be estimated is another issue 
when attempting to model choice data. It is commonly assumed, for practical reasons, that it 
will take the form of a linear-in-parameters function (Ryan et al., 2007). 
𝑉𝑖𝑛 = 𝐴𝑆𝐶𝑖 + 𝛽1𝑋𝑖1 + ⋯ + 𝛽𝐾𝑋𝑖𝐾 (6.10) 
Equation 6.10 is a linear-in-parameters indirect utility function where there are K attributes 
and generic coefficients (βk) across all alternatives. ASCi is an alternative specific constant 
which captures the mean effect of the unobserved factors in the error terms for each of the 
alternatives. 
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Figure 6.6 Screenshot of a Typical DCE Task in the Online Survey 
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The multinomial logit (MNL) model is the typical first choice when analysing choice data 
where there were two or more alternatives to choose from (McFadden, 1973). The underlying 
assumption of the MNL model is that the disturbances, Ɛin, are independent and identically 
distributed (IID) extreme value type 1 (Gumbel) with mode zero and variance 
𝜇2𝜋2
6
 where µ is 
a positive scale parameter. This gives rise to equation 6.11: 
𝑃𝑖𝑛 =
𝑒𝜇𝑉𝑖𝑛
∑ 𝑒𝜇𝑉𝑗𝑛𝑗∈𝐶𝑛
 (6.11) 
In a single sample where a linear-in-parameters utility function is assumed, it is not possible 
to separate the scale parameter (µ) from that of tastes (β’s); we can only identify the product 
of the two. For this reason it is typically assumed that the scale parameter is equivalent to one; 
this assumption can be relaxed with alternative models. 
The MNL model is estimated by finding the values of the β’s that maximise the following 
log-likelihood function (equation 6.12): 
𝐿𝑛𝐿 = ∑ ∑ 𝑦𝑖𝑛(𝑙𝑛(𝑃𝑖𝑛)) = ∑ ∑ 𝑦𝑖𝑛
𝑖∈𝐶𝑛
{𝛽′𝑋𝑖𝑛 − 𝑙𝑛 ∑ 𝑒𝛽′𝑋𝑗𝑛
𝑗∈𝐶𝑛
}
𝑁
𝑛=1𝑖∈𝐶𝑛
𝑁
𝑛=1
 (6.12) 
The assumption of independent errors leads to the independence of irrelevant alternatives 
(IIA) property (equation 6.13):  
𝑃𝑖𝑛
𝑃𝑘𝑛
=
𝑒𝑉𝑖𝑛/ ∑ 𝑒𝑉𝑗𝑛𝑗
𝑒𝑉𝑘𝑛/ ∑ 𝑒𝑉𝑗𝑛𝑗
=
𝑒𝑉𝑖𝑛
𝑒𝑉𝑘𝑛
= 𝑒𝑉𝑖𝑛−𝑉𝑘𝑛  (6.13) 
This assumption suggests that adding or removing an alternative will not affect the choice 
probabilities of the other alternatives in the same proportion. The IIA assumption might not 
always hold and a number of alternative models exist that relax it (Lancsar & Louviere, 
2008).  
The type of choice behaviour that a researcher expects to observe from a sample will typically 
influence the type of choice model used. Researchers are encouraged to consider the possible 
existence of preference heterogeneity in their data (Hauber et al., 2016). This is the 
assumption that preferences differ across individuals, even after any observable differences in 
their characteristics are taken into account. The MNL model does not allow for preferences to 
differ across individuals, hence it assumes preference homogeneity. Given the inability of the 
MNL model to take preference heterogeneity into account, as well as the problematic IIA 
assumption, it is rarely considered appropriate to use this model in isolation. 
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In anticipation of preference heterogeneity, the primary model of interest in this project is the 
mixed logit (MXL) model, also known as the random parameters logit model (Hess & Train, 
2017). The mixed logit choice probability is given by equation 6.14: 
𝑃𝑖𝑛 = ∫
𝑒𝒙
′
𝑖𝑛𝜷
∑ 𝑒𝒙
′
𝑗𝑛𝜷
𝑗∈𝐶𝑛
𝑓(𝜷|𝜽)𝑑𝜷 (6.14) 
Where f(β|θ) is the density function of β. Given that respondents will make several choices in 
the DCE, the probability of a particular sequence of choices is given by equation 6.15: 
𝑆𝑛 = ∫ ∏ ∏ [
𝑒𝒙
′
𝑖𝑛𝑡𝜷
∑ 𝑒𝒙
′
𝑗𝑛𝑡𝜷
𝑗∈𝐶𝑛
]
𝑦𝑗𝑛𝑡
𝑓(𝜷|𝜽)𝑑𝜷
𝐽
𝑗=1
𝑇
𝑡=1
 (6.15) 
Where yjnt = 1 if the individual chose alternative j in choice situation t and 0 otherwise. The θ 
parameters can be estimated by maximising the simulated log-likelihood function (equation 
6.16): 
𝑆𝐿𝐿 = ∑ 𝑙𝑛
𝑁
𝑛=1
{
1
𝑅
∑ ∏ ∏ [
𝑒𝒙
′
𝑖𝑛𝑡𝜷𝑛
[𝑟]
∑ 𝑒𝒙
′
𝑗𝑛𝑡𝜷𝑛
[𝑟]
𝑗∈𝐶𝑛
]
𝑦𝑗𝑛𝑡𝐽
𝑗=1
𝑇
𝑡=1
𝑅
𝑟=1
} (6.16) 
Where 𝜷𝑛
[𝑟]
 is the r-th draw for individual n from the distribution of β. This approach can be 
implemented in Stata using the user-written mixlogit command (Hole, 2007a). 
In lieu of any evidence that there are interactions that should be taken into account, a main 
effects MXL model is the a priori preferred specification for analysing the choice data. All 
variables will be modelled as random and normally distributed. The indirect utility function 
will be linear and additive and specified as in equation 6.17: 
𝑉𝑗 = 𝛼𝐴𝑆𝐶 + 𝛽1𝐿𝑒𝑛𝑔𝑡ℎ + 𝛽2𝐹𝐵𝑃ℎ𝑜𝑛𝑒 + 𝛽3𝐹𝐵𝑂𝑛𝑙𝑖𝑛𝑒 + 𝛽4𝐹𝐵𝑇𝑒𝑥𝑡
+ 𝛽5𝑅𝐸𝑇𝑒𝑥𝑡 + 𝛽6𝑅𝐸𝑃ℎ𝑜𝑛𝑒 + 𝛽7𝑅𝐸𝑂𝑛𝑙𝑖𝑛𝑒 + 𝛽8𝑂𝑇𝐴𝑝𝑝
+ 𝛽9𝑂𝑇𝑊𝑒𝑏 + 𝛽10𝑂𝑇𝐵𝑜𝑡ℎ + 𝛽11𝑂𝑢𝑡𝑐𝑜𝑚𝑒 + 𝛽12𝐶𝑜𝑠𝑡 
(6.17) 
Where ASC is an alternative-specific constant that is equal to one in alternatives one and two 
of each choice task (indicating a WLM programme). Length, outcome and cost are all 
continuous variables. The other variables are categorical and dummy coded. 
The sign on the model coefficients indicates whether a change in the attribute level has a 
positive or negative effect on utility, however the magnitude of the coefficients in their own 
right provide little meaningful information. Additionally, given the fact that scale will differ 
across models for each user group, the coefficients cannot be meaningfully compared across 
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models (Vass, Wright et al., 2017). This poses a challenge when it comes to determining 
whether differences in the results are due to differences in preferences or differences in scale. 
Given that this analysis will compare preferences across four user groups (as opposed to two) 
and intends to use the MXL model, the traditional method of identifying and adjusting for 
differences in scale using MNL models i.e. the Swait and Louviere test (Swait & Louviere, 
1993) cannot easily be applied. Adjustments using this approach are only suitable for MNL 
models. As preference heterogeneity is likely to exist (and therefore MNL models are not 
desirable in this context), the preferred approach is to focus on the issue of preference 
heterogeneity rather than scale heterogeneity.  
As coefficients will not be adjusted as a result of any possible scale heterogeneity between 
user groups, two approaches are taken to interpret the data which are not affected by 
differences in scale. One approach is to estimate the relative importance for each attribute as a 
percentage for each user group using the method used by Jiang & Fraenkel (2017). The first 
stage of this process is to determine the utility range for each attribute. For example, imagine 
a categorical variable where the smallest coefficient is -0.5 and the largest coefficient is 0.5; 
here, the range is equal to one. For a continuous variable that has levels spanning 0 to 30 (e.g. 
the cost coefficient in this DCE), the range is 30 multiplied by the coefficient. The relative 
importance is then calculated by dividing the range for each individual attribute by the total 
range (all attributes). This information can be compared across models as is necessary to 
examine RQ1 in this project because the effect of the scale parameter is removed. 
Another approach to compare the results from each model is to estimate marginal rates of 
substitution (MRS). A MRS that is of particular interest for RQ2 is willingness to pay (WTP). 
This can be calculated using equation 6.18: 
𝑊𝑇𝑃 = −
𝛽𝑋
𝛽𝐶𝑜𝑠𝑡
 (6.18) 
Where βX is the coefficient for the attribute or attribute level of interest. It is not necessarily 
the case that MRS examined should be WTP, however this provides the easiest information to 
interpret. The user-written command wtp in STATA allows for WTP estimates to be 
calculated post-estimation with accompanying confidence intervals (Hole, 2007b). 
It should also be noted that scale heterogeneity can exist between individuals within each user 
group (Vass, Wright et al., 2017). One approach to deal with this when using MXL models is 
to estimate a full covariance matrix, as differences in scale within a model is a form of 
correlation across coefficients (Hess & Train, 2017). Therefore, MXL models will be 
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estimated with a full covariance matrix in the first instance. However, this requires that a 
significant number of additional parameters are estimated and, as a result, may be a challenge 
to run. 
6.5 The Contingent Valuation Tasks 
In order to provide additional data for research question two, CV questions were included as 
part of the survey. It was decided that the format of the CV questions would be open-ended to 
reduce the likely time commitment required from the respondents. In addition, as the concept 
of WLM and WLM interventions specifically are defined within the DCE task, and because 
the DCE task is more cognitively demanding, it was decided that the CV questions should be 
presented afterwards. The CV questions used in the survey are unique in three ways: the 
individual respondent determines the perspective of the question; the WLM programme being 
valued is determined by the respondent’s own direct rankings of the attribute levels used in 
the DCE; and WTP is elicited multiple times for the same programme, but with various 
different outcomes (i.e. levels of weight re-gain). These are addressed in turn in more detail 
below. 
6.5.1 Perspective 
The type of value elicited from a CV question varies depending on the wording of the 
question (Smith, 2007). For example, an individual that has a normal BMI classification could 
be asked how much they are willing to pay for a WLM intervention to use now (i.e. a use 
value); in this example, the respondent must imagine that they do in fact need a WLM 
intervention. As explained in Chapter Two, other common perspectives give rise to option 
values or an estimate of a caring externality. 
The main focus of this project is to examine the differences in preferences between different 
samples, rather than the effect of alternate perspectives on preferences. Despite this it was 
decided that respondents should only see a relevant perspective for them (rather than just 
one), as it was hypothesised that this pragmatic approach would generate more realistic data. 
The hypothesis is that forcing an individual that would happily state outright that they have 
absolutely no interest in a WLM programme to provide a WTP value for a WLM programme 
is not likely to provide valuable or reliable responses, even if they are asked to pretend that 
they do need a WLM programme. The selection of a relevant perspective was done by using 
the following survey question to split the respondents into groups (hereby referred to as the 
‘self-selection question’): 
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“Would you like a weight loss maintenance programme, similar to those described in the 
choice scenarios, to be made available? (Please choose one option)” 
The possible responses to this question and the CV task that would follow each response are 
described in table 6.5. 
Table 6.5 Responses to the CV Self-Selection Question & Associated CV Task 
Responses to the Self-Selection Question Associated CV Task 
1. Yes – because I would like to use a programme like this Use Value 
2. Yes – because I would like to use a programme like this & I want 
it to be available for others to use too 
Use Value 
3. Yes – because I might want to use a programme like this in future Use Value 
4. Yes – because I might want to use a programme like this in future 
& I want it to be available for others to use too 
Use Value 
5. Yes – I would not use it myself, but I want it to be available for 
others to use 
Caring Externality 
6. No – I do not think a programme like this should be made available None 
 
If a respondent selected options one to four and were faced with the use value CV task, they 
would initially see the following question (the programme described varies across respondents 
– see section 6.5.2): 
“Would you be willing to pay to take part in this weight loss maintenance programme 
if it was offered to you?” 
If the respondent answered “no” to the above question the task would end. However, if they 
answered “yes”, the respondent would then be asked: 
“What is the maximum amount you would be willing to pay (per month, for 12 months) 
to take part in this weight loss maintenance programme?” 
Respondents were given the option to state that they are not sure how much they are willing to 
pay. After responding to this question, respondents would see the previous question again, with 
a marginally different programme defined in terms of weight re-gain (see section 6.5.3) and the 
process would continue until they stated that they are not willing to pay for a programme (or 
until they reached the 100% weight re-gain outcome; see section 6.5.3). 
Respondents choosing option five in the self-selection question would face the caring 
externality question, where the WLM programme is not specifically defined: 
“Would you be willing to pay (as a one-off payment) to enable a weight loss 
maintenance programme to be provided to those that need it?” 
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If the respondent answered “no” to the above question the task would end. However, if they 
answered “yes”, the respondent would then be asked: 
“What is the maximum amount that you would be willing to pay (as a one-off 
payment) in order to enable a weight loss maintenance programme to be provided to 
one individual for 12 months?” 
Respondents were given the option to state that they are not sure how much they are willing 
to pay. Once an answer is given the task ends for these respondents.  
Following the CV tasks, all respondents are directed to an open-ended comment box. For 
those that selected option six in the self-selection question, they would be directed to this 
comment box straight away (i.e. they would not complete a CV task). The assumption is that 
these respondents would not be willing to pay for a WLM programme and might not provide 
meaningful data if they were asked to pretend that they needed a WLM programme, given 
that they do not think that WLM programmes (as described in the survey) should be made 
available. 
6.5.2 The Object Being Valued 
With any CV question, it is important to be clear as to what the respondent is being asked to 
value. In 1993, the National Oceanic and Atmospheric Administration (NOAA) stated the 
following in their report: 
“If CV surveys are to elicit useful information about willingness to pay, respondents 
must understand exactly what it is they are being asked to value (or vote upon) and 
must accept the scenario in formulating their responses. Frequently, CV surveys have 
provided only sketchy details about the project(s) being valued and this calls into 
question the estimates derived therefrom.” (Arrow et al., 1993, p.13) 
As the questions were delivered after the DCE task it was decided to utilise the attributes & 
levels from the DCE to describe the WLM programmes to the respondent in the use value CV 
task. However, as no clear a priori expectations existed regarding how individuals might 
value some of the attributes in the DCE task, it would have been somewhat arbitrary to 
specify a single WLM programme. As a result it was decided that the respondent’s directly-
elicited rankings (from the questions prior to the DCE task) would be used and the 
combination of the respondents “most preferred” attribute levels would be shown for the 
following three attributes: delivery of feedback about your weight; delivery of reminders to 
weigh yourself; and availability of online tool(s). The intention was to try and ensure that the 
respondents saw a programme that, at the very least, had the potential to be of value to them. 
In theory, this would improve the response rate. Whilst some individuals may have a strong 
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preference regarding the length of the programme, this attribute was not varied between 
respondents because it was decided to elicit WTP per month for a WLM programme with an 
overall length of 12 months (to enable clearer comparisons with the DCE WTP estimates). 
The outcome attribute was changed iteratively (see section 6.5.3) but in the first WTP 
question this was set to 0% weight re-gain. This meant that, if the respondents’ directly-
elicited rankings were accurate, or at least stable, across the survey, it could be concluded that 
if the respondent was not willing to pay for the WTP programme shown in the first iteration 
then the respondent would be willing to pay for any WLM programme. In other words, the 
assumption is that if the respondent would not pay for their most-preferred programme with 
the best possible outcome, they would not be willing to pay for any programme. 
In the caring externality CV task, the WLM programme was not specifically defined. It was 
decided that defining the WLM programme was not necessary considering that it would be 
consumed by someone else and that defining a specific programme could lead to biased 
responses. For example, defining the programme using the respondents’ preferred attribute 
levels from the ranking exercise could artificially inflate the WTP estimate (and vice versa).  
6.5.3 Iterative Outcomes 
This is only relevant for respondents that self-selected options one to four (use value CV task). 
As stated previously, the first CV question used the 0% weight re-gain outcome. In order to 
examine the importance of the outcome on respondents’ willingness to pay, this was changed 
iteratively. If a respondent stated that they were willing to pay for a WLM programme that 
results in 0% weight re-gain, then the respondent would be asked if they would be willing to 
pay for a programme that results in 10% weight re-gain (where all else would remain equal). 
This continued up to 8 times (i.e. all of the attribute levels for the ‘weight re-gain’ attribute), 
with the process ceasing if the respondent expressed that they would not be willing to pay for 
a particular WLM programme. The idea was that this could provide more useful information 
for the NULevel trial, given that the trial outcomes had not been determined at this stage.  
After an examination of the pilot data from the Research Now pilot on 2nd February 2016, it 
became clear that some respondents did not notice the change in the outcome attribute 
between the different iterations due to unexpected results and some comments in the open-
ended comment box that followed the CV task. This was addressed by highlighting the 
changes to the weight re-gain attribute on the page in yellow. In the subsequent pilot on 10th 
February 2016 it appeared that confusion regarding this process had been significantly 
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reduced. Figure 6.7 shows how a typical question in a use value CV task was displayed to 
respondents if they made it to the second iteration (10% weight re-gain). 
Figure 6.7 Screenshot of a Typical Use Value CV question in the Online Survey
 
6.6 Sociodemographic & Health Questions 
Sociodemographic information is highly useful when comparing the characteristics of 
different samples. It is common to use such information as covariates in different analyses 
(e.g. the logit models for the rationality tests, see section 6.4.3). The sociodemographic 
questions used in the survey included: marital status; highest educational qualification; 
number of dependent children; age of youngest dependent child; number of individuals that 
the individual lives with; employment status and; household income (banded). The wording 
of these questions was taken directly from the wording used in the NULevel trial in the 
baseline questionnaire. This was due to the fact that the initial plan was to not include these 
questions in the trial sample and to instead link trial participants’ data from the trial with the 
data obtained in this project. This plan was later changed (see section 6.8) but the wording of 
the questions remained the same on the basis that they were appropriate for use in this project. 
Generic health information is also useful when comparing the characteristics of different 
samples. Whilst information about respondents’ weight is collected during the screening 
questions, generic health information can provide a broader insight into the health status of 
respondents. Due to this, the EuroQol Group’s EQ-VAS and EQ-5D-5L generic measures of 
health status were included following the sociodemographic questions (Herdman et al., 2011). 
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The EQ-VAS is a tool that asks respondents to indicate how good or bad their own health is 
on that day on a scale of 0 (worst imaginable health state) to 100 (best imaginable health 
state). The EQ-5D-5L describes health on five dimensions: pain/discomfort; (ability to take 
part in) usual activities; anxiety/depression; mobility; self-care. Within each dimension there 
are five options (levels) ranging from extreme problems or no problems at all. The descriptive 
data is informative in its own right but is commonly also converted into a utility value on a 
scale where 0 is equivalent to being dead and 1 is equivalent to perfect health, with negative 
values (worse than dead) possible. The values for each health state vary depending on the 
tariff used but given the currently limited options available for this particular instrument, the 
tariff for England developed by Devlin et al. (2017) will be used in this project. 
In addition to the EQ-VAS and EQ-5D-5L, both samples faced an additional question asking 
respondents about the BMI classification that they believed that they fit into. It was thought 
that this question might provide useful information when combined with the BMI 
classification derived from the height and weight information in the screening questions. In 
other words, a variable indicating whether respondents got their BMI classification incorrect 
(and in which direction) could potentially be used as a covariate in some analyses.   
Finally, two additional questions were provided to the online panel sample only. The first was 
to explore whether individuals that were classified as overweight or obese according to BMI 
may be due to bodybuilding or other athletic activity rather than, for example, a sedentary 
lifestyle (Jonnalagadda et al., 2004). This is because there may be substantial differences in 
the needs of such individuals in relation to WLM programmes. The second was a question 
asking whether the individuals had taken part in a weight loss maintenance programme (of 
any kind) before. This was included to explore the assumption that most individuals in the 
online panel sample would not have experienced WLM programme. 
6.7 Attitudinal Questions 
Whilst not critical for addressing the research questions in this thesis, attitudinal questions 
were also included in the survey in the final section. Of particular interest was the possible 
effect on preferences of negative attitudes towards obese individuals, given that respondents 
in the non-user group may never have had any individual experience of being overweight or 
obese. To explore this the Belief About Obese Persons (BAOP) scale was included (Allison et 
al., 1991). This scale consists of eight statements where respondents are asked to indicate 
whether they agree or disagree (slightly, moderately or strongly). The scoring system can be 
found in Appendix B-4; higher scores indicate a stronger belief that obesity is not under the 
obese person’s control. An alternate scale, the Universal Measure of Bias: Fat version (UMB-
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FAT) was also considered (Latner et al., 2008) but later rejected in favour of the BAOP scale 
due to concerns about the term ‘fat’ from the NULevel trial team and a member of the 
Newcastle University Ethics Committee (see section 6.8 and Appendix B-6). 
A short-form version of the Marlowe-Crowne scale was also included (Reynolds, 1982). This 
is a well-known scale from clinical psychology that examines whether respondents are likely 
to be susceptible to socially desirable responding (i.e. answering how they think they should 
answer). This was included in part because issues around weight can be quite sensitive to 
some individuals but also as a potentially useful measure when examining various aspects of 
the survey such as stated WTP in the caring externality CV task and self-reported BMI. The 
original scale consists of 33 items (Crowne & Marlowe, 1960), however the version used in 
this survey contains only 13 items (Short Form C). A shorter questionnaire was preferable due 
to the length of the survey. The scoring system can be found in Appendix B-5; higher scores 
potentially indicate that individuals answer in ways that exaggerate their good qualities and 
minimise their bad ones. 
The final question of the survey asks to what extent respondents agree with the following 
statement: 
“Answers to this survey will affect the organisation of/delivery of weight loss maintenance 
programmes.” 
The purpose of this question was to explore whether any differences in preferences across the 
user groups could be explained by the fact that, in some user groups, more people 
agree/disagree with this statement. For example, it could be the case that respondents that 
believe their responses to the survey could be influential may have stated higher WTP values 
in the CV task. 
6.8 Ethical Approval 
Ethical approval for the delivery of the survey to the online panel sample was sought from 
Newcastle University Faculty of Medical Sciences Ethics Committee, with the original 
application sent on 26th March 2015. Responses from two members of the Committee were 
received on 19th May 2015 which raised some minor issues with the information page (shown 
to users prior to starting the survey; see the full survey in Appendix B-1 for the final version) 
and an attitudinal scale that had previously been considered for inclusion in the survey (UMB-
Fat). These responses can be found in Appendix B-6. Amendments to the survey were made 
and responses were sent to the Ethics Committee later that day and ethical approval was 
granted on 18th June 2015 (Code 00874/2015). 
98 
 
As alluded to earlier, the original plan was to make an ethics amendment to the NULevel 
trial’s NHS ethics application in order to provide the survey to the NULevel trial participants. 
This would have allowed data linkage between this project and the NULevel trial. However, 
this plan later changed due to time constraints and ethical approval for the delivery of the 
survey to NULevel participants was sought from Newcastle University Faculty of Medical 
Sciences Ethics Committee. This was obtained via an ethics amendment to the existing 
(approved) ethics application for the online sample, which also included a range of updates to 
the survey following piloting. The amendment was requested on 26th October 2015 and 
granted on 6th January 2016 (Code 00874_1/2016). The final approval letter can be found in 
Appendix B-7. 
6.9 Conclusion 
This chapter outlined the design process for a survey aimed at providing sufficient data in 
order to test the three research questions outlined in Chapter Five. This included the context 
for the survey (case study), the intended sampling process, a section-by-section breakdown of 
the design process for the survey including an overview of intended data analyses, and the 
ethical approval process. The following three chapters will provide the results from the data 
collection and analysis for the online panel sample, the trial sample and the two combined, 
respectively. 
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Chapter 7. Results from the NULevel Trial Sample 
 
The aim of this chapter is to present and summarise the results from the NULevel trial sample 
in relation to the three research questions presented in Chapter Five. The first research 
question relates to whether preferences for a health service differ significantly between 
different user groups (e.g. trial arms), as shown by the results of a DCE. The second, split into 
two parts, first examines whether WTP estimates are different between user groups and 
secondly whether estimates differ between methodologies (DCE and CV). The final research 
question examines whether certain user groups have better defined preferences using the 
results of embedded rationality tests in the survey.  
The chapter begins with a detailed description of the recruitment of the NULevel trial 
participants (section 7.1) and their characteristics (section 7.2). Each research question is then 
addressed in turn with both a description of the results as well as discussion (sections 7.3-7.6). 
Finally, a summary of the results is provided to end the chapter (section 7.7). 
7.1 Response Rates 
The survey was hosted online by a market research company (Research Now; 
http://www.researchnow.com) and NULevel trial participants were invited to participate via 
email. The URL that linked participants to the survey contained a unique code for each trial 
participant in order to keep track of the number of unique responses and to avoid contacting 
individuals that had already completed the survey. 
NULevel trial participants were only invited to participate in the survey if they had previously 
consented to being contacted about future related studies at Newcastle University. This was 
the case for 247 of the 288 trial participants (86%). The details of participants that had 
consented were passed on iteratively by a member of the NULevel trial team because 
participants could not be contacted until after their 12-month assessment in the trial. As a 
result, email invitations to participate in the survey were sent out on three different occasions 
in 2016: 25th February (n=150), 21st April (n=34) and 27th June (n=63). Participants that had 
not responded within four weeks were sent an email reminder, with the exception of the 63 
participants that were invited on 27th June. This is because data collection for the PhD project 
formally ended two weeks later on 11th July in order to allow enough time for data analysis to 
be completed and the results to be written up in time to meet the thesis submission target. 
Additionally, while 247 invitations were sent, six invitations were not successfully delivered. 
Of the 241 successfully invited participants the total number of complete responses was 113, 
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providing an effective 47% response rate (although in practice recruitment continued beyond 
11th July 2016). A flowchart of the recruitment process can be found in figure 7.1. 
Figure 7.1 Flowchart of the Trial Sample Recruitment Process 
 
Analysis of the codes that were embedded in the invitation URLs to identify respondents 
indicated that 27 unique trial participants accessed the survey but failed to complete it (up 
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until 11th July 2016). These respondents were evenly split across the two arms of the trial; 14 
were in the treatment arm and 13 were in the control arm. It was not possible to contact 
participants that accessed the survey but failed to complete it to determine their reasons for 
this.  
However, there were some technical issues with the delivery of the survey that may explain 
the incomplete responses (as well as the response rate on the whole). First, when the survey 
was initially rolled out, the market research company’s usual security settings were enabled. 
These settings are in place to prevent individuals in their online panels from filling out 
surveys multiple times. Due to the settings, some NULevel trial participants could not access 
the survey and others could not return to the survey if they left in error. Secondly, in the 
NULevel trial most correspondence occurred over mobile phone. As a result, a significant 
percentage of respondents attempted to access the survey using a mobile phone. Once this was 
realised by the market research company, they indicated that the survey was unstable when 
accessed using a mobile phone and future invitation emails were adjusted accordingly. 
However, this is likely to have had an effect as the first wave of invitations covered more than 
half of the total participants that were available to be contacted. 
7.2 Respondent Characteristics 
The 113 respondents that completed the survey were spread relatively evenly across trial 
arms: 52 were in the treatment arm and 61 were in the control arm. Table 7.1 summarises the 
characteristics of respondents across the whole trial, as well as split by trial arm. 
On the whole, respondents are closer to retirement age than working age, very well educated 
and much more likely to be female than male. Most respondents are employed (full-time or 
part-time) and those that are not are typically retired. Household income is slightly more 
varied across the sample, with a significant number of respondents in each of the categories. 
With regards to health-related characteristics, the majority of the sample are overweight or 
obese (in equal proportions) however the general health measures suggest that health is good 
on the whole; the average VAS value is 79 and the average EQ-5D-5L utility value is 0.887. 
There is very little evidence to suggest that characteristics differ significantly between 
respondents from each of the trial arms, as indicated by the p-values in table 7.1. The only 
characteristic where there is some (moderate) evidence to suggest that the two trial arms differ 
is the BMI classifications. The control arm has far more obese individuals and fewer 
overweight individuals relative to the treatment arm. This is a logical difference, given that 
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the control arm had not recently received a weight loss maintenance intervention for a 12-
month period. 
Table 7.1 Respondent Characteristics (Trial Sample) 
 
All Treatment Control p-values1 
n 113 52 61  
Age (mean) 49 48 50 0.493 
18-24 0 (0%) 0 (0%) 0 (0%)  
25-34 12 (11%) 4 (8%) 8 (13%)  
35-44 34 (30%) 14 (27%) 20 (33%)  
45-54 32 (28%) 17 (33%) 15 (25%)  
55+ 35 (31%) 17 (33%) 18 (30%)  
Gender    0.251 
Male 29 (26%) 16 (31%) 13 (21%)  
Female 84 (74%) 36 (69%) 48 (79%)  
BMI Classification 
 
  0.041 
Normal  7 (6%) 2 (4%) 5 (8%)  
Overweight 53 (47%) 31 (60%) 22 (36%)  
Obese 53 (47%) 19 (37%) 34 (56%)  
Education    0.498 
Higher (University) 65 (58%) 34 (65%) 31 (51%)  
Further (College) 23 (20%) 10 (19%) 13 (21%)  
Secondary (School) 20 (18%) 6 (12%) 14 (23%)   
None 2 (2%) 1 (2%) 1 (2%)  
Other 3 (3%) 1 (2%) 2 (3%)  
Employment    0.406 
Employed (full-time) 64 (57%) 29 (56%) 35 (57%)  
Employed (part-time) 13 (12%) 5 (10%) 8 (13%)  
Student 1 (1%) 0 (0%) 1 (2%)  
Retired 20 (18%) 13 (25%) 7 (11%)  
Homemaker/Caregiver 4 (4%) 2 (4%) 2 (3%)  
Unemployed 2 (4%) 1 (2%) 1 (2%)  
Other 9 (2%) 2 (4%) 7 (11%)  
Household Income    0.439 
£20,000 or less 18 (16%) 7 (13%) 11 (18%)  
£20,001 - £40,000 39 (35%) 22 (42%) 17 (28%)  
£40,001 - £60,000 33 (29%) 13 (25%) 20 (33%)  
£60,001 and above 23 (20%) 10 (19%) 13 (21%)  
Health (Visual Analogue Scale; 0=Dead, 100=Perfect Health)  0.888 
Mean 79.0 79.2 78.8  
(Standard Deviation) (17.11) (17.52) (16.89)  
Health (EQ-5D-5L Utilities2; 0=Dead, 1=Perfect Health)  0.999 
Mean 0.887 0.888 0.887  
(Standard Deviation) (0.128) (0.145) (0.112)  
1p-values based on chi2 tests (categorical) and one-way ANOVA (continuous)  
2English population utilities from Devlin et al. (2017) 
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7.3 Research Question One 
RQ1: To what extent do preferences for a health service, elicited via a discrete choice 
experiment, differ between different user groups, and why might these differences occur? 
7.3.1 Results 
Table 7.2 presents the output from mixed logit models with all parameters set as random (and 
normally distributed) using 1,000 Halton draws. This means that preference heterogeneity is 
controlled for and the coefficients are the mean values for each parameter, hence the standard 
deviations are also reported. Models were also estimated with a full covariance matrix in 
order to try and address (within-sample) scale heterogeneity; however, the results were 
deemed unreliable. The results in table 7.2 are generally consistent with the results from 
conditional logit models that were also estimated (see Appendix C-1), indicating that the 
results are relatively robust. The statistical significance of numerous standard deviations 
across the three models in table 7.2 indicates the presence of preference heterogeneity 
between respondents, suggesting that mixed logit models are more suitable than conditional 
logit models in this case. 
The results from model one in table 7.2 suggest that respondents from the NULevel trial did 
not typically make choices based on the length of the programme (as indicated by the lack of 
statistical significance for the length coefficient). This model suggests that respondents 
strongly prefer to receive feedback via text message relative to face to face (1.006, p<0.01). 
There is also some mild evidence to suggest that respondents prefer to receive feedback via 
phone call relative to face to face (0.500, p<0.1). With respect to receiving feedback via 
online tool(s) relative to face to face it appears that respondents are indifferent, however there 
is evidence of preference heterogeneity here indicated by the statistically significant standard 
deviation. Regardless of the delivery mode, respondents prefer to receive reminders relative to 
not receiving any. There is a clear hierarchy here, with reminders via the online tool(s) the 
most preferred and reminders via text message the least preferred. It is also the case that, 
while indifferent to each online tool individually, respondents appear to prefer the 
combination of a mobile phone application and a website over not having any form of online 
tools (0.543, p<0.05). Finally, respondents prefer lower weight re-gain (-0.071, p<0.01) and 
programmes that cost less (-0.232, p<0.01), although there is clear preference heterogeneity 
associated with these attributes. 
Models two and three in table 7.2 represent the treatment and control arms of the trial, 
respectively. There are some noticeable differences in the magnitudes and statistical 
significance of coefficients between the two models. For example, it appears that the control 
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arm has a stronger preference for the delivery of feedback via phone call as well as via text 
message relative to the treatment arm. In addition, it appears that the strong preference for all 
forms of reminders in model one may largely be driven by the control arm, as the coefficients 
are all larger and more consistent in their statistical significance (all significant at the 1% 
level). It also appears that the overall preference for the combination of a mobile phone 
application and website in model one is driven by the control arm, as the coefficient is 
statistically insignificant for the treatment arm in model two. Finally, the outcome coefficient 
is nearly 50% larger and the cost coefficient is around 38% larger for the control arm in model 
three compared with the treatment arm in model two, however the overall scale of the 
coefficients across model three appears to be larger relative to model two. 
Table 7.2 Results from the Mixed Logit Models (Trial Sample) 
 1. All Participants 2. Treatment Arm 3. Control Arm 
  Coefficient Std. Dev. Coefficient Std. Dev. Coefficient Std. Dev. 
Alt-Specific Constant -0.039  3.492 *** 0.591  2.978 *** -0.115  3.937 *** 
 (0.493)  (0.538)   (0.733)  (0.633)   (0.928)  (0.832)  
Length (months) 0.016   0.066 *** 0.030   0.087 ** -0.009   -0.030   
  (0.015)   (0.020)   (0.023)   (0.039)   (0.023)   (0.027)   
Delivery of Feedback1                 
via Phone Call 0.500 * -0.079   0.285  -0.426   1.049 ** 0.819  
 (0.266)  (0.384)   (0.375)  (0.622)   (0.515)  (0.652)  
via the Online Tool(s) -0.324  -1.555 *** -0.694 * -0.139   -0.150  2.815 *** 
 (0.308)  (0.465)   (0.388)  (0.679)   (0.557)  (0.748)  
via the Text Message 1.006 *** 0.752 ** 0.81 ** 0.578   1.693 *** -0.538  
 (0.251)  (0.302)   (0.356)  (0.466)   (0.496)  (0.468)  
Reminders2                         
via Text Message 0.665 *** 0.553   0.570 * -0.075   1.182 *** 1.268 *** 
 (0.238)  (0.409)   (0.321)  (0.446)   (0.448)  (0.447)  
via Phone Call 0.879 *** 0.723 ** 0.668 * -0.224   1.557 *** 0.619  
 (0.294)  (0.320)   (0.398)  (0.585)   (0.571)  (0.457)  
via the Online Tool(s) 1.414 *** 0.018   1.392 *** 0.018   1.462 *** -1.172 * 
  (0.317)   (0.404)   (0.447)   (0.437)   (0.552)   (0.606)   
Online Tool3                 
App Only 0.329  0.238   0.200  -0.579   0.786 * 1.046 * 
 (0.244)  (0.635)   (0.339)  (0.641)   (0.449)  (0.545)  
Website Only -0.003  -0.382   -0.277  -0.616   0.621  0.520  
 (0.274)  (0.344)   (0.378)  (0.655)   (0.489)  (0.404)  
App & Website 0.543 ** 1.293 *** -0.166  1.065 ** 1.442 *** 2.251 *** 
 (0.260)  (0.405)   (0.364)  (0.467)   (0.516)  (0.721)  
Weight Re-gain (%) -0.071 *** 0.054 *** -0.059 *** -0.037 *** -0.089 *** 0.085 *** 
  (0.009)   (0.007)   (0.010)   (0.007)   (0.018)   (0.019)   
Personal Cost (£/month) -0.232 *** 0.181 *** -0.201 *** 0.195 *** -0.278 *** 0.27 *** 
  (0.032)   (0.023)   (0.039)   (0.038)   (0.052)   (0.055)   
Observations (Sample Size) 3,390 1,560 1,830 
Log Likelihood -701 -333 -358 
AIC  1,426  692 742 
BIC  1,506  762  814 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1. 1 Base level “face to face” feedback; 2 Base level “no 
reminders”; 3 Base level “no online tool”  
107 
 
Additional analysis must be conducted in order to meaningfully compare the results across the 
three models, given the potential differences in scale between samples. Figure 7.2 illustrates 
the relative importance of each attribute for each user group, based on the method outlined in 
section 6.4.7. This involves comparing the range of each attribute relative to the total range 
for all attributes. The ranges for each attribute were calculated using the coefficients from 
table 7.2 i.e. the main effects mixed logit models. When calculating the ranges for each 
attribute, coefficients were treated as equal to zero if they were not statistically significant at 
the 10% level. Hence, for some attributes relative importance is equal to zero. 
Figure 7.2 Relative Importance of the Attributes (Trial Sample) 
 
Figure 7.2 provides some insight into how the preferences of respondents from each trial arm 
differed. The greatest difference is for the relative importance of the online tool attribute; this 
is because, with no statistically significant coefficients in model two of table 7.2, the relative 
importance of this attribute is calculated as 0% for the treatment arm. Other differences in the 
relative importance of the attributes between the two trial arms are minimal. 
In addition to relative importance calculations, an additional area of analysis that can provide 
insight relates to the opt-out option. In total, only one individual in the trial sample chose the 
opt-out option (no programme) in every scenario; this individual was part of the treatment 
arm. On average, respondents in the treatment arm opted out 2.1 times throughout the DCE 
task compared to an average of 1.7 in the control arm (the median value was one for both 
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arms). On the whole, this suggests that respondents from the trial sample were quite unlikely 
to select the opt-out option. 
Additional choice models were also estimated in order to test the significance of attribute 
interactions and to identify whether differences in preferences may be observed based on 
observable characteristics of the respondents (i.e. those that were not varied in the user group 
definitions).  
Results from conditional logit models that contained three interaction terms based on a priori 
expectations (length & cost; outcome & cost; length & outcome) can be found in Appendix 
C-2. In the full sample model there was moderate evidence (p<0.05) to suggest that there is an 
interaction between length and outcome, as well as length and cost. The coefficients on both 
terms were positive but of extremely small magnitude. Likelihood ratio tests between the 
conditional logit models with and without interactions provided weak evidence (p<0.1) that 
the models with interactions provided a better model fit for the full sample but no evidence 
for the models split by trial arm. As a result, it was not felt that it would be beneficial to 
incorporate the interaction terms into the more flexible mixed logit models as this would 
reduce their likelihood of converging, with little expected benefit to model fit. 
Whilst the respondent characteristics in table 7.1 indicate very few observable differences 
between the two trial arms, additional models were estimated containing interactions between 
the alternative-specific constant and various demographic variables. The variables considered 
related to age groups, gender, highest educational qualification, employment status and 
income band. Appendix C-3 provides the results from mixed logit models that included these 
interactions terms, which were not modelled as random parameters. Some of the interaction 
coefficients were statistically significant across the three models, however the overall 
conclusion regarding the preferences of the trial sample were not drastically different. Larger 
differences were observed between the trial arms, including differences in WTP estimates (not 
reported), with the vast majority of the attribute coefficients in the control arm model being 
statistically significant. However, the large alternative specific constant (21.393, p<0.01) 
raised concerns about the reliability of these results. In addition, likelihood ratio tests 
indicated that model fit had improved for the individual arm models but had not improved for 
the pooled, whole trial sample. This raised additional concerns, therefore it was determined 
that these models were not reliable. Given the lack of statistically significant differences in the 
characteristics of the two trial arms, it was felt that the main effects models are likely to be 
reliable on their own. 
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7.3.2 Discussion 
The DCE results appear to be relatively robust across different specifications. It is interesting 
that the length attribute does not appear to have influenced the choices made by the 
respondents. In the context of WLM this is a sensible finding, given that longer programmes 
are likely to provide better outcomes but are also associated with higher costs. Respondents 
appear to value feedback via text message but there is little evidence to suggest that other 
delivery modes are acceptable. This could be explained by the fact that text messages were 
used in the NULevel trial for communication purposes. Respondents also appear to prefer 
reminders over having no reminders, which ultimately is an important part of the intervention. 
However, it is interesting that respondents do not have a stronger preference in the DCE 
results for reminders via text message, given that this is the delivery mode used in the 
NULevel trial. It also appears that respondents do not have a strong preference for the online 
tools, with only the coefficient on the combination of an app and a website being positive and 
statistically significant (at the 5% level). This may be a reflection of the fact that the trial itself 
provided a website which might not have been enjoyed relative to the numerous free, 
commercial resources that exist in the market. However, the prospect of an app in 
combination with this may have been tempting, or at least indicated to respondents that a 
programme that provides both is better value. Finally, it is unsurprising that the outcome and 
cost attributes were highly dominant given that these have strong implications for service 
users. The negative coefficients and the magnitude of the relative importance of these two 
attributes are important when it comes to considering the face validity of these results. 
The comparisons of choice models and relative importance between the trial arms provides 
little evidence to suggest there are any significant differences between the two arms, although 
the control arm may have a stronger preference for online tools. This would be consistent with 
the theory that the online tools in the trial were suboptimal and therefore not considered 
particularly important to the treatment arm. 
There was no evidence to suggest that the included attribute interactions were statistically 
significant, nor was there any convincing evidence that demographic interactions were 
statistically significant. While this may be seen as positive, given that it provides a relatively 
strong justification to focus solely on the main effects models, it may be the case that there is 
a lack of statistical power in the models. In other words, due to the small sample size the 
models with interaction terms may not have enough statistical power to identify possible 
effects.  
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7.3.3 Conclusion 
The results from the DCE suggest that trial participants have preferences for various different 
components of WLM programmes including “process” attributes (those that affect the 
delivery of the service) as well as the outcome and cost of the programmes. That being said, 
the outcome and cost attributes appear to be highly dominant when it comes to the choice 
made by respondents. There is little clear evidence to suggest that preferences differ across 
the two arms of the trials. Additionally, there is next to no evidence that any attribute or 
demographic interactions are statistically significant although this could be due to issues with 
statistical power. 
7.4 Research Question Two Part A 
RQ2a: To what extent do WTP estimates differ between different user groups, and why might 
these differences occur? 
7.4.1 Results (CV) 
Table 7.3 contains the results for each group to the self-selection question; the question that 
determined whether respondents would be provided with a CV exercise or not. A chi-square 
test suggests that the responses to this question do not significantly vary across the trial arms 
(p>0.1). However, if similar responses are collapsed (i.e. one and two; three and four - see 
table 6.5 in Chapter Six), a chi2 test provides moderate evidence (p<0.05) to suggest that the 
responses differ across the trial arms. The apparent differences between the two trial arms are 
that far more people in the control arm selected the option “I would not use X but I want it to 
be available for others” and a higher proportion of respondents in the treatment arm indicated 
that they would “like to use” a WLM programme. Regardless, the vast majority of 
respondents were forwarded to the use value CV task; 94% of respondents from the treatment 
arm and 89% of respondents from the control arm. 
As outlined in Chapter Six, the use value CV questions included in the survey provide WTP 
estimates for each individual respondent’s preferred set-up of a WLM intervention, excluding 
the length (as this was held static at 12 months) and weight re-gain (as this changed in each 
question). Table 7.4 describes the most commonly valued WLM programme from the use 
value CV task, which did not differ between the two trial arms. However, whilst this was the 
most frequent, it was by no means valued by the majority of respondents. In fact, a very large 
range of different programmes were valued across the two arms of the sample; 11 in the 
treatment arm and 19 in the control arm.
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Table 7.3 Responses to the CV Self-Selection Question (Trial Sample) 
 
Response to the “Interest Question” 
All Treatment Control 
n % n % n % 
1. I would like to use x 17 15% 8 15% 9 15% 
2. I would like to use x & want it to be available for others 42 37% 25 48% 17 28% 
3. I might want to use x 13 12% 4 8% 9 15% 
4. I might want to use x & want it to be available for others 31 27% 12 23% 19 31% 
5. I would not use x but I want it to be available for others 9 8% 2 4% 7 11% 
6. I do not think x should be made available  1 1% 1 2% 0 0% 
Total 113 100% 52 100% 61 100% 
       
x = a programme like this (referring to the hypothetical programmes from the DCE task) 
 
Responses 1-4 – forwarded to the “use value” WTP exercise;  
Response 5 – forwarded to the “externality” WTP exercise;  
Response 6 – forwarded to open-ended comment box.
112 
 
Table 7.4 Most Commonly Valued Programmes in the Use Value CV Task (Trial 
Sample) 
Attribute Control Arm Treatment Arm 
Delivery of Feedback via Text Message via Text Message 
Delivery of Reminders via Text Message via Text Message 
Availability of Online Tool(s) Website & App Website & App 
 N=12/54 (22%) N=22/49 (45%) 
 
The questions began by asking respondents if they would be willing to pay for a programme 
with a weight re-gain outcome of 0% and subsequently asked for a maximum price that 
respondents would be willing to pay (per month for 12 months). The outcome was then 
adjusted to the next weight re-re-gain level (i.e. 10%) and the task was repeated. This 
happened until the respondent stated that they were not willing to pay for the specified 
programme. Table 7.5 presents the full results from the use value CV exercise. Three 
respondents were removed from the analysis for indicating that they would be willing to pay 
more at a higher level of weight re-gain (referred to as the ‘logic rule’ hereafter). It was 
assumed that such instances represented erroneous responses or a failure of the respondent to 
fully understand the task. Note that these respondents are still incorporated into the ‘stated’ 
column because they indicated a willingness to pay regardless.  
Of the 103 respondents that faced the task, 81 (79%) stated that they would be willing to pay 
for the WLM programme at 0% weight re-gain. Of those, 67 provided WTP values with a 
median value of £10.00 and a mean value of £17.81. The results split by trial arm indicate that 
much of the variation in WTP came from respondents in the control arm; the maximum value 
in the treatment arm was £30 whereas the maximum value in the control arm was £250. In 
terms of median WTP, the values did not vary at 10% or 20% weight re-gain (i.e. it remained 
at £10.00) and median WTP was identical across trial arms for the 0%, 10% and 20% 
outcome levels. By 60% weight re-gain only 13 respondents indicated that they were willing 
to pay for the programme and only 9 respondents provided a WTP value. When comparing 
the two arms of the trial, it appears that similar numbers of respondents were willing to pay 
(and provided a value) for a programme at each outcome level. One-way ANOVA suggests 
that the average values for each trial arm are not statistically significantly different from one 
another. 
113 
 
Table 7.5 WTP Estimates from the Use Value CV Task (Trial Sample) 
 
  All Respondents (n=113) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD 
0% 103 81 79% 67 65% £10.00 £17.81 32.19 
10% 81 63 78% 50 62% £10.00 £13.66 16.36 
20% 63 43 68% 30 48% £10.00 £10.07 5.79 
40% 43 24 56% 14 33% £8.00 £8.29 5.61 
60% 24 13 54% 9 38% £5.00 £7.11 6.13 
80% 13 5 38% 3 23% £5.00 £8.67 10.02 
90% 5 4 80% 2 40% £3.00 £3.00 2.83 
100% 4 4 100% 2 50% £3.00 £3.00 2.83 
 
                
  Treatment Arm (n=52) Control Arm (n=61) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP)   Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD n n % n % Median Mean SD 
0% 49 39 80% 32 65% £10.00 £12.91 6.39 54 42 77% 35 65% £10.00 £22.29 43.95 
10% 39 35 71% 26 53% £10.00 £11.27 6.17 42 28 52% 24 44% £10.00 £16.25 22.70 
20% 35 22 45% 13 27% £10.00 £10.62 6.85 28 21 39% 17 31% £10.00 £9.65 5.01 
40% 22 12 24% 7 14% £5.00 £7.57 6.50 21 12 22% 7 13% £10.00 £9.00 4.97 
60% 12 5 10% 3 6% £2.00 £7.67 10.69 12 8 15% 6 11% £7.50 £6.83 3.76 
80% 5 4 8% 2 4% £10.50 £10.50 13.44 8 1 2% 1 2% £5.00 £5.00 - 
90% 4 3 6% 1 2% £1.00 £1.00 - 1 1 2% 1 2% £5.00 £5.00 - 
100% 3 3 6% 1 2% £1.00 £1.00 - 1 1 2% 1 2% £5.00 £5.00 - 
Percentages are based on the number of individuals that were forwarded to the exercise from each user group in the first instance (underlined). 
1Those that selected “yes” when asked whether they would be willing to pay (those that select “no” exit the exercise at that stage). 
2Those that provided a value when asked for the maximum amount that they would be willing to pay and did not increase their value at any point during the task (‘logic rule’)
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7.4.2 Discussion (CV) 
The results suggest that the vast majority (n=103; 91%) of respondents from the trial sample 
would, or might, want to use a WLM programme like the ones from the DCE task. Of these, 
81 (79%) would be willing to pay for a WLM programme with their preferred set-up (in terms 
of delivery of reminders, delivery of feedback and availability of online tools) and the best 
possible outcome (0% weight re-gain). There is little difference in the proportion of 
respondents that were willing to pay at this outcome level in each treatment arm; 80% of 
respondents in the treatment arm and 77% of respondents in the control arm. Hence, while 
these are positive results from the perspective of the NULevel trial, there is no evidence to 
suggest that those with experience of the full intervention are more willing to pay than those 
that only received the control intervention.  
A difference between the trial arms can be seen when looking at how many respondents drop 
out of the CV task when weight re-gain changes from 0% to 10%. In the treatment arm, 4 
respondents drop out (10%) whereas in the control arm 14 respondents drop out (33%). It may 
be the case that the treatment arm have a greater tolerance for minor weight re-gain, which 
could be explained by their active participation in the trial. That is, these individuals might 
have a better understanding of the difficulties of achieving 0% weight re-gain through their 
experience of monitoring their weight on a regular basis. Therefore, these individuals may be 
more likely to view a small amount of weight re-gain as a positive outcome, which is how it 
would be regarded by healthcare professionals, considering the outcomes observed in trials of 
WLM interventions (Dombrowski et al., 2014). 
On the whole the data performs as expected, with fewer people being willing to pay as the 
efficacy of the programme decreases. Median WTP decreases steadily as efficacy decreases 
and mean WTP decreases at every outcome level with one exception between the 60% and 
80% outcome levels. Due to the use of the ‘logic rule’, this increase is explained by an 
individual with a low WTP value leaving the task after the 60% outcome level, rather than 
individuals increasing their values at 80%. As a result, it seems fair to conclude that this 
atypical CV task was relatively successful in practice. 
7.4.3 Results (DCE) 
WTP estimates can also be generated from the DCE by calculating the marginal rate of 
substitution (MRS) between an attribute or attribute level and the cost attribute as explained in 
section 6.4.7. Only three of the attributes and attribute levels are statistically significant at the 
1% significance level in the models for each trial arm in table 7.2: reminders via the online 
tool(s); weight re-gain; and cost. Table 7.6 contains the WTP estimates for reminders via the 
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online tool(s) for each trial arm using the models from table 7.2. 
 
Table 7.6 WTP Estimates from the DCE for the Online Tool(s) Attribute (Split by Trial 
Arm) 
Group 
WTP for Reminders via the 
Online Tool(s) 
Confidence Interval 
[Lower, Upper] 
Treatment £6.94 [£2.77, £11.11] 
Control £5.27 [£1.48, £9.05] 
 
The WTP estimates, considering that they relate to monthly payments, are substantive. When 
comparing the magnitude of the estimates between the two trial arms, there is a sizeable 
difference of £1.67. However, the confidence intervals are particularly wide for both 
estimates, with considerable overlap. As a result, there is no evidence that the estimates differ 
between the trial arms. Table 7.7 contains the WTP estimates for weight re-gain for each trial 
arm using the models from table 7.2. 
 
Table 7.7 WTP Estimates from the DCE for the Weight Re-Gain Attribute (Split by 
Trial Arm) 
Group WTP for % weight re-gain 
Confidence Interval 
[Lower, Upper] 
Treatment -£0.30 [-£0.40, -£0.20] 
Control -£0.32 [-£0.39, -£0.25] 
 
The results are interpreted as such: the treatment arm is willing to pay £0.30 on average to 
avoid a percentage point increase in weight re-gain, relative to £0.32 in the control arm. It 
should be clear given the overlap in the confidence intervals that these estimates are not 
statistically significantly different from one another. Figure 7.3 illustrates the WTP estimates 
for weight re-gain for both the pooled sample and the individual trial arms. 
Given this lack of difference across the trial arms, table 7.8 lists the WTP estimates for every 
attribute or attribute level that is statistically significant at the 10%, 5% or 1% level using the 
full sample results in model 1 from table 7.2. There are some substantive WTP estimates for 
various delivery modes of feedback and reminders as well as for the combination level of the 
online tool attribute. For example, respondents would be willing to pay an extra £2.87 per 
month on average to receive reminders via text message. While there is only one instance 
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where the confidence interval covers both a positive and a negative value (for feedback via 
phone call), however the confidence intervals are wide for most estimates. This means that, 
although it is generally clear whether the estimates are positive or negative, there is little 
confidence with respect to whether the estimates are close to the true values. In contrast, the 
confidence interval for the WTP estimate for weight re-gain is particularly narrow providing 
some evidence to suggest that the estimate is reasonably reliable. 
Figure 7.3 WTP Estimates from the DCE for Weight Re-Gain (Trial Sample) 
 
 
Table 7.8 WTP Estimates from the DCE (All Trial Participants) 
Attribute/Attribute Level WTP Estimate 
Confidence Interval  
[Lower, Upper] 
Feedback: Phone £2.16 [-£0.08, £4.40] 
Feedback: Text £4.34 [£2.15, £6.53] 
Reminders: Text £2.87 [£0.80, £4.94] 
Reminders: Phone £3.79 [£1.34, £6.25] 
Reminders: Online £6.10 [£3.51, £8.69] 
Online: Website & App £2.34 [£0.08, £4.60] 
Weight Re-Gain (%) -£0.31 [-£0.37, -£0.25] 
 
 
-£0.45 -£0.40 -£0.35 -£0.30 -£0.25 -£0.20 -£0.15
Whole
Treatment
Control
Whole
Treatment
Control
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7.4.4 Discussion (DCE) 
There is no evidence to suggest that WTP estimates differ substantially between trial arms, 
which is not surprising given the results of models two and three in table 7.2. However, a 
substantial number of WTP estimates can be estimated based on model one from table 7.2 for 
all respondents. It appears that respondents are willing to pay significant amounts per month 
to receive feedback via phone call or via text message. Respondents were also willing to pay 
substantial amounts per month to receive reminders (in particular via the online tool(s)), as 
well as to have access to a combination of both a website and an app. Of all of the WTP 
estimates, the one with the narrowest confidence interval is unsurprisingly the WTP estimate 
for weight re-gain (given the statistical significance of the corresponding coefficients in table 
7.2). 
7.4.5 Conclusion 
With respect to RQ2a, there appears to be little evidence to suggest that WTP estimates differ 
between respondents in each arm of the NULevel trial. The inability to identify a difference 
may be due to low sample sizes in both tasks, given the complexity of the choice models and 
the lack of observations in the CV task. Nonetheless, the preferred specification of the choice 
model provides evidence that respondents are willing to pay for various components of WLM 
programmes and the CV results suggest that a large proportion of respondents are willing to 
pay for an efficacious programme. 
7.5 Research Question Two Part B 
RQ2b: How might WTP estimates differ if they are elicited indirectly or directly? 
7.5.1 Results 
Comparisons between the WTP estimates from the CV task (direct) and the DCE (indirect) 
could be made in a number of different ways. One approach would be to calculate an average 
WTP estimate from the CV questions for the most preferred programme (as determined by the 
ranking questions at the start of the survey) and compare this with an estimate from the DCE 
results based on the same programme; this is similar to what has been done elsewhere (van 
der Pol et al., 2008). However, given the statistical insignificance of numerous attribute levels 
in the DCE analysis this approach is unlikely to provide a convincing comparison.  
An alternative approach, given the results of the two individual tasks, is to use the iterative 
nature of the CV questions to identify a WTP estimate for a percentage point change in 
weight re-gain. As these have already been identified in the DCE (WTPDCE hereafter), the 
estimates from the CV task can be directly compared (WTPCV hereafter). To generate the 
WTPCV estimates, a variable was generated whereby the WTP value at 10% weight re-gain 
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was subtracted from the WTP value at 0% weight re-gain and divided by 10. Table 7.9 
contains the mean WTPCV as well as the WTPDCE estimate. 
Table 7.9 DCE and CV Comparison in WTP for 1% Increase in Weight Re-Gain (Trial 
Sample) 
Group WTPDCE WTPCV Difference p-value 
All 
Respondents 
-£0.31 -£0.62 £0.31 0.4967 
 
The average WTPCV values are not statistically significantly different across the trial arms (p-
values>0.1; not reported). Additionally, as indicated by the p-value in table 7.9, there does not 
appear to be a statistically significant difference between the WTPDCE and the average WTPCV 
value for all respondents. Due to the exceptionally large WTP estimates from the CV task, 
there is a high variance associated with the WTPCV value. This, coupled with the small sample 
sizes, has resulted in the large p-value. 
7.5.2 Discussion 
There appears to be no statistically significant difference between the average direct and 
indirect WTP estimates for the trial participants. As alluded to in the previous section, the 
WTPCV estimate appears to be inflated due to some large values provided in task at the 0% 
outcome level. Even after removing any WTP values that exceed £100 per month, which 
decreases the WTPCV estimate to -£0.17, there is no evidence of a difference between the 
WTPDCE and WTPCV estimates. Previous studies have provided mixed evidence as to whether 
WTP estimates differ between these two methodologies, with at least one study indicating no 
difference between estimates (Ryan, 2004a). However, the comparison being made here is 
perhaps atypical given the isolation of a single component of the WLM programme that was 
valued in the CV task. 
7.5.3 Conclusion 
On the whole there is no evidence to suggest that the WTP estimates from the two preference 
elicitation tasks differ. However, it could be the case that there is not enough data to identify a 
difference in this case. Regardless, the approach taken here is somewhat atypical and it may 
be unwise to compare these results with those from the existing literature. 
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7.6 Research Question Three 
RQ3: To what extent do certain groups have better defined preferences than other user 
groups, and why might these differences occur? 
7.6.1 Results 
Two rationality tests were embedded within the DCE in order examine how well-defined 
respondents’ preferences are, as described in Chapter Six. Table 7.10 presents the pass rates 
for the transitivity test (using two definitions), the dominance test and a combination of the 
three for all respondents as well as split across trial arms. 
Table 7.10 Embedded DCE Rationality Test Results (Trial Sample) 
Group Dominance 
Weak 
Transitivity 
Strong 
Transitivity 
All 3 
All 110/113 (97%) 111/113 (98%) 78/113 (69%) 75/113 (66%) 
Treatment 51/52 (98%) 52/52 (100%) 39/52 (75%) 38/52 (73%) 
Control 59/61 (97%) 59/61 (97%) 39/61 (64%) 37/61 (61%) 
 
The results in table 7.10 are extremely positive; almost all respondents passed the dominance 
test and the weak transitivity test. Furthermore, the pass rate for the strong transitivity test is 
particularly high at 69% of respondents, given that the probability of passing the test at 
random is 11%. The pass rates for all three tests combined is largely reflective of the strong 
transitivity test pass rates due to the exceptionally high pass rates for the other two tests. 
When comparing the two trial arms, the differences in proportions of respondents passing the 
tests are not statistically significant at even the 10% significance level.  
As mentioned in section 6.4.3, logit models could be estimated in order to formally examine 
the factors that may influence the probability of an individual passing one or all of the 
rationality tests. However, the lack of variation in the dependent variables (dummy variables 
indicating whether the test was passed) caused by the high pass rates for the weak transitivity 
and the dominance tests meant that these models would not run due to collinearity. Logit 
models for the strong transitivity test and the combination of all three did not produce logical, 
or statistically significant results either. This is revisited in section 9.5 where data from the 
trial and the online panel are pooled. 
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7.6.2 Discussion 
The rationality test results suggest that respondents from the trial participant sample largely 
behave in a ‘rational’ manner. Only three respondents in the sample failed the dominance test 
and only two failed the weak transitivity test. The latter is particularly interesting. As 
explained in Chapter Six, passing the weak transitivity test means that the respondent has not, 
at any stage within the three test scenarios, contradicted their rank-order of the three WLM 
programmes. This is a necessary but insufficient condition for passing the strong transitivity 
test. A respondent that passes the weak transitivity test but fails the strong transitivity test 
does so because their rank-order is contradicted in relation to their rank-ordering of the opt-
out option (no programme). Even if the rank-ordering of the opt-out option is considered 
important, the majority of respondents also passed the strong transitivity test too, suggesting 
that respondents in this sample were highly consistent in their responses. Whether this 
constitutes a sample of individuals with ‘well-defined’ preferences is up for debate, however 
it certainly appears that respondents in this sample rarely contradicted themselves when 
expressing their preferences in the DCE task. 
One might speculate that the impressive pass rates are due to the high education levels of the 
respondents. Ultimately it is not possible to determine whether this is the case using this 
sample alone; this hypothesis is revisited in Chapter Nine. 
7.6.3 Conclusion 
The results of the rationality tests are particularly strong for the trial participant sample. The 
difference in pass rates between the two arms of the trial are minimal and not statistically 
significant. The factors that influence pass rates could not be explored with this small, and 
relatively homogenous, sample. 
7.7 Overall Conclusion 
On the whole, the DCE results suggest that respondents from the NULevel trial have 
relatively strong preferences for a wide range of characteristics of WLM programmes. These 
preferences go beyond the basic characteristics such as cost and the health outcome and 
include characteristics that relate to the process of care. The DCE results also allow the 
calculation of several WTP estimates, given that many attributes and attribute levels are 
statistically significant. The vast majority of these WTP estimates were sizeable but 
confidence intervals were very wide. In addition, the CV results suggest that the majority of 
respondents from the NULevel trial would be willing to pay for a WLM programme 
providing that it is efficacious. The average WTP values at 0% and 10% weight re-gain are 
substantial, suggesting that respondents value such programmes if they are clinically 
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effective. Finally, it also appears that the respondents have relatively well-defined preferences 
in that the majority passed the embedded rationality tests in the DCE. Throughout, there was 
little evidence to suggest that preferences differed between participants in the two arms of the 
trial, although sample sizes were relatively low for both arms. 
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Chapter 8. Results from the Online Panel Sample 
 
The aim of this chapter is to present and summarise the results from the online panel sample 
in relation to the three research questions presented in Chapter Five. The first research 
question relates to whether preferences for a health service differ significantly between 
different user groups, as shown by the results of a DCE. The second, split into two parts, first 
examines whether WTP estimates are different between user groups and secondly whether 
estimates differ between methodologies (DCE and CV). The final research question examines 
whether certain user groups have better defined preferences using the results of embedded 
rationality tests in the survey.  
The chapter begins with a detailed description of the recruitment of the online panel (section 
8.1) and the characteristics of each user group (section 8.2). Each research question is then 
addressed in turn with both a description of the results as well as discussion (sections 8.3-8.6). 
Finally, a summary of the results is provided to end the chapter (section 8.7). 
8.1 Response Rates 
Recruitment for the online panel sample began on 10th February and concluded on 18th 
February 2016. A total of 682 individuals completed the online survey; a flowchart of the 
recruitment process described below can be found in figure 8.1. The survey was hosted by a 
market research company (Research Now; http://www.researchnow.com), who used their 
extensive panel of respondents to generate the sample. Some individuals were directly invited 
to participate in the survey, whereas others were not invited but could access the survey 
through hyperlinks when logged into the website using their personal user accounts. Due to 
this, it is not possible to generate a true response rate for the online panel sample as the 
number of individuals that were invited will be exceeded by the number of individuals that 
actually accessed the survey. 
However, some information is known about the individuals that accessed the survey and 
failed to complete it. A total of 909 individuals accessed the survey but made it no further 
than the information pages (i.e. they exited before the consent page). This may have been due 
to concerns about the content or the time commitment of the survey.  
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Figure 8.1 Flowchart of the Online Panel Recruitment Process 
 
An additional 4,696 individuals provided consent but did not make it any further than the 
screening questions. The main purpose of the screening questions was to classify the 
respondents into either: the ‘potential service user’ (PSU) group (those that met the NULevel 
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trial criteria); the ‘potential beneficiary’ (PB) group (those that did not meet the criteria but 
are obese or overweight); or the ‘non-user’ (NU) group (those with a normal BMI). Of these 
4,696 individuals, 3,871 could not continue beyond the screening questions due to full quotas. 
This means that, for example, if an individual that was eligible for the PB group filled out the 
screening questions once that particular group had received enough responses, they would be 
unable to progress any further. Contact with Research Now during recruitment confirmed that 
the PSU group was the reason for the high number of rejected respondents. This was expected 
due to the challenging inclusion criteria described in Chapter Six. A further 680 individuals 
were excluded from the survey based on their responses to the screening questions 
(irrespective of the user group quotas). These individuals may have been underweight or 
pregnant, for example. Finally, 145 respondents failed to complete the screening questions 
once they had begun the survey. It may have been the case that these individuals would have 
been excluded, or removed due to full quotas, had they completed the screening questions.  
In total, 339 respondents successfully made it past the screening questions but failed to go on 
to complete the survey. Of these individuals, only 79 made it to the DCE task (note that only 
the screening and attribute/attribute level ranking questions preceded the DCE task). As a 
result, it would seem fair to conclude that relatively little survey drop-out occurred during the 
critical components of the survey (i.e. the DCE or the CV task). 
8.2 Respondent Characteristics 
Due to the quotas in place that required at least 210 respondents for each user group, the 682 
respondents that completed the survey were spread relatively evenly across the three user 
groups: 210 potential service users; 243 potential beneficiaries and; 229 non-users. Table 8.1 
summarises the characteristics of respondents from the whole sample and across each of the 
three user groups. On the whole, the respondents are closer to retirement age than working 
age, well-educated and slightly more likely to be female compared to male. With regards to 
employment, those that are employed (full-time or part-time) or retired make up the vast 
majority of the sample. General health is good on average, as determined by the average 
visual analogue scale (VAS) scores and EQ-5D-5L utility values. 
As a result of the recruitment process, there are significant differences between the three user 
groups with regards to weight-related characteristics. All respondents in the PSU group are 
obese, 63% of respondents in the PB group are overweight and 37% obese, while all 
respondents in the NU group have a normal BMI. All respondents in the PSU group had 
attempted to lose weight in the previous 12 months, compared with 68% and 55% of the PB 
and NU groups, respectively. 
125 
 
The fact that over half of the NU group attempted to lose weight in the last 12 months could 
be considered surprising given that these individuals have a normal BMI classification. It 
could be the case that some of these respondents were previously overweight, however it is 
not possible to determine whether this was the case. Regardless, this is arguably positive 
considering the topic of the survey as it is likely to aid respondent understanding of WLM and 
potentially reduce hypothetical bias. The general health measures suggest that there are 
differences between the user groups with regards to health that go beyond the BMI 
classification differences. Both the VAS and EQ-5D-5L average values are significantly 
different across the three user groups (p<0.01) according to one-way ANOVA. It appears that 
the NU group has significantly better health according to these measures relative to the other 
two groups. 
Other differences exist between the user groups that were not expected. Average age, the 
gender-split, and employment statuses across the three groups are significantly different from 
one another according to chi2 tests (p<0.01). It appears that this can be explained by the PB 
group in particular. The PB group contains older respondents on average, more male 
respondents than any other group, as well as more retired respondents. This may have had an 
effect on the education variable, given that younger individuals are more likely to have 
attended university (Blanden & Machin, 2004), although the evidence to suggest that highest 
educational qualifications differ significantly across the three groups is not particularly strong 
(p=0.05). 
It is not ideal that the characteristics of the groups differ (beyond differences in weight-related 
characteristics that occurred due to the user group definitions) because results will be 
compared between the user groups. If these characteristics were similar between the groups it 
would be easier to attribute any differences in preferences to the user group classifications. 
However, it should be noted that household income does not appear to differ across each of 
the groups (p=0.55). This is important because ability to pay has been shown to affect WTP 
(Klose, 1999), and this means that there is no significant evidence to suggest that ability to 
pay will differ substantially between respondents in each of the three user groups. 
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Table 8.1 Respondent Characteristics (Online Panel Sample) 
 
Potential 
Service User 
(PSU) 
Potential 
Beneficiary 
(PB) 
Non-User 
(NU) 
p-value1 
n 210 243 229  
Age (mean) 44 50 45 0.000 
18-24 9 (4%) 7 (3%) 14 (6%)  
25-34 48 (23%) 41 (17%) 54 (24%)  
35-44 55 (26%) 38 (16%) 54 (24%)  
45-54 50 (24%) 52 (21%) 35 (15%)  
55+ 48 (23%) 105 (43%) 72 (31%)  
Gender    0.000 
Male 87 (41%) 139 (57%) 89 (39%)  
Female 123 (59%) 104 (43%) 140 (61%)  
BMI Classification    0.000 
Normal  0 (0%) 0 (0%) 229 (100%)  
Overweight 0 (0%) 153 (63%) 0 (0%)  
Obese 210 (100%) 90 (37%) 0 (0%)  
Attempted to lose weight in the 12 months prior to the survey? 0.000 
Yes 210 (100%) 166 (68%) 125 (55%)  
No 0 (0%) 77 (32%) 104 (45%)  
Highest Level Qualification 0.054 
Higher (University) 92 (44%) 97 (40%) 109 (48%)  
Further (College) 52 (25%) 78 (32%) 67 (29%)  
Secondary (School) 60 (29%) 56 (23%) 46 (20%)  
None 6 (3%) 8 (3%) 4 (2%)  
Other 0 (0%) 4 (2%) 3 (1%)  
Employment Status    0.004 
Employed (full-time) 107 (51%) 113 (47%) 94 (41%)  
Employed (part-time) 39 (19%) 41 (17%) 57 (25%)  
Student 2 (1%) 3 (1%) 8 (3%)  
Retired 25 (12%) 60 (25%) 37 (16%)  
Homemaker/Caregiver 19 (9%) 13 (5%) 15 (7%)  
Unemployed 16 (8%) 12 (5%) 10 (4%)  
Other 2 (1%) 1 (<1%) 8 (3%)  
Household Income    0.545 
£20,000 or less 54 (26%) 68 (28%) 48 (21%)  
£20,001 - £40,000 80 (38%) 72 (30%) 84 (37%)  
£40,001 - £60,000 41 (20%) 58 (24%) 57 (25%)  
£60,001 and above 35 (17%) 45 (19%) 40 (17%)  
Health (Visual Analogue Scale; 0=Dead, 100=Perfect Health) 0.001 
Mean 73.5 74.9 80.2  
(Standard Deviation) (20.09) (18.39) (17.62)  
Health (EQ-5D-5L Utilities2; 0=Dead, 1=Perfect Health) 0.001 
Mean 0.870 0.881 0.927  
(Standard Deviation) (0.187) (0.188) (0.116)  
1p-values based on chi2 tests (categorical) and one-way ANOVA (continuous); 
2English population utilities from Devlin et al. (2017) 
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8.3 Research Question One 
RQ1: To what extent do preferences for a health service, elicited via a discrete choice 
experiment, differ between different user groups, and why might these differences occur? 
8.3.1 Results 
Table 8.2 presents the results using mixed logit models with all parameters set as random (and 
normally distributed) using 1,000 Halton draws. Hence, the coefficients are the mean values 
for each parameter. Models were also estimated with a full covariance matrix in order to try 
and address (within-sample) scale heterogeneity; however, the results were deemed 
unreliable. The results in table 8.2 are generally consistent with results from the conditional 
logit models that were also estimated, although slightly more coefficients are statistically 
significant in the conditional logit models. The conditional logit models can be found in 
Appendix D-1. 
The results in table 8.2 suggest that respondents in every user group prefer shorter 
programmes that are more efficacious and less costly. Across each of the three models the 
coefficients for these variables are statistically significant at the 1% level and have identical 
signs throughout. The finding that all respondents prefer to spend less and prefer better health 
outcomes is important with respect to the face validity of the choice models. 
In contrast to the consistent statistical significance of the other attributes, the coefficients for 
the levels of the feedback, reminders and online tool(s) attributes vary in their significance 
across the three models. Model one suggests that respondents in the PSU group are indifferent 
to the majority of the levels associated with these three attributes. There is weak evidence to 
suggest that respondents in this group have a preference for receiving an app (0.242, p<0.1) as 
well as both an app and website (0.240, p<0.1). Model two suggests that respondents in the 
PB group prefer to receive feedback via text message relative to face to face (0.337, p<0.01), 
and there is weak evidence to suggest that feedback via the online tool(s) is also preferred to 
face to face feedback (0.219, p<0.1). This model also suggests that respondents prefer to 
receive reminders via the online tool(s) relative to receiving no reminders (0.343, p<0.01) and 
there is weak evidence of a preference for reminders via text message (0.216, p<0.1). Model 
three suggests that respondents in the NU group prefer feedback via both online tool(s) and 
via text message relative to face to face feedback (0.566, p<0.01 and 0.615, p<0.01, 
respectively). Furthermore, this model also suggests that the respondents in this group prefer 
to receive reminders via text messages and via the online tool(s) relative to not receiving any 
(0.425, p<0.01 and 0.352, p<0.05, respectively). 
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Table 8.2 Results from the Mixed Logit Models (Online Panel Sample) 
 
1. Potential Service 
User 
2. Potential 
Beneficiary 
3. Non-User 
  Coefficient Std. Dev. Coefficient Std. Dev. Coefficient Std. Dev. 
Alt-Specific Constant 2.380 *** 2.357 *** 3.012 *** 2.675 *** 2.897 *** 3.569 *** 
 (0.301)  (0.256)  (0.315)  (0.294)  (0.379)  (0.527)  
Length (months) -0.031 *** 0.029 * -0.028 *** 0.040 *** -0.036 *** -0.070 *** 
  (0.008)  (0.015)  (0.008)  (0.015)  (0.009)  (0.013)  
Delivery of Feedback1             
via Phone Call 0.179  0.422  0.218  0.914 *** 0.129  -0.089  
 (0.144)  (0.343)  (0.146)  (0.257)  (0.149)  (0.315)  
via the Online Tool(s) 0.199  0.670 *** 0.219 * -0.073  0.566 *** 0.088  
 (0.148)  (0.256)  (0.130)  (0.526)  (0.150)  (0.329)  
via the Text Message 0.181  -0.148  0.337 *** -0.138  0.615 *** -0.355  
 (0.131)  (0.290)  (0.123)  (0.316)  (0.142)  (0.246)  
Reminders2             
via Text Message 0.144  -0.255  0.216 * 0.701 *** 0.425 *** 0.352  
 (0.124)  (0.376)  (0.125)  (0.192)  (0.135)  (0.264)  
via Phone Call -0.040  -0.617 *** 0.142  0.279  0.103  -0.231  
 (0.150)  (0.223)  (0.134)  (0.301)  (0.156)  (0.476)  
via the Online Tool(s) 0.020  -0.238  0.343 *** 0.226  0.352 ** -0.382 * 
  (0.143)  (0.336)  (0.132)  (0.303)  (0.153)  (0.231)  
Online Tool3             
App Only 0.242 * -0.003  0.129  0.102  0.224  0.138  
 (0.134)  (0.253)  (0.127)  (0.234)  (0.140)  (0.294)  
Website Only 0.211  0.446  -0.054  0.499 * 0.197  -0.831 *** 
 (0.146)  (0.289)  (0.143)  (0.269)  (0.159)  (0.223)  
App & Website 0.240 * 0.144  0.137  0.575 *** -0.044  -0.623 *** 
 (0.130)  (0.359)  (0.127)  (0.221)  (0.140)  (0.234)  
Weight Re-gain (%) -0.026 *** 0.029 *** -0.017 *** 0.023 *** -0.018 *** 0.026 *** 
  (0.003)  (0.003)  (0.002)  (0.003)  (0.003)  (0.004)  
Personal Cost (£/month) -0.140 *** 0.138 *** -0.156 *** 0.128 *** -0.197 *** 0.158 *** 
  (0.014)  (0.013)  (0.013)  (0.012)  (0.018)  (0.016)  
Observations (Sample Size) 6,300 7,290 6,870 
Log Likelihood -1,505 -1,752 -1,587 
AIC  3,036  3,530 3,200 
BIC  3,124  3,620  3,289 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1 
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool”  
 
As outlined in Chapter Six, additional analysis must be conducted in order to compare the 
results across the three models. Figure 8.2 illustrates the relative importance of each attribute 
for each user group, based on the method outlined in section 6.4.7 of Chapter Six. The ranges 
for each attribute were calculated using the results from table 8.2 i.e. the main effects mixed 
logit models. When calculating the ranges for each attribute, coefficients were treated as equal 
to zero if they were not statistically significant at the 10% level. Hence, for some attributes 
relative importance is equal to zero. 
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Figure 8.2 Relative Importance of the Attributes (Online Panel Sample)
 
It is clear from figure 8.2 that the outcome and cost attributes were highly dominant 
regardless of the user group. The relative importance of the outcome attribute is greater for 
the PSU group (33%) relative to the PB group (22%) and greater for the PB group relative to 
the NU group (19%). The difference in the relative importance of the outcome attribute for 
the PSU group compared to the NU group is particularly large (14 percentage points). The 
opposite trend is apparent for the cost attribute, although the relative importance of the cost 
attribute for the PB and NU groups is identical (61%). 
In addition to relative importance calculations, an additional area of analysis that can provide 
insight relates to the opt-out option. Four participants in the PSU group chose the opt-out 
option (no programme) in every scenario relative to three in the PB group and nine in the NU 
group. Furthermore, the average number of opt-outs per respondent were 2.2 for the PSU and 
PB groups compared with 2.9 for the NU group. 
Additional choice models were also estimated in order to test the significance of attribute 
interactions and to identify whether differences in preferences may be observed based on 
observable characteristics of the respondents (i.e. those that were not varied in the user group 
definitions).  
Results from conditional logit models that contained three interaction terms based on a priori 
expectations (length & cost; outcome & cost; length & outcome) can be found in Appendix 
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D-2. These suggest that there is weak evidence that the interaction between length and 
outcome is significant for the PSU group (-0.0002, p<0.1) and moderate evidence that the 
interaction between length and cost is significant for the PB group (-0.0009, p<0.05). No 
other interactions were found to be statistically significant. Likelihood ratio tests between the 
conditional logit models with and without interactions provided weak evidence (p<0.1) that 
the models with interactions provided a better model fit for the PSU and PB groups but no 
evidence for the NU group. Given this weak evidence overall of the importance of the 
interaction terms, it was not felt that it would be beneficial to incorporate them into the more 
flexible mixed logit models as this would reduce their likelihood of converging, with little 
expected benefit to model fit. 
The respondent characteristics in table 8.1 indicate substantial differences between the three 
user groups. Therefore, additional models were estimated containing interactions between the 
alternative-specific constant and various demographic variables. The variables considered 
related to age groups, gender, highest educational qualification, employment status and 
income band. Appendix D-3 provides the results from mixed logit models that included these 
interactions terms, which were not modelled as random parameters. Across the three models, 
very few interactions were statistically significant. In addition, the effect on the coefficients of 
the attribute/attribute level variables was minimal and WTP estimates (not reported) did not 
differ substantially from those generated using the main effects models (see 8.4.3). Likelihood 
ratio tests confirmed that the addition of the demographic interactions did not lead to a 
statistically significant improvement in log-likelihood and therefore model fit. As a result, the 
main effects models presented in table 8.2 remain as the preferred specification. 
8.3.2 Discussion 
The differences between models one to three in table 8.2, and illustrated in figure 8.2, would 
appear to suggest that individuals in the PSU group are more sensitive to negative outcomes 
(higher weight re-gain) relative to the other two groups, whereas individuals in the NU group 
are more price sensitive relative to the other two groups. These results are intuitive as it would 
be expected that respondents in the PSU group care more about the outcome of the service 
relative to others, and that they would be less price sensitive relative to the NU group, as 
respondents within the PSU group are more likely to be interested in using the service. On the 
other hand, as the outcome attribute was also presented as an absolute value, it could be the 
case that the driver of the coefficient differences was the fact that the absolute differences 
between attribute levels were larger for those in the PSU group relative to others (due to the 
higher average weight). 
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It is perhaps surprising that the attribute interactions were not statistically significant across 
the models estimated for each user group (Appendix D-2). It would seem logical to consider: 
the total cost of the programme (cost & length); the rate of weight re-gain (outcome & 
length); or even the cost per weight re-gain avoided (cost & outcome). However, DCE tasks 
are cognitively demanding and it may simply be too much for the average respondent to 
consistently assess these combinations of attributes, alongside all the other attributes. 
There is no evidence to suggest that demographic characteristics have influenced the results, 
despite the differences in observable characteristics between the three user groups. It can 
therefore be concluded with relative confidence that the differences in preferences observed is 
likely to be due to the way in which the groups were defined i.e. their relative experience of 
the health issue and current weight status. 
8.3.3 Conclusion 
The results suggest that preferences for WLM programmes do differ across the three user 
groups, however the differences are somewhat limited. For example, there are no instances 
where a statistically significant coefficient is positive in one model but negative in another. 
Nonetheless, there are clear differences in the significance of attributes and attribute levels, as 
well as in the relative importance of the attributes. 
8.4 Research Question Two Part A 
RQ2a: To what extent do WTP estimates differ between different user groups, and why might 
these differences occur? 
8.4.1 Results (CV) 
Table 8.3 contains the results for each group to the self-selection question; the question that 
determined whether respondents would be faced with a CV exercise or not. Chi2 tests provide 
convincing evidence (p<0.01) that the responses to this question significantly vary across the 
three user groups, even if similar responses are collapsed (e.g. one and two; three and four). 
Combining responses one and two, it is clear that a higher proportion of the PSU group wish 
to use a WLM programme like the ones described in the DCE task relative to the other two 
groups (the specific order is PSU>PB>NU). The proportion of respondents stating that they 
might want to use a WLM programme (responses three and four) is similar between the PSU 
and PB groups, with a lower proportion in the NU group. Combining all four responses shows 
that a significantly different proportion of each user group went on to face the use value CV 
exercise; 84% of the PSU group, 74% of the PB group and 54% of the NU group. 
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Table 8.3 Responses to the CV Self-Selection Question (Online Panel Sample) 
 
Response to the “Interest Question” 
PSU PB NU Total 
n % n % n % n % 
1. I would like to use x 37 18% 26 11% 24 10% 87 13% 
2. I would like to use x & want it to be available for others 50 24% 45 19% 20 9% 115 17% 
3. I might want to use x 44 21% 52 21% 37 16% 133 20% 
4. I might want to use x & want it to be available for others 45 21% 57 23% 44 19% 146 21% 
5. I would not use x but I want it to be available for others 21 10% 34 14% 77 34% 132 19% 
6. I do not think x should be made available  13 6% 29 12% 27 12% 69 10% 
Total 210 100% 243 100% 229 100% 682 100% 
        
x = a programme like this (referring to the hypothetical programmes from the DCE task) 
 
Responses 1-4 – forwarded to the “use value” WTP exercise;  
Response 5 – forwarded to the “externality” WTP exercise;  
Response 6 – forwarded to open-ended comment box.
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As outlined in Chapter Six, the use value CV questions included in the survey provide WTP 
estimates for each individual respondent’s preferred set-up of a WLM intervention, excluding 
the length (as this was held static at 12 months) and weight re-gain (as this changed in each 
question). The questions began by asking respondents if they would be willing to pay for a 
programme with a weight re-gain outcome of 0% and subsequently asked for a maximum 
price that respondents would be willing to pay. The outcome was then adjusted to the next 
level (i.e. 10%) and the task was repeated. This happened until the respondent stated that they 
were not willing to pay for the specified programme.  
Table 8.4 summarises the most common set-up of the WLM programme valued in the use 
value task, which did not differ across the three user groups. However, whilst this was the 
most common programme, very few participants overall actually valued this particular set-up. 
In total, participants in the PSU group valued 31 different variants relative to 41 in the PB 
group and 34 in the NU group. Thus, there was a wide range of variety across the 
respondents. 
Table 8.4 Most Commonly Valued Programmes in the Use Value CV Task (Online Panel 
Sample) 
Attribute 
Potential Service 
User 
Potential 
Beneficiary 
Non-User 
Delivery of Feedback via Text Message via Text Message via Text Message 
Delivery of Reminders via Text Message via Text Message via Text Message 
Availability of Online Tool(s) Website & App Website & App Website & App 
 N=40/176 (23%) N=28/180 (16%) n=21/125 (17%) 
 
Table 8.5 presents the full results from the use value CV exercise. In total, 31 respondents 
were removed from the analysis for indicating that they would be willing to pay more at a 
higher level of weight re-gain (the ‘logic rule’). It was assumed that such instances 
represented erroneous responses or a failure of the respondent to fully understand the task. 
Note that these 31 respondents are still incorporated into the ‘stated’ column because they 
indicated a willingness to pay regardless. The number of individuals that provided a WTP 
value sharply decreased as weight re-gain increased and the majority of respondents were not 
willing to pay beyond 40% weight re-gain. The proportion of individuals within each group 
that provided a WTP value when weight re-gain was set at 0% follows the expected pattern 
(PSU > PB > NU), but the differences in proportions diminishes as the level of weight re-gain 
increases.  
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Table 8.5 WTP Estimates from the Use Value CV Task (Online Panel Sample) 
  Potential Service User (PSU) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD 
0% 176 118 67% 93 53% £10.00 £14.28 13.50 
10% 118 91 52% 60 34% £10.00 £11.93 8.52 
20% 91 59 34% 29 16% £10.00 £11.90 6.20 
40% 59 32 18% 11 6% £5.00 £9.00 6.32 
60% 32 17 10% 4 2% £12.50 £11.00 5.23 
80% 17 12 7% 2 1% £10.00 £10.00 0.00 
90% 12 11 6% 2 1% £10.00 £10.00 0.00 
100% 11 11 6% 2 1% £10.00 £10.00 0.00 
 
                
  Potential Beneficiary (PB) Non-User (NU) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP)   Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD n n % n % Median Mean SD 
0% 180 115 64% 81 45% £10.00 £13.84 15.89 125 76 61% 58 46% £10.00 £13.91 16.66 
10% 115 95 53% 62 34% £10.00 £11.97 10.58 76 62 50% 45 36% £10.00 £13.13 18.64 
20% 95 68 38% 46 26% £10.00 £10.48 8.39 62 47 38% 30 24% £10.00 £12.57 20.97 
40% 68 32 18% 20 11% £8.50 £8.30 4.05 47 22 18% 11 9% £5.00 £16.27 31.49 
60% 32 16 9% 9 5% £10.00 £10.33 4.97 22 18 14% 7 6% £10.00 £20.43 35.43 
80% 16 13 7% 6 3% £10.00 £11.00 6.32 18 13 10% 4 3% £12.50 £32.50 41.73 
90% 13 12 7% 4 2% £12.50 £13.75 4.79 13 9 7% 3 2% £10.00 £11.67 2.89 
100% 12 7 4% 3 2% £15.00 £15.00 5.00 9 7 6% 2 2% £12.50 £12.50 3.54 
Percentages are based on the number of individuals that were forwarded to the exercise from each user group in the first instance (underlined). 
1Those that selected “yes” when asked whether they would be willing to pay (those that select “no” exit the exercise at that stage). 
2Those that provided a value when asked for the maximum amount that they would be willing to pay and did not increase their value at any point during the task (‘logic rule’).
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This effect happens almost instantly; when weight re-gain increases from 0% to 10%, 33 
(35%) individuals in the PSU group were no longer willing to pay compared to 19 (24%) and 
13 (22%) of the PB and NU groups, respectively.  
In the PSU and PB groups average WTP increases after 40% weight re-gain (after 20% for the 
NU group). A closer look at the data shows that while most individuals decrease their values 
as weight re-gain increases, there is a small percentage of individuals that state a constant 
WTP value throughout the task. This latter group of individuals are far more likely to remain 
in the task until the later levels of weight re-gain, making them a bigger proportion of the 
sample at these stages, increasing the average WTP values. One-way ANOVA suggests that 
the mean values at each weight re-gain level are not statistically significantly different across 
the three user groups. The similarity between the values provided by each group are clearest 
when looking at the median values, which are identical for every group for the first three 
weight re-gain levels (£10 at 0%, 10% and 20%).  
8.4.2 Discussion (CV) 
The findings from the CV task are generally sensible in that fewer respondents were willing to 
pay for a WLM programme as the efficacy decreased. Additionally, it is logical that fewer 
respondents in the NU group would be willing to pay for a WLM programme given that they 
seemingly have less need for such a programme. 
Perhaps the biggest concern with the CV results is the increasing average WTP values as 
weight re-gain increases in table 8.5. As explained, this is largely due to individuals stating 
that they would be willing to pay the same amount regardless of the outcome. While this may 
seem like irrational behaviour, it may be unjustified to remove these individuals from the 
analysis for this reason alone. Constant WTP values may be an expression of the individuals’ 
strong preference for the service to be made available. Additionally, with an intervention such 
as this the health outcome is largely in control of the service user. It may be the case that 
some of these individuals consider the stated outcome level to be irrelevant for this reason and 
choose to ignore it. However, while this issue may appear significant, it is important to note 
that very few respondents remain in the analysis when the average WTP values start to 
increase (no more than 11 in each user group).  
A particularly interesting finding from the CV task is that a greater proportion of individuals 
in the PSU group exit the task when weight re-gain increases to 10% from 0%. This is in line 
with the findings from the DCE results in section 8.3 that suggest that individuals in the PSU 
group are more negatively affected by an increase in weight re-gain than the other groups. 
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It was hypothesised that individuals in the PSU group would be willing to pay more than 
those in the PB group and that the latter would be willing to pay more than those in the NU 
group. It may be the case that individuals are providing values that represent the amount that 
they would expect to pay if the service were to be made available, rather than the maximum 
amount that they would be willing to pay. The former may be more consistent across the 
whole sample as many individuals are aware of the costs of lifestyle services such as gyms 
and weight loss programmes. Alternatively, it could be the case that the levels in the DCE 
task (provided before the CV task for all respondents) have framed the responses to some 
extent; the mean WTP at 0% weight re-gain was around £14, which is roughly in the middle 
of the range from the DCE (£0-30). 
8.4.3 Results (DCE) 
As explained in Chapter Six, WTP estimates can also be generated from the DCE by 
calculating the marginal rate of substitution (MRS) between an attribute or attribute level and 
the cost attribute. Only a small number of attributes and attribute levels were statistically 
significant in all three models in table 8.2: cost, length & outcome. As the idea of paying for a 
change in programme length makes little sense in this context, comparisons will be made 
across the three groups by looking at WTP estimates for a change in outcome. 
Table 8.6 contains WTP estimates for a unit change in the outcome attribute, split by each 
group. These are calculated by taking the ratio of the coefficients for weight re-gain and cost, 
as explained in Chapter Six. The estimates represent willingness to pay for a single percentage 
point increase in weight re-gain. As this is an undesirable change, the WTP estimates are 
negative.  
Table 8.6 WTP Estimates from the DCE (Online Panel Sample) 
Group WTP for % weight re-gain 
Confidence Interval  
[Lower, Upper] 
Potential Service User (PSU) -£0.19 [-£0.23, -£0.14] 
Potential Beneficiary (PB) -£0.11 [-£0.14, -£0.08] 
Non-User (NU) -£0.09 [-£0.12, -£0.06] 
 
It appears that the WTP estimate for the PSU group differs from the PB and NU groups, with 
the latter two groups providing relatively similar estimates. This can be seen in figure 8.3 
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where there is no overlap between in the confidence interval for the PSU group with the other 
two groups. The significant overlap between the confidence intervals for the estimates from 
the PB and NU groups suggest that the difference between the WTP estimates is unlikely be 
statistically significant.  
Figure 8.3 WTP Estimates from the DCE for Weight Re-Gain (Online Panel Sample)
 
To understand the interpretation of these results, consider the following comparison between a 
programme with 40% weight re-gain and a programme with 20% weight re-gain. The PSU 
group would pay £3.80 more per month for the latter programme than the former, compared 
to £2.20 for the PB group and £1.80 for the NU group. 
8.4.4 Discussion (DCE) 
The differences in WTP estimates are not surprising given the DCE results illustrated in 
figure 8.2. From this figure, it was clear that as you move across the groups (i.e. from PSU to 
PB to NU) the relative importance of weight re-gain decreased and the relative importance of 
cost increased. This has created differences in WTP estimates, given that these are calculated 
by taking the ratio of the two coefficients. The results fit a priori expectations that more 
‘experienced’ respondents would be willing to pay more for a service. However, as is the case 
for any DCE results of this nature, the WTP estimates should be taken with caution as they 
are derived in an indirect manner. That is, individuals are not stating their willingness to pay 
but implying it.  
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8.4.5 Conclusion 
It appears that WTP estimates for the CV task do not differ significantly between the three 
user groups. However, the WTP estimates derived from the DCE task do appear to differ 
between PSU group and the other two groups. Hence, these results are somewhat inconclusive 
with regard to overall differences in willingness to pay. 
8.5 Research Question Two Part B 
RQ2b: How might WTP estimates differ if they are elicited indirectly or directly? 
8.5.1 Results 
The approach taken to compare WTP estimates from the DCE and CV task from the previous 
chapter will be used here. This involves using the iterative nature of the CV questions to 
identify a WTP estimate for a percentage point change in weight re-gain. As these have 
already been identified in the DCE (WTPDCE hereafter), the estimates from the contingent 
valuation task can be directly compared (WTPCV hereafter). To generate the WTPCV 
estimates, a variable was generated whereby the WTP value at 10% weight re-gain was 
subtracted from the WTP value at 0% weight re-gain and divided by 10. Table 8.7 contains 
the mean WTPCV as well as the WTPDCE estimates from table 8.6, split by group. 
Table 8.7 DCE and CV Comparison in WTP for 1% Increase in Weight Re-gain (Online 
Panel Sample) 
Group WTPDCE WTPCV Difference p-value 
PSU -£0.19 -£0.34 £0.15 0.178 
PB -£0.11 -£0.22 £0.11 0.087 
NU -£0.09 -£0.19 £0.10 0.045 
 
The average WTPCV values are not statistically significantly different across the three user 
groups (p-values>0.1, not reported). Additionally, as indicated by the p-values in table 8.7, 
there does not appear to be a statistically significant difference between the WTPDCE and the 
average WTPCV value for the PSU groups. A closer look at the data suggests that this is due to 
the large variance in WTPCV for this group that results from respondents that provided values 
suggesting that they would pay multiple pounds less per month for a single percentage point 
increase in weight re-gain. On the other hand, the difference between WTPDCE and WTPCV for 
the PB group is significant at the 10% level and the difference for the NU group is statistically 
significant at the 5% significance level. Whilst these groups also suffered from large values in 
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the CV task, it appears that there may be a significant difference between estimates generated 
from the two methodologies. In this case, the estimates from the CV task are approximately 
twice the size of those from the DCE task. 
8.5.2 Discussion 
One possible reason for the lack of a statistically significant difference between the two 
estimates for the PSU group, despite the seemingly large difference, is due to the range of 
values expressed within the CV task and the fact that a mean estimate was used. As indicated 
in the previous subsection, some of the differences between WTP at 0% and 10% in the CV 
task were infeasibly large and inflated the mean value. However, a median could not be used 
for the WTPCV estimates instead because for every group the median value was zero, 
indicating that most individuals did not adjust their WTP estimate between 0% and 10% 
weight re-gain in the CV task. As a result it is hard to conclude whether there is a significant 
difference between WTP values when elicited directly or indirectly. This is clearly a 
weakness with the approach taken to generate WTP estimates for a percentage point increase 
in weight re-gain in the CV task, which has arisen due to the nature of the task itself. 
There is weak evidence (p<0.1) to suggest that the estimates for the PB group are significantly 
different and moderate evidence (p<0.05) for the NU group, with the magnitudes of the 
WTPCV estimates larger than the WTPDCE estimates. This finding would be in contrast with 
the findings of other studies that make similar comparisons (van der Pol et al., 2008; Ryan & 
Watson, 2009; Danyliv et al., 2012). However, it could be the case that the comparison being 
made in this study is too different to compare with prior findings in the literature. This is 
because this comparison looks at WTP estimates for ‘parts’ of a WLM programme rather than 
comparing ‘whole’ WLM programmes. Hence, the comparison approach employed here may 
have reduced the potential differences in WTP estimates that previous studies identified, 
specifically those that could be attributed to ‘part-whole bias’ (Cookson, 2003). 
When comparing two methodologies it is also important to consider framing effects. While 
the CV and DCE task in this survey were similar in that programmes were described using the 
same attributes, there were some inevitable differences. Firstly, the length of the programme 
in the CV task was set at 12 months in order to ensure that WTP estimates were comparable 
across individuals. Had this been set at a different level, the WTP estimates may have 
differed. For example, the DCE results suggested that respondents preferred shorter 
programmes therefore WTPCV estimates may have been higher (per month) if the level had 
been set at six months. On the other hand, there is no specific reason to believe that this would 
have resulted in differences in the estimates when compared across user groups.  
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It should be noted that some details from the DCE task were not included in the CV task due 
to concerns over respondent fatigue. For example, it was not reiterated in the CV task that 
individuals are expected to re-gain 100% of their lost weight without a programme. As well as 
this, corresponding absolute weight re-gain values were not listed alongside the proportional 
levels in the CV task as they were in the DCE. This latter point may be important if 
respondents in the DCE were strongly influenced by the absolute values. As discussed in 
section 8.3, it could be that respondents in the PSU group were more strongly influenced by 
the weight re-gain attribute as a result of their higher absolute values relative to the other two 
groups. This could be the reason for the larger WTPDCE estimate (in absolute terms) for the 
PSU group relative to the other two groups, and hence this may explain why no such 
differences between groups were found in the CV task. 
8.5.3 Conclusion 
On the whole, the results are inconclusive regarding the potential differences between indirect 
(DCE) and direct WTP estimates (CV). There is moderate evidence that WTPCV estimates are 
larger than WTPDCE estimates for one of the user groups, however the comparison made in 
this study is atypical and it is therefore difficult to contrast this finding with the existing 
literature. 
8.6 Research Question Three 
RQ3: To what extent do certain groups have better defined preferences than other user 
groups, and why might these differences occur? 
8.6.1 Results 
It was hypothesised in Chapter Six that, as the most experienced individuals in the online 
panel sample based on observable characteristics, the PSU group may have ‘better defined’ 
preferences towards WLM programmes than the other two user groups. To test this 
hypothesis, two rationality tests were embedded into the DCE task. Table 8.8 presents the 
pass rates for the transitivity test (using both definitions), the dominance test and a 
combination of all three.  
The results in table 8.8 show that the majority of respondents pass the weak transitivity and 
dominance tests. If respondents randomly responded to the DCE questions, there would be a 
75% probability that the weak transitivity test would be satisfied. As such the results appear 
favourable for this test across all user groups with at least 93% of respondents passing in each 
user group. In addition, strictly speaking, the probability that a respondent would pass the 
dominance test at random is 50% and therefore the results for this test are positive in this 
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respect with at least 90% of respondents passing in each user group. Pass rates are 
substantially lower for the strong transitivity test, under 57% for each group but never less 
than half. However, the probability of passing this test at random is far lower than the other 
tests (11%). On the whole, it appears that the results of the rationality tests are favourable for 
all tests and across all user groups. There is little variation in the pass rates between the three 
groups, suggesting that their classification into these groups has little to no influence on the 
probability of passing. 
Table 8.8 Embedded DCE Rationality Test Results (Online Panel Sample) 
Group Dominance 
Weak 
Transitivity 
Strong 
Transitivity 
All 3 
PSU 193/210 (92%) 201/210 (96%) 117/210 (56%) 110/210 (52%) 
PB 223/243 (92%) 226/243 (93%) 125/243 (51%) 114/243 (47%) 
NU 207/229 (90%) 221/229 (97%) 118/229 (52%) 106/229 (46%) 
 
In order to formally examine the factors that may influence the probability of an individual 
passing one or all of the rationality tests, a series of models were estimated. In each model in 
table 8.9, a dummy dependent variable was used to indicate whether individuals passed the 
dominance test (model one), the weak transitivity test (model two), the strong transitivity test 
(model three) or all of the tests (model four). The models were estimated using logistic 
regression and as such the coefficients have little practical meaning, therefore marginal effects 
at the means were calculated and are reported alongside the coefficients in table 8.9.  
Model one suggests that being heavier and being interested in a WLM programme (as 
determined by the self-section question) are associated with a decreased probability of passing 
the dominance test. The marginal effect for the former is small (0.2% for every kilogram) and 
significant at the 1% level, whereas the marginal effect for the latter is larger (3.5%) but is 
only significant at the 10% level. There is also weak evidence (10% level) to suggest that 
older age is associated with an increased probability of passing the dominance test. Being in 
the PSU group (relative to the NU group) is associated with a 7.1% increase in the probability 
of passing the dominance test. Similarly, being in the PB group (relative to the NU group) is 
associated with a 4.7% increase in the probability of passing the dominance test.  
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Table 8.9 Rationality Test Logit Models (Online Panel Sample) 
  1. Dominance 2. Weak Transitivity 3. Strong Transitivity 4. All Tests 
  Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. 
Age 0.135 * 0.009 * 0.104  0.004   0.018  0.004   0.040  0.010  
  (0.073)  (0.005)   (0.098)  (0.003)   (0.041)  (0.010)   (0.041)  (0.010)  
Age2 -0.001  -0.000   -0.001  -0.000   -0.000  -0.000   -0.000  -0.000  
  (0.001)  (0.000)   (0.001)  (0.000)   (0.000)  (0.000)   (0.000)  (0.000)  
Higher Education -0.196  -0.013   0.086  0.003   0.488  0.122   0.425  0.106  
  (1.072)  (0.069)   (1.092)  (0.038)   (0.500)  (0.125)   (0.499)  (0.125)  
Further Education -0.497  -0.032   0.517  0.018   0.397  0.099   0.154  0.038  
  (1.075)  (0.070)   (1.117)  (0.038)   (0.504)  (0.126)   (0.504)  (0.126)  
Secondary Education 0.297  0.019   1.161  0.040   0.425  0.106   0.357  0.089  
  (1.114)  (0.072)   (1.180)  (0.040)   (0.511)  (0.127)   (0.510)  (0.127)  
Other Education -0.918  -0.059   -0.241  -0.008   0.356  0.089   -0.247  -0.062  
  (1.554)  (0.100)   (1.602)  (0.055)   (0.935)  (0.233)   (0.991)  (0.247)  
Employed (FT/PT) -0.526  -0.034   -0.445  -0.015   -0.096  -0.024   -0.153  -0.038  
  (0.402)  (0.026)   (0.507)  (0.017)   (0.199)  (0.049)   (0.198)  (0.049)  
Married/Cohabiting 0.089  0.006   -0.499  -0.017   0.096  0.024   0.093  0.023  
  (0.312)  (0.020)   (0.455)  (0.015)   (0.180)  (0.045)   (0.180)  (0.045)  
DCE Block 1 0.119  0.008   1.013 ** 0.035 ** 0.305  0.076   0.281  0.070  
  (0.395)  (0.026)   (0.489)  (0.017)   (0.221)  (0.055)   (0.223)  (0.056)  
DCE Block 2 0.087  0.006   0.725  0.025   0.542 ** 0.135 ** 0.572 ** 0.143 ** 
  (0.403)  (0.026)   (0.471)  (0.016)   (0.226)  (0.056)   (0.227)  (0.057)  
DCE Block 3 -0.037  -0.002   1.393 ** 0.048 ** 0.804 *** 0.200 *** 0.735 *** 0.184 *** 
  (0.404)  (0.026)   (0.589)  (0.019)   (0.229)  (0.057)   (0.228)  (0.057)  
Found DCE Difficult 0.335  0.022   -0.190  -0.007   -0.449 *** -0.112 *** -0.356 ** -0.089 ** 
  (0.301)  (0.019)   (0.369)  (0.013)   (0.162)  (0.040)   (0.162)  (0.040)  
Weight (kg) -0.025 *** -0.002 *** 0.011  0.000   0.005  0.001   -0.002  -0.000  
  (0.009)  (0.001)   (0.013)  (0.000)   (0.006)  (0.001)   (0.005)  (0.001)  
Interested in Using a WLM Programme -0.546 * -0.035 * -0.298  -0.010   0.251  0.062   0.060  0.015  
  (0.299)  (0.019)   (0.387)  (0.013)   (0.179)  (0.045)   (0.178)  (0.045)  
Potential Service User 1.099 ** 0.071 ** -0.640  -0.022   -0.033  -0.008   0.279  0.070  
  (0.489)  (0.031)   (0.675)  (0.023)   (0.271)  (0.067)   (0.269)  (0.067)  
Potential Beneficiary 0.731 * 0.047 * -1.124 ** -0.039 ** -0.165  -0.041   0.019  0.005  
  (0.419)  (0.027)   (0.534)  (0.018)   (0.228)  (0.057)   (0.227)  (0.057)  
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  1. Dominance 2. Weak Transitivity 3. Strong Transitivity 4. All Tests 
  Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. 
Constant 1.241     -0.072     -1.449     -1.591    
  (1.817)       (2.314)       (1.047)       (1.049)       
Observations 682 682 682 682 
Pseudo R2 0.0751 0.0908 0.0289 0.0272 
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Model two suggests that being in the PB group (relative to the NU group) is associated with a 
3.9% decrease in the probability of passing the weak transitivity test (significant at the 5% 
level). The block of the DCE also appears to have some influence on the probability of 
passing the treat.  Model three suggests that finding the DCE task difficult to complete is 
associated with an 11.2% decrease in the probability of passing the strong transitivity test 
(significant at the 1% level). Similar to model two for the weak transitivity test, this model 
also suggests that the block of the DCE that the respondents faced influenced their probability 
of passing. However, the coefficients on the user group variables are not statistically 
significant. Finally, model four suggests that finding the DCE task difficult to complete is 
associated with an 8.9% decrease in the probability of passing all the tests (although this is 
only significant at the 5% level). Similar to models two and three, this model also suggests 
that the block of the DCE that the respondents faced influenced their probability of passing all 
of the tests.  
8.6.2 Discussion 
The results indicate that very few of the included independent variables were statistically 
significant. There were some differences between the user groups in relation to the likelihood 
of passing the rationality tests, although there were relatively minor and none of the 
coefficients on the user group variables were highly statistically significant (i.e. at the 1% 
level). Table 8.8 indicated that there was a relatively large difference between the combined 
(all tests) pass rate for the PSU group relative to the other two groups. Therefore, it is 
surprising that no user group dummies were found to be significant in model four in table 8.9. 
With regards to the other variables that were found to be significant, the most logical is the 
finding that difficulty in completing the DCE task was associated with a reduced likelihood of 
passing the strong transitivity test (as well as the combination of all three). It is easy to 
imagine how a respondent that is struggling to make decisions in the DCE may be less likely 
to pass the test; their preferences may not have been well defined and hence been inconsistent 
throughout the task. In contrast, there are several unexpected statistically significant variables. 
It is unclear why weight may influence the pass rate of the dominance test, although this 
effect was minimal. It is also not clear why the block of the DCE that respondents were 
assigned to influences the likelihood of passing the transitivity tests. It may be the case that 
the scenarios that preceded or succeeded the transitivity test scenarios influenced the 
difficulty of the test for respondents. It could be the case that this effect would have been 
minimised had the order of the (regular i.e. non-test) scenarios been randomised.  
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8.6.3 Conclusion 
While the pass rates for the rationality tests are positive, there is little evidence to suggest that 
pass rates vary across the three user groups. Several factors have been identified that may 
influence the likelihood of respondents passing the rationality tests that may warrant further 
exploration in future research. 
8.7 Overall Conclusion 
The results presented in this chapter provide mixed evidence relating to research questions 
one to three. With regards to research question one, it appears that preferences do differ across 
the three user groups when examining the results of the DCE. Those in the PSU group seem 
to be more strongly affected by worse weight re-gain outcomes than those in the other two 
groups, as hypothesised. Additionally, those in the PB and NU groups appear to be more price 
sensitive than the PSU group. This is in line with the a priori expectations that non-users 
would be less interested in the service (as reflected in the fact that they are less willing to pay 
for a programme). Research question two involved the examination of differences in WTP 
estimates across the three user groups. While the DCE provided evidence that WTP estimates 
are larger (in absolute terms) for the PSU group as hypothesised, the CV task found no 
differences between the three user groups. There was also only mild evidence that the WTP 
estimates from the DCE and the CV tasks differed, with the CV estimates being larger than 
those from the DCE. Finally, analysis relating to research question three indicated that there 
are next to no differences in the pass rates of the rationality tests across the three user groups. 
As such, it would appear that there is little evidence to suggest that any of the groups have 
‘better defined’ preferences over another group in the online panel sample. On the whole, it 
appears that only the basic DCE results provide convincing evidence that preferences differ 
across the three user groups. 
 
146 
 
Chapter 9. Comparison of Results from the Trial and the Online Panel 
 
The aim of this chapter is to collate and compare the results from the two samples in Chapters 
Seven and Eight in relation to the three research questions presented in Chapter Six. The first 
research question relates to whether preferences for a health service differ significantly 
between different user groups, as shown by the results of a DCE. The second, split into two 
parts, first examines whether WTP estimates are different between user groups and secondly 
whether estimates differ between methodologies. The third research question examines 
whether certain user groups have better defined preferences using the results of embedded 
rationality tests in the survey. The fourth and final research question examines whether 
differences in preferences could be explained by the recruitment vehicle. 
The chapter begins with a comparison of the characteristics of each user group (section 9.1). 
In this chapter, the trial sample will not be split due to the lack of evidence to suggest that 
characteristics and preferences significantly differ between the two trial arms, as shown in the 
previous chapter. Following the comparison of characteristics, each research question is 
addressed in turn with a comparison of the results and a discussion (sections 9.2-9.6). Finally, 
a summary of the results is provided to end the chapter (section 9.7). 
9.1 Respondent Characteristics 
9.1.1 Results 
Table 9.1 combines tables 7.1 and 8.1 from the previous two chapters in order to examine 
how respondent characteristics may differ across the four key user groups that will be 
examined in this chapter. From this point, the trial sample will be considered as a single user 
group, referred to as ‘service users’ (SU) due to their experience in the trial. 
One-way ANOVA suggests that the average ages of each user group differ (p<0.01). Post-hoc 
analysis using Tukey-Kramer pairwise comparisons suggest differences occur between the 
PSU and PB groups, the PB and NU groups, as well as the SU and PSU groups. Additionally, 
chi2 tests suggest that the spread of ages across the five categories displayed in table 9.1 differ 
across the four groups (p<0.01). 
The gender split also differs across the four groups (p<0.01), with far more females present in 
the SU group relative to any other. Additionally, only the PB group has a higher proportion of 
males relative to females. The spread of BMI classifications is also variable across the four 
groups; however, this is due to the screening/recruitment process. 
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There also appears to be a slightly different spread of educational qualifications across the 
four groups (p<0.05). This is most noticeable when focusing on the proportion of individuals 
with university-level qualifications, which range from 58% of the SU group to 40% of the PB 
group. No other qualification level has such a wide range across the four groups. 
Employment status also differed across the four groups (p<0.01) and this can be seen clearly 
in a number of areas. For example, 57% of the SU group are employed full-time compared to 
41% in the NU group. The latter has the highest proportion of part-time workers (25%) of the 
four groups. Additionally, 25% of the PB group are retired compared to 12% of the PSU 
group. On the other hand, the spread of household incomes did not vary significantly across 
the four user groups (p>0.1). Unsurprisingly, given the screening process, average weight 
varies across the four user groups (p<0.01). Pairwise comparisons suggest that there are 
statistically significant differences in the average values in all comparisons except for that of 
the SU and PB group (mean difference of 1.6kg). 
One-way ANOVA suggests that the average values from the generic health measures (VAS 
and EQ-5D-5L) also differ across the four user groups (p<0.01). Post-hoc analysis suggests 
that the differences occur between the larger average values in the NU group relative to the 
PSU and PB groups. Statistically significant differences were not detected between the NU 
group and the SU group for either measure, however this may be more reflective of the 
relatively small sample size for the SU group than a lack of a difference. 
9.1.2 Discussion 
It is unsurprising that there are differences between the user groups with regards to weight, 
BMI and generic health measures as all of the groups were defined by a combination of their 
weight and in many cases their weight loss history. It is, however, a concern that the groups 
differ widely in their other characteristics given that comparisons will be made across the four 
groups. On the other hand, it is promising that there are no statistically significant differences 
between the four groups with respect to the spread of household income, however each 
category covers a range of £20,000 or more and is not particularly sensitive for this reason. 
The household income question in the survey had double the number of categories than those 
presented in table 9.1, however no significant differences are found when looking at the full 
spread of categories either (p>0.1).  
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Table 9.1 Respondent Characteristics (All Four User Groups) 
Sample Trial Online Panel 
User Group 
Service User 
(SU) 
Potential 
Service User 
(PSU) 
Potential 
Beneficiary 
(PB) 
Non-User 
(NU) 
n 113 210 243 229 
Age (mean) 49 44 50 45 
18-24 0 (0%) 9 (4%) 7 (3%) 14 (6%) 
25-34 12 (11%) 48 (23%) 41 (17%) 54 (24%) 
35-44 34 (30%) 55 (26%) 38 (16%) 54 (24%) 
45-54 32 (28%) 50 (24%) 52 (21%) 35 (15%) 
55+ 35 (31%) 48 (23%) 105 (43%) 72 (31%) 
Gender     
Male 29 (26%) 87 (41%) 139 (57%) 89 (39%) 
Female 84 (74%) 123 (59%) 104 (43%) 140 (61%) 
BMI Classification     
Normal  7 (6%) 0 (0%) 0 (0%) 229 (100%) 
Overweight 53 (47%) 0 (0%) 153 (63%) 0 (0%) 
Obese 53 (47%) 210 (100%) 90 (37%) 0 (0%) 
Respondent Weight (Kilogrammes)    
Mean 86.3 98.0 87.9 64.9 
(Standard Deviation) (17.93) (16.72) (16.10) (10.05) 
Highest Level Qualification    
Higher (University) 65 (58%) 92 (44%) 97 (40%) 109 (48%) 
Further (College) 23 (20%) 52 (25%) 78 (32%) 67 (29%) 
Secondary (School) 20 (18%) 60 (29%) 56 (23%) 46 (20%) 
None 2 (2%) 6 (3%) 8 (3%) 4 (2%) 
Other 3 (3%) 0 (0%) 4 (2%) 3 (1%) 
Employment Status     
Employed (full-time) 64 (57%) 107 (51%) 113 (47%) 94 (41%) 
Employed (part-time) 13 (12%) 39 (19%) 41 (17%) 57 (25%) 
Student 1 (1%) 2 (1%) 3 (1%) 8 (3%) 
Retired 20 (18%) 25 (12%) 60 (25%) 37 (16%) 
Homemaker/Caregiver 4 (4%) 19 (9%) 13 (5%) 15 (7%) 
Unemployed 2 (2%) 16 (8%) 12 (5%) 10 (4%) 
Other 9 (8%) 2 (1%) 1 (<1%) 8 (3%) 
Household Income     
£20,000 or less 18 (16%) 54 (26%) 68 (28%) 48 (21%) 
£20,001 - £40,000 39 (35%) 80 (38%) 72 (30%) 84 (37%) 
£40,001 - £60,000 33 (29%) 41 (20%) 58 (24%) 57 (25%) 
£60,001 and above 23 (20%) 35 (17%) 45 (19%) 40 (17%) 
Health (Visual Analogue Scale; 0=Dead, 100=Perfect Health) 
Mean 79.0 73.5 74.9 80.2 
(Standard Deviation) (17.11) (20.09) (18.39) (17.62) 
Health (EQ-5D-5L Utilities1; 0=Dead, 1=Perfect Health) 
Mean 0.887 0.870 0.881 0.927 
(Standard Deviation) (0.128) (0.187) (0.188) (0.116) 
1English population utilities from Devlin et al. (2017) 
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9.2 Research Question One 
RQ1: To what extent do preferences for a health service, elicited via a discrete choice 
experiment, differ between different user groups, and why might these differences occur? 
9.2.1 Results 
Table 9.2 combines the majority of the information from tables 7.2 and 8.2 from the previous 
two chapters. Therefore, the results presented in table 9.2 are from mixed logit models using 
1000 Halton draws where all parameters are modelled as random and normally distributed. 
Other models that have been estimated using this data in Chapters Seven and Eight and will 
not be considered in this chapter for the reasons previously described. The differences in 
preferences between the four user groups are clear to see in table 9.2 with regards to the 
magnitudes and statistical significance of the coefficients in each model. The remainder of 
this subsection will describe the results one attribute at a time. 
The first clear difference between the four models is the significance of the length attribute. 
Unlike the other three groups, the statistically insignificant coefficient in model one suggests 
that the SU group are, on average, indifferent to the length of the WLM programme. There is 
significant preference heterogeneity for this attribute in all models suggesting that, although 
many people in the PSU, PB and NU groups prefer shorter programmes, there is some 
disparity in preferences within these groups. 
The results for the delivery of feedback attribute are slightly more mixed across the four 
models. There is weak evidence to suggest that the SU group prefer to receive feedback via 
phone call relative to face to face (p<0.1), however models two to four suggest that the other 
three groups are indifferent. There is strong evidence to suggest that the NU group prefer to 
receive feedback via the online tool(s) relative to face to face (p<0.01) and weak evidence of a 
similar preference in the PB group (p<0.1). In contrast, there is evidence for all groups apart 
from the PSU group (where the coefficient is insignificant) of a preference for receiving 
feedback via text message relative to face to face (p<0.1). 
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Table 9.2 Results from the Mixed Logit Models (All Four User Groups) 
 1. Service User 2. Potential Service User 3. Potential Beneficiary 4. Non-User 
Variables Coefficients Std. Devs. Coefficients Std. Devs. Coefficients Std. Devs. Coefficients Std. Devs. 
Alternative-Specific Constant -0.0390 3.492*** 2.380*** 2.357*** 3.012*** 2.675*** 2.897*** 3.569*** 
 (0.493) (0.538) (0.301) (0.256) (0.315) (0.294) (0.379) (0.527) 
Length (months) 0.0163 0.0657*** -0.0313*** 0.0285* -0.0285*** 0.0398*** -0.0356*** -0.0697*** 
 (0.0154) (0.0197) (0.00769) (0.0154) (0.00758) (0.0149) (0.00913) (0.0126) 
Feedback1         
via Phone Call 0.500* -0.0792 0.179 0.422 0.218 0.914*** 0.129 -0.0890 
 (0.266) (0.384) (0.144) (0.343) (0.146) (0.257) (0.149) (0.315) 
via the Online Tool(s) -0.324 -1.555*** 0.199 0.670*** 0.219* -0.0731 0.566*** 0.0876 
 (0.308) (0.465) (0.148) (0.256) (0.130) (0.526) (0.150) (0.329) 
via Text Message 1.006*** 0.752** 0.181 -0.148 0.337*** -0.138 0.615*** -0.355 
 (0.251) (0.302) (0.131) (0.290) (0.123) (0.316) (0.142) (0.246) 
Reminders2         
via Text Message 0.665*** 0.553 0.144 -0.255 0.216* 0.701*** 0.425*** 0.352 
 (0.238) (0.409) (0.124) (0.376) (0.125) (0.192) (0.135) (0.264) 
via Phone Call 0.879*** 0.723** -0.0400 -0.617*** 0.142 0.279 0.103 -0.231 
 (0.294) (0.320) (0.150) (0.223) (0.134) (0.301) (0.156) (0.476) 
via the Online Tool(s) 1.414*** 0.0178 0.0200 -0.238 0.343*** 0.226 0.352** -0.382* 
 (0.317) (0.404) (0.143) (0.336) (0.132) (0.303) (0.153) (0.231) 
Online Tool3         
App Only 0.329 0.238 0.242* -0.00304 0.129 0.102 0.224 0.138 
 (0.244) (0.635) (0.134) (0.253) (0.127) (0.234) (0.140) (0.294) 
Website Only -0.00326 -0.382 0.211 0.446 -0.0537 0.499* 0.197 -0.831*** 
 (0.274) (0.344) (0.146) (0.289) (0.143) (0.269) (0.159) (0.223) 
App & Website 0.543** 1.293*** 0.240* 0.144 0.137 0.575*** -0.0442 -0.623*** 
 (0.260) (0.405) (0.130) (0.359) (0.127) (0.221) (0.140) (0.234) 
Outcome (% weight re-gain) -0.0712*** 0.0539*** -0.0264*** 0.0289*** -0.0168*** 0.0226*** -0.0178*** 0.0263*** 
 (0.00884) (0.00687) (0.00300) (0.00308) (0.00222) (0.00271) (0.00282) (0.00376) 
Cost (£ per month) -0.232*** 0.181*** -0.140*** 0.138*** -0.156*** 0.128*** -0.197*** 0.158*** 
 (0.0323) (0.0227) (0.0145) (0.0134) (0.0133) (0.0116) (0.0177) (0.0165) 
Sample Size (Observations) 113 (3,390) 210 (6,300) 243 (7,290) 229 (6,870) 
Log Likelihood -701 -1,505 -1,752 -1,587 
AIC 1,426 3,036 3,530 3,200 
BIC 1,506 3,124 3,620 3,289 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1; 1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
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The results for the delivery of reminders attribute are also mixed across the models. Every 
delivery method is preferred to not receiving reminders by the SU group (model one), with a 
clear hierarchy from text message being the least preferred to online tools being the most 
preferred. In contrast, no delivery method is clearly preferred (or considered worse) to 
receiving no reminders in the PSU group (model two), as evidenced by the lack of statistically 
significant coefficients. There is weak evidence (p<0.1) to suggest that the PB group (model 
three) prefer to receive reminders via text message, and strong evidence to suggest that they 
prefer to receive reminders via the online tool(s) (p<0.01). There is no evidence to suggest 
that this group prefer receiving reminders via phone call relative to not receiving any. This 
latter point is also the case for the NU group (model four), where there is strong evidence to 
suggest a preference for receiving reminders via text message (p<0.01) and moderate 
evidence to suggest a preference for receiving reminders via online tool(s) (p<0.05), relative 
to not receiving any reminders. 
When comparing the results of all four groups, the availability of online tool(s) appears to be 
one of the least important attributes across the board. The strongest evidence of a preference 
for a level of this attribute is in the SU group (model one) where there is moderate evidence 
(p<0.05) of a preference for having both a mobile application and a website, relative to not 
having either. There is also weak evidence (p<0.1) to suggest that the PSU group (model two) 
prefer to have a mobile application alone, or a combination of a website and mobile 
application, relative to not having either. No coefficients are statistically significant for this 
attribute in the PB and NU groups (models three and four). It should be noted that there is a 
lot of preference heterogeneity associated with this attribute, particularly for the combination 
of a mobile application and website where the standard deviations are statistically significant 
at the 1% level in all models apart from model two. 
The weight re-gain and cost attributes were both highly statistically significant (p<0.01) in all 
models and the coefficients had relatively large, negative coefficients. Relative importance 
calculations provide an insight into how important these attributes were relative to the others 
and avoids the scale issues when comparing coefficients across models. Figure 9.1 presents 
the relative importance of each attribute for each user group and illustrates the dominance of 
these two attributes. However, there are clear differences across the four groups. The weight 
re-gain attribute is more important for the SU group relative to the PSU, PB and NU groups 
(with a preference order of SU > PSU > PB > NU). In contrast, the cost attribute is more 
important for the NU and PB groups relative to the PSU and SU groups (with a preference 
order of NU = PB > PSU > SU). This is all roughly in line with a priori expectations. 
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Figure 9.1 Relative Importance of the Attributes (All Four User Groups)
 
9.2.2. Discussion 
The models in table 9.2 suggest that preferences differ in many ways across the four user 
groups. It is interesting that those involved in the trial, the SU group, do not have a clear 
tendency to select a programme over the opt-out option whereas the other three groups do 
(based on the coefficient for the alternative-specific constant). It is likely that this group has a 
better comprehension of what it is like to take part in such a programme, even if they did not 
partake (control arm), and hence are more willing to select the opt-out option when the 
characteristics do not suit them. 
It is also interesting that those in the SU group do not appear to be affected by the length of 
the WLM programme. In practice, healthcare professionals would hope that individuals do 
not base their decision to take part in such a programme on this particular characteristic. It 
could be the case that this groups’ relatively greater experience of the issue (WLM) is being 
reflected here. In other words, those with a good understanding of the difficult nature of 
achieving WLM may be more likely to accept that there is no quick-fix and that a longer 
programme has its merits for this reason. 
It was not obvious a priori when it came to potential differences that might occur with regards 
to the ‘process’ characteristics (i.e. feedback, reminders, online tools). The results across the 
four models present a varied picture, although there are no dramatic differences between the 
groups that are statistically significant (e.g. different signs). Feedback delivery preferences 
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vary slightly, however there is broad agreement that feedback via text message is preferable to 
face to face feedback (with the exception of the PSU group; model two). Online tools also 
appear to not be particularly desirable, with little evidence to suggest that people based their 
choices on this attribute, unless both a mobile application and a website were included. That 
being said, this attribute level was still insignificant for both the PB and NU groups (models 
three and four). 
However, it is interesting to see that the SU group has such strong preferences for reminders 
relative to the other three groups. Those involved in the both arms of the trial are likely to 
have, at times, struggled to remember to weigh themselves each day (note that only the 
treatment arm received reminders). It appears that the groups from the online panel may have 
underestimated this element of the WLM programmes presented to them due to their relative 
lack of experience.  
Some of the most striking differences between the four user groups occur in relation to the 
weight re-gain and cost attributes; figure 9.1 illustrates this clearly. The trends in relative 
importance of these two attributes align with a priori expectations. It was expected that those 
in the SU group would care more about weight re-gain relative to other groups, and it was 
hypothesised that this group would care less about cost as a result. This is important in terms 
of the face validity of the results. 
9.2.3 Conclusion 
Overall, preferences do appear to differ across the four user groups in several different ways. 
The clearest differences can be seen when looking at the relative importance of attributes such 
as weight re-gain and cost, with the most experienced group caring relatively more about 
weight re-gain and less about cost than any other group. 
9.3 Research Question Two Part A 
RQ2a: To what extent do WTP estimates differ between different user groups, and why might 
these differences occur? 
9.3.1 Results (CV) 
Table 9.3 contains the results for each group to the self-selection; the question that determined 
whether respondents would be faced with a CV exercise or not. Chi2 tests provide convincing 
evidence (p<0.01) that the responses to this question significantly vary across the four user 
groups, even if similar responses are collapsed (e.g. one and two; three and four).  
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Table 9.3 Responses to the CV Self-Selection Question (All Four User Groups) 
 
Response to the “Interest Question” 
SU PSU PB NU Total 
n % n % n % n % n % 
1. I would like to use x 17 15% 37 18% 26 11% 24 10% 104 13% 
2. I would like to use x & want it to be available for others 42 37% 50 24% 45 19% 20 9% 157 20% 
3. I might want to use x 13 12% 44 21% 52 21% 37 16% 146 18% 
4. I might want to use x & want it to be available for others 31 27% 45 21% 57 23% 44 19% 177 22% 
5. I would not use x but I want it to be available for others 9 8% 21 10% 34 14% 77 34% 141 18% 
6. I do not think x should be made available  1 1% 13 6% 29 12% 27 12% 70 9% 
Total 113 100% 210 100% 243 100% 229 100% 795 100% 
           
 
x = a programme like this (referring to the hypothetical programmes from the DCE task) 
 
Responses 1-4 – forwarded to the “use value” WTP exercise;  
Response 5 – forwarded to the “externality” WTP exercise;  
Response 6 – forwarded to open-ended comment box.
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Table 9.4 WTP Estimates from the Use Value CV Task (All Four User Groups) 
 
  Service User (SU) Potential Service User (PSU) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP)   Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD n n % n % Median Mean SD 
0% 103 81 79% 67 65% £10.00 £17.81 32.19 176 118 67% 93 53% £10.00 £14.28 13.50 
10% 81 63 61% 50 49% £10.00 £13.66 16.36 118 91 52% 60 34% £10.00 £11.93 8.52 
20% 63 43 42% 30 29% £10.00 £10.07 5.79 91 59 34% 29 16% £10.00 £11.90 6.20 
40% 43 24 23% 14 14% £8.00 £8.29 5.61 59 32 18% 11 6% £5.00 £9.00 6.32 
60% 24 13 13% 9 9% £5.00 £7.11 6.13 32 17 10% 4 2% £12.50 £11.00 5.23 
80% 13 5 5% 3 3% £5.00 £8.67 10.02 17 12 7% 2 1% £10.00 £10.00 0.00 
90% 5 4 4% 2 2% £3.00 £3.00 2.83 12 11 6% 2 1% £10.00 £10.00 0.00 
100% 4 4 4% 2 2% £3.00 £3.00 2.83 11 11 6% 2 1% £10.00 £10.00 0.00 
 
                
  Potential Beneficiary (PB) Non-User (NU) 
Weight 
Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP)   Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD n n % n % Median Mean SD 
0% 180 115 64% 81 45% £10.00 £13.84 15.89 125 76 61% 58 46% £10.00 £13.91 16.66 
10% 115 95 53% 62 34% £10.00 £11.97 10.58 76 62 50% 45 36% £10.00 £13.13 18.64 
20% 95 68 38% 46 26% £10.00 £10.48 8.39 62 47 38% 30 24% £10.00 £12.57 20.97 
40% 68 32 18% 20 11% £8.50 £8.30 4.05 47 22 18% 11 9% £5.00 £16.27 31.49 
60% 32 16 9% 9 5% £10.00 £10.33 4.97 22 18 14% 7 6% £10.00 £20.43 35.43 
80% 16 13 7% 6 3% £10.00 £11.00 6.32 18 13 10% 4 3% £12.50 £32.50 41.73 
90% 13 12 7% 4 2% £12.50 £13.75 4.79 13 9 7% 3 2% £10.00 £11.67 2.89 
100% 12 7 4% 3 2% £15.00 £15.00 5.00 9 7 6% 2 2% £12.50 £12.50 3.54 
Percentages are based on the number of individuals that were forwarded to the exercise from each user group in the first instance (underlined) 
1Those that selected “yes” when asked whether they would be willing to pay (those that select “no” exit the exercise at that particular stage) 
2Those that provided a value when asked for the maximum amount that they would be willing to pay and did not increase their value at any point during the task (‘logic rule’)
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Combining responses one and two, it is clear that a higher proportion of the SU group wish to 
use a WLM programme like the ones described in the DCE task relative to the other three 
groups (the specific order is SU > PSU > PB > NU). The proportion of respondents stating 
that they might want to use a WLM programme (responses three and four) are fairly similar 
across the four user groups. Combining all four responses shows that a significantly different 
proportion of each user group went on to face the “use value” contingent valuation exercise; 
from 91% of the SU group to 54% of the NU group (once again following the order of SU > 
PSU > PB > NU). 
Table 9.4 presents the full results from the use value CV exercise. One-way ANOVA suggests 
that the mean values at each weight re-gain level are not statistically significantly different 
across the four user groups. The similarity between the values provided by each group are 
clearest when looking at the median values, which are identical for every group for the first 
three weight re-gain levels (£10 at 0%, 10% and 20%). As explained in the previous chapters, 
the average values increase as the sample size decreases (from around 60% weight re-gain 
onward) due to the way that some individuals responded to the questions (not changing their 
value as weight re-gain increases). 
9.3.2 Discussion (CV) 
The differences in interest between the four groups, as determined by the self-selection 
question, provide clear evidence that these groups differ in more than just their weight loss 
and weight loss maintenance history. In other words, there is a notable difference in their 
desire to participate in a WLM programme. The spread of proportions of people responding 
that they wish to use a WLM programme is largely as expected (SU > PSU > PB > NU). 
However, it would not have been surprising if the SU group had a slightly lower proportion, 
given that roughly half of this group had been ‘treated’. In fact, there is no statistically 
significant difference between the responses to the self-selection question between the two 
trial arms (as shown in Chapter Seven). This could be due to the fact that trial participants 
found that the intervention was beneficial, and/or that an alternate version of the trial 
intervention would be helpful to them in future. 
Despite the differences in interest, the average WTP values between the four user groups are 
not statistically significantly different from one another. It could be the case that, although the 
user groups differ on average, the individuals that believe that a WLM programme is relevant 
to them have a similar perception of the market value of the service. While a respondent with 
a normal BMI would have been classified as a ‘non-user’ it cannot be determined that the 
respondent has no history of a higher BMI classification or attempted weight loss. In fact, 
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many individuals that are not considered high-risk (e.g. not obese) are still concerned about 
their weight and make regular attempts to lose weight (Santos et al., 2017). As such, while 
there may be fewer individuals in the NU group that feel that they would use a WLM 
programme on the whole, the individuals that are interested in such a programme may have 
strong and well-defined preferences that are in line with those with clear experience of WLM 
programmes (e.g. the SU group).  
9.3.3 Results (DCE) 
Table 9.5 contains WTP estimates for weight re-gain for each of the four user groups; these 
are calculated by taking the ratio of the coefficients for weight re-gain and cost, as explained 
in Chapter Six.  
 
Table 9.5 WTP Estimates from the DCE (All Four User Groups) 
Group 
WTP for % weight 
re-gain 
95% Confidence Interval  
[Lower, Upper] 
Service User (SU) -£0.31 [-£0.37, -£0.25] 
Potential Service User (PSU) -£0.19 [-£0.23, -£0.14] 
Potential Beneficiary (PB) -£0.11 [-£0.14, -£0.08] 
Non-User (NU) -£0.09 [-£0.12, -£0.06] 
 
The results are interpreted as such: individuals from the SU group would pay £3.07 less per 
month for a programme if weight re-gain increased by 10 percentage points. In comparison, 
the PSU group would pay £1.90 less per month, the PB group £1.10 less per month and the 
NU group £0.90 less per month.  
The lack of overlap in the 95% confidence intervals of the SU and PSU groups relative to all 
other groups suggest that these estimates are statistically significantly different from each 
other and the other groups. However, it would appear that the estimates for the PB and NU 
groups are not significantly different from one another, given the significant overlap in the 
confidence intervals. This is illustrated in figure 9.2. 
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Figure 9.2 WTP Estimates from the DCE for Weight Re-Gain (All Four User Groups)
 
9.3.4 Discussion (DCE) 
It is interesting that there are statistically significant differences in WTP between the user 
groups. The differences are roughly in line with a priori expectations: it was expected that 
individuals from the SU group would be willing to pay more to avoid weight re-gain relative 
to the other groups. It was also expected that the PSU group would be willing to pay more to 
avoid weight re-gain relative to the PB and NU groups. However, it is somewhat surprising 
that there is no statistically significant difference between the PB and NU groups. On the 
other hand, the distinction between these two groups is relatively minor (overweight vs. 
normal BMI classification). 
Despite the fact that differences exist it is not necessarily the case that they are economically 
meaningful. For example, if a programme set at a price of £10 per month turned out to be less 
effective than expected by 10 percentage points (weight re-gain) then individuals in the SU 
group would only be willing to pay £6.93 per month, on average. In comparison, individuals 
in the NU group would be willing to be pay £9.10 per month, on average. These are relatively 
small differences, considering that one user group has an observable need for a WLM 
programme whereas the other group have no observable need at all. However, it should be 
noted that these are monthly WTP estimates and hence the absolute difference would be much 
larger over the course of a typical WLM programme (e.g. 6-24 months). 
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9.3.5 Conclusion 
There appears to be differences between the user groups in relation to the WTP estimates 
derived from the DCE, with the most experienced groups (SU and PSU) appearing to be 
willing to pay significantly more than the less experienced (PB and NU) groups. In contrast, 
no such differences can be identified from the WTP estimates from the CV task.  
9.4 Research Question Two Part B 
RQ2b: How might WTP estimates differ if they are elicited indirectly or directly? 
9.4.1 Results 
As explained in previous chapters, there are several methods that have been used in the past to 
compare WTP estimates from a DCE and a CV task. In this empirical work, the iterative 
nature of the CV questions was used to generate a WTP estimate for a percentage point 
change in weight re-gain. As these have already been identified in the DCE (WTPDCE 
hereafter), the estimates from the CV task can be directly compared (WTPCV hereafter). Table 
9.6 contains the mean WTPCV as well as the WTPDCE estimates from table 9.5, split by group. 
Table 9.6 DCE and CV Comparison in WTP for 1% Increase in Weight Re-Gain (All 
Four User Groups) 
Group WTPDCE WTPCV Difference p-value 
SU -£0.31 -£0.62 £0.31 0.497 
PSU -£0.19 -£0.34 £0.15 0.178 
PB -£0.11 -£0.22 £0.11 0.087 
NU -£0.09 -£0.19 £0.10 0.045 
 
The average WTPCV values are not statistically significantly different across the four user 
groups (p-value>0.1). Additionally, as indicated by the p-values in table 9.6, there are no 
statistically significant difference at the 1% level between the WTPDCE and the average 
WTPCV value for any of the four user groups. There is some moderate evidence to suggest 
that the estimates vary between the two tasks for the NU group, specifically that the WTPCV 
estimate is larger (in absolute terms). This trend is repeated in the other user groups, however 
there is no convincing evidence that the estimates are statistically significantly different. 
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9.4.2 Discussion 
There is little convincing evidence that the WTP estimates from the CV and the DCE are 
statistically significantly different. Part of the issue may be that the CV estimates are based on 
very few responses; the approach taken here requires individuals to have provided values in 
the CV task when weight re-gain was set at both 0% and 10% (n=62 for the PB group and 
n=45 for the NU group). The self-selection question might not have helped either, as this will 
have guided some respondents away from the use value CV task. That being said, there was a 
clear justification for taking this approach in that individuals that would not like to use a 
WLM programme should be less likely to be willing to pay for one. 
9.4.3 Conclusion 
There appears to be no evidence of a difference between WTP estimates when they are 
elicited via CV and DCE. It could be the case that data limitations are responsible here, as 
sample sizes were not large for the WTPCV estimates. As a result, it would be wise to avoid 
concluding that there isn’t a difference. Ideally an adequately powered study should be 
designed; the current study however provides valuable information to help inform the size of 
that study. 
9.5 Research Question Three 
RQ3: To what extent do certain groups have better defined preferences than other user 
groups, and why might these differences occur? 
9.5.1 Results 
Two rationality tests were embedded within the DCE in order examine how well-defined 
respondents’ preferences are, as described in Chapter Six. Table 9.7 presents the pass rates for 
the dominance test, the transitivity tests (two definitions), and a combination of the three for 
all four user groups. 
Table 9.7 Embedded DCE Rationality Test Results (All Four User Groups) 
Group Dominance 
Weak 
Transitivity 
Strong 
Transitivity 
All 3 
SU 110/113 (97%) 111/113 (98%) 78/113 (69%) 75/113 (66%) 
PSU 193/210 (92%) 201/210 (96%) 117/210 (56%) 110/210 (52%) 
PB 223/243 (92%) 226/243 (93%) 125/243 (51%) 114/243 (47%) 
NU 207/229 (90%) 221/229 (97%) 118/229 (52%) 106/229 (46%) 
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The results in table 9.7 are positive on the whole. The vast majority of respondents in each 
user group passed the dominance and weak transitivity tests. In addition, at least half of all 
respondents in each user group passed the strong transitivity test. There are very few 
differences in the pass rates between the PSU, PB and NU groups, however the SU group has 
better pass rates for all tests relative to these three groups. 
In order to formally examine the factors that may influence the probability of an individual 
passing one or all of the rationality tests, a series of models were estimated. The models 
consisted of a dummy dependent variable that indicated whether respondents passed the test 
and were estimated using logistic regression. As such, the coefficients have little practical 
meaning, therefore marginal effects at the means were calculated and are reported alongside 
the coefficients in table 9.8.  
Model one suggests that individuals with a higher weight are slightly less likely to pass the 
dominance test (p<0.01); 0.1% less likely for every additional kilogram. Additionally, there is 
strong evidence (p<0.01) to suggest that individuals from the SU group are more likely, by 
10.3%, to pass the dominance test and moderate evidence (p<0.05) to suggest that individuals 
from the PSU group are more likely, by 6.1% to pass the dominance test, relative to the NU 
group. 
Model two suggests that there are some differences in the pass rates of the weak transitivity 
test depending on the block of the DCE that the respondent was assigned to. Specifically, 
there is moderate evidence (p<0.05) to suggest that individuals in blocks one and three of the 
DCE were more likely, by around 3-4%, to pass the test relative to block four. Additionally, 
there is moderate evidence (p<0.05) to suggest that individuals in the PB group were less 
likely pass the test relative to the NU group, by around 3%. 
Model three also suggests that there are some differences in the pass rates of the strong 
transitivity test depending on the block of the DCE that the respondent was assigned to. 
Specifically, respondents assigned to block three appear to be around 19% more likely to pass 
this test and the effect is significant at the 1% level. It also appears that respondents that found 
the DCE difficult (according to a difficulty question post-DCE) were 11% less likely to pass 
the test relative to those that did not find it difficult (p<0.01). Additionally, there is moderate 
evidence (p<0.05) to suggest that respondents that stated that they were interested in using a 
WLM programme (responses one and two to the self-selection question; see table 9.3) were 
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8% more likely to pass the test. Finally, there is moderate evidence (p<0.05) to suggest that 
individuals in the SU group were 18% more likely to pass this test. 
Model four combines the all three rationality tests. It provides moderate-strong evidence that 
respondents assigned to blocks two and three of the DCE were more likely, by 12% and 18% 
respectively, to pass all three tests relative to block four. There is also moderate evidence 
(p<0.05) to suggest that respondents that found the DCE difficult were less likely, by 9%, to 
pass all three tests. Finally, this model provides strong evidence to suggest that respondents in 
the SU group are 23% more likely to pass the combination of all three rationality tests relative 
to the other user groups. 
9.5.2 Discussion 
The finding that heavier respondents are less likely to pass the dominance test may be due to a 
misunderstanding surrounding the weight re-gain attribute. As the absolute value would be 
greater for heavier respondents, it may be more tempting for respondents to select the 
dominated option if they incorrectly believe that this attribute refers to weight loss, despite the 
fact that the dominated option is also associated with a higher cost. 
It is interesting to see that the block of the DCE that respondents were assigned to appears to 
have an impact on the pass rates of transitivity tests. It may be the case that certain blocks 
contained alternatives that were slightly more similar to those in the transitivity test scenarios, 
which impacted the likelihood of a respondent passing the test. Alternatively, this could be a 
random effect. Regardless, it may have been wise to randomise the order of the scenarios in 
the DCE such that any potential effect of the scenarios that come before and after the 
transitivity test scenarios is minimised. An exploration into the reasons behind this finding 
may be interesting as part of future research.  
Despite all of this, the most striking result from the models in table 9.8 is that respondents 
from the trial (SU group) are 23% more likely to pass the combination of all three rationality 
tests. While the importance attributed to these tests is debateable, it is undeniable that higher 
pass rates are preferable. For one group to have such a significantly higher probability of 
passing the tests relative to the others is therefore hard to ignore. In addition, the fact that it is 
the SU group that are more likely to pass the tests fits nicely with the hypotheses of this 
project. It was expected that those with the most relevant experience, of both the health issue 
and of treatment, would provide ‘better quality’ preference data. The results here suggest that 
this hypothesis was correct, provided that higher rationality test pass rates can reasonably be 
considered an indicator of better quality preference data. 
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Table 9.8 Rationality Test Logit Models (All Four User Groups) 
  1. Dominance 2. Weak Transitivity 3. Strong Transitivity 4. All Tests 
  Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. 
Age 0.131 * 0.007 * 0.095  0.003  0.035  0.009   0.053  0.013  
 (0.071)  (0.004)   (0.096)  (0.003)  (0.039)  (0.010)   (0.039)  (0.010)  
Age2 -0.001  -0.000   -0.001  -0.000  -0.000  -0.000   -0.000  -0.000  
 (0.001)  (0.000)   (0.001)  (0.000)  (0.000)  (0.000)   (0.000)  (0.000)  
Higher Education -0.237  -0.013   0.053  0.002  0.289  0.071   0.217  0.054  
 (1.069)  (0.060)   (1.093)  (0.034)  (0.477)  (0.118)   (0.476)  (0.119)  
Further Education -0.508  -0.029   0.469  0.015  0.293  0.072   0.067  0.017  
 (1.073)  (0.061)   (1.118)  (0.035)  (0.481)  (0.119)   (0.480)  (0.120)  
Secondary Education 0.188  0.011   0.857  0.027  0.192  0.047   0.120  0.030  
 (1.104)  (0.062)   (1.157)  (0.036)  (0.487)  (0.120)   (0.486)  (0.121)  
Other Education -0.885  -0.050   -0.160  -0.005  -0.282  -0.070   -0.755  -0.189  
 (1.533)  (0.086)   (1.588)  (0.050)  (0.828)  (0.205)   (0.865)  (0.216)  
Employed (FT/PT) -0.617  -0.035   -0.239  -0.007  -0.120  -0.030   -0.198  -0.049  
 (0.399)  (0.022)   (0.478)  (0.015)  (0.187)  (0.046)   (0.186)  (0.047)  
Married/Cohabiting 0.030  0.002   -0.566  -0.018  0.009  0.002   -0.012  -0.003  
 (0.306)  (0.017)   (0.449)  (0.014)  (0.169)  (0.042)   (0.168)  (0.042)  
DCE Block 1 0.267  0.015   1.038 ** 0.032 ** 0.160  0.040   0.193  0.048  
 (0.381)  (0.021)   (0.480)  (0.015)  (0.203)  (0.050)   (0.204)  (0.051)  
DCE Block 2 0.207  0.012   0.745  0.023  0.406 * 0.100 * 0.472 ** 0.118 ** 
 (0.389)  (0.022)   (0.463)  (0.015)  (0.210)  (0.052)   (0.211)  (0.053)  
DCE Block 3 0.040  0.002   1.192 ** 0.037 ** 0.766 *** 0.189 *** 0.729 *** 0.182 *** 
 (0.383)  (0.022)   (0.536)  (0.016)  (0.213)  (0.053)   (0.211)  (0.053)  
Found DCE Difficult 0.353  0.020   -0.255  -0.008  -0.462 *** -0.114 *** -0.365 ** -0.091 ** 
 (0.292)  (0.016)   (0.360)  (0.011)  (0.153)  (0.038)   (0.153)  (0.038)  
Weight (kg) -0.025 *** -0.001 *** 0.008  0.000  0.003  0.001   -0.003  -0.001  
 (0.009)  (0.000)   (0.012)  (0.000)  (0.005)  (0.001)   (0.005)  (0.001)  
Interested in Using a WLM Programme -0.472  -0.027   -0.118  -0.004  0.337 ** 0.083 ** 0.185  0.046  
 (0.290)  (0.016)   (0.377)  (0.012)  (0.164)  (0.040)   (0.162)  (0.041)  
Service User 1.819 *** 0.103 *** 0.648  0.020  0.717 ** 0.177 ** 0.930 *** 0.233 *** 
 (0.694)  (0.037)   (0.857)  (0.026)  (0.279)  (0.069)   (0.277)  (0.069)  
Potential Service User 1.079 ** 0.061 ** -0.498  -0.016  0.013  0.003   0.301  0.075  
 (0.477)  (0.027)   (0.659)  (0.021)  (0.258)  (0.064)   (0.256)  (0.064)  
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  1. Dominance 2. Weak Transitivity 3. Strong Transitivity 4. All Tests 
  Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. Coeff. Mfx. 
Potential Beneficiary 0.718 * 0.041 * -1.059 ** -0.033 ** -0.125  -0.031   0.043  0.011  
 (0.409)  (0.023)   (0.525)  (0.016)  (0.222)  (0.055)   (0.221)  (0.055)  
Constant 1.375     0.149    -1.316     -1.427    
 (1.796)     (2.264)    (0.997)     (0.998)    
Observations 795 795 795 795 
Pseudo R2 0.0814 0.0898 0.0400 0.0392 
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9.5.3 Conclusion 
On the whole, the results to the rationality tests are extremely positive for all user groups, 
perhaps indicating that the preference data is of a high quality. However, the SU group are 
23% more likely pass the combination of all three tests relative to the other user groups. This 
is a substantial considering that observable characteristics were controlled for. It may be the 
case that individuals that have experienced the health issue as well as a related healthcare 
intervention are more likely to be engaged in a preference elicitation task. This would perhaps 
suggest that samples made of such individuals are preferable from a researcher’s perspective. 
9.6 Research Question Four 
RQ4: To what extent might differences in preferences between the user groups be attributed 
to the recruitment vehicle? 
The focus of the previous sections has been on differences in preferences between the four 
user groups that were outlined in the framework in Chapter Five. In contrast, the focus of 
research question four is the overall difference in preferences (and in the data more generally) 
between the trial and online panel samples. This section will summarise the overall 
differences between the two samples in relation to research questions one to three, with 
additional analysis provided as necessary where data from the three user groups recruited via 
the online panel are pooled. 
9.6.1 Comparison of the Trial & Online Panel Samples: Research Question One 
Section 9.2 illustrated how the preferences of individuals in the SU group differed from those 
of the PSU, PB and NU groups. In contrast, when comparing the latter three groups, the 
differences were not as substantive. Table 9.9 provides the DCE results from the SU group 
(the trial sample) with results from the PSU, PB and NU groups combined (the online panel 
sample). 
Even though coefficients cannot be meaningfully compared, some differences are clear from 
observing the statistical significance of the coefficients. For example, those in the trial sample 
do not appear to care about the length of the programme, whereas the online panel sample 
prefer shorter programmes. There is also fairly strong evidence that every feedback delivery 
mode is preferred to face to face feedback for the online panel sample, but the trial sample do 
not appear to prefer feedback via the online tool(s) over face to face feedback. Reminders 
appear to be important in both samples, however the online panel do not appear to favour 
reminders via phone call over not receiving reminders at all. In addition, the online panel 
sample slightly prefer reminders via text message over reminders via the online tool(s), 
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whereas the opposite is the case for the trial sample. Neither sample expressed 
overwhelmingly strong preferences for online tools, with the online panel appearing to prefer 
having an app over both a website and an app. In contrast, the trial sample only appear to have 
a preference for having both a website and an app. Unsurprisingly, and a measure of face 
validity, both samples prefer a lower amount of weight re-gain and lower cost. 
Table 9.9 Results from the Mixed Logit Models (Trial vs. Online Panel) 
 1. Trial Sample 2. Online Panel Sample 
  Coefficient Std. Dev. Coefficient Std. Dev. 
Alternative Specific 
Constant -0.039  3.492 *** 2.782 *** 2.82 *** 
 (0.493)  (0.538)   (0.186)  (0.164)  
Length (months) 0.016   0.066 *** -0.03 *** 0.044 *** 
  (0.015)   (0.020)   (0.005)   (0.008)   
Delivery of Feedback1            
via Phone Call 0.500 * -0.079   0.168 ** -0.367  
 (0.266)  (0.384)   (0.080)  (0.224)  
via the Online Tool(s) -0.324  -1.555 *** 0.296 *** -0.149  
 (0.308)  (0.465)   (0.078)  (0.363)  
via the Text Message 1.006 *** 0.752 ** 0.355 *** -0.110  
 (0.251)  (0.302)   (0.073)  (0.187)  
Reminders2                 
via Text Message 0.665 *** 0.553   0.255 *** -0.537 *** 
 (0.238)  (0.409)   (0.072)  (0.123)  
via Phone Call 0.879 *** 0.723 ** 0.077  -0.455 *** 
 (0.294)  (0.320)   (0.082)  (0.164)  
via the Online Tool(s) 1.414 *** 0.018   0.239 *** -0.086  
  (0.317)   (0.404)   (0.078)   (0.177)   
Online Tool3            
App Only 0.329  0.238   0.191 ** 0.033  
 (0.244)  (0.635)   (0.075)  (0.149)  
Website Only -0.003  -0.382   0.098  0.388 ** 
 (0.274)  (0.344)   (0.082)  (0.188)  
App & Website 0.543 ** 1.293 *** 0.122 * 0.425 *** 
 (0.260)  (0.405)   (0.073)  (0.148)  
Weight Re-gain (%) -0.071 *** 0.054 *** -0.02 *** 0.025 *** 
  (0.009)   (0.007)   (0.001)   (0.002)   
Personal Cost (£ per 
month) -0.232 *** 0.181 *** -0.159 *** 0.138 *** 
  (0.032)   (0.023)   (0.008)   (0.007)   
Observations (Sample Size) 3,390 20,460 
Log Likelihood -701 -4,876 
AIC  1,426  9,778 
BIC  1,506  9,881 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
 
As has been done throughout the results chapters of this thesis, figure 9.3 provides estimates 
of the relative importance of each attribute according to the two models in table 9.9. There are 
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some major differences in the relative importance of the attributes between the two samples. 
Whilst the relative importance of the weight re-gain attribute is 42% for the trial sample, it is 
only 24% for the online panel sample. In addition, the relative importance of the cost attribute 
for the trial sample is 41%, whereas it is 58% for the online panel sample.  
On the whole, figure 9.3 suggests that the online panel sample care more about cost, less 
about weight re-gain and more about the length of the programme relative to the trial sample. 
One could conclude that this is a result of a lack of focus on the issue at hand (weight 
management and weight loss maintenance) from those in the online panel relative to those in 
the trial. Additionally, figure 9.3 is eye-opening in that it highlights that the trial sample also 
care more about the key process attributes (delivery modes for feedback and reminders, 
availability of the online tools) relative to the online panel sample. Slight differences in the 
relative importance of these attributes between the user groups within the online panel made 
this effect less prominent in figure 9.2. On the whole, it seems that there are significant 
differences in preferences between the trial sample and the online panel sample.  
Figure 9.3 Relative Importance of the Attributes (Trial vs. Online Panel)
 
9.6.2 Comparison of the Trial & Online Panel Samples: Research Question Two 
Section 9.3 illustrated how differences in WTP estimates from the four user groups. Table 
9.10 contains the DCEWTP estimates for the two samples separately. The difference between 
the two estimates is clear, with the estimate almost triple the size in the trial sample relative to 
the online panel. In addition, the confidence intervals do not overlap at all and hence these 
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two estimates are likely to be statistically significantly different from one another. This is 
perhaps unsurprising, given that there were statistically significant differences between the 
DCEWTP estimates of the SU and the PSU groups. 
Table 9.10 WTP Estimates from the DCE (Trial vs. Online Panel) 
Group 
WTP for % weight 
re-gain 
95% Confidence Interval  
[Lower, Upper] 
Trial Sample -£0.31 [-£0.37, -£0.25] 
Online Panel Sample -£0.12 [-£0.14, -£0.11] 
 
Table 9.11 highlights how the trial sample differed from the online sample overall in terms of 
the self-selection question. Over half of the trial sample (52%) stated that they would like to 
use a WLM intervention compared with 30% of the online panel sample (42% of the PSU 
group; 30% of the PB group; and 19% of the NU group). When combining these figures with 
responses three and four (where respondents stated that they might want to use a WLM 
programme), 91% of the trial sample would, or might want, to use a WLM intervention 
compared with 71% of the online panel sample (84% of the PSU group; 74% of the PB group; 
and 54% of the NU group). Given the differences identified in table 9.3, a large part of this 
can be put down to the NU group where almost half of the sample responded with option five 
or six (46%); which is a measure of face validity. 
Table 9.11 Responses to the CV Self-Selection Question (Trial vs. Online Panel) 
Response to the “Interest Question” Trial Online Panel 
1. I would like to use x 17 (15%) 87 (13%) 
2. I would like to use x & want it to be available for others 42 (37%) 115 (17%) 
3. I might want to use x 13 (12%) 133 (20%) 
4. I might want to use x & want it to be available for others 31 (27%) 146 (21%) 
5. I would not use x but I want it to be available for others 9 (8%) 132 (19%) 
6. I don’t think x should be made available 1 (1%) 69 (10%) 
 113 (100%) 682 (100%) 
x = a programme like this (referring to the hypothetical programmes from the DCE task) 
Responses 1-4 – forwarded to the “use value” WTP exercise; Response 5 – forwarded to the “externality” WTP 
exercise; Response 6 – forwarded to open-ended comment box 
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Table 9.12 contains the WTPCV estimates after pooling the results from the three user groups 
that were recruited via the online panel. Despite the differences in WTPDCE estimates in table 
9.10 and the differences in responses to the self-selection question shown in table 9.11, the 
median and mean values in table 9.12 do not vary substantially between the two samples. 
One-way ANOVA confirms that there are no statistically significant differences between the 
two samples in relation to the WTPCV estimates at any level of weight re-gain. 
Table 9.12 DCE and CV Comparison in WTP for 1% Increase in Weight Re-Gain (Trial 
vs. Online Panel)  
Trial Sample 
Weight Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD 
0% 103 81 79% 67 65% £10.00 £17.81 32.19 
10% 81 63 61% 50 49% £10.00 £13.66 16.36 
20% 63 43 42% 30 29% £10.00 £10.07 5.79 
40% 43 24 23% 14 14% £8.00 £8.29 5.61 
60% 24 13 13% 9 9% £5.00 £7.11 6.13 
80% 13 5 5% 3 3% £5.00 £8.67 10.02 
90% 5 4 4% 2 2% £3.00 £3.00 2.83 
100% 4 4 4% 2 2% £3.00 £3.00 2.83 
Online Panel Sample 
Weight Re-Gain 
  Stated1 Provided2 Willingness to Pay (WTP) 
n n % n % Median Mean SD 
0% 481 309 64% 232 48% £10.00 £14.03 15.12 
10% 309 248 52% 167 35% £10.00 £12.27 12.62 
20% 248 174 36% 105 22% £10.00 £11.47 12.82 
40% 174 86 18% 42 9% £6.00 £10.57 16.47 
60% 86 51 11% 20 4% £10.00 £14.00 20.85 
80% 51 38 8% 12 2% £10.00 £18.00 24.66 
90% 38 32 7% 9 2% £10.00 £12.22 3.63 
100% 32 25 5% 7 1% £10.00 £12.86 3.93 
Percentages are based on the number of individuals that were forwarded to the exercise from each user group in 
the first instance (underlined);  
1Those that selected “yes” when asked whether they would be willing to pay (those that select “no” exit the 
exercise at that particular stage);  
2Those that provided a value when asked for the maximum amount that they would be willing to pay and did not 
increase their value at any point during the task (“logic rule”). 
 
9.6.3 Comparison of the Trial & Online Panel Samples: Research Question Three 
The results in table 9.8 highlight that there are very few differences with respect to the 
rationality test pass rates between the three user groups recruited via the online panel. In 
model four, the coefficients on the PSU and PB variables are not statistically significant 
whereas the coefficient on the SU variable is. The interpretation provided in the previous 
section was that being in the SU group is associated with a 23% increase in the probability of 
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passing all of the rationality tests. An alternative interpretation is that being in the trial sample 
is associated with a 23% increase in the probability of pass all of the rationality tests relative 
to being in the online panel sample (as the trial sample is the SU group). 
9.6.4 Discussion (Research Question Four) 
There are clear differences between the trial sample and the online panel sample in most of 
the key analyses. However, due to the sampling process, there are also clear differences in the 
level of experience of individuals within each sample. It is therefore very challenging to 
identify whether the recruitment source or the user group classification is the primary source 
of differences in preferences. That being said, the results from previous sections of this 
chapter show that there are differences between the three user groups recruited via the online 
panel. Therefore, it would seem logical to conclude that differences in experience are likely to 
lead to differences in preferences without ruling out that the recruitment vehicle could also 
play a role.  
9.7 Overall Conclusion 
The comparisons of the results from each of the four user groups indicate that there are some 
substantive differences in preferences. The DCE results illustrate that certain aspects of WLM 
interventions are not important to some user groups but are important to others (on average). 
The relative importance of the weight re-gain and cost attributes clearly differs across the four 
user groups in a logical manner, with the most experienced group caring the most about 
weight re-gain and caring the least about cost. These differences give rise to the differing 
WTP estimates from the DCE, with the SU group willing to pay three times more to avoid a 
percentage increase in weight re-gain relative to the NU group. In contrast, no differences 
were identified between the four user groups in relation to the WTP estimates from the CV 
task. This could be due to data limitations, framing, or it could be a legitimate finding. If the 
latter is true, researchers might wish to consider the payment vehicle (i.e. DCE vs CV) if the 
primary study aim is to estimate WTP.  
It also appears that more experienced individuals (i.e. those in the SU group) may provide 
higher quality data in the sense that they are less likely to fail rationality tests. This particular 
finding is the most relevant with respect to research question four, as no statistically 
significant differences were identified between the three user groups recruited via the online 
panel. Therefore, if any of the differences identified in the empirical work are to be explained 
by the recruitment vehicle rather than the level of experience, this would appear the most 
likely. In contrast, differences in preferences and WTP estimates from the DCE do not appear 
to be fully explained by the recruitment vehicle alone. 
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Chapter 10. Discussion and Conclusions 
 
The aim of this chapter is to provide a discussion of the findings from this thesis. The first 
section provides an overview of what the thesis aimed to achieve. The second section outlines 
the main contributions to knowledge from this thesis in relation to the four research questions. 
The third section provides the main implications of the thesis to stakeholders such as 
researchers and policymakers. The fourth section outlines some strengths and broad 
limitations of the approach taken in the thesis. The fifth section provides a series of 
suggestions surrounding related future research. The sixth and final section concludes the 
chapter and the thesis. 
10.1 Thesis Outline 
This thesis began with an outline of the relevant economic theory (Chapter Two) and two 
reviews of existing literature relating to the increasing use of preference studies in health 
economics and healthcare decision-making (Chapters Three and Four). It then presented a 
theoretical framework describing how respondent samples might differ when recruited for 
preference studies that focus on healthcare interventions. It then set out a series of research 
questions to test the framework (Chapter Five). The design of an online survey was then 
outlined. This survey required two recruitment processes, both with complex screening 
questions. It contained both a DCE and a CV task along with additional data collection 
relating to general health, demographic and attitudinal information (Chapter Six). The 
remaining chapters reported the results for the trial sample (Chapter Seven), the online panel 
sample (Chapter Eight) and the combined analyses (Chapter Nine) and discussed the 
implications of the results. 
The overall aim of this thesis was to explore whether, and how, differences in individuals’ 
experience of a healthcare intervention and/or a health issue might influence their preferences 
for a related healthcare intervention. The following four research questions were examined to 
achieve this aim: 
1. To what extent do preferences for a health service, elicited via a DCE, differ between 
different user groups, and why might these differences occur? 
2. In relation to WTP estimates: 
a. To what extent do the estimates differ between different user groups, and why 
might these differences occur? 
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b. To what extent do the estimates differ if they are elicited indirectly (via DCE) 
or directly (via CV)? 
3. To what extent do certain user groups have better defined preferences than other user 
groups, and why might these differences occur? 
4. To what extent might differences in preferences between the user groups be attributed 
to the recruitment vehicle? 
The case study used in this thesis was that of a WLM intervention from the NULevel trial 
(Evans et al., 2015; see section 6.1). Whilst lifestyle interventions are increasingly improving 
when it comes to helping individuals to lose weight, very few are successful in promoting 
long-term maintenance of weight loss (Dombrowski et al., 2014). Weight loss and WLM are 
well understood and widely applicable to the general population; it is estimated that 40% of 
adults attempted to lose weight between 2010 and 2015 worldwide (Santos et al., 2017). As a 
result, this case study is particularly useful because observed differences in preferences are 
perhaps more likely to be attributable to genuine tastes rather than misunderstandings.  
10.2 Contributions to Knowledge 
10.2.1 Research Question One 
Very little evidence exists regarding the differences in results that might occur when samples 
of respondents with different levels of prior experience complete a DCE. In fact, a recently 
published paper (August 2017) that set out a research agenda for patient preference studies 
highlighted this as an important area for further research (Levitan et al., 2017). This thesis has 
provided evidence to suggest that preferences elicited using a DCE differ across all of the user 
groups presented in the framework in Chapter Five. Therefore, preferences may indeed differ 
according to the relative experience of the respondents. 
This is particularly interesting in the case of the SU, PSU, and PB groups because all of these 
groups could be considered as samples of ‘patients’ and previous chapters have highlighted 
the increasing interest in patient preference studies (see section 3.4 in particular). The 
relatively large difference between the SU and PSU groups suggests that results from 
preference studies may differ even if detailed inclusion and exclusion criteria from clinical 
trials are replicated when recruiting via an online panel. This difference may be due to relative 
experience, the recruitment vehicle, or a mixture of the two. Nonetheless, this may have 
implications for future preference studies with regard to their approach to recruiting patient 
samples. Furthermore, the results from this thesis suggest that the PB group are not 
particularly different from non-users in relation to their preferences for WLM interventions. 
This could be a useful finding for preference studies that focus on areas such as preventative 
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interventions or vaccinations. In existing studies, the focus may have been on identifying an 
at-risk group of the general population, whereas the results from this thesis suggest that there 
might not be a big difference between an at-risk group and a random sample.  
However, the case study used here may have had an effect. In the PB group, 63% of 
individuals were overweight and the remainder were obese, whereas 100% of the NU group 
had a normal BMI classification. Whilst the make-up of the two groups are significantly 
different with respect to BMI, it is not necessarily the case that an overweight individual in 
the PB group believes that they are significantly different to an individual in the NU group 
with a normal BMI. That is, the individual in the PB group may not be aware that they are at-
risk in this context. In another context, these groups might be defined such that at-risk 
individuals are more likely to be aware that they are at-risk, which could result in greater 
differences in preferences between the at-risk (PB) group and a group of non-users. 
10.2.2 Research Question Two 
It follows from research question one that there is currently little evidence regarding the 
differences in WTP estimates that might occur when samples of respondents with different 
levels of prior experience complete a DCE. Nonetheless, the limited published evidence 
suggests that there can be very large disparities in WTP between different groups (Najafzadeh 
et al, 2013; Finkelstein et al. 2015; Tinelli et al., 2016). The results from this thesis add to this 
sparse literature by providing evidence that WTP differs between the groups defined in this 
study. In contrast to the literature (see section 4.2.3), the differences identified in the DCE are 
not of a large magnitude, perhaps due to the scale of the cost attribute (£0-30). The key WTP 
estimate that is focused on in this thesis (% change in weight re-gain) ranged from -£0.31 for 
the SU group to -£0.09 for the NU group. However, these estimates are for a percentage point 
change in weight re-gain, and the payment frequency is monthly, therefore the differences 
become substantial when comparing two WLM interventions with vastly different levels of 
efficacy. For example, imagine an intervention (A) that is entirely effective (0% weight re-
gain) and compare it with an intervention (B) that is not entirely effective (say 40% weight re-
gain). On average, individuals from the SU group would pay approximately £12.40 less per 
month for intervention B relative to intervention A. In contrast, individuals from the NU 
group would pay £3.60 less per month for intervention B relative to intervention A (on 
average). Two interventions with such drastically different outcomes may be an extreme 
example but nonetheless the magnitude of, and differences in, WTP are substantial. It should 
also be stressed that these are monthly price differences, hence over the length of a WLM 
intervention (e.g. 6-24 months) the estimates, as well as the difference between them, become 
174 
 
even larger in terms of magnitude. The existing evidence suggests that different samples or 
subgroups can lead to different WTP estimates (Najafzadeh et al, 2013; Finkelstein et al. 
2015; Tinelli et al., 2016), and the evidence provided in this thesis adds to this evidence base, 
as well as providing credibility to the hypothesis that this is due to differences in relative 
experience. Thus, it is important for future DCE studies to consider the effect of the sample 
composition on the WTP estimates generated in the study. 
The CV task also generated WTP estimates that were compared across the groups. Unlike the 
DCE task, the WTP estimates across the groups were not statistically significantly different 
from one another. This is a curious finding, given the differences in the DCE task. However, 
it may be that the timing of the task (directly following the DCE, which suggested prices for a 
WLM intervention), the nature of the task (iterative and based on preferred attribute levels) 
and the manner of the responses (wide variance) has influenced this finding. It would 
therefore be unwise to conclude on the basis of the evidence in this thesis that CV tasks are 
any less susceptive to differences in WTP values between groups with differing experience. 
Future studies that aim make comparisons between different user groups’ responses to a CV 
task would benefit from ensuring that the task does not follow a cognitively demanding task 
such as a DCE and would also benefit from larger sample sizes than those obtained the 
empirical work of this thesis in order to improve precision and to explore preference 
heterogeneity. 
In addition to the examination of differences in WTP, the CV task in this thesis provides some 
insight into the appropriateness of using ranking information and an iterative approach that 
focuses on the key outcome of the intervention being valued. Whilst the responses were 
generally logical, a significant number of respondents stated the same value throughout the 
task, which is a concern as the only change in the programmes between questions was a 
negative one. Therefore, future studies may be better advised to use a more typical CV 
approach, using a format such as dichotomous choice or payment card (see section 3.2). 
Regarding the second part of research question two, differences in WTP estimates between 
the DCE and CV, the results from this thesis are inconclusive. The DCE results (i.e. numerous 
insignificant coefficients) meant that WTP estimates could only compared by looking at WTP 
for weight re-gain in both tasks. For the CV task, this meant taking the difference between the 
first two questions to isolate the weight re-gain attribute, which reduced the sample size 
considerably and is not a typical approach to analysing CV data. Therefore, whilst no 
convincing evidence of a difference was identified, it would not be wise to conclude that there 
is no difference between WTP estimates that are elicited directly (CV) or indirectly (DCE). 
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10.2.3 Research Question Three 
The results from this thesis suggest that, even after controlling for observable characteristics 
such as age, gender, highest educational qualification and employment status, individuals in 
the SU group were more likely to pass the dominance and the strong transitivity tests that 
were embedded into the DCE task. In addition, table 9.8 suggests that there could be a 
hierarchy with respect to the probability of passing the dominance test (SU > PSU > PB > 
NU), which fits with the hypothesis that those with more experience have ‘better defined’ 
preferences and are thus more likely to pass a rationality test. However, such a clear effect is 
not evident for the transitivity tests, with the least likely group to pass the weak transitivity 
test being the PB group (as opposed to the NU group). Nonetheless, it does appear that the 
most experienced group with respect to WLM and WLM interventions (the SU group) are the 
most likely to pass the combination of all three tests. This could have implications for future 
research because, if the tests are considered to be meaningful in terms of data quality, one 
might conclude that more experienced samples will provide better quality data. Whilst one 
interpretation of this is that individuals in the SU group have ‘better defined’ preferences 
relative to those in the other groups, another is simply that these individuals have a more 
vested interest in engaging in this research (as participants of the NULevel trial). 
The dominance test used information from a direct ranking exercise to provide a dominant 
alternative from the individual respondents’ perspective. This was necessary because the best 
option for delivery of reminders or feedback, and the availability of online tools was not clear 
from the researchers’ perspective. The high pass rates for each group, with an overall 
combined pass rate of 92% is particularly promising and future research where dominant 
attribute levels are unclear could follow the approach used in this thesis. The fact that so many 
different WLM programmes were valued in the CV task (also based on the rankings) provides 
support for the decision to use the ranking data in the dominance test rather than pre-
specifying a ‘dominant’ alternative.  
The pass rates for the transitivity tests were also particularly high. Most DCE studies in 
healthcare do not contain a transitivity test (de Bekker-Grob et al., 2012; Clark et al., 2014), 
which could be due to the extra time required at the design stage or because dominance tests 
are simply better known and generally accepted. However, the pass rates for the transitivity 
tests were reasonably high considering the probability of passing them at random, providing 
some evidence to suggest that such tests could be a good alternative to dominance tests. Given 
that dominance tests have been criticised for being too easy to pass (Miguel et al., 2005), the 
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findings from this thesis might justify an increased utilisation of transitivity tests in studies 
that use DCEs.  
10.2.4 Research Question Four 
Whilst there are instances where preferences differ across the three user groups recruited from 
the online panel (PSU, PB and NU groups), the largest differences exist between the SU 
group and these three groups. As such, the exact driver of the differences identified in this 
thesis is unclear. It could be the case that individuals that are recruited to clinical trials are 
unique and cannot be easily compared with a group of individuals that appear similar on paper 
(e.g. the PSU group). Trial participants may be atypical to the general patient population; they 
are willing to dedicate a considerable amount of time to be involved in research despite not 
being guaranteed to receive any health benefits. In addition, individuals from the NULevel 
trial may have had a more vested interest than those in the online panel because the survey 
was based on an intervention that they understood and potentially experienced. It may also be 
the case that online panel participants are atypical; they are incentivised to complete surveys 
and these incentives may attract a specific type of individual. This might help to explain the 
limited differences between the PSU, PB and NU groups that were recruited from the online 
panel.  
However, it is challenging to disentangle the effect of experience and the effect of the 
recruitment vehicle. There are observable differences in the preferences of the online panel 
groups (PSU, PB and NU groups) with respect to the general DCE results and the WTP 
estimates from the DCE. However, there were no significant differences in the pass rates of 
the rationality tests between these three groups. Therefore, it would appear that the rationality 
tests are the main area where differences between the four user groups might be explained by 
the recruitment vehicle. It could be the case that individuals in the trial had a greater incentive 
to focus on the survey, given that they might have been interested in providing feedback, and 
possibly interested in receiving the NULevel trial intervention beyond the clinical trial. 
However, it is not possible to prove that the recruitment vehicle is the main driver of the 
differences in rationality test pass rates. If a future study replicated the approach used in this 
thesis, this effect could be explored in further detail with larger sample sizes. A larger sample 
size drawn from both arms of the trial could enable clear comparisons between the two arms 
and, accompanied by the recruitment of a PSU group from an online panel, a comparison 
could be made between the control arm and the PSU group. This might provide a clearer 
insight into this research question because the control arm could be more similar to the PSU 
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group than the treatment arm. However, this would not fix the potential issue of trial 
participants being atypical to the general patient population. 
10.3 Thesis Implications to Different Stakeholders 
10.3.1 Researchers 
The results from this thesis provide a relatively clear message to researchers: it is important to 
consider the relative experience of the respondents in your sample. Ultimately, preference 
heterogeneity will always exist but attempts can (and arguably should) be made to minimise 
this by keeping the experience of the treatment or condition fairly consistent across 
respondents. The importance of this will only increase over time, given the increased interest 
in eliciting patient preferences (see section 10.5). 
Researchers should also keep in mind the possible differences that might occur between 
‘patients’ recruited from trials and those from online panels. This will always be a challenging 
area for research, as individuals from trials are highly experienced by definition and 
potentially atypical because of their willingness to enter a study that in itself might be 
considered an onerous undertaking without any direct personal gains in health; their 
preferences may simply reflect this. However, if respondents that appear similar to the trial 
participants, but are recruited from online panels, express very different preferences to those 
from trials then it is important to be aware that this difference could be down to more than the 
relative experience of the respondents. 
Finally, will all of this in mind, it should be increasingly important for researchers to describe 
and justify their choice of respondent sample. Very few studies provide descriptive data 
regarding the relative experience of their respondents in relation to the health condition and its 
treatment, which could easily be changed. Furthermore, very few studies provide justification 
for their initial choice of respondent sample. It may often be the case that the sample recruited 
is the easiest sample to identify, and perhaps linked to a wider piece of work. This is an 
understandable justification but it is often missing in subsequent publications. 
10.3.2 Policymakers 
Policymakers are increasingly under pressure to consider the patient voice in decision-
making. This is considered a positive for most individuals involved in health-related research 
and policymaking. However, policymakers need to be aware of the existence of preference 
heterogeneity and its potential impact on the results of studies because of the knock-on effect 
with regard to the generalisability of results. Policymakers may be ill-advised to continue 
calling for patient preference studies because there needs to be a more in-depth consideration 
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of the type of patients that should be providing preferences. For example, if the study is being 
used to predict uptake, perhaps ‘potential service users’ or ‘potential beneficiaries’ would be 
more relevant. Alternatively, if an intervention is being refined, perhaps ‘service user’ 
preferences are the most relevant as they have experience of the intervention. The subtle 
differences here are important if, as suggested in this thesis, results from preference studies 
differ across these groups. 
10.4 Strengths and Limitations 
This thesis has several notable strengths. First, it provides evidence on how preferences might 
differ between user groups with different levels of experience using a DCE. Very few 
published studies have explored this area to date, and there have been specific calls for further 
research in this area this year (Levitan et al., 2017). The interest in this subject area is not 
solely due to academic curiosity but also due to the increased application of data from DCE 
studies in healthcare decision-making. This can be seen clearly in table 3.1; five of the ten 
examples of DCEs being formally incorporated into economic evaluations have been 
published in the past three years. In addition the most recent example, which elicits 
preferences from both a patient and a general public sample, cites a publication that was based 
on Chapter Three of this thesis when explaining their recruitment strategy (Mott & 
Najafzadeh, 2016). The authors state that the choice of whose preferences to elicit is 
important to consider (Watson et al., 2017). Another strength is that this thesis did not stick 
with the ‘patient vs. general public’ dichotomy but instead put forward a framework that 
could potentially help to explain differences within patient and general public samples 
(section 5.2). The WLM intervention used as a case study in this thesis enabled this 
framework to be put into practice, but there are many other ways in which the framework 
could be utilised in future. For example, the framework could be readily applied in other 
health contexts and its use does not need to be restricted to preference studies. Finally, another 
strength is that the online survey used in the empirical work was novel in a number of ways 
(see Chapter Six). For example, the ranking data was used in one of the rationality tests in the 
DCE, as well as in the CV task. In addition, both absolute and relative values were used to 
describe the weight re-gain attribute in the DCE and respondents viewed this information in 
the units of measurement that they preferred. The overall face validity of the results and the 
pass rates for the rationality tests may not have been as encouraging had this not been done. 
The CV task itself was also novel, requiring respondents to essentially ‘self-select’ the type of 
CV question that they faced and using a range of different health outcomes in order to explore 
the extent to which this influenced WTP.  
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Section 10.2 discussed the results relating to the four research questions and highlighted some 
of the limitations of the methodological approaches and the data. In addition, there are several 
broader limitations that cut across all of the empirical work in this thesis that need to be 
acknowledged. First, the framework tested in the empirical work of this thesis (section 5.2) 
could be criticised as overly simplistic, given that experience can differ in many other ways. 
This could relate to experience of a friend or family member’s health issue or treatment, as 
outlined by Dolan (1999). In other words, experience by proxy is not accounted for in this 
framework. It is also the case that the framework does not allow for differences in length of 
experience. For example, in the context of this study, an individual that has struggled with 
their weight for many years may have different preferences to someone that has only recently 
become overweight or obese. However, the framework used in this thesis is meant to be 
pragmatic such that it can be tested, and incorporating more complexity into the framework 
would reduce its practicality. That being said, it is not necessarily the case that this framework 
could be readily applied in all other health settings. For example, in clinical settings it may be 
challenging to recruit individuals in the PSU group as it may not be feasible (or ethical) to 
approach individuals that require surgery after it is known that surgery is required, but before 
the treatment has been delivered. It may also be challenging to apply the framework in other 
public health settings where interventions are provided en masse and not consumed by 
individuals in the same way as the intervention in this study (e.g. advertising campaigns for 
smoking cessation). In such cases, it is likely to be difficult to identify the four user groups in 
the framework, as individuals in all groups may have experience of the intervention. 
It is also the case that the DCE design, in particular the identification of attributes and levels, 
did not involve any qualitative research with individuals from any of the four user groups. 
This is a limitation because it means that, although the attributes and levels were informed by 
a relevant systematic review and expert consultation, the DCE design was ultimately 
researcher-led. It is therefore possible that there were attributes and/or levels that would have 
been important to respondents that were not included in the DCE design, which could have 
influenced the choices that were made during the task. That being said, as explained in section 
6.4.1, it could have been challenging to incorporate qualitative feedback in this study given 
that four user groups with different levels of experience were to be recruited and a single DCE 
design was required in order to make reasonable comparisons. Nonetheless, the importance of 
qualitative research to inform DCE design has been stressed recently in the literature (Vass, 
Rigby et al., 2017) and should be an important consideration for all future DCE studies. 
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Another limitation is that, whilst Chapter Three highlighted the relevance of the preference 
debate in health economics, the empirical work did not make a typical ‘patient vs. general 
public’ comparison. That is, a random, fully representative sample of the UK general 
population was not recruited as part of this study. Instead, purposive sampling was used for 
the online panel to ensure that at least 200 respondents were recruited for the PSU, PB and 
NU groups. Had the online panel sample been random and fully representative (i.e. a general 
public sample), it might not have been varied enough to obtain sample sizes that were large 
enough for each of these groups. However, despite this limitation, there is an increasing 
emphasis on the consideration of patient preferences in (largely regulatory) decision-making 
in both the literature (Mühlbacher, 2015; Johnson & Zhou, 2016; Mühlbacher et al., 2016), 
and in guidance from decision-makers (FDA, 2016; FDA, 2017), which has increased 
throughout the duration of this work. It is therefore highly likely that comparisons between 
different types of user group would be of greater interest amongst researchers and 
policymakers than further ‘patient vs. general public’ comparisons. Another limitation is that 
the empirical work in this thesis cannot determine whether differences in preferences are due 
to differences in experience or differences in the recruitment vehicle (i.e. trial vs. online 
panel). However, preferences do appear to differ between the three groups recruited via the 
online panel, providing some evidence to suggest that not all individuals in the online panel 
are alike. Whilst this is a significant empirical challenge to overcome, section 10.2.4 provided 
a suggestion as to how future work might overcome this limitation.  
Finally, another limitation that applies to the entirety of the empirical work is that the sample 
sizes could have been larger, allowing more detailed comparisons to be made. However, there 
was a clear upper limit for the SU group due to the size of the NULevel trial, and larger 
sample sizes for the online panel would not have made up for this. Given the data 
requirements for choice modelling, future studies would be well advised to recruit large 
numbers of respondents in every group of interest when using a DCE (e.g. several hundred), 
especially if comparisons across samples or subgroups are to be conducted. 
10.5 Future Research 
10.5.1 Stated Preference Studies 
This thesis has provided an insight into how preferences may differ in stated preference 
studies when the samples recruited differ in relation to their prior experiences of the 
condition, treatment of the condition, and also in the survey recruitment process. However, 
the insight provided by this work is not sufficient to draw confident conclusions about what 
may happen in other contexts. As a result, further research would be beneficial. In particular, 
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it would be useful to explore whether the differences in WTP estimates and rationality test 
pass rates between patients in clinical trials and potential patients from online panels that are 
observed in this study are observed in other contexts (e.g. different types of public health and 
healthcare interventions). Existing literature does seem to provide some support that WTP 
estimates are likely to differ between groups (Najafzadeh et al., 2013; Finkelstein et al. 2015), 
but little research exists in relation to differences in rationality test pass rates.  It would also 
be interesting to examine whether the minor differences observed between the three groups 
recruited via the online panel would be exacerbated in another context. One might expect to 
see greater differences in a more clinical context where attributes may relate to adverse events 
and where process attributes may be less well understood by the average individual. For 
example, a process attribute for an anticoagulant therapy might be “availability of an antidote 
in the case of a bleed”, whereas one of the process attributes used in the empirical work in this 
thesis was “availability of a website or mobile phone application (for tracking weight)”. This 
would be particularly important with respect to regulatory decision-making as this focuses on 
benefit-risk trade-offs, which may be difficult to understand without any prior experience of 
the health issue or its treatment. 
Another avenue for further research would be to examine the external validity of DCEs, 
which to date has only been examined in a small number of studies (Clark et al., 2014). WLM 
interventions would be better suited to this than many other healthcare services, given that in 
future they could realistically be purchased and consumed on the free market (as opposed to 
being provided via the NHS), much like commercial weight loss programmes. In such a study 
it may be useful to explore whether, and to what extent, experience affects external validity. 
This could help to improve the accuracy of future DCE studies. 
10.5.2 HTA Decision-Making 
In practice, it might be unlikely for HTA decisions to be made based solely on the relative 
importance of a small range of attributes included in a DCE. Instead, results from DCEs 
might be used to provide additional information for use in formal economic evaluations, such 
as those outlined in table 3.1. Therefore, future research that looks at how preferences differ 
between groups could take a broader approach and examine the potential knock-on effects on 
economic evaluations resulting from the findings of preference studies. The key question is: 
could the differences in preferences potentially lead to different conclusions being drawn 
from an economic evaluation depending on whose preferences are considered? One can 
speculate that the differences observed in WTP estimates derived from the DCE conducted in 
this project would not have led to drastically different conclusions being drawn from an 
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economic evaluation, given the small magnitude of the differences. However, this might not 
be the case in other studies and other contexts.  
The question of whether relative experience (of a health issue and/or its treatment) affects 
preferences is likely to become increasingly important if calls for a more patient-centric HTA 
process (Mühlbacher, 2015) are taken seriously by decision-makers. That being said, the 
current emphasis on using CUA might present stumbling block for meeting such calls from a 
pragmatic perspective. This is because there are only limited opportunities to incorporate 
patient preferences within a QALY framework advocated by agencies such as NICE, with 
perhaps the obvious option (using health state utilities derived from patients) proving to be 
contentious in some countries such as the UK, as discussed in Chapter Three. Furthermore, as 
discussed in Chapter Three, it has been suggested for some time that DCEs can be used to 
incorporate the patient voice into CBA through WTP estimates derived from stated preference 
studies (McIntosh, 2006). The use of CBA may be particularly appropriate for public health 
interventions, as the potential wider societal effects of such interventions might warrant a 
broader economic evaluation. However, estimating WTP in a health context is likely to be 
contentious because of resistance to putting a monetary value on life (Zweifel et al., 2009). 
10.5.3 Regulatory Decision-Making 
Given the issues outlined in the previous section, it perhaps makes sense that the 
incorporation of patient preferences into healthcare decision-making appears to be more 
advanced in a regulatory context. In the regulatory space trade-offs between risk and benefit 
have been required for some time, and these could potentially be delivered using stated 
preference studies (Ho et al., 2015). The implementation of new legislation in the USA over 
the past two years has highlighted the importance of considering the patient experience during 
the drug development process. The legislation has led to the FDA producing a plan for 
issuance of “patient-focused drug development guidance” (FDA, 2017), which will lead to a 
series of new guidance documentation being finalised between 2019 and 2021. It would seem 
likely that this guidance will lead to a rise in the collection and incorporation of patient 
preference data in regulatory decision-making in the US and, as outlined in section 3.4, there 
is a similar focus in Europe. 
A recent editorial has considered the current practice with regard to using DCEs for informing 
benefit-risk assessments and has raised the issue of whose preferences are most suitable to 
elicit, as well as highlighting the issue of preference heterogeneity (Vass & Payne, 2017). 
Whilst the DCE used in the empirical work of this thesis did not contain a risk attribute, it 
may well be possible that benefit-risk trade-offs would differ depending on the make-up of 
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respondent samples. As quantitative preference information elicited from patients, using the 
likes of DCEs, are increasingly being incorporated into regulatory decision-making, it is 
important for future studies to explore how patients with differing levels of experience might 
have different preferences in relation to benefit-risk trade-offs. 
10.5.4 Multi-Criteria Decision-Analysis 
In addition, future research could extend beyond the current status quo in healthcare decision-
making. It has recently been highlighted that there is potential for DCEs to be used in 
healthcare decision-making within a multi-criteria decision-analysis (MCDA) framework 
(Thokala et al., 2016; Marsh, Goetghebeur et al., 2017). MCDA has been put forward as a 
potential alternative to the likes of CUA, CBA or traditional risk-benefit assessment. MCDA 
is an umbrella term representing a highly flexible set of techniques used to assist in decision-
making in any potential context. Broadly speaking, MCDA requires a set of criteria that are 
critical to the decision problem at hand, which are scored based on the available evidence and 
weighted according to stakeholder preferences. The weights may be derived from patient 
preferences using a DCE, although other techniques may also be used (Tervonen et al., 2017).  
Whether MCDA is likely to be acceptable to decision-makers is another story. The NICE 
reference case is very specific and aims to maximise comparability between economic 
evaluations by recommending, for example, a single instrument for generating HSUVs and so 
forth. It might be the case that agencies such as NICE would wish to employ MCDA in a 
similar manner. This might involve: the use of a single set of (static) criteria; a standardised 
approach to scoring; and a single set of criteria weights. The latter would make it very 
difficult to incorporate patient preferences, as the patient population would differ across 
economic evaluations. There are also numerous methodological concerns regarding the use of 
MCDA for HTA that would need to be resolved before this could become a reality (Marsh, 
Sculpher et al., 2017).  
Nonetheless, there is an apparent appetite amongst some researchers in health economics to 
explore how MCDA might be used for HTA (Marsh, Goetghebeur et al., 2017). If this 
continues, future research may wish to explore how using different types of respondents to 
weight the criteria might result in different decisions in a MCDA framework. 
10.6 Conclusion 
This thesis began by reviewing the relevant economic theory, the use of quantitative 
preference information in health economics and the ‘preference debate’. This was followed by 
a systematic review that explored the question of whose preferences are typically elicited in 
184 
 
published DCE studies. Following this, a framework was set out that could be used to classify 
survey respondents in relation to their experience of a healthcare intervention and/or a health 
issue. The empirical work tested whether preferences differed between the four different user 
groups defined within the framework. The results suggest that preferences differ, to varying 
extents, between the four user groups. The most pronounced differences were between the 
group recruited via an RCT relative to the three groups recruited from an online panel with 
respect to the DCE results and the WTP estimates derived from them. No differences in WTP 
estimates from the CV task between the four groups were observed, though this may have 
been due to data limitations. In addition, there is evidence to suggest that more experienced 
individuals are more likely to pass rationality tests. 
The findings of this thesis will be particularly useful for researchers that design preference 
studies using the likes of DCEs. At present, there are very few studies that explore how 
preferences differ according to the level of experience of the respondents. In addition, there is 
an increasing interest in the use of patient preferences studies, particularly in the regulatory 
space. An increase in demand for patient preference studies for use in decision-making will 
mean that it will become increasingly important to understand how preferences might differ 
between different types of respondent for both researchers and policymakers. It would seem 
that experienced respondents (i.e. the SU group in this study) are likely to provide better 
quality data, but express different preferences to less experienced respondents. 
Future research could build upon the empirical work conducted in this thesis. There are many 
other contexts in which a preference study could be conducted, and different recruitment 
modes for study participants can provide unique opportunities to explore how preferences 
differ. In addition, future studies may wish to explore how these differences in preferences 
could affect the outcomes of HTAs and BRAs. Following on from this, if researchers continue 
to push for its increased application in healthcare decision-making, researchers might wish to 
explore this question in the context of MCDA. 
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Abstract 
The normative debate surrounding whose preferences should be used in health state valuation 
has been widely covered with both discussion and empirical papers.  The importance of this 
debate lies in how the use of different perspectives for health state utility values affects the 
results of economic evaluations, and hence decision-making. Following the same logic, the 
use of more general preference data from different populations is also likely to have an effect 
on decision-making. 
This paper will contribute to the ongoing preference debate by considering an increasingly 
popular methodology used in health economics to elicit preferences, the discrete choice 
experiment (DCE). Using descriptive statistics from a review of recently conducted DCEs to 
inform this paper, the choice of whose preferences are typically elicited will be investigated. 
It is expected that the majority of DCE studies elicit the preferences of patients rather than the 
general public, in contrast to the dominance of public preferences in health state valuation due 
to methodological arguments that feed into guidance documents e.g. those from the National 
Institute for Health and Care Excellence (NICE). 
This paper aims to highlight the need for more discussion on whose preferences to elicit when 
using DCEs by raising various normative arguments that support the use of different 
perspectives. If DCEs are to be used in decision-making, as is often claimed, this area 
deserves greater attention.   
207 
 
1. Introduction 
In health economics, whose preferences are used as the basis of health state valuations within 
cost-utility analysis (CUA) for health technology assessment is a subject of debate (Brazier et 
al., 2005). CUA is perhaps the most prevalent form of economic evaluation in health care, 
which involves a comparison of the costs of alternative health programmes within the health 
care sector with the benefits, which are reported in the form of the incremental health 
improvement attributable to the programme (Drummond et al., 2005, p. 137). The most 
commonly used measure of incremental health improvement is the quality-adjusted life year 
(QALY); a combined measure of both quality and quantity of life. QALYs are calculated by 
adjusting the length of time affected through the health outcome by the utility value of the 
resulting health status (Drummond et al., 2005, p. 14). Utility values typically vary between 0 
(which represents being dead) and 1 (which represents full health); hence 1 QALY is 
equivalent to a year in full health.  
In the UK the National Institute for Health and Care Excellence (NICE) advocates the use of 
CUA for health technology assessment. The reference case suggests that when undertaking a 
CUA the utility values used should be provided by a sample of the general population rather 
than patients that have experienced the health states (NICE, 2013). The normative debate as to 
whose preferences should be used for health state valuation has been widely covered within 
the literature in both discussion and empirical papers (Boyd et al., 1990; Dolan, 1999; Ubel et 
al., 2003; Brazier et al., 2005; Dolan, 2008; Dolan and Kahneman, 2008; Gandjour, 2010; 
Weyler and Gandjour, 2011) but no clear consensus has been reached due to its subjective 
nature. 
Despite the advocacy of CUA in health technology assessment, this method of economic 
evaluation is unable to take into account the wider societal benefits associated with health 
care interventions. In the case of public health interventions, where the benefits are likely to 
go beyond the individual receiving the intervention, the use of CUA may not be appropriate. 
This has been identified as an issue by NICE, which states that more focus should be placed 
on cost-benefit analysis (CBA) over CUA when it comes to the appraisal of public health 
programmes (NICE, 2012). CBA is a form of economic evaluation that is grounded in welfare 
economic theory, measuring all of the relevant societal costs and benefits of an intervention in 
commensurate units (Drummond et al., 2005, p. 16). The overall net benefit is calculated and 
used to determine whether or not resources should be allocated to providing the intervention. 
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A significant difficulty with the use of CBA is the valuation of all of the societal benefits in 
monetary terms as market prices do not always exist. For example, the monetary benefit of a 
reduced waiting time for an NHS-provided surgery is not known because in the UK patients 
using the NHS do not pay for this directly. Stated preference methods can be used to simulate 
markets such that values representing individuals’ willingness-to-pay (WTP) for various 
outcomes can be inferred for use in CBA (willingness-to-accept, WTA, can also be 
estimated). In the UK, the HM Treasury Green Book advocates the use of stated preference 
methods where appropriate (HM-Treasury, 2011). 
A commonly used stated preference method in health economics is the discrete choice 
experiment (DCE). DCE methodology was first developed in mathematical psychology and 
has since been used in a range of different fields such as market research, transport economics 
and environmental economics (Ryan and Farrar, 2000). In a typical DCE, participants are 
given scenarios where they must choose between hypothetical options; each option is 
presented as a set of common attributes with differing levels. For example, respondents may 
have to choose between two hypothetical GP appointments where the common attributes are 
“distance”, “waiting time” and “personal cost”, but the levels of each option differ. 
Respondents are expected to choose the option that they prefer, which is interpreted as the 
option that will maximise their utility. When a number of respondents choose between the 
various scenarios, researchers can examine the responses to determine the relative importance 
of the attributes and the levels of those attributes. Furthermore, when an attribute relating to 
personal cost is included WTP estimates can be calculated, which could be used in CBAs. 
Consequently, results from DCE studies could potentially be used to aid the design or 
determine the provision of health care. 
It has been acknowledged that DCE methodology has improved significantly in recent years 
(Louviere and Lancsar, 2009) and within health economics DCEs have become increasingly 
popular over time (Ryan and Gerard, 2003; de Bekker-Grob et al., 2012; Clark et al., 2014). 
They have been used to elicit preferences towards a wide variety of issues from different 
perspectives including, but not limited to, preferences of the general public towards priority 
setting (Lancsar et al., 2011; Brazier et al., 2013) and health professionals’ preferences for 
various jobs (Huicho et al., 2012; Pedersen and Gyrd-Hansen, 2013).  
The most common use of DCEs in health economics overall is to elicit the preferences of 
patients or the general public towards a selection of (hypothetical) health care services, which 
are typically aimed at addressing a specific health issue. A common claim within such studies 
is that the results of the DCE will provide relative preference information with respect to the 
209 
 
health care service in question, which could later be used in the design, or in determining the 
provision, of said health care services. Due to the relative popularity of DCE studies of this 
nature, the focus of this paper will be to look at whose preferences are typically being elicited 
within this particular section of the literature. A significant proportion of the arguments made 
within the preference debate in the health state valuation literature appear to be valid when 
considering the use of such DCE results. This paper aims to use these to put forward the 
question: whose preferences should be elicited if results from these DCEs are to be used in 
decision-making?  
This paper will be set out as follows. Section 2 will provide an overview of the existing 
preference debate in the health state valuation literature to provide a background for the 
subsequent discussion. Section 3 will examine the current trends in DCE studies and raise the 
issues surrounding whose perspective may be more appropriate in various circumstances. 
Section 4 raises some further issues and ideas for future research, and Section 5 concludes. 
2. The preference debate in health state valuation 
In 1996 the Washington Panel on Cost-effectiveness in Health and Medicine provided 
guidance with regards to a variety of methodological issues in the economic evaluation of 
health care interventions (Gold et al., 1996). One suggestion by the panel was that the utility 
values used to calculate QALYs should be based on general public preferences rather than 
patient preferences. This advice was very influential and was reflected in economic guidelines 
produced in England and Wales as well as elsewhere (Brazier et al., 2005). Despite the impact 
on economic guidelines, the debate as to whether patients should have a role in valuing health 
states due to their relative experience continued. 
According to Dolan (1999), the principal reason for the Washington Panel’s recommendation 
was that since the general public bears the costs associated with resource-allocation decisions, 
they should also have some say in the determination of the benefits. In addition to this, 
general public values may be less likely to be affected by self-interest and strategic biases 
than those of patients; this was argued using the notion of the general public acting under a 
“veil of ignorance” (Gold et al., 1996). In other words if the general public do not know 
whether they will experience the health state in future, there is little incentive to respond 
dishonestly because they are “blind” to their own self-interest. 
In contrast, the main argument for using patient preferences is that patients have experience of 
their condition whereas the general public would have to imagine themselves experiencing the 
health state, which may be problematic (Dolan, 2008). It may be very difficult for an 
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individual to imagine themselves in a particular health state, and it could be the case that their 
valuation of the state is significantly affected due to this. A typical example of this difficulty 
is the situation where a patient may feasibly be able to adapt to a change in health state, yet a 
member of the general public may not be able to envisage such adaptation (Menzel et al., 
2002). Furthermore, patients are considered the winners and losers of any final policy 
decision and the public may not actually want to be involved in the decision-making process 
(Brazier et al., 2007, pp. 114-7). 
Even the theoretical foundation of this debate in preference-utilitarian theory and welfare 
economics has been discussed (Gandjour, 2010), yet this arguably only matters if the values 
are found to differ in practice. When empirically tested it is generally found that discrepancies 
do indeed exist between the two populations and that typically patients value health states that 
they have experienced higher than the general public (Boyd et al., 1990; Menzel et al., 2002; 
Ubel et al., 2003). A number of reasons as to why discrepancies may occur have been 
suggested such as: the issue of adaptation to health states by patients; the problem of 
insufficient information being provided to the general public; and the fact that the general 
public may be less willing to state a timescale after which they would be unwilling to endure 
the state any further (Menzel et al., 2002; Ubel et al., 2003; Weyler and Gandjour, 2011).  
Clearly the choice of whose preferences should be elicited in health state valuation matters 
due to a variety of normative arguments and the fact that the utility values have been shown to 
differ in practice. It seems sensible to assume that several of these arguments may be valid in 
other areas within health economics where preferences are elicited. Thus, the choice of 
perspective in DCEs in health economics is of interest. 
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3. A commentary on current DCE trends 
3.1. The literature search 
A literature search was undertaken in January 2014 using the Medline database to identify all 
of the studies in health economics that used a DCE between 2009 and 2013 as these years 
were not covered by a published systematic review at the time. The search terms used were 
taken from two previous systematic reviews of the DCE literature in health economics (Ryan 
and Gerard, 2003; de Bekker-Grob et al., 2012). To test the search strategy beforehand, the 
search was performed for the years 2001 to 2008 to try and identify the papers from the de 
Bekker-Grob et al. (2012) review and all of the papers were successfully identified. Following 
this, the search was performed again for the years 2009 to 2013 and a total of 1,136 journal 
articles were initially identified. Figure 1 illustrates how the number of papers was 
subsequently narrowed down from this point. It was decided that the most recent 3 years of 
DCE studies would be sufficient to reflect current practice due to the large number of studies 
over this time period. Further to this, as previously mentioned, the only studies that were 
included were those eliciting the preferences of patients or the general public for health care 
services. This resulted in a total of 121 studies being included in the final analysis. 
Key information was extracted from the 121 included studies such as whose preferences were 
being elicited, the types of attribute used in the paper and the way in which the results were 
presented. For the purpose of this exercise a patient population was defined as a clear group of 
individuals, all of whom had experience of a condition that the hypothetical service(s) 
described in the DCE tasks were addressing (or were acting as a proxy on behalf of those that 
had such experience). As a result, any DCEs surrounding screening, vaccinations or 
preventative services in general were typically considered to use a public population, even if 
only a subsection of the general public were included in the sample (e.g. those most at risk). 
Where a health care service was not clearly directed at a particular disease, the population 
were only defined as patients if they were recruited whilst waiting for, or shortly after 
receiving, an equivalent service. In other words the criteria for a population to be defined as 
patients in this paper was that they must have clearly had some experience of either the 
condition or the service that relates to the topic of the DCE task.  
It should be made clear at this point that the use of the terms “patient perspective” and 
“general public perspective” in this paper refer to the characteristics of the sample that is 
responding to the DCE task. Within a DCE task, respondents may be asked to consider a 
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perspective other than their own; this has not been investigated in this paper but will be 
discussed briefly in Section 4. 
Figure 1 – PRISMA flow diagram detailing literature search 
 
 
 
 
 
 
 
Table 1 – Definitions of the three different categories of DCE study included in this 
paper 
Category Definition 
A 
Studies with a DCE that contains attributes describing the consumer experience 
of a health care service but does not contain any attributes relating to health 
outcomes. 
B 
Studies with a DCE that contains attributes describing the consumer experience 
of a health care service as well as attributes describing the outcome(s) of the 
service. 
Medline search for DCE studies 
between 2009-13 
N=1136 
Title and abstract check for 
relevance  
N=370 
Studies from only 2011-13 
N=269 
Studies included in final analysis  
N=121 
148 studies excluded based on 
screening of full-text article: 
• 42 service provider prefs. 
• 20 priority setting 
• 19 health state valuation 
• 21 not a DCE  
• 8 not “health economics” 
• 22 comparison papers  
• 5 already published 
• 11 currently not accessible 
 
101 studies excluded from the years 
2009 and 2010 
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C 
Studies with a DCE that contains attributes describing the outcomes of a health 
care service but does not contain any attributes relating the consumer 
experience of the service. 
 
When looking at DCE studies that elicit preferences towards health care services, there 
appears to be three distinct categories under which they may fall. Table 1 defines these three 
categories. The reason that these have been identified is that they are essentially asking for 
three different things. Category A studies will identify the relative importance of various 
attributes relating to how a health care service is being delivered; things such as the waiting 
time, the distance, the personnel involved and the frequency of the service. It makes sense that 
the results from such a study could be used to design a service that would be most convenient 
for patients and maximise uptake rates. Category C studies do something very different; they 
identify the relative importance of the various possible health outcomes from a health care 
service. In other words, they can tell researchers what the most important health outcomes are 
so that services could be designed to focus on the most important outcomes. Category B 
studies contain both consumer experience and outcome attributes, and hence do something 
slightly different again. In these DCEs, respondents are essentially being made to consider 
whether they would be willing to sacrifice some of their health to receive a service that is 
more convenient or preferable in some way. Researchers have the ability to compute marginal 
rates of substitution within DCEs and hence in studies such as these, consumer experience 
attributes could be valued in terms of health outcomes. 
Similar distinctions between the types of DCE studies that look at health care services already 
appear to have been made (de Bekker-Grob et al., 2012; Clark et al., 2014), but very little 
discussion exists surrounding whose preferences might be most suitable to elicit in such 
studies. Bryan and Dolan (2004) raised a number of issues that should be discussed 
surrounding the use of DCEs in health economics. One area that they addressed were 
“normative issues”, of which they made the point that if DCE results are to be used in 
policymaking, consideration needs to be given towards whose preferences are relevant for 
which policies. This paper will try to add to their points by considering current practice. 
3.2. Trends across study categories 
Table 2 shows how the studies were split across the different perspectives as well as the 
categories defined in Table 1. The clearly dominant perspective is that of the patient, with a 
total of 82 (68%) studies using this perspective. DCEs that look only at consumer experiences 
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(category A) or at both consumer experiences and outcomes (category B) were most the 
common (38% and 54.5% of all studies, respectively), whereas those that focused only on 
outcomes (category C) were particularly uncommon (7.5% of all studies). Within each 
category the choice of perspective varied slightly, however the patient perspective was 
consistently the most popular. 
Table 2 – DCE studies split across category and perspective 
 
Category A Category B Category C Total 
Public 20 (43.5%) 17 (25.8%) 2 (22%) 39 (32%) 
Patient 26 (56.5%) 49 (74.2%) 7 (78%) 82 (68%) 
Total 46 66 9 121 
 
Given that there is a dominance of patient preferences in current practice, it seems appropriate 
to consider what this actually would mean if the results of the DCE studies were to be used in 
decision-making. For category A studies it would mean that patients (i.e. the consumer) are 
typically the ones shaping health care services in terms of considering the importance of the 
various attributes of their delivery. This seems reasonable given their relative experience of 
their condition and/or similar services although, much like in the preference debate in health 
state valuation, it could be argued that public values should be used. One point that could be 
raised is that designing a service to meet patient preferences can have resource implications 
and hence there may be opportunity costs, which the patients may not necessarily incur. For 
category C studies it would mean that patients are typically the ones that are informing service 
providers and decision-makers of the relative importance of the various health outcomes. 
Once again, this seems fairly reasonable given their experience of the condition because the 
general public may not be able to understand the severity of various outcomes, or be fully able 
to appreciate the fact that people can adapt to their health conditions. 
For category B studies, the most common type, the choice of perspective becomes slightly 
more interesting. As it stands, patients would typically be the ones that are providing relative 
preference information towards the non-health attributes of health care services, having been 
made to consider the importance of the health outcome(s) of the service simultaneously. In 
such DCEs, patients are essentially valuing health because they (unless they have strictly 
dominant preferences towards an outcome attribute) are trading off health for non-health 
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improvements. It seems somewhat contradictory that while public preferences are usually 
recommended for use in the valuation of health states, patient preferences are overwhelmingly 
being elicited to value health care services, even when the outcome of the service is included 
in the valuation task. It’s quite plausible that patients, due to their experience, care strongly 
about non-health attributes, whereas a member of the general public may have a narrower, 
health-focused point of view as argued by Bryan and Dolan (2004). If the latter is found to be 
true, it may be hard to distinguish whether this finding is due to a lack of understanding of the 
DCE tasks on the part of the general public, or whether this is a reflection of their true 
preferences. Regardless, the choice of perspective in this category appears to be far more 
significant than the others because two important and very different elements of health care 
have to be considered simultaneously by the respondents, and there is arguably more reason to 
believe that this may vary across the two populations. 
The point could be made that if the results are only to be used in the design of services, this 
issue is slightly less significant because the relative importance of the non-health attributes is 
what matters. On the other hand, we cannot be sure that the relative importance of the non-
health attributes is entirely unaffected by the inclusion of the outcome attribute(s). That is to 
say, we cannot be sure that the same conclusions would be reached if an identical DCE had 
been given out to the same respondents but without the outcome attribute(s). This is known as 
the independence of irrelevant alternatives (IIA) assumption, which is implicit in the 
multinominal logit (MNL) model that is often used when analysing data from DCEs. The IIA 
assumption can be relaxed by using alternative models, but the MNL was one of the more 
commonly used models between 2001 and 2008 in DCE studies in health economics (de 
Bekker-Grob et al., 2012). 
3.3. Trends across countries 
A further point raised by Bryan and Dolan (2004) was that DCE studies eliciting patient 
preferences are arguably more applicable to private health insurance schemes, rather than the 
predominantly tax-based systems found in the UK and many other European countries. 
Clearly the dominant perspective of the most recent DCE studies eliciting preferences for 
health care services overall is that of the patient, however it could be the case that there is 
significant variation across the various countries. 74.4% of the 121 studies included in this 
paper came from only six countries; USA, United Kingdom, Australia, The Netherlands, 
Canada and Germany. Table 3 illustrates the proportions of the two perspectives according to 
country and study category.  
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Despite the variation in the health care systems of these six countries, each country elicited 
preferences from patients more often than the general public. As health care in the USA is 
largely provided through private health insurance schemes, this seems to follow the point 
made by Bryan and Dolan (2004). On the other hand, 38.5% of the studies from the USA used 
a general public perspective and only the Netherlands had a higher proportion (40%). 
Furthermore only 27.3% of the studies from the UK adopted a general public perspective 
despite the UK health care system being publicly funded.  
The other four countries sit between the UK and the USA elsewhere along the spectrum 
between publicly funded health care and private health insurance schemes, utilising both in 
varying capacities. Due to the differing nature of the health care systems, it may be helpful to 
see how the choice in perspective matches up with government expenditure on health care. 
Table 3 – DCE studies from six countries split across category and perspective 
  
Public % Patient % Total 
USA All 10 38.5% 16 61.5% 26 
 
Cat A 6 75.0% 2 25.0% 8 
 
Cat B 4 23.5% 13 76.5% 17 
 
Cat C 0 0.0% 1 100.0% 1 
United Kingdom All 6 27.3% 16 72.7% 22 
 
Cat A 3 33.3% 6 66.7% 9 
 
Cat B 2 28.6% 5 71.4% 7 
 
Cat C 1 16.7% 5 83.3% 6 
Australia All 3 23.1% 10 76.9% 13 
 
Cat A 0 0.0% 4 100.0% 4 
 
Cat B 3 37.5% 5 62.5% 8 
 
Cat C 0 0.0% 1 100.0% 1 
The Netherlands All 4 40.0% 6 60.0% 10 
 
Cat A 2 50.0% 2 50.0% 4 
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Cat B 2 33.3% 4 66.7% 6 
 
Cat C 0 - 0 - 0 
Canada All 3 30.0% 7 70.0% 10 
 
Cat A 2 40.0% 3 60.0% 5 
 
Cat B 1 20.0% 4 80.0% 5 
 
Cat C 0 - 0 - 0 
Germany All 0 0.0% 9 100.0% 9 
 
Cat A 0 0.0% 2 100.0% 2 
 
Cat B 0 0.0% 7 100.0% 7 
 
Cat C 0 - 0 - 0 
Total 
 
26 29% 64 71% 90 
 
Table 4 shows the percentage of health care expenditure in each country that is from the 
government, and the percentage of the DCE studies included in this paper that used a public 
perspective. The countries are ranked based on these figures, and there are significant 
differences between the two sets of rankings. This illustrates that there no obvious link 
between the way in which health care is funded and the choice of perspective utilised in DCE 
studies eliciting preferences towards health care services. It appears, from this evidence, that 
the type of health care system in place is not a driving factor when researchers decide whose 
preferences to elicit in such DCE studies. 
Table 4 – A comparison between government expenditure on health and DCE 
perspectives 
 Government expenditure on 
health*  
Public perspective DCE studies  
Country Percentage Relative Rank Percentage Relative Rank 
United 
Kingdom 
84.1% 1 27.3% 4 
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The Netherlands 79% 2 40% 1 
Germany 76.9% 3 0% 6 
Canada 70.6% 4 30% 3 
Australia 68% 5 23.1% 5 
USA 47.7% 6 38.5% 2 
*”General government expenditure on health as a percentage of total expenditure on health” from WHO (2012) 
World Health Statistics Part III (actual figures from 2009). 
 
3.4. Trends across studies with cost attributes 
The importance of perspective can be argued further when considering how DCE results 
could be used in determining the provision of health care services. Providing that they include 
a cost attribute, DCEs can be used to generate willingness-to-pay (WTP) estimates, which can 
then be incorporated into economic evaluations. Table 5 is identical to Table 2 but the studies 
that did not include a cost attribute in the DCE task have been removed. 
Table 5 - DCE studies with cost attributes split across category and perspective 
 
Category A Category B Category C Total 
Public 14 11 0 25 
Patient 12 30 1 43 
Total 26 41 1 68 
 
The majority (56.2%) of DCE studies included a cost attribute, however it appears more 
common that a cost attribute would be included in a DCE with a public perspective 
(25/39=64.1%) than in a DCE with a patient perspective (43/82=52.4%). In fact, despite there 
being more DCE studies that only look at consumer experiences (category A) with a patient 
perspective in total, there were more public perspective DCE studies with a cost attribute in 
this category. This trend is not repeated in the DCE studies that consider both consumer 
experiences and outcomes (category B) however, where the majority (30/41=73%) of the 
studies with cost attributes used the patient perspective. In the DCE studies that only consider 
outcomes (category C) only one study included a cost attribute, and this used the patient 
perspective. 
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One of the main uses for WTP estimates in health economics is for use in CBAs, which weigh 
up the societal costs and benefits of a health care service. Given this societal perspective it 
seems somewhat contradictory, albeit unsurprising, that the majority of DCE studies with cost 
attributes use the patient perspective (43/68=63.2%). It would seem that the majority of the 
WTP estimates that are being calculated from DCE studies looking at health care services are 
not appropriate for use in a traditional, welfarist CBA. On the other hand, it should be noted 
that it is possible that WTP estimates from patients could be incorporated into other economic 
evaluations that adopt a narrower perspective (but not as narrow as a traditional CUA), 
although these are rare. 
4. Further discussion 
Section 3 has shown that a number of arguments exist to suggest that the choice of 
perspective between a patient and general public sample in a DCE study is important if the 
results are to be used in decision-making. Little research has been undertaken to examine the 
differences in preferences that may exist by undertaking a DCE study with both a patient and 
a general public population. One study that did do this in the context of preferences for health 
care services is Najafzadeh et al. (2013). The study, based in Canada, elicited preferences 
towards hypothetical genomic testing for guiding cancer treatment (described as an aggressive 
but curable cancer). The patient sample was made up of current and former cancer patients 
(n=38) and a selection of the general public sample were matched to the patient sample using 
propensity scoring (n=533 to n=83). The authors found that the two samples expressed 
different preferences regarding the value of the various aspects of genomic testing, with 
patients caring more about the sensitivity of the tests and being more willing to opt-out of a 
test if it was not sensitive enough. The differences in preferences lead to large differences in 
WTP estimates, both for individual attribute levels as well as genomic tests overall. While 
empirical evidence on the differences between patient and general public preferences is 
scarce, the fact that they do vary in the case of Najafzadeh et al. (2013) is unsurprising given 
the differences in experiences between the two samples.  
Further research into the differences between patient and general public preferences may be 
useful for a number of reasons. For example, it could be that general public preferences are 
consistently different, and if it appears to be due to a lack of experience of the condition 
and/or similar health care services, there may be a strong argument for the use of patient 
preferences in decision-making. This could ultimately mean that patients become a driving 
force behind the way in which services are designed (which can have resource implications), 
or even more significantly, whether certain services are provided at all. If a similar case to 
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that of the preference debate in health state valuation is made for general public preferences to 
be used instead, further research in this area may help to aid the design of DCEs such that the 
general public have the best possible opportunity to engage and express their preferences in a 
more accurate manner. This is because research in this area may help to highlight the 
difficulties that the general public experience when responding to DCE surveys. 
Further consideration could be given with regards to the choice of perspective beyond the 
somewhat narrow definitions of a “patient sample” and “general public sample” used in this 
paper. Dolan et al. (2003) developed a conceptual framework of the different perspectives that 
could be adopted by respondents in studies that elicit preferences for use in informing 
resource allocation decisions in health care. They suggest that there are three ways in which a 
respondent may be asked to think about the exercise at hand; on a personal level (only 
concerning oneself), a societal level (concerning everybody else in society), or a socially 
inclusive level (concerning everybody else in society as well as oneself). Further to this, the 
authors make the point that respondents will either have some uncertainty surrounding 
whether they may need the health care in future (referred to as the ex ante context) or they 
may be told that they will need it (referred to as the ex post context). This results in a total of 
six different perspectives that can be adopted. Further work will be done to examine the wider 
variety of such perspectives, although some difficulties can be foreseen such as limited 
reporting of the wording used in the DCE task. It is important to note however, that these are 
perspectives that respondents are being asked to adopt, and systematic differences between a 
patient sample and a general public sample are likely to still exist even if they are asked to 
adopt the same perspective within the DCE tasks. 
5. Conclusion 
This paper has provided a summary of the arguments that could be put forward surrounding 
the elicitation of patient or general public preferences towards hypothetical health services 
using DCEs. Current practice shows that the patient perspective is more popular in DCE 
studies, however when considering how the results may be used in decision-making a number 
of normative issues arise, many of which have been discussed in the past as part of the 
preference debate in health state valuation.  
Further research into how the results from DCEs may be affected by the status of the 
respondent would appear to be useful in determining the importance of these issues in this 
context; however it seems that further consideration and discussion would be beneficial if 
DCEs are to play a role in decision-making. 
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A-2 Data Extraction Table for 2011 to 2013 
                    
 
Reference Information Discrete Choice Experiment Information Output Information 
 
ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
1-1 
Ahmed 
Journal of the 
American Academy 
of Nurse 
Practitioners 
USA A Public 383 1 
Personal 
Cost 
1 0 1 0 1 1 0 0 0 0 
 
201
1-2 
Bech Health Economics DK A Public 1053 1 
Personal 
Cost 
1 0 1 0 1 1 0 0 0 0 
 
201
1-3 
Bijlenga Health Economics NL B Public 88 1 
Personal 
Cost 
1 0 1 1 1 1 0 0 0 0 
 
201
1-4 
Bogelund 
Current Medical 
Research & Opinion 
DK B Patient 270 1 
Personal 
Cost 
0 0 1 1 0 1 0 0 0 0 
 
201
1-5 
Boonen 
Health Services 
Research 
NL A Public 1875 1 
Copayme
nt, 
Discount 
0 0 1 0 1 1 1 0 0 1 
 
    A Public 1907 1 
Copayme
nt, 
Discount 
0 0 1 0 1 1 1 0 0 1 
 
201
1-6 
Brown  Haemophilia USA B Patient 53 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 1 0 
 
201
1-7 
Casciano 
The International 
Journal of Clinical 
Practice 
Multi B Patient 14033 0 N/A 0 1 1 1 0 0 0 0 1 0 
 
201
1-8 
Damen 
Journal of Plastic, 
Reconstructive & 
Aesthetic Surgery 
NL B Patient 272 0 N/A 1 1 1 1 1 0 0 0 0 0 
 
201
1-9 
Darba 
Osteoporosis 
International 
ESP A Patient 166 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
1-10 
Flood Vaccine USA B Public 544 0 N/A 0 1 1 1 0 0 0 0 1 0 
 
201
1-11 
Flood Clinical Pediatrics USA B Public 451 0 N/A 0 0 1 1 0 0 0 0 1 0 
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Reference Information Discrete Choice Experiment Information Output Information 
 
ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
1-12 
Goto Value in Health JP B Patient 600 0 N/A 0 1 1 1 1 0 0 0 0 0 
 
201
1-13 
Guo Value in Health CA B Patient 194 0 N/A 0 1 1 1 1 0 0 0 1 0 
 
201
1-14 
Hauber 
Journal of 
Dermatological 
Treatment 
USA B Patient 419 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 0 
 
201
1-15 
Howard Value in Health AUS A Patient 130 1 
Personal 
Cost 
0 1 0 1 1 0 0 0 0 0 
 
201
1-16 
Kruk 
Health Services 
Research 
LR A Public 1431 1 
Personal 
Cost 
1 0 1 0 1 0 0 0 0 0 
 
201
1-17 
Laver BMC Geriatrics AUS B Patient 21 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 0 
 
201
1-18 
Lloyd 
International 
Journal of 
Technology 
Assessment in 
Health Care 
UK B Patient 200 0 N/A 1 0 1 1 1 0 0 0 0 0 
 
201
1-19 
Lloyd 
Clinical 
Therapeutics 
UK B Patient 252 1 
Personal 
Cost 
0 0 1 1 0 1 0 1 0 1 
 
201
1-20 
Mheen 
Medical Decision 
Making 
NL A Patient 308 0 N/A 1 1 1 0 1 0 0 0 1 0 
 
201
1-21 
Mohamed Haemophilia USA B Patient 147 0 N/A 0 1 1 1 1 0 0 0 1 0 
 
201
1-22 
Musters  
Human 
Reproduction 
NL B Patient 206 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 0 
 
201
1-23  
Oteng 
Health Services 
Research 
CA B Public 1157 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 0 
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Reference Information Discrete Choice Experiment Information Output Information 
 
ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
1-24 
Park 
Telemedicine & e-
Health 
SK A Patient 118 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 1 1 
 
201
1-25 
Poulos 
Social Science &  
Medicine 
VN B  Public 299 1 
Personal 
Cost 
0 1 1 1 0 1 0 0 0 1 
 
201
1-26 
Robertson 
Journal of Health 
Services Research 
& Policy 
UK A Patient 2181 0 N/A 0 0 1 0 1 0 0 1 0 0 
 
201
1-27 
Scalone 
Sexually 
Transmitted 
Diseases 
Multi B Patient 154 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 1 
 
201
1-28 
Schaarschm
idt 
Archives of 
Dermatology 
DE B Patient 163 1 
Personal 
Cost 
1 1 1 1 1 0 0 0 1 0 
 
201
1-29 
Schwappac
h 
Pharmacoepidemio
logy & Drug Safety 
DE A Patient 1000 0 N/A 0 0 1 0 1 0 0 1 0 1 
 
201
1-30 
Scotland  Birth UK B Patient 730 0 N/A 1 0 1 1 1 0 1 0 0 0 
 
201
1-31 
Stockwell Vaccine USA B Public 258 0 N/A 0 0 1 1 0 0 0 0 1 0 
 
201
1-32 
Swinburn BJU International UK C Patient 332 0 N/A 0 0 0 1 1 0 1 1 0 0 
 
201
1-33 
van Gils 
Patient Preference 
& Adherence 
NL A Patient 46 1 
Copayme
nt, Bonus 
1 0 1 0 1 0 0 1 0 0 
 
201
1-34 
van 
Houtven 
Medical Decision 
Making 
USA B Patient 570 0 N/A 0 1 1 1 1 0 0 0 0 0 
 
201
1-35 
Sanders Spinal Cord USA B Patient 66 1 
Personal 
Cost 
0 0 1 1 0 0 0 0 1 1 
 
201
1-36 
Hong 
Journal of the 
American 
Pharmacists 
Association 
USA A Public 355 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 1 0 
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Reference Information Discrete Choice Experiment Information Output Information 
 
ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
1-37 
Fegert 
Expert Reviews of 
Pharmacoeconomic
s & Outcomes 
Research 
DE B Patient 121 0 N/A 0 0 1 1 1 0 0 0 0 0 
 
201
1-38 
Yi 
European Journal 
of Pain 
UK A Patient 124 0 N/A 1 0 1 0 1 0 0 0 0 1 
 
201
1-39 
Waltzman 
Annals of Plastic 
Surgery 
USA A Public 111 0 N/A 0 0 1 0 1 0 0 0 1 0 
 
201
1-40 
Bridges 
Health Policy and 
Planning 
SA B Public 640 0 N/A 0 0 1 0 0 0 0 1 0 0 
 
201
1-41 
Waschbush 
Journal of Clinical 
Child & Adolescent 
Psycology 
USA B Patient 183 1 
Personal 
Cost 
0 1 1 1 1 0 0 0 1 0 
 
201
1-42 
Laver 
Journal of 
Rehabilitation 
Medicine 
AUS B Patient 50 1 
Personal 
Cost 
0 0 1 1 1 1 1 0 0 0 
 
201
1-43 
Mohamed 
Pharmacoeconomic
s 
USA C Patient 138 0 N/A 0 0 0 1 1 0 0 0 1 0 
 
201
2-1 
Bowen 
Health Technology 
Assessment 
UK C Public 213 0 N/A 1 0 0 1 1 0 1 0 0 0 
 
201
2-2 
Bridges Lung Cancer UK C Patient 89 0 N/A 0 0 0 1 0 0 0 1 1 0 
 
201
2-3 
Bridges Patient SA B Public 645 0 N/A 1 0 1 0 1 0 0 0 1 0 
 
201
2-4 
Burnett 
Arthritis Care & 
Research 
CA B Patient 105 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 1 0 
 
201
2-5 
Cheng 
BMC Medical 
Research 
Methodology 
CA A Patient 468 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 1 0 
 
201
2-6 
Damman 
Medical Decision 
Making 
NL A Public 714 0 N/A 1 1 1 0 1 0 0 1 1 0 
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Reference Information Discrete Choice Experiment Information Output Information 
 
ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
    A Public 589 0 N/A 1 0 1 0 1 0 0 1 1 0 
 
201
2-7 
Gerard Value in Health UK A Patient 451 0 N/A 0 0 1 0 1 0 0 0 0 1 
 
201
2-8 
Gidengil Vaccine USA A Public 558 1 
Personal 
Cost 
0 1 1 0 1 1 0 0 0 0 
 
201
2-9 
Hancock-
Howard 
Birth Defects 
Research (Part A) 
CA A Public 175 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
2-10 
Kauf Patient Multi B Patient 284 0 N/A 1 1 1 0 1 0 0 0 1 0 
 
201
2-11 
King 
British Journal of 
Cancer 
AUS C Patient 357 0 N/A 0 0 0 1 1 0 0 0 0 0 
 
201
2-12 
Laba 
BMC Family 
Practice 
AUS B Public 161 1 
Personal 
Cost 
0 1 1 1 0 0 0 0 1 0 
 
201
2-13 
Landfeldt 
Human 
Reproduction 
SE A Patient 294 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 1 0 
 
201
2-14 
Manjunath Epilepsy USA B Patient 193 1 
Personal 
Cost 
0 0 1 1 0 1 0 0 1 1 
 
201
2-15 
Marti 
European Journal 
of Health 
Economics 
CH B Patient 131 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 0 
 
201
2-16 
Miners 
Sexually 
Transmitted 
Infections 
UK A Patient 3358 0 N/A 1 0 1 0 0 0 0 1 0 0 
 
201
2-17 
Mohamed 
Journal of Medical 
Economics 
USA A Patient 318 0 N/A 0 0 1 0 0 0 0 0 1 0 
 
201
2-18 
Morton 
American Journal 
of Kidney Disease 
AUS B Patient 178 0 N/A 1 0 1 1 0 0 1 1 0 0 
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ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
2-19 
Naik-
Panvelkar 
Journal of Asthma AUS B Patient 80 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
 
201
2-20 
Paczkowski Plos One ET A Public 1006 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 0 0 
 
201
2-21 
Philips Health Policy ??? A Patient 350 0 N/A 1 0 1 0 1 0 0 0 1 0 
 
201
2-22 
Pignone 
Journal of General 
Internal Medicine 
USA B Public 104 1 
Personal 
Cost 
0 0 1 1 0 0 0 0 1 0 
 
201
2-23 
Rennie Value in Health UK A Public 473 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
2-24 
Schiotz 
Patient Education 
& Counseling 
DK A Patient 2187 1 
Personal 
Cost 
0 0 1 0 0 1 0 0 0 0 
 
201
2-25 
Schmieder 
Journal of the 
American Academy 
of Dermatology 
DE B Patient 163 1 
Personal 
Cost 
0 1 1 1 1 0 0 0 1 0 
 
201
2-26 
Sung 
Journal of Clinical 
Epidemiology 
CA A Patient 274 0 N/A 0 1 1 0 1 0 0 0 0 1 
 
201
2-27 
Goodall Health Policy AUS A Patient 161 0 N/A 0 0 1 0 1 0 0 0 0 0 
 
201
2-28 
Tinelli BMC Dermatology UK C Patient 183 1 
Personal 
Cost 
0 0 0 1 1 1 0 0 0 0 
 
201
2-29 
Tong 
The Annals of 
Thoracic Surgery 
USA B Patient 224 0 N/A 0 1 1 1 0 0 0 0 1 0 
 
201
2-30 
Wong 
Journal of Medical 
Economics 
USA B Patient 272 0 N/A 0 1 1 1 0 0 0 0 1 0 
 
201
2-31 
Yeo Diabetic Medicine UK A Patient 160 0 N/A 1 0 1 0 1 0 1 0 0 0 
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ID 
Lead 
Author 
Journal Country 
Objecti
ve1 
Perspec
tive 
Sampl
e Size 
Cos
t 
Payment 
Vehicle 
Time Risk 
Proc
ess 
Outco
me 
Coeffs2 WTP3  MRS4 ORs5 RI %6 Uptake 
 
201
3-1 
Alayi-
Goebbels 
Value in Health NL B Patient 273 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
 
201
3-2 
Augustovski Value in Health AR B Patient 240 1 
Personal 
Cost 
0 1 1 1 1 0 0 0 0 0 
 
201
3-3 
Best 
Perspectives on 
Sexual & 
Reproductive 
Health 
USA A Public 266 0 N/A 0 1 1 0 1 0 0 0 0 0 
 
201
3-4 
Boeri 
Journal of Health 
Economics 
UK B Public 493 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
3-5 
Brenner 
Journal of General 
Internal Medicine 
Multi B Public 306 0 N/A 0 1 1 0 0 0 0 0 1 0 
 
201
3-6 
Carroll Prenatal Diagnosis UK B Public 106 1 
Personal 
Cost 
1 0 1 1 1 1 0 0 0 0 
 
201
3-7 
Chu 
Geriatrics 
Gerontology 
International 
CN A Patient 1540 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
3-8 
Cunningha
m 
Journal of 
Abnormal Child 
Psychology 
CA A Patient 1059 0 N/A 0 0 1 0 1 0 0 0 0 1 
 
201
3-9 
Cunningha
m 
Journal of Health 
Communication: 
International 
Perspectives 
CA A Public 1129 0 N/A 0 0 1 0 1 0 0 0 1 1 
 
201
3-10 
de Bekker-
Grob 
British Journal of 
Cancer 
NL B Public 459 1 
Personal 
Cost 
0 1 1 0 1 1 1 0 0 0 
 
201
3-11 
Deal Value in Health CA B Patient 361 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 0 
 
201
3-12 
Dixon 
Health 
Expectations 
UK A Patient 77 0 N/A 0 0 1 0 1 0 0 0 0 0 
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201
3-13 
Dwight 
Johnson 
General Hospital 
Psychiatry 
USA A Patient 63 1 
Personal 
Cost 
0 0 1 0 0 0 0 1 0 0 
 
201
3-14 
Gelhorn 
Diabetes, Obesity & 
Metabolism 
UK C Patient 100 0 N/A 0 1 0 1 1 0 0 0 1 0 
 
201
3-15 
Glenngard 
Nordic Journal of 
Psychiatry 
Multi B Patient 285 1 
Personal 
Cost 
0 1 1 1 1 1 0 0 0 0 
 
201
3-16 
Gonzalez Headache USA C Patient 510 0 N/A 0 1 0 1 1 0 0 0 1 0 
 
201
3-17 
Hall 
Medical Decision 
Making 
AUS A Patient 72 0 N/A 0 0 1 0 1 0 0 0 0 0 
     
A Patient 96 0 N/A 0 0 1 0 1 0 0 0 0 0 
 
201
3-18 
Hauber 
Osteoarthritis & 
Cartilage 
UK C Patient 294 0 N/A 0 1 0 1 0 0 1 0 1 0 
 
201
3-19 
Hauber 
Patient Preference 
& Adherence 
USA B Patient 1114 1 
Personal 
Cost 
0 1 1 1 0 1 0 0 1 1 
 
201
3-20 
Kjaer 
European Journal 
of Health 
Economics 
GL A Public 194 1 
Tax 
Increase 
0 0 1 0 1 1 0 0 0 0 
 
201
3-21 
Knox 
Social Science &  
Medicine 
AUS B Public 527 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
 
201
3-22 
Kobayashi 
International 
Journal of Health 
Care Quality 
Assurance 
JP A Public 111 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 1 0 
 
201
3-23 
Krucien Thorax FR B Patient 121 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 0 
 
201
3-24 
Laba 
BMC 
Musculoskeletal 
Disorders 
AUS B Patient 188 1 
Personal 
Cost 
0 0 1 1 0 1 0 1 0 1 
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201
3-25 
Lathia 
Support Care 
Cancer 
CA B Patient 88 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 0 1 
 
201
3-26 
Llewellyn BMJ Open UK A Public 233 0 N/A 0 0 1 0 0 0 0 1 0 0 
 
201
3-27 
Lynn 
Health 
Expectations 
UK B Patient 146 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 0 
 
201
3-28 
Mattsson Maturitas SE B Patient 423 1 
Personal 
Cost 
0 0 1 1 0 1 0 0 0 0 
 
201
3-29 
Meghani 
BMC Medical 
Informatics & 
Decision Making 
USA B Patient 241 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 1 0 
 
201
3-30 
Miller 
Journal of Medical 
Economics 
USA B Patient 205 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 0 0 
 
201
3-31 
Milte 
Journal of 
Rehabilitation 
Medicine 
AUS B Patient 87 0 N/A 0 1 1 1 1 0 1 0 0 0 
 
201
3-32 
Mohamed 
Diabetes & 
Metabolism 
Multi B Patient 383 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 0 
 
201
3-33 
Moia 
Internal Emergency 
Medicine 
IT A Patient 255 1 
Personal 
Cost 
0 1 1 0 1 1 0 0 0 0 
 
201
3-34 
Muhlbacher 
International 
Journal of 
Integrated 
Medicine 
DE A Patient 110 0 N/A 0 0 1 0 1 0 0 0 0 0 
 
201
3-35 
Muhlbacher 
Health Economics 
Review 
DE B Patient 218 0 N/A 0 1 1 1 1 0 0 0 0 0 
 
201
3-36 
Pignone 
JAMA Internal 
Medicine 
Multi C Public 302 0 N/A 0 1 0 0 0 0 0 0 1 0 
 
201
3-37 
Poulos 
Arthritis Care & 
Research 
USA B Patient 296 0 N/A 0 1 1 0 1 0 0 0 0 0 
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201
3-38 
Sadique Plos One UK A Public 369 1 
Personal 
Cost 
0 1 1 0 1 1 0 0 0 1 
 
201
3-39 
Schaarschm
idt 
Journal of the 
European Academy 
of Dermatology 
and Venereology 
DE B Patient 163 1 
Personal 
Cost 
0 0 1 1 0 0 0 0 1 0 
 
201
3-40 
Shingler 
Journal of Medical 
Economics 
UK B Patient 99 0 N/A 0 0 1 1 0 0 0 1 0 0 
 
201
3-41 
Terris-
Prestholt 
Plos One SA B Public 1017 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 1 1 
 
201
3-42 
Tsunematsu 
Asian Pac Journal of 
Cancer 
JP A Public 993 1 
Personal 
Cost 
0 0 1 0 0 0 0 0 1 0 
 
201
3-43 
Veldwijk BMC Public Health NL B Patient 1250 1 
Personal 
Cost 
0 0 1 1 1 0 0 0 0 1 
 
201
3-44 
Whitty Plos One AUS A Patient 91 1 
Personal 
Cost 
0 0 1 0 1 0 0 0 0 0 
 
201
3-45 
Zimmerman
n 
Journal of Affective 
Disorders 
DE B Patient 227 0 N/A 0 1 1 1 1 0 0 0 1 0 
 
201
3-46 
Ahn 
Telemedicine & e-
Health 
SK A Public 400 1 
Personal 
Cost 
0 0 1 0 1 1 0 0 1 1 
 
201
3-47 
Parkinson 
Applied Health 
Economics and 
Health Policy 
AUS B Public 175 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
      
Public 179 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
      
Public 181 1 
Personal 
Cost 
0 0 1 1 1 1 0 0 0 0 
 
201
3-48 
Wittink Patient USA A Public 86 0 N/A 0 1 1 0 1 0 0 0 0 0 
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201
3-49 
Pisa Patient DE B Patient 300 0 N/A 0 0 1 1 1 0 0 0 1 0 
 
1 = Included, 0 = Not Included 
1For information on objectives, see Appendix A.1; 2Coeffs = Coefficients (regression output); 3WTP = Willingness to Pay; 4MRS = Marginal rates of substitution; 5ORs = Odds Ratios; 6RI %; 
Relative Importance 
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A-3 Data Extraction Table for 2014 to March 2017 
No. Lead Author Year Journal Quote on Sample Recruitment Strategy Classification 
5 Alten 2016 Patient Pref Adherence 
"The following inclusion criteria were to be met by patients: subjects had to be diagnosed 
with RA, at least 18 years of age, show a sufficient level of proficiency in the German 
language, and be treated with at least one DMARD [disease-modifying anti rheumatic 
drug]." 
Patient 
11 Benning 2014 Value Health 
"On this platform, 1277 individuals from the general Dutch population in the age category 
55 to 75 years started our online survey in the period mid-May to the end of May 2012. … 
Finally, the data of 631 Dutch respondents in the age category 55 to 75 years who have no 
experience with CRC were used in the analysis." 
General Public 
14 Bewtra 2015 Am J Gastroenterol 
“Patients were eligible if they were ≥18 years of age with an ICD-9 code for UC (556.0–
556.6 and 556.8–556.9) or CD (555.0–555.2, 555.9) and an outpatient gastroenterology 
visit in the prior 2 years." 
Patient 
21 Brown 2014 
Advances in Health 
Economics and Health 
Services Research 
"The survey was fielded to a U.S. sample of 307 girls aged 13–17 years who had not yet 
received an HPV vaccine in June 2008." 
General Public 
23 Buchanan 2016 Patient 
"The sampling population selected for this DCE was UKCLL patients as it is recommended 
that DCEs are under-taken in populations with experience in the area of interest" 
Patient 
43 Determann 2014 PLoS One 
"A market research company (Flycatcher) was hired to administer the online 
questionnaire to a representative sample of the general adult population of the 
Netherlands." 
General Public 
59 
Garcia - 
Dominguez 
2016 Patient Pref Adherence 
"Patients aged 18 years or older with a diagnosis of RRMS or SPMS (MS type was reported 
by the patient and not con-firmed by any other data source) were included in the study." 
Patient 
77 Hauber 2015 Diabetes Therapy 
"To qualify for inclusion in this study, patients had to (1) be aged 18 years or older; (2) 
have a self-reported  physician  diagnosis  of  T2DM;  (3)  be currently taking one OAD or 
no OAD to treat their  T2DM;  and  (4) be not currently  taking injectable T2DM  
treatments  (e.g., insulin and glucagon-like 1 receptor agonist)." 
Patient 
89 Holmes 2016 
British Journal of Clinical 
Pharmacology 
"Community-dwelling, hypertensive patients recruited from nine European countries were 
invited to complete a discrete choice experiment (DCE)" 
Patient 
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No. Lead Author Year Journal Quote on Sample Recruitment Strategy Classification 
105 Kistler 2015 Patient Pref Adherence 
"Two  team  members  enrolled  a  volunteer  sample  of community-dwelling older adults 
(i.e., older adults not residing  in  a  long-term  care  facility  or  other  institution)  aged 
70–90  years,  with  no  personal  history  of  CRC  or  inflammatory  bowel  disease." 
General Public 
108 Knight 2015 Medical Decision Making 
"Participants were eligible for the survey if they were 50 years of age or older and a 
United States resident." 
General Public 
111 Kromer 2015 PLoS One 
"Inclusion criteria were age 18 years and moderate-to-severe psoriasis according to the 
criteria of the Committee for Medicinal Products for Human Use (CMPH), i.e., PASI 10 in 
the course of the disease, involvement of head, palms or plantar surfaces, or psoriatic 
arthritis according to Classification of Psoriatic Arthritis (CASPAR) criteria with any skin 
involvement" 
Patient 
122 Lehman 2016 Radiotherapy & Oncology 
“Patients were eligible if they were diagnosed with Stage III NSCLC and were to receive 
definitive CRT. Patients were identified at the weekly Lung Cancer Multi-disciplinary 
Meeting" 
Patient 
123 Levitan 2015 Psychiatric Services 
"Respondents who were at least18 years of age and who had a self-reported physician 
diagnosis of schizophrenia were identified via a pre-screening survey and were recruited 
through Kantar Health’s online patient panel in May 2012." 
Patient 
126 Louder 2016 Am Health Drug Benefits 
"For participation in the study, patients had to be aged 21 to 80 years at the time of 
survey administration, be currently enrolled in a fully insured Humana commercial health 
plan with medical and pharmacy benefits, and to have had at least 2 RA-related medical 
claims in the previous 12 months, at least 30 days apart, as identified by International 
Classification of Diseases, Ninth Revision, Clinical Modification diagnosis code 714.0 
(rheumatoid arthritis)." 
Patient 
137 Medina-Lara 2014 Malaria Journal 
"Eight different choice questions were randomly allocated and presented to each 
household head in a community survey of health-seeking behaviour for treating fever in 
adults and children in the Zomba District of Malawi." 
General Public 
149 Mohamed 2016 Patient 
"To be included in the study, respondents were required to be aged C18 years, have a self-
reported physician diagnosis of CF, or be the parent of a paediatric patient(aged 6–17 
years) with CF, and the patient must have stated that they have tested positive for P. 
aeruginosa in their lung culture at least twice a year (self-reported)." 
 
Patient 
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No. Lead Author Year Journal Quote on Sample Recruitment Strategy Classification 
171 Noble 2015 Haemotologica 
"Patients were eligible if they met the following criteria: Histologically confirmed cancer; 
Receiving ongoing treatment for cancer (chemotherapy and or radiotherapy); 
Radiologically confirmed symptomatic deep vein thrombosis (DVT) and/or pulmonary 
embolus (PE); Receiving anticoagulation for their diagnosed DVT and/or PE; Receiving 
anticoagulation for no more than six months." 
Patient 
173 O'Hara 2016 Can J Surg 
"We recruited adult patients with end-stage shoulder OA waiting for TSA surgery to 
complete the DCE questionnaire. All participants were recruited from a single surgeon’s 
practice located in metropolitan Ontario. " 
Patient 
181 Posnett 2015 Patient Pref Adherence 
"A prospective, internet-based, double-blind survey recruited adult participants with self-
reported OAK in one or both knees.  Previous studies have shown that self-reported 
physician-level diagnoses of osteoarthritis (OA) are reliable, with a concordance of 86.9% 
with primary-care records." 
Patient 
205 Tokes  2014 J Gen Intern Med 
"Participants were screened to meet key target criteria: 18–65 years old; Chinese, Korean, 
or Vietnamese ethnicity; with a doctor’s diagnosis of CHB at least 6 months previously; on 
current antiviral treatment for CHB treatment (Treated) or naïve to CHB antiviral 
treatment (Treatment-naïve); and with no participation in CHB studies in the last 6 
months." 
Patient 
208 Uemura 2016 BMC Urol 
"Inclusion criteria were as follows: (1) aged 20 years or older, (2) diagnosed with CRPC, 
(3)chemotherapy-naïve, (4) able to read and understand Japanese, and (5) provided 
written informed consent." 
Patient 
209 Ultz 2014 
Therapeutic Advances in 
Neurological Disorders 
"Patients with relapsing–remitting MS (n = 156) completed a questionnaire assessing 
treatment preferences," 
Patient 
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B-1 Full Online Survey 
The notes were originally intended for the online programmers at Research Now 
(http://www.researchnow.com) and aimed to provide clarifications. In addition, please note 
that the “Online Panel” sample was previously referred to as the “General Population” sample 
and the “Trial” sample was previously referred to as the “Patient” sample. 
Study information page: Survey of attributes influencing individual 
decisions to participate in weight loss maintenance programmes 
We are inviting you to take part in a research project that is investigating factors that determine 
participation in weight loss maintenance programmes. This project is being carried out by 
researchers at Newcastle University. 
What is the research about? 
Programmes to promote weight loss are highly effective, but people tend to struggle to maintain 
weight loss over the longer-term. It is important that any weight that is lost is not put back on 
so that the side effects of being overweight (such as increased risk of diabetes, heart disease 
and some types of cancer) can be avoided. Approaches to help people keep off the weight they 
have lost have been developed but we need to show how well they work and what features of 
these approaches help or hinder people using them. 
This research aims to identify which characteristics of weight loss maintenance programmes 
are most important to people when deciding whether or not to participate in them. For example, 
some programmes may last for a year and provide feedback via text messages, whereas others 
may be shorter but provide ‘face to face’ feedback.  
What will it involve and what happens to the information that is collected? 
If you decide to take part in this study, we will ask you to complete a survey. The survey will 
take approximately 20-30 minutes to complete. First you will be presented with a series of 
questions containing descriptions of two different weight loss maintenance programmes. For 
each of these questions you will be asked which weight loss maintenance programme you would 
prefer. Following this, we will ask you questions about whether you would like to participate 
in a weight loss maintenance programme, questions about yourself (e.g. your age, education, 
and household income, etc.) and your health, as well as questions about your attitudes and 
beliefs about obesity in general. 
255 
 
All of the information that you provide in the survey will be strictly confidential and your data 
will be stored safely and securely. Your individual responses will be anonymous and accessed 
on a secure network by the researchers from Newcastle University responsible for the survey. 
Individual responses to this survey will not be published however unidentifiable grouped 
responses may be used in future publications as a result of this study. 
You can withdraw from the study at any time. If you have any questions or comments, please 
contact David Mott using the contact details below. 
By ticking the box below “I agree to participate in this study” and continue to the survey you 
are indicating your agreement with the following: 
1. I have read the information about this study 
2. I understand that my participation in this study is voluntary 
3. I understand that I am free to withdraw my participation at any time during completion 
of the survey 
4. I understand that responses I provide to the survey questions will be anonymous, and 
that no personally identifiable information about me will appear in any report or article 
based on the findings of this study 
 
⃝ I agree to participate in this study 
⃝ I do not agree to participate in this study 
 
 
If you require further information about this study, please contact David Mott (PhD Student at 
Newcastle University): 
Email: d.j.mott@newcastle.ac.uk 
Telephone: 07545 174428 
  
CONTINUE TO THE SURVEY 
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1. Screening Questions 
Note  
GENERAL POPULATION SAMPLE: 
The aim of these questions is to identify whether the respondent is eligible to respond to the 
survey. In addition, the questions will be used to sort the respondent into one of three groups: 
1. Potential Service User (Required n=200 total, n=50 for each block of “Scenario 
Questions”) 
2. Potential Beneficiary (Required n=200 total, n=50 for each block of “Scenario 
Questions”) 
3. Non-User (Required n=200 total, n=50 for each block of “Scenario Questions”) 
PATIENT SAMPLE: 
All patients are eligible to respond to the survey and do not need to be grouped in any way 
(hence less questions in this section for them). 
 
GP & P: Q1. What is your age? _____ years old 
 
GP & P: Q2. What is your gender? 
□ Male     □ Female 
 
GP: Q3. Are you currently pregnant or breastfeeding? 
□ Yes     □ No 
 
P: Q4. Please enter your NULevel Trial ID: ___________________ 
 
Note  
GENERAL POPULATION SAMPLE: 
Respondents must be aged 18+ as indicated by Q1 to continue the survey. 
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If a respondent is female as indicated by Q2 then ask Q3, otherwise move to Q5. 
If the answer to Q3 is “Yes”, the respondent is not eligible to continue the survey. 
If the answer to Q3 is “No”, move to Q5. 
PATIENT SAMPLE: 
All above information in Q1, 2 & 4 is required to continue. 
 
GP & P: Q5. What are your preferred units of measurement for height & weight? 
□ Metres (m) / Kilograms (kg) □ Feet and Inches (ft & in) / Stones and Pounds (st & lb)
  
□ Feet and Inches (ft & in) / Pounds (lb) 
 
Note 
GENERAL POPULATION AND PATIENT SAMPLE: 
Only use the preferred unit of measurement from Q5 from here on (i.e. questions on weight 
in this section and formatting of weight re-gain characteristic in Section 2 scenarios). 
 
GP & P: Q6a. What is your height? ______cm  or _____feet _____inches 
GP & P: Q6b. Are you certain about your height or is this an estimate/guess?   
   □ Certain  □ Estimate/Guess 
 
GP & P: Q7a. What is your current weight? ______lbs or _____st_____lb 
 or ______kg 
GP & P: Q7b. Are you certain about your current weight or is this an estimate/guess?  
   □ Certain  □ Estimate/Guess 
 
GP & P: Q8. What is your ethnic group? 
White       Black 
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□ British      □ Caribbean 
□ Irish       □ African 
□ Any other White background:   □ Any other Black background: 
______________________________________________________________________ 
 
Mixed Race      Asian or Asian British 
□ White & Black Caribbean    □ Indian 
□ White & Black African    □ Pakistani 
□ White & Asian     □ Bangladeshi 
□ Any other mixed background:   □ Chinese 
___________________________________  □ Any other Asian background: 
      _________________________________ 
Other Ethnic Group     Other 
□ Arab       □ Prefer not to say 
□ Any other ethnic group       
_____________________________________   
 
Note  
GENERAL POPULATION SAMPLE: 
If any part of Q5-Q8 is missing (response of “Prefer not to say” in Q8 counts as missing 
info), the respondent is not eligible to continue the survey as this information is needed to 
calculate BMI. 
Calculating BMI 
𝐵𝑀𝐼 =  
𝑊𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑘𝑖𝑙𝑜𝑔𝑟𝑎𝑚𝑠
(𝐻𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑚𝑒𝑡𝑟𝑒𝑠)2
 
Or 
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 𝐵𝑀𝐼 =
𝑊𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑝𝑜𝑢𝑛𝑑𝑠
(𝐻𝑒𝑖𝑔ℎ𝑡 𝑖𝑛 𝑖𝑛𝑐ℎ𝑒𝑠)2
 × 703 
(1 stone = 14 pounds & 1 foot = 12 inches) 
BMI Classifications 
For respondents answering Q8 as “Indian”, “Pakistani”, “Bangladeshi”, “Chinese” or “Any 
other Asian background”: 
Underweight – BMI less than 18.5 
Normal weight – BMI of 18.5 up to 22.9 
Overweight – BMI of 23 up to 27.4 
Obese – BMI of 27.5 and above 
For all other ethnic groups in Q8: 
Underweight – BMI less than 18.5 
Normal weight –  BMI of 18.5 up to 24.9 
Overweight – BMI of 25 up to 29.9 
Obese – BMI of 30 and above 
 
Grouping according to BMI classification 
If they are underweight, or weigh over 175kg/385lbs/27st 7lbs, they are not eligible to 
continue the survey. 
If they are normal weight, they are a non-user and only answer Q9 (also Q10 if answer to 
Q9 is “no”). This is the end of the screening questions. 
If they are overweight, they are a potential beneficiary and only answer Q9 (also Q10 if 
answer to Q9 is “no”). This is the end of the screening questions. 
If they are obese they answer Q9: 
If the answer is “no”, they are a potential beneficiary and answer Q10 only. This is the end 
of the screening questions. 
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If the answer is “yes” they move to Q11. If the answer to Q11 indicates that in the past 12 
months they have maintained 5% weight loss (i.e. weight reported in Q7a is at least 5% 
lower than weight reported in Q11a), they move to Q12. If not, they are a potential 
beneficiary and this is the end of screening questions. 
If those that move to Q12 answer “no” they are a potential beneficiary and this is the end of 
screening questions. If they answer “yes”, they move to Q13. 
If those that move to Q13 answer “no” they are a potential beneficiary and this is the end of 
screening questions. If they answer “yes”, they are a potential service user and this is the end 
of the screening questions. 
 
PATIENT SAMPLE: 
All of the information in Q5-8 is required to continue. Q8 is the end of this section for this 
sample. 
 
GP: Q9. Have you attempted to lose weight in past 12 months? 
□ Yes     □ No 
 
GP: Q10. Have you ever attempted to lose weight? 
□ Yes     □ No 
 
GP: Q11a. What was your highest weight in the past 12 months? _______ lbs 
 ___st____lbs  or  ______kg 
GP: Q11b. Are you certain about your highest weight in the past 12 months or is this an 
estimate/guess?   □ Certain  □ Estimate/Guess 
 
GP: Q12. Are you able to use a set of scales to weigh yourself? (It doesn’t matter if you don’t 
own a set of scales) 
□ Yes     □ No 
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GP: Q13. Do you have access to a mobile phone that can connect to the Internet?  
□ Yes     □ No 
 
2. Scenario Questions 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND 
PATIENT SAMPLE 
 
Weight Loss Maintenance 
A lot of people successfully lose weight in order to feel better and to improve their health. 
Despite this success it can be difficult to keep the weight off over time. This is particularly true 
when people reach their target weight and try to remain at this weight - this is called “weight 
maintenance”. 
Research suggests that most people that have lost weight tend to put the weight back on within 
3-5 years. Programmes have been developed in order to help prevent this happening to people 
that have lost weight – these are called “weight loss maintenance programmes”. 
The questions in this section will ask you about your preferences for different kinds of “weight 
loss maintenance programmes”. The programmes described in this section are based on a real 
weight loss maintenance programme that has been tested. You will be asked to make choices 
between different versions of this programme, as if you were making the choice to take part in 
a programme in real life. 
It doesn’t matter if you do not think you need to take part in a programme, please imagine 
that you do need a programme (i.e. you have lost weight, and want to keep it off). 
Weight Loss Maintenance Programmes 
  
In every weight loss maintenance programme described in this section, if you were to take part 
you would be provided with a set of scales to weigh yourself with. You would be asked to 
weigh yourself using these scales every day and to not let anybody else use the scales. The 
scales automatically send information about your weight to the programme organisers. 
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Other parts of the programmes vary: 
  
1. The length of each programme will vary from 6 to 24 months. You would not be forced to 
stay in the programme for the full length of time. 
2. In most programmes you would be reminded if you forget to weigh yourself. This would 
only happen if you didn’t weigh yourself within a 48 hour period, and you would only 
receive one reminder. The way in which these reminders are sent to you will vary 
depending on the programme. 
3. In every programme you would receive some feedback from the programme staff about 
your progress. The amount of feedback you receive will depend on your progress, but this 
would normally be around twice a month. The way in which you receive this would vary 
depending on the programme. 
4. Some programmes may provide you with an online tool (e.g. website or mobile phone 
application) to track your weight independently. In some programmes, it may be the case 
that you only receive reminders to weigh yourself and/or feedback on your progress from 
these online tools. 
5. Remember that it is normal for people to re-gain weight following weight loss. The 
amount of weight re-gain that you would expect to experience would vary depending on 
the programme from 0% to 100% of your initial weight loss. The amount of weight re-
gain is based on you participating in the programme for the full length of time. 
6. Each programme would have a different monthly cost, which would be paid for by 
yourself if you were to take part. 
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Ranking Exercise 
The characteristics of the weight loss maintenance programmes described in this section are 
summarised in the table below, along with the possible options for each characteristic. 
Characteristic Summary Possible Options 
Length of the 
Programme 
How long the programme will last in total 
(in months). 
6 months; 12 months; 18 
months; 24 months 
Delivery of 
Reminders to 
Weigh 
Yourself 
How you are reminded if you forget to 
weigh yourself for over 48 hours (if you are 
reminded at all). 
No reminders; via phone 
call; via text message; via 
the online tool(s) 
Delivery of 
Feedback from 
Programme 
Staff 
How you will receive feedback on your 
progress from programme staff.  
Via phone call; via text 
message; via the online 
tool(s); face to face 
Availability of 
Online Tools 
to Track Your 
Progress 
The type of online tool(s) provided, if any, 
so that you can track your progress 
independently. 
No online tool; website 
only; mobile phone 
application only; website 
& mobile phone 
application 
Weight Re-
gain 
The amount of weight that you re-gain, as a 
percentage of the amount that you lost 
originally. 
0%; 10%; 20%; 40%; 
60%; 80%; 90%; 100%  
Personal Cost 
(per month) 
The cost, to you, of the programme each 
month. 
£0; £10; £20; £30 
 
Q1. Please rank these characteristics in order of importance to you, where 1 represents the 
“most important” characteristic and 6 represents the “least important” characteristic. 
1. 5. 
2. 6. 
3.  
4.  
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Q2a. Please rank the possible options for “Length of the Programme” in order of your 
preference, where 1 represents the “most preferred” characteristic and 4 represents the “least 
preferred” characteristic. 
1.  
2.  
3.  
4.  
 
Q2b. Please rank the possible options for “Delivery of Reminders” in order of your preference, 
where 1 represents the “most preferred” characteristic and 4 represents the “least preferred” 
characteristic. 
1.  
2.  
3.  
4.  
  
Q2c. Please rank the possible options for “Delivery of Feedback” in order of your preference, 
where 1 represents the “most preferred” characteristic and 4 represents the “least preferred” 
characteristic. 
1.  
2.  
3.  
4.  
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Q2d. Please rank the possible options for “Availability of Online Tools” in order of your 
preference, where 1 represents the “most preferred” characteristic and 4 represents the “least 
preferred” characteristic. 
1.  
2.  
3.  
4.  
  
Q2e. Please rank the possible options for “Weight Re-Gain” in order of your preference, where 
1 represents the “most preferred” characteristic and 8 represents the “least preferred” 
characteristic. 
1. 5. 
2. 6. 
3. 7. 
4. 8. 
  
Q2f. Please rank the possible options for “Personal Cost (per month)” in order of your 
preference, where 1 represents the “most preferred” characteristic and 4 represents the “least 
preferred” characteristic. 
1.  
2.  
3.  
4.  
Note 
These questions should be drag & drop exercises 
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Practice Scenario 
This is a practice scenario to show you how the questions will be set out. If you forget what a characteristic means, you can hover over the name 
of it e.g. “Length of Programme” to see its definition again. 
Imagine that you lost 10% of your current body weight. This would mean that you lost X of weight. Normally when people lose weight, they put 
all of it back on. 
Programme A and Programme B could help you to avoid putting this X of weight back on by asking you to weigh yourself every day (using scales 
that would be given to you) and providing you with regular feedback about your weight. There may also be online tools that you can use to track 
your weight on your own. 
Imagine that you are offered the two programmes described below. Try and decide which programme you would want to take part in if this 
happened in real life. If you would not want to take part in either programme, you can select “No Programme”. 
 Programme A Programme B No Programme 
Length of the Programme 18 months 12 months 
Most people re-gain 100% 
of their weight loss without 
a programme - this would be 
X for you 
Delivery of Feedback from Programme 
Staff 
Via phone call Via text message 
Delivery of Reminders to Weigh 
Yourself 
Via the online tool Via phone call 
Availability of Online Tools to Track 
Your Progress  
Mobile application only No online tool 
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Weight Re-Gain 
40% (this would be 40%∙X for 
you) 
60% (this would be 60%∙X for 
you) 
Personal Cost £20 a month £10 a month 
    
1. Which option would you choose? □ □ □ 
2. Of the remaining two, which option 
would you choose? 
□ □ □ 
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Note 
In the actual practice scenario Programme A will consist of the characteristics ranked as most preferred in the ranking scenario, and 
Programme B will consist of the characteristics ranked as least preferred. 
X is 10% of the respondent’s current weight, calculated from Q7 in the screening questions section.  
The unit of measurement used to describe X will be based on the answer to Q5 in the screening questions section. 
Within the table in each scenario X will be multiplied by the percentage in the “Weight Re-Gain” cells for Programmes A and B. 
 
Formatting requests: 
Only show question (1) initially i.e. all 3 options. 
After the respondent has answered (1) please remove the column that corresponds to the choice made in (1) and then present question (2). 
Also, please present the definitions of each attribute from page 2 of this section (not the shorter summaries) when a respondent’s mouse hovers 
over the related cell in the table. 
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Note 
The following 13 questions should be in the same format as the “Practice Scenario”, containing all of the text apart from the italic text at the very 
top. 
The question IDs e.g. B1-1/B2-1/B3-1/B4-1 should not be visible to respondents, but it would be useful to have this identifier in the data once 
the survey responses have been collected. 
GENERAL POPULATION SAMPLE: 
The 13 questions will vary depending on the block that is randomly assigned to the respondent (1, 2, 3 or 4).  
PATIENT SAMPLE: 
The 13 questions will vary depending on the block that is assigned to the respondent (1, 2, 3 or 4), which has been predetermined based on their 
NULevel Trial ID (Q4 in Section 1). The excel spreadsheet “Patients – Assigned Blocks.xlsx” shows which block to use according to each 
possible NULevel Trial ID. 
GENERAL POPULATION AND PATIENT SAMPLE: 
The scenario questions for each block can be found in the following files: 
Scenario Questions – Block 1.docx 
Scenario Questions – Block 2.docx 
Scenario Questions – Block 3.docx 
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Scenario Questions – Block 4.docx 
In other words, block 1 questions are the same for a general population respondent or a patient respondent. 
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Difficulty Question 
How difficult did you find the scenario questions to answer? 
Very 
difficult 
Moderately 
difficult 
Slightly 
difficult 
Neither 
difficult 
nor easy 
Slightly 
easy 
Moderately 
easy 
Very easy 
□ □ □ □ □ □ □ 
 
 
Interest Question 
Would you like a weight loss maintenance programme, similar to those described in the choice 
scenarios, to be made available? (Please choose one option) 
□ [1] Yes – because I would like to use a programme like this  
□ [2] Yes – because I would like to use a programme like this & I want it to be available for 
others to use too  
□ [3] Yes – because I might want to use a programme like this in future  
□ [4] Yes – because I might want to use a programme like this in future & I want it to be 
available for others to use too 
□ [5] Yes – I would not use it myself, but I want it to be available for others to use 
□ [6] No – I do not think a programme like this should be made available  
Note 
If the answer to this 1, 2, 3 or 4 then the respondents move to Section 3 – Version 1.  
If the answer to this is 5, respondents move to Section 3 – Version 2.  
If the answer to this is 6, respondents move to Section 3 – Version 3. 
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3. Willingness to Pay Questions 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND 
PATIENT SAMPLE 
 
VERSION 1 
According to your responses earlier in the survey, the following weight loss maintenance 
programme contains some of your preferred characteristics: 
 Your Favourite Programme 
Delivery of Feedback  
Rank 1 from Q2b in “Ranking 
Exercise” 
Delivery of Reminders  
Rank 1 from Q2c in “Ranking 
Exercise” 
Availability of Online 
Tools 
Rank 1 from Q2d in “Ranking 
Exercise” 
Weight Re-gain 0% 
 
Note 
In the weight loss maintenance programme described, the levels come from Q2b to Q2d in 
the “Ranking Exercise” in Section 2. They are the levels assigned the rank “1” in these 
questions (i.e. the most preferred). 
 
Q1a. Would you be willing to pay to take part in this weight loss maintenance programme if it 
was offered to you? 
□ Yes     □ No 
If the answer to Q1a is “Yes” then move to Q1b, if “No” then move to Q9. 
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Q1b. What is the maximum amount you would be willing to pay (per month, for 12 months) 
to take part in this weight loss maintenance programme?  
 £__________ a month (for 12 months)  □ I don’t know 
Now move to Q2a. 
 
Q2-Q8. See note 
 
Note 
The following questions, Q2-8, will follow the same format as Q1a and Q1b. However, the 
level of “Weight Re-Gain” will be adjusted from 10% to 20% to 40% to 60% to 80% to 
90% and, finally, to 100% in Q8. 
If during any of the part a’s, the respondent states that they would not be willing to pay for 
the programme, the respondent will move to Q9. 
 
Now move to Q9. 
 
Q9. Do you have any comments?  
___________________________________________________________________________ 
___________________________________________________________________________ 
___________________________________________________________________________ 
Now move to Section 4. 
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3. Willingness to Pay Questions 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND 
PATIENT SAMPLE 
 
VERSION 2 
Q1a. Would you be willing to pay (as a one-off payment) to enable a weight loss maintenance 
programme to be provided to those that need it? 
□ Yes     □ No 
If the answer to Q1a is “Yes”, move to Q1b. If the answer is “No”, move to Q2. 
 
Q1b. What is the maximum amount that you would be willing to pay (as a one-off payment) 
in order to enable a weight loss maintenance programme to be provided to one individual for 
12 months?   
£__________ (one-off payment)    □ I don’t know 
 
Q2. Do you have any comments?  
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
Now move to Section 4. 
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3. Willingness to Pay Questions 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND 
PATIENT SAMPLE 
 
VERSION 3 
Q1. Do you have any comments?  
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________
___________________________________________________________________________ 
Now move to Section 4.  
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4. About You 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND 
PATIENT SAMPLE 
 
These questions ask about you and the people you live with (your household). 
 
Q1. What is your current marital status? 
□ Married    □ Co-habiting    □ Separated  
□ Divorced    □ Widowed    □ Never Married 
 
Q2. What was your highest level of qualification when you finished your education? 
□ Masters/PGCE/PhD   □ 1st Degree (e.g. BA) □ HND/HNC 
□ A Level   □ GCSE/O Level/CSE  □ None 
□ Other:___________________________________________________________________ 
 
Q3. How many dependent children (under 16 years) are you responsible for? ________ 
 
Q4. What is the age of the youngest dependent child under the age of 16 for which you are 
responsible? ________ years 
 
Q5. Including dependent children, how many people currently live with you? ________ 
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Q6. What is your current employment status? 
□ Full employment  □ Part-time employment  □ Student 
□ Retired   □ Homemaker    □ Caring for someone 
□ Unemployed (not actively seeking work)  □ Unemployed (actively seeking work) 
□ Other:_______________________________________________________________ 
 
Q7. Please estimate your annual household income from all sources (before tax and including 
your partner/spouse and any other employed household members) 
□ Under £10,000 □ £10,001-£20,000 □ £20,001-£30,000 □ £30,001-£40,000 
□ £40,001-£50,000 □ £50,001-£60,000 □ £60,001-£70,000 □ Above £70,000 
Now move to Section 5.  
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5. About Your Health 
These questions will ask you about your health. 
GP & P: Q1. To help people say how good or bad a health state is, we have drawn a scale 
(rather like a thermometer) on which the best state you can imagine is marked 100 and the worst 
state you can imagine is marked 0. 
We would like you to indicate on this scale how good or bad your own health is today, in your 
opinion. Please do this by drawing a line from the box below to whichever point on the scale 
indicates how good or bad your health state is today. 
 
 
  
Best imaginable health state 
 
Your own 
health state 
today 
100 
 
90 
 
80 
 
70 
 
60 
 
50 
 
40 
 
30 
 
20 
 
10 
 
0 
 
Worst imaginable health 
state 
Answer: 
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GP & P: Q2. Under each heading, please tick the ONE box that best describes your health 
TODAY. 
 
MOBILITY 
□ I have no problems in walking about 
□ I have slight problems in walking about 
□ I have moderate problems in walking about 
□ I have severe problems in walking about 
□ I am unable to walk about 
 
SELF-CARE 
□ I have no problems washing or dressing myself 
□ I have slight problems washing or dressing myself 
□ I have moderate problems washing or dressing myself 
□ I have severe problems washing or dressing myself 
□ I am unable to wash or dress myself 
 
USUAL ACTIVITIES (e.g. work, study, housework, family or leisure activities) 
□ I have no problems doing my usual activities 
□ I have slight problems doing my usual activities 
□ I have moderate problems doing my usual activities 
□ I have severe problems doing my usual activities 
□ I am unable to do my usual activities 
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PAIN / DISCOMFORT 
□ I have no pain or discomfort 
□ I have slight pain or discomfort 
□ I have moderate pain or discomfort 
□ I have severe pain or discomfort 
□ I have extreme pain or discomfort 
 
ANXIETY / DEPRESSION 
□ I am not anxious or depressed 
□ I am slightly anxious or depressed 
□ I am moderately anxious or depressed 
□ I am severely anxious or depressed 
□ I am extremely anxious or depressed 
 
GP & P: Q3. Which of the following categories do you believe you currently fit into? 
□ Underweight  □ Healthy Weight □ Overweight  □ Obese 
 
GP: Q4. Do you regularly play intensive sport or “body build”? 
□ Yes     □ No 
 
GP: Q5. Have you ever taken part in a weight loss maintenance programme (of any kind)? 
□ Yes     □ No 
Now move to Section 6.  
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Section 6: Attitudes & Beliefs Surrounding Obese Persons and Related Issues 
Note 
THIS SECTION IS IDENTICAL FOR BOTH THE GENERAL POPULATION AND PATIENT SAMPLE 
 
 
I strongly 
agree 
I 
moderately 
agree 
I slightly 
agree 
I slightly 
disagree 
I 
moderately 
disagree 
I strongly 
disagree 
Obesity often occurs when eating is used as a form of 
compensation for lack of love or attention. 
      
In many cases, obesity is the result of a biological 
disorder. 
      
Obesity is usually caused by overeating.       
Most obese people cause their problem by not getting 
enough exercise. 
      
Most obese people eat more than non-obese people.       
The majority of obese people have poor eating habits 
that lead to their obesity. 
      
Obesity is rarely caused by a lack of willpower.       
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People can be addicted to food, just as others are 
addicted to drugs, and these people usually become 
obese. 
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 True False 
It is sometimes hard for me to go on with my work if I am not 
encouraged. 
  
I sometimes feel resentful when I don’t get my way.   
On a few occasions, I have given up doing something because I 
thought too little of my ability. 
  
There have been times when I felt like rebelling against people in 
authority even though I knew they were right. 
  
No matter who I’m talking to, I’m always a good listener.   
There have been occasions when I took advantage of someone.   
I’m always willing to admit it when I make a mistake.   
I sometimes try to get even rather than forgive and forget.   
I am always courteous, even to people who are disagreeable.   
I have never been irked when people expressed ideas very different 
from my own. 
  
There have times when I was quite jealous of the good fortune of 
others. 
  
I am sometimes irritated by people who ask favours of me.   
I have never deliberately said something that hurt someone’s feelings.   
 
Q. To what extent do you agree with the following statement? 
“Answers to this survey will affect the organisation of/delivery of weight loss maintenance 
programmes”   
Strongly 
disagree 
Moderately 
disagree 
Slightly  
disagree 
Neither 
agree or 
disagree 
Slightly 
agree 
Moderately 
agree 
Strongly 
agree 
□ □ □ □ □ □ □ 
 
Thank you for taking the time to complete this survey. 
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B-2 Ngene Code 
;alts = alt1, alt2, alt3 
;block = 4 
;rows = 40 
;eff = (mnl,d) 
;cond: 
if(alt1.ONLINE=3,alt1.FEEDBACK=[0,1,3]), 
if(alt2.ONLINE=3,alt2.FEEDBACK=[0,1,3]), 
if(alt1.ONLINE=3,alt1.REMINDERS=[0,1,3]), 
if(alt2.ONLINE=3,alt2.REMINDERS=[0,1,3]) 
;model: 
U(alt1) = b2 * LENGTH[6,12,18,24] + b3.dummy[0|0|0] * FEEDBACK[0,1,2,3] + 
b4.dummy[0|0|0] * REMINDERS[0,1,2,3] + b5.dummy[0|0|0] * ONLINE[0,1,2,3]  
+ b6[(u,-0.001,0)] * OUTCOME[0,10,20,40,60,80,90,100] + b7[(u,-0.001,0)] * 
COST[0,10,20,30] + b8 * COST * LENGTH + b9 * OUTCOME * LENGTH / 
U(alt2) = asc1 + b2 * LENGTH + b3 * FEEDBACK + b4 * REMINDERS + b5 * 
ONLINE + b6 * OUTCOME + b7 * COST + b8 * COST * LENGTH + b9 * OUTCOME 
* LENGTH / 
U(alt3) = asc2 + b6 * OUTCOME1[100] + b7 * COST1[0] $ 
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B-3 DCE Experimental Design 
 Alternative 1 Alternative 2 
choice block length feedback reminder online outcome cost length feedback reminder online outcome cost 
1 3 18 2 1 1 60 10 12 3 0 3 40 20 
2 1 24 0 1 0 100 30 24 2 3 1 0 0 
3 3 6 3 3 1 0 0 6 2 0 2 100 30 
4 4 6 2 0 1 10 0 18 3 2 2 80 20 
5 1 18 1 2 0 40 20 12 3 1 3 60 10 
6 4 6 3 2 1 100 0 6 2 1 2 0 30 
7 4 18 0 1 2 60 10 12 2 2 0 40 20 
8 3 12 2 3 2 80 20 18 3 2 1 20 10 
9 4 12 1 0 3 80 10 18 0 3 1 20 20 
10 3 18 2 3 1 90 10 12 3 2 0 10 20 
11 2 12 2 2 0 80 10 18 3 3 2 20 20 
12 3 24 2 1 0 0 0 24 1 2 1 100 30 
13 4 24 3 1 0 90 30 6 0 2 1 90 20 
14 4 24 1 3 3 0 30 24 0 0 0 100 0 
15 1 18 0 3 3 40 20 6 3 1 1 90 0 
16 4 24 1 2 2 0 30 24 3 3 3 100 0 
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 Alternative 1 Alternative 2 
choice block length feedback reminder online outcome cost length feedback reminder online outcome cost 
17 2 12 3 0 3 40 20 18 0 3 0 60 10 
18 3 24 2 0 2 90 30 12 0 2 0 20 10 
19 3 18 3 1 3 20 10 6 1 3 1 90 30 
20 2 24 3 3 2 100 0 24 2 1 1 0 30 
21 2 18 1 0 2 60 10 12 0 1 3 40 20 
22 2 24 0 0 3 10 0 6 2 3 2 10 0 
23 1 6 1 1 3 10 30 24 0 0 2 10 20 
24 2 12 2 3 0 60 20 18 1 1 1 40 10 
25 3 18 3 3 0 20 20 12 1 0 3 60 10 
26 4 6 0 0 0 10 30 24 1 2 2 10 0 
27 1 12 3 2 2 20 30 12 1 0 0 80 0 
28 2 18 2 2 1 80 20 12 1 3 0 20 10 
29 3 24 1 2 1 90 10 6 3 0 2 90 0 
30 1 6 2 2 2 100 0 6 1 0 1 0 30 
31 1 24 1 0 0 10 0 18 0 3 3 80 30 
32 1 12 3 0 1 20 20 18 1 3 3 80 10 
33 3 12 1 1 2 80 10 24 0 0 3 10 30 
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 Alternative 1 Alternative 2 
choice block length feedback reminder online outcome cost length feedback reminder online outcome cost 
34 4 6 0 0 1 100 30 6 2 2 2 0 0 
35 4 12 3 3 3 40 20 18 0 1 2 60 10 
36 2 6 0 0 2 0 0 6 3 1 0 100 30 
37 2 6 0 3 0 90 0 24 2 2 1 90 0 
38 1 6 0 2 2 20 30 24 2 0 0 80 30 
39 2 12 0 1 3 60 10 18 3 3 0 40 20 
40 1 18 3 0 2 40 20 12 1 1 3 60 10 
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B-4 Beliefs about Obese Persons Scale Scoring System 
Step 1: Multiply the response to the following items by -1 (i.e., reverse the direction of 
scoring):  Item1, Items 3 through Item 6, Item 8 
Step 2: Sum the responses to all items. 
Step 3: Add 24 to the value obtained in Step 2.  This value is the BAOP score.   
Higher numbers indicate a stronger belief that obesity is not under the obese person’s control. 
These measures and additional psychometric information can be found in the following 
reference: Allison, DB. Handbook of Assessment Methods for Eating Behaviors and Weight-
Related Problems. Measures, Theory, and Research. Thousand Oaks, CA: Sage Publications. 
 
B-5 Marlowe Crowne Scale Scoring System 
Add 1 point to the score for each true response to statements 5, 7, 9, 10, and 13. Add 0 points 
to the score for each false response to these statements. 
Add 1 point to the score for each false response to statements 1, 2, 3, 4, 6, 8, 11, and 12. Add 
0 points to the score for each true response to these statements. 
See: Andrews, P. & Meyer, R.G. (2003) Marlowe-Crowne Social Desirability Scale and short 
Form C: forensic norms. Journal of clinical psychology. 59 (4), 483–492. 
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B-6 Ethics Review – Comments from Reviewers 
 
Faculty of Medical Sciences 
Application Case No. 00874 
 
Reviewer One 
Name of Reviewer: Mark Pearce 
Date: 18/05/2015 
Reviewer’s Report 
1. HAS THE RESEARCHER ADEQUATELY ADDRESSED THE ETHICAL ISSUES 
RAISED BY THIS PROPOSAL?   
No 
My only real concerns are for the information sheet 
Why is the name of the research survey company crossed out? 
I think the section on data anonymity needs to be clearer. What’s currently written is true for 
publications (i.e. aggregated data), but individual level data are to be held by the survey 
company and, presumably, to be accessed in that way by the researcher. I don’t have a 
problem with them doing this, assuming all data are secure, etc, but this should be made clear 
in the information sheet 
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Faculty of Medical Sciences 
Application Case No. 00874 
 
Reviewer Two 
Name of Reviewer: Ruben Thanacoody 
Date: 01/05/2015 
Reviewer’s Report 
1. HAS THE RESEARCHER ADEQUATELY ADDRESSED THE ETHICAL ISSUES 
RAISED BY THIS PROPOSAL?   
YES 
However, note that this ethics application relate to the survey for the general public only.  An 
ethics amendment is required for patient in the NULevel trial. 
Part 5 od [sic] survey. Please ensure that the note that the questions being asked are based on 
Latner et al. is included in the online survey. Some people might find the term “fat people” 
rather derogatory. 
I confirm that there are no outstanding ethical issues with this proposal and I recommend it 
for ethical approval for the period stated in the application. 
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B-7 Ethical Approval Letter 
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C-1 Conditional Logit Models (Main Effects) 
 (1) (2) (3) 
Variables All Treatment Control 
Alternative-Specific Constant -0.209 -0.219 -0.194 
 (0.222) (0.327) (0.305) 
Length (months) 0.00924 0.0173 0.00204 
 (0.00771) (0.0113) (0.0107) 
Feedback1    
via Phone Call 0.0722 -0.0749 0.198 
 (0.142) (0.212) (0.193) 
via the Online Tool(s) -0.250* -0.536** -0.00521 
 (0.146) (0.220) (0.198) 
via Text Message 0.532*** 0.396** 0.670*** 
 (0.132) (0.193) (0.183) 
Reminders2    
via Text Message 0.400*** 0.364* 0.441** 
 (0.129) (0.192) (0.175) 
via Phone Call 0.401*** 0.300 0.494** 
 (0.151) (0.226) (0.204) 
via the Online Tool(s) 0.553*** 0.620*** 0.506** 
 (0.149) (0.225) (0.202) 
Online Tool3    
App Only 0.183 0.161 0.198 
 (0.139) (0.205) (0.191) 
Website Only 0.0464 -0.0579 0.146 
 (0.151) (0.224) (0.207) 
App & Website 0.221* 0.0136 0.393** 
 (0.127) (0.191) (0.173) 
Outcome (% weight re-gain) -0.0253*** -0.0250*** -0.0258*** 
 (0.00184) (0.00267) (0.00257) 
Cost (£ per month) -0.0723*** -0.0700*** -0.0754*** 
 (0.00560) (0.00801) (0.00793) 
Sample Size (Observations) 3,390 1,560 1,830 
Log Likelihood -923.9 -430.4 -487.1 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
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C-2 Conditional Logit Models (Main Effects & Attribute Interactions) 
 (1) (2) (3) 
Variables All Treatment Control 
Alternative-Specific Constant -0.294 -0.248 -0.328 
 (0.266) (0.393) (0.366) 
Length (months) -0.0310* -0.0257 -0.0327 
 (0.0182) (0.0260) (0.0260) 
Feedback1    
via Phone Call 0.00771 -0.113 0.121 
 (0.146) (0.219) (0.199) 
via the Online Tool(s) -0.330** -0.569** -0.108 
 (0.155) (0.231) (0.211) 
via Text Message 0.449*** 0.353* 0.563*** 
 (0.136) (0.200) (0.189) 
Reminders2    
via Text Message 0.416*** 0.370* 0.457*** 
 (0.129) (0.191) (0.176) 
via Phone Call 0.376** 0.301 0.446** 
 (0.151) (0.226) (0.205) 
via the Online Tool(s) 0.635*** 0.707*** 0.574*** 
 (0.156) (0.233) (0.212) 
Online Tool3    
App Only 0.0691 0.0690 0.0759 
 (0.145) (0.212) (0.202) 
Website Only 0.00547 -0.114 0.117 
 (0.155) (0.230) (0.211) 
App & Website 0.186 -0.0322 0.368** 
 (0.130) (0.195) (0.177) 
Outcome (% weight re-gain) -0.0353*** -0.0331*** -0.0372*** 
 (0.00480) (0.00681) (0.00683) 
Cost (£ per month) -0.103*** -0.0952*** -0.111*** 
 (0.0143) (0.0205) (0.0202) 
Interaction: Length*Outcome 0.000441** 0.000507 0.000347 
 (0.000216) (0.000314) (0.000304) 
Interaction: Length*Cost 0.00132** 0.00157* 0.00103 
 (0.000640) (0.000947) (0.000889) 
Interaction: Outcome*Cost 0.000166 -7.88e-05 0.000391 
 (0.000186) (0.000273) (0.000257) 
Sample Size (Observations) 3,390 1,560 1,830 
Log Likelihood -920.4 -428.6 -484.8 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
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C-3 Mixed Logit Models (Main Effects & Demographic Interactions) 
 All Participants Treatment Arm Control Arm 
Variables Coeff. Std. Dev. Coeff. Std. Dev. Coeff. Std. Dev. 
Alternative-Specific Constant 2.702 2.437*** 4.587 -2.594** 21.393*** 8.150*** 
 (4.136) (0.530) (3.713) (1.080) (6.295) (2.016) 
Length (months) 0.012 0.088*** 0.047 0.162*** -0.038 0.352*** 
 (0.017) (0.022) (0.034) (0.043) (0.050) (0.086) 
Feedback1       
via Phone Call 0.621** -0.532 0.461 0.951 2.481** 4.095*** 
 (0.290) (0.467) (0.507) (0.596) (1.201) (1.335) 
via the Online Tool(s) -0.170 1.843*** -0.885 -0.363 0.856 5.938*** 
 (0.328) (0.496) (0.541) (0.527) (0.929) (1.456) 
via Text Message 1.080*** 0.246 1.038** 1.026 4.765*** 2.371*** 
 (0.260) (0.358) (0.471) (0.714) (1.252) (0.738) 
Reminders2       
via Text Message 0.746*** 0.161 0.900* 0.600 1.791** 3.052*** 
 (0.244) (0.401) (0.480) (0.638) (0.782) (0.926) 
via Phone Call 0.859*** 0.874*** 0.721 -1.314** 4.738*** 0.381 
 (0.308) (0.319) (0.564) (0.593) (1.327) (0.790) 
via the Online Tool(s) 1.363*** 0.128 1.905*** 0.671 5.406*** -3.419*** 
 (0.338) (0.336) (0.614) (0.506) (1.527) (0.944) 
Online Tool3       
App Only 0.280 0.730* -0.135 -1.186** 2.579** 2.729*** 
 (0.261) (0.378) (0.506) (0.488) (1.183) (1.049) 
Website Only 0.084 0.390 0.055 -1.425** 1.672* 4.689*** 
 (0.274) (0.329) (0.529) (0.609) (0.963) (1.244) 
App & Website 0.475* -1.558*** -0.058 -2.150*** 3.381*** -5.994*** 
 (0.278) (0.435) (0.498) (0.669) (1.113) (1.568) 
Outcome (% weight re-gain) -0.071*** 0.043*** -0.099*** 0.071*** -0.263*** 0.242*** 
 (0.010) (0.006) (0.022) (0.019) (0.058) (0.054) 
Cost (£ per month) -0.217*** 0.212*** -0.238*** 0.362*** -1.002*** 0.720*** 
 (0.027) (0.031) (0.054) (0.094) (0.225) (0.167) 
ASC Interactions       
Age 35-44 -2.362**  2.165  -5.546  
 (1.159)  (2.269)  (4.148)  
Age 45-54 -2.739  0.918  -6.803*  
 (1.868)  (2.285)  (3.589)  
Age 55+ -2.418*  3.631  -8.372**  
 (1.433)  (3.610)  (3.311)  
Female 0.977  1.282  7.707***  
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 All Participants Treatment Arm Control Arm 
Variables Coeff. Std. Dev. Coeff. Std. Dev. Coeff. Std. Dev. 
 (0.814)  (1.558)  (2.665)  
Postgraduate Qualification -4.241***  -8.859***  -8.349**  
 (1.138)  (2.608)  (3.487)  
Undergraduate Qualification -2.603**  -11.010***  -1.461  
 (1.286)  (3.240)  (3.441)  
HND/HNC Qualification -3.199**  -10.968***  -16.870***  
 (1.510)  (3.630)  (5.041)  
A Level Qualification -0.782  -0.624  -21.204***  
 (1.372)  (3.750)  (6.159)  
Full-Time Employed 1.976  4.986**  3.161  
 (1.475)  (2.353)  (4.585)  
Part-Time Employed 0.491  11.054***  0.020  
 (1.582)  (3.855)  (4.633)  
Retired 0.465  1.192  17.430**  
 (1.792)  (2.582)  (7.977)  
Income £10-20k 1.317      
 (4.294)      
Income £20-30k 1.172  -0.368  -20.290**  
 (4.335)  (1.845)  (8.371)  
Income £30-50k -2.426  -7.534***  -15.752***  
 (4.174)  (2.479)  (5.768)  
Income £40-50k 0.140  -0.804  -19.238***  
 (4.415)  (1.978)  (6.984)  
Income £50-60k 0.582  -14.434***  -15.539**  
 (4.346)  (5.093)  (7.436)  
Income £60-70k 0.016  -0.582  -15.350**  
 (4.273)  (2.000)  (7.062)  
Income over £70k 0.648  -4.601*  -24.884***  
 (4.506)  (2.378)  (8.376)  
Observations 3,390 1,560 1,830 
Log Likelihood -689.9 -314.1 -332.7 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1; 1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
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D-1 Conditional Logit Models (Main Effects) 
 (1) (2) (3) 
Variables Potential Service 
User 
Potential 
Beneficiary 
Non-User 
Alternative-Specific Constant 0.886*** 1.056*** 0.803*** 
 (0.148) (0.138) (0.144) 
Length (months) -0.0204*** -0.0182*** -0.0203*** 
 (0.00521) (0.00491) (0.00506) 
Feedback1    
via Phone Call 0.102 0.173* 0.0376 
 (0.0981) (0.0932) (0.0979) 
via the Online Tool(s) 0.0758 0.0876 0.232** 
 (0.0977) (0.0926) (0.0958) 
via Text Message 0.0968 0.192** 0.317*** 
 (0.0909) (0.0856) (0.0898) 
Reminders2    
via Text Message 0.0758 0.177** 0.274*** 
 (0.0864) (0.0817) (0.0857) 
via Phone Call -0.0126 0.0975 0.0847 
 (0.0961) (0.0920) (0.0967) 
via the Online Tool(s) -0.0625 0.179** 0.217** 
 (0.0938) (0.0883) (0.0923) 
Online Tool3    
App Only 0.148 0.0867 0.0510 
 (0.0957) (0.0903) (0.0951) 
Website Only 0.228** 0.0982 0.162 
 (0.101) (0.0963) (0.100) 
App & Website 0.217** 0.204** 0.0915 
 (0.0917) (0.0864) (0.0914) 
Outcome (% weight re-gain) -0.0131*** -0.00941*** -0.00768*** 
 (0.000999) (0.000930) (0.000958) 
Cost (£ per month) -0.0526*** -0.0623*** -0.0636*** 
 (0.00324) (0.00306) (0.00315) 
Sample Size (Observations) 210 (6,300) 243 (7,290) 229 (6,870) 
Log Likelihood -1,927 -2,203 -2,162 
AIC 3,880 4,432 4,350 
BIC 3,968 4,522 4,439 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool” 
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D-2 Conditional Logit Models (Main Effects & Attribute Interactions) 
 (1) (2) (3) 
Variables Potential Service 
User 
Potential 
Beneficiary 
Non-User 
Alternative-Specific Constant 1.168*** 0.924*** 0.778*** 
 (0.186) (0.177) (0.182) 
Length (months) -0.0123 -0.00594 -0.0244*** 
 (0.00982) (0.00899) (0.00912) 
Feedback1    
via Phone Call 0.105 0.203** 0.0523 
 (0.0997) (0.0950) (0.0992) 
via the Online Tool(s) 0.137 0.0768 0.229** 
 (0.101) (0.0950) (0.0984) 
via Text Message 0.127 0.215** 0.310*** 
 (0.0927) (0.0871) (0.0916) 
Reminders2    
via Text Message 0.0705 0.169** 0.275*** 
 (0.0866) (0.0822) (0.0860) 
via Phone Call -0.00282 0.0856 0.0826 
 (0.0966) (0.0931) (0.0971) 
via the Online Tool(s) -0.0771 0.157* 0.221** 
 (0.0944) (0.0890) (0.0932) 
Online Tool3    
App Only 0.156 0.118 0.0551 
 (0.0964) (0.0921) (0.0961) 
Website Only 0.219** 0.128 0.164 
 (0.102) (0.0965) (0.101) 
App & Website 0.205** 0.244*** 0.0917 
 (0.0929) (0.0881) (0.0932) 
Outcome (% weight re-gain) -0.00792*** -0.00826*** -0.00791*** 
 (0.00261) (0.00245) (0.00246) 
Cost (£ per month) -0.0511*** -0.0466*** -0.0598*** 
 (0.00816) (0.00759) (0.00769) 
Interaction: Length*Outcome -0.000221* -3.02e-05 9.92e-05 
 (0.000118) (0.000109) (0.000114) 
Interaction: Length*Cost 0.000262 -0.000883** 4.01e-05 
 (0.000372) (0.000354) (0.000369) 
Interaction: Outcome*Cost -0.000123 -6.19e-05 -0.000103 
 (0.000119) (0.000114) (0.000110) 
Sample Size (Observations) 210 (6,300) 243 (7,290) 229 (6,870) 
Log Likelihood -1,923 -2,200 -2,161 
AIC 3,878 4,432 4,354 
BIC 3,986 4,542 4,463 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool”
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D-3 Mixed Logit Models (Main Effects & Demographic Interactions) 
 Potential Service User (PSU) Potential Beneficiary (PB) Non-User (NU) 
Variables Coeff. Std. Dev. Coeff. Std. Dev. Coeff. Std. Dev. 
Alternative-Specific Constant 3.933*** 2.291*** 5.541*** 2.437*** 4.711** 3.227*** 
 (1.263) (0.278) (1.387) (0.280) (1.876) (0.385) 
Length (months) -0.031*** 0.031** -0.028*** 0.051*** -0.036*** 0.064*** 
 (0.008) (0.013) (0.008) (0.011) (0.009) (0.011) 
Feedback1       
via Phone Call 0.181 0.446 0.229 -0.990*** 0.140 -0.119 
 (0.146) (0.298) (0.151) (0.240) (0.148) (0.325) 
via the Online Tool(s) 0.207 0.699*** 0.236* -0.409 0.550*** -0.128 
 (0.151) (0.245) (0.136) (0.285) (0.148) (0.303) 
via Text Message 0.189 -0.172 0.339*** -0.301 0.587*** 0.187 
 (0.132) (0.303) (0.127) (0.251) (0.140) (0.269) 
Reminders2       
via Text Message 0.144 -0.306 0.205 0.827*** 0.393*** 0.464* 
 (0.126) (0.314) (0.130) (0.185) (0.133) (0.279) 
via Phone Call -0.039 -0.619*** 0.162 0.136 0.079 0.561** 
 (0.151) (0.224) (0.138) (0.362) (0.160) (0.266) 
via the Online Tool(s) 0.020 -0.242 0.389*** 0.410* 0.331** 0.339 
 (0.144) (0.296) (0.140) (0.219) (0.151) (0.274) 
Online Tool3       
App Only 0.244* -0.001 0.123 0.090 0.201 -0.290 
 (0.135) (0.260) (0.131) (0.248) (0.140) (0.329) 
Website Only 0.211 0.442 -0.099 -0.449* 0.205 0.588** 
 (0.147) (0.288) (0.145) (0.265) (0.154) (0.270) 
App & Website 0.241* 0.324 0.167 -0.571*** 0.028 -0.499* 
 (0.132) (0.285) (0.127) (0.221) (0.139) (0.286) 
Outcome (% weight re-gain) -0.027*** 0.029*** -0.019*** 0.023*** -0.017*** 0.026*** 
 (0.003) (0.003) (0.002) (0.003) (0.003) (0.003) 
Cost (£ per month) -0.141*** 0.137*** -0.160*** 0.131*** -0.197*** 0.157*** 
 (0.014) (0.013) (0.014) (0.012) (0.018) (0.014) 
ASC Interactions       
Age 25-34 -2.625**  -1.974  -2.343  
 (1.281)  (1.280)  (1.795)  
Age 35-44 -2.559**  -1.063  -2.776  
 (1.264)  (1.322)  (1.743)  
Age 45-54 -2.649**  -2.814**  -1.714  
 (1.318)  (1.212)  (1.762)  
Age 55+ -2.100  -2.162*  -3.021*  
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 Potential Service User (PSU) Potential Beneficiary (PB) Non-User (NU) 
Variables Coeff. Std. Dev. Coeff. Std. Dev. Coeff. Std. Dev. 
 (1.338)  (1.180)  (1.783)  
Female 0.028  0.003  -0.267  
 (0.505)  (0.510)  (0.615)  
Postgraduate Qualification 0.029  -0.605  -0.610  
 (0.702)  (0.692)  (1.065)  
Undergraduate Qualification 0.172  -0.056  0.094  
 (0.599)  (0.689)  (0.872)  
HND/HNC Qualification -0.004  -0.532  0.702  
 (0.797)  (0.755)  (1.225)  
A Level Qualification 0.141  -0.158  1.891**  
 (0.716)  (0.621)  (0.841)  
Full-Time Employed 1.222*  -0.217  0.941  
 (0.676)  (0.814)  (0.859)  
Part-Time Employed 1.594**  -0.840  0.497  
 (0.713)  (0.830)  (0.902)  
Retired 0.012  -1.333  1.482  
 (0.959)  (0.829)  (1.091)  
Income £20-30k -0.348  0.758  -0.566  
 (0.683)  (0.775)  (0.800)  
Income £30-50k -0.123  1.373*  -0.187  
 (0.716)  (0.813)  (1.065)  
Income £40-50k -0.206  0.082  -0.058  
 (0.768)  (0.755)  (0.823)  
Income £50-60k 0.954  0.092  -1.575  
 (0.995)  (0.756)  (1.062)  
Income £60-70k -0.445  0.368  -0.214  
 (0.938)  (0.886)  (1.076)  
Income over £70k -0.395  0.463  -0.076  
 (0.894)  (0.903)  (0.965)  
Observations 6,300 7,290 6,870 
Log Likelihood -1499 -1741 -1575 
Standard errors in parentheses; *** p<0.01, ** p<0.05, * p<0.1;  
1 Base level “face to face” feedback; 2 Base level “no reminders”; 3 Base level “no online tool”
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Appendix E. Future Writing Plan 
 
Paper 1: Whose Preferences are Elicited in Discrete Choice Experiments? A Systematic 
Review 
Based on: Chapter 4 
First Target: Value in Health 
Second Target: Applied Health Economics & Health Policy 
Submission Date: Early 2018 
Authors: David Mott, Laura Ternent, Luke Vale 
 
Paper 2: A Framework for Classifying Respondent Samples in Discrete Choice Experiments 
Based on: Chapter 5 
First Target: Health Economics (Letter) 
Second Target: The Patient 
Submission Date: Early 2018 
Authors: David Mott, Laura Ternent, Luke Vale 
 
Paper 3: Trial Participants’ Preferences for the NULevel Weight Loss Maintenance 
Intervention: A Discrete Choice Experiment 
Based on: Chapter 7 
First Target: Obesity 
Second Target: BMC Public Health 
Submission Date: Mid 2018 
Authors: David Mott, Laura Ternent, Luke Vale, Falko Sniehotta, Liz Evans, Frauke Becker 
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Paper 4: How Do Preferences for a Weight Loss Maintenance Intervention Differ According 
to Experience? A Discrete Choice Experiment 
Based on: Chapter 9 
First Target: Social Science and Medicine 
Second Target: Medical Decision Making 
Submission Date: Mid 2018 
Authors: David Mott, Laura Ternent, Luke Vale 
 
